NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR DIAGNOSING AND TREATING COMPLICATIONS OF PREGNANCY

Statement as to Federally Sponsored Research

This research was funded, in part, by NIH Grant R03 DK064255-02. The U.S. government has certain rights to the invention.

Field of the Invention

In general, this invention relates to the detection and treatment of subjects having a pregnancy related hypertensive disorder.

Background of the Invention

Pre-eclampsia is a syndrome of hypertension, edema, and proteinuria that affects 5 to 10% of pregnancies and results in substantial maternal and fetal morbidity and mortality. Pre-eclampsia accounts for at least 200,000 maternal deaths worldwide per year. The symptoms of pre-eclampsia typically appear after the 20th week of pregnancy and are usually detected by routine measuring of the woman's blood pressure and urine. However, these monitoring methods are ineffective for diagnosis of the syndrome at an early stage, which could reduce the risk to the subject or developing fetus, if an effective treatment were available.

Currently there are no known cures for pre-eclampsia. Pre-eclampsia can vary in severity from mild to life-threatening. A mild form of pre-eclampsia can be treated with bed rest and frequent monitoring. For moderate to severe cases, hospitalization is recommended and blood pressure medication or anticonvulsant medications to prevent seizures are prescribed. If the condition becomes life threatening to the mother or the baby the pregnancy is terminated and the baby is delivered pre-term.

The proper development of the fetus and the placenta is mediated by several growth factors or angiogenic factors. Careful regulation of angiogenic and mitogenic signaling pathways is critical for maintaining appropriate proliferation, migration, and angiogenesis by trophoblast cells in the developing placenta. While several of these factors, such as VEGF and PlGF, have been identified, there are still many proteins for which a role in the pathogenesis of pre-eclampsia or eclampsia has not yet been identified.

There is a need for methods of accurately diagnosing subjects at risk for or having pregnancy related hypertensive disorders, such as pre-eclampsia or eclampsia, particularly before the onset of the most severe symptoms. A treatment that would save maternal and fetal lives and prevent premature deliveries is also needed.

Summary of the Invention

We have discovered a means for diagnosing and effectively treating pregnancy related hypertensive disorders, including pre-eclampsia and eclampsia. In some cases both the diagnosis and treatment may occur prior to the development of symptoms. Such early diagnosis and treatment could save maternal and fetal lives and prevent premature deliveries.

We have discovered that the levels of expression of genes encoding the following secreted gene products (with GenBank numbers shown in parentheses) were significantly upregulated in the placental samples taken from women with pre-eclampsia as compared to placental specimens obtained from normal pregnant patients: follistatin related protein (U76702), interleukin 8 (M28130), inhibin A (M13981), VEGF-C (U43142), angiogenin (M11567), beta fertilin (U38805), hypothetical protein (AL039458), leukocyte associated Ig-like receptor secreted protein (AF013250), erythroid differentiation protein (J03634), adipogenesis inhibitory factor (X58377), corticotropin releasing factor binding protein (X58022), alpha-1 anti-chymotrypsin (X68733), insulin-like growth factor binding protein-5 (L27559), CD33L (D86368), cytokine

receptor like factor 1 (AF059293), platelet derived endothelial growth factor (NP_001953), lysyl hydroxylase isoform 2 (U84573), stanniocalcin precursor (U25997), secreted frizzled related protein (AF056087), and galectin-3 (NM_002306). We have also discovered that expression levels of the gene for the following secreted gene products were significantly decreased in placental samples taken from women with pre-eclampsia: alpha defensin (L12691), ADAM-TS3 (AB002364), cholecystokinin precursor (AW043690), interferon stimulated T-cell alpha chemoattractant precursor (AF030514), and azurocidin (M96326). These genes and the polypeptides encoded by the genes can be used to diagnose, treat, manage, and prevent pregnancy related hypertensive disorders.

We have also discovered intracellular targets that are differentially expressed in pre-eclamptic placentas and are suitable candidates for screening of novel therapeutic compounds. The intracellular gene products that are increased in pre-eclamptic placentas are: sperminine oxidase (U01134), UDP glycosyltransferase 2 family polypeptide B28 (AF 091582), neurotrophic tyrosine kinase receptor 2 (X 63759), neutral endopeptidase (J03779), CDC28 protein kinase regulatory subunit 2 (X54942) and beta glucosidase (J03060). The intracellular gene products that are decreased in pre-eclamptic placentas are: lanosterol synthase (U22526), calcium/calmodulin-dependent serine protein kinase (AI688589), estrogen receptor-alternatively spliced transcript H (X86816), chemokine (CX3C motif) receptor 1 (U27699), tyrosinase-related protein 1 (M20681), hydoxy-delta-5-steroid dehydrogenase (AL080151), dihydropyramidinase-like-4 (J03634), and cytochrome P450-family 11 (D84361).

For the purposes of the descriptions below, all of the polypeptides described above are collectively referred to as "the polypeptides of the invention." The polypeptides are further grouped as "secreted polypeptides" and "intracellular polypeptides" as described above. While the detailed description presented herein refers specifically to polypeptides associated with

specific GenBank accession numbers, it will be clear to one skilled in the art that the detailed description can also apply to family members, isoforms, homologs, and/or variants that are substantially identical to the specified polypeptides.

Based on this data, we have discovered that compounds that decrease the levels or biological activity of a polypeptide of the invention for which the gene was upregulated in pre-eclampsia can be used to treat or prevent pregnancy related hypertensive disorders, such as pre-eclampsia or eclampsia, in a subject. Similarly, we have discovered that compounds that increase the levels or biological activity of a polypeptide of the invention for which the gene was downregulated in samples from women with pre-eclampsia can be used to treat or prevent pregnancy related hypertensive disorders, such as pre-eclampsia or eclampsia, in a subject. Such agents include, but are not limited to, antibodies specific to the protein, nucleobase oligomers for antisense or RNAi targeting the protein, purified proteins, purified natural or synthetic compounds, chemical compounds, and small molecules.

Accordingly, the disclosure features methods for measuring the levels of any one or more of the polypeptides (secreted or intracellular) of the invention or a nucleic acid encoding a polypeptide of the invention as a detection tool for early diagnosis and management of pregnancy related hypertensive disorders, such as pre-eclampsia or eclampsia.

In a first aspect, there is provided a

method of diagnosing a subject as having, or having a predisposition to, a pregnancy related hypertensive disorder, said method comprising measuring the level of at least one polypeptide, or a fragment thereof, in a sample from said subject, wherein said at least one polypeptide, or fragment thereof, is selected from the group consisting of follistatin related protein, interleukin 8, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein,

insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, and beta glucosidase, and wherein an increase in the level of said at least one polypeptide, or fragment thereof, as compared to the level in a normal reference, is a diagnostic indicator of said pregnancy related hypertensive disorder or a predisposition to said pregnancy related hypertensive disorder.

In a second aspect, there is provided a

method of diagnosing a subject as having, or having a predisposition to, a pregnancy related hypertensive disorder, said method comprising measuring the level of a nucleic acid molecule in a sample from said subject, said nucleic acid molecule selected from the group consisting of nucleic acids encoding follistatin related protein, interleukin 8, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, insulin-like growth factor binding protein-5, CD33L, cytokine

receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, and beta glucosidase, wherein an increase in the level of said nucleic acid molecule, as compared to the level in a normal reference, is a diagnostic indicator of said pregnancy related hypertensive disorder or a predisposition to said pregnancy related hypertensive disorder.

In a third aspect, there is provided a

method of diagnosing a subject as having, or having a predisposition to, a pregnancy related hypertensive disorder, said method comprising measuring the level of a nucleic acid molecule in a sample from said subject, said nucleic acid molecule selected from the group consisting of nucleic acids encoding alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11, wherein a decrease in the level of said nucleic acid molecule, as compared to the level in a normal reference is a diagnostic indicator of said pregnancy related hypertensive disorder or a predisposition to said pregnancy related hypertensive disorder.

In a fourth aspect, there is provided a

method of diagnosing a subject as having, or having a predisposition to, a pregnancy related hypertensive disorder, said method comprising determining the nucleic acid sequence of a gene encoding a polypeptide selected from the group consisting of follistatin related protein, interleukin 8, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein

kinase regulatory subunit 2, and beta glucosidase, wherein an alteration in the subject's nucleic acid sequence that is an alteration that increases the expression level or biological activity of the gene product in said subject diagnoses the subject with said pregnancy related hypertensive disorder or a predisposition to said pregnancy related hypertensive disorder.

In a fifth aspect, there is provided a

method of diagnosing a subject as having, or having a predisposition to a pregnancy related hypertensive disorder, said method comprising determining the nucleic acid sequence of a gene encoding a polypeptide selected from the group consisting of: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-
alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11, wherein an alteration in the subject's nucleic acid sequence that is an alteration that decreases the expression level or biological activity of the gene product in said subject diagnoses the subject with said pregnancy related hypertensive disorder or a predisposition to said pregnancy related hypertensive disorder.

In a sixth aspect, there is provided a

kit for the diagnosis of a pregnancy related hypertensive disorder, or a predisposition to a pregnancy related hypertensive disorder in a subject comprising the following:

(a) a nucleic acid sequence or a sequence complementary thereto selected from the group consisting of nucleic acids sequences that encode any of the following polypeptides: follistatin related protein, interleukin 8, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, insulin-like

growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral

endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11; and

(b) instructions for the use of said nucleic acid sequence or sequence complementary thereto for the diagnosis of a pregnancy related hypertensive disorder in a subject.

In a seventh aspect, there is provided a

kit for the diagnosis of a pregnancy related hypertensive disorder in a subject comprising the following:

(a) a component useful for detecting a polypeptide selected from the group consisting of follistatin related protein, interleukin 8, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral

endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, lanosterol synthase,

calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11; and

(b) instructions for the use of said component for the diagnosis of a pregnancy related hypertensive disorder in said subject.

In an eighth aspect, there is provided a

nucleic acid array comprising one or more substrate supports that are stably associated with a plurality of polynucleotide probes, wherein said polynucleotide probes are capable of hybridizing under highly stringent conditions to RNA transcripts, or the complements thereof, of genes encoding proteins selected from the group consisting of follistatin related protein, interleukin 8, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11.

In a ninth aspect, there is provided a

polypeptide array comprising one or more substrate supports that are stably associated with a plurality of polypeptides selected from the group consisting of follistatin related protein, interleukin 8, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted

protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related

protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11; variants of said polypeptides; antibodies specific for said polypeptides or variants; or any combination of said polypeptides, variants, or antibodies.

Disclosed is a method of diagnosing a subject as

having or having a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, that includes measuring the level of any one or more of the following secreted or intracellular polypeptides, or fragments thereof, in a sample from the subject: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein (GenBank Accession Number AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-

chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, and beta-glucosidase. In this method, an increase (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more) in the level of any one or more of the above polypeptides, or fragments thereof, as compared to a normal reference sample, standard or level is a diagnostic indicator of a pregnancy related hypertensive disorder, or a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The method can also include measuring two, three, four, or five or more of the secreted or intracellular polypeptides listed above, or fragments thereof. In preferred embodiments, the polypeptide is follistatin related protein, inhibin-A, beta fertilin, insulin-like growth factor binding protein-5, or secreted frizzled related protein.

Non-limiting examples of pregnancy related hypertensive disorders include pre-eclampsia, eclampsia, gestational hypertension, chronic hypertension, HELLP syndrome, and pregnancy with a small for gestational age infant (SGA).

Also disclosed is a method of diagnosing a subject as having or having a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, that includes measuring the level of any one ore more of the following secreted or intracellular polypeptides, or fragments thereof, in a sample from the subject: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine receptor 1, tyrosinase-related

protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11. In this method, a decrease (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more) in the level of any one or more of the above polypeptides, or fragments thereof, as compared to a normal reference sample, standard, or level is a diagnostic indicator of a pregnancy related hypertensive disorder, or a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.

For any of the diagnostic methods that include measuring the level of a polypeptide or fragment thereof, the measuring can be done using an immunological assay (e.g., an ELISA or a western blot). The method can also include measuring two, three, four, or five or more of the secreted or intracellular polypeptides or the nucleic acids encoding the polypeptides listed above, or fragments thereof. The measuring can also be performed for more than one polypeptide at a time, using for example, microarrays which can be formatted as an array of binding molecules (e.g., an array of antibodies, also known as antibody arrays) to detect the polypeptides of the invention, or as an array of polypeptides of the invention, also known as protein arrays, which can be used to detect levels of antibodies to the polypeptides in a biological sample.

Also disclosed is a method of diagnosing a subject as having or having a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, that includes measuring the level of a nucleic acid molecule encoding any one of the following secreted or intracellular polypeptides, or fragments thereof, in a sample from the subject: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein (GenBank Accession Number AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin

precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, and beta-glucosidase. In this method, an increase (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more) in the level of any one or more of the nucleic acid molecules encoding the above polypeptides, or fragments thereof, as compared to a normal reference sample, standard, or level is a diagnostic indicator of a pregnancy related hypertensive disorder, or a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. In preferred embodiments, the nucleic acid encodes follistatin related protein, inhibin-A, beta fertilin, insulin-like growth factor binding protein-5, or secreted frizzled related protein.

Also disclosed is a method of diagnosing a subject as having or having a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, that includes measuring the level of a nucleic acid molecule encoding any one of the following secreted or intracellular polypeptides, or fragments thereof, in a sample from the subject: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11. In this method, a decrease (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more) in the level of a nucleic acid molecule encoding any one or more of the above polypeptides, or fragments thereof, as compared to a normal reference sample, standard, or level is a diagnostic indicator of a pregnancy related hypertensive disorder, or a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.

The methods above can also include measuring two, three, four, or five or more of the nucleic acids encoding the secreted or intracellular polypeptides listed above, or fragments thereof.

The diagnosis of a pregnancy related hypertensive disorder or a predisposition to a pregnancy related hypertensive disorder can result from an alteration (e.g., an increase or decrease) in the relative level of a polypeptide of the invention as compared to a normal reference sample or from the detection of an absolute level of a polypeptide of the invention that is above or below a normal reference level. The diagnosis can also result from an alteration in the level of a polypeptide as compare to the level in a prior sample obtained from the same subject. In additional preferred embodiments, the reference standard or level is a level or number derived from such a sample. In additional preferred embodiments, the reference sample is obtained at least 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 9 weeks, 12 weeks, 15 weeks, 18 weeks or more prior to the measuring of the levels for diagnosis. The reference standard or level can also be a value derived from a normal subject that is matched to the sample subject by at least one of the following criteria: gestational age of the fetus, age of the mother, blood pressure prior to pregnancy, blood pressure during pregnancy, BMI of the mother, weight of the fetus, prior diagnosis of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, and a family history of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. In additional preferred embodiments, the reference sample is a sample taken from a non-pregnant subject; a pregnant subject that does not have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia or a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia; or a purified protein at known normal concentrations or a level representative of any of the reference samples described above.

In additional preferred embodiments, the method further includes measuring the level of at least one of sFlt-1, VEGF, PlGF, or soluble endoglin

polypeptide in a sample from a subject as described in U.S. Patent Application Publication Numbers 20040126828, 20050025762, and 20050170444; PCT Publication Numbers WO 2004/008946 and WO 2005/077007; and U.S Patent Application Serial Number 11/235,577. The method can also include measuring the level of at least two of sFlt-1, VEGF, PlGF, or soluble endoglin polypeptide in a sample from a subject and calculating the relationship between the levels of sFlt-1, VEGF, PlGF, or soluble endoglin using a metric, where an alteration in the relationship between the levels in the subject sample relative to a reference sample diagnoses a pregnancy related hypertensive disorder or a predisposition to a pregnancy related hypertensive disorder. In preferred embodiments, the method also includes determining the body mass index (BMI), the gestational age (GA) of the fetus, or both and including the BMI or GA or both in the metric. For example, the metric can be a pre-eclampsia anti-angiogenic index (PAAI): [sFlt-1/VEGF + PlGF], a soluble endoglin anti-angiogenic index: (sFlt-1 + 0.25(soluble endoglin polypeptide))/PlGF, sFlt1/PLGF, (sFlt1+soluble endoglin)/PlGF, (sFlt1+soluble endoglin+follistatin related protein)/PlGF, or any combination thereof.

Also disclosed is a method of diagnosing a subject as having, or having a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, that includes determining the nucleic acid sequence of a gene encoding a polypeptide selected from the group consisting of: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral

endopeptidase, CDC28 protein kinase regulatory subunit 2, and beta glucosidase. An alteration in the subject's nucleic acid sequence that is an alteration that increases the expression level or biological activity of the gene product in the subject diagnoses the subject with a pregnancy related hypertensive disorder, or a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or a propensity to develop such a condition.

Also disclosed is a method of diagnosing a subject as having, or having a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, that includes determining the nucleic acid sequence of a gene encoding a polypeptide selected from the group consisting of: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11. An alteration in the subject's nucleic acid sequence that is an alteration that decreases the expression level or biological activity of the gene product in the subject diagnoses the subject with a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.

In preferred embodiments of any of the above aspects, the polypeptide or the nucleic acid encoding the polypeptide is follistatin related protein, inhibin-A, beta fertilin, insulin-like growth factor binding protein-5, or secreted frizzled related protein.

In additional embodiments of any of the above aspects, the levels are measured on two or more occasions and a change in the levels between measurements is a diagnostic indicator of pregnancy related hypertensive disorder, or a predisposition to a pregnancy related hypertensive disorder, such

as pre-eclampsia or eclampsia. In preferred embodiments, an alteration (e.g., an increase or a decrease of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more) in the level of any of the polypeptides of the invention or nucleic acids encoding a polypeptide of the invention from the first measurement to the next measurement is a diagnostic indicator of pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. Desirably, the diagnostic methods are used to diagnose a pregnancy related hypertensive disorder prior to the onset of symptoms (e.g., at least 4, 5, 6, 7, 8, 9, or 10 weeks prior).

In various embodiments of any of the above diagnostic aspects, the pregnancy related hypertensive disorder is pre-eclampsia, eclampsia, gestational hypertension, chronic hypertension, HELLP syndrome, or pregnancy with an SGA infant.

In various embodiments of the above aspects, the sample is a bodily fluid (e.g., urine, blood, amniotic fluid, serum, saliva, plasma, or cerebrospinal fluid) of the subject in which the polypeptide or nucleic acid encoding a polypeptide of the invention is normally detectable. In additional embodiments, the sample is a tissue or a cell (e.g., placental tissue or placental cells, endothelial cells, leukocytes, and monocytes). In other embodiments of the above aspects, the subject is a pregnant human, a post-partum human, or a non-pregnant human. In other embodiments of the above aspects, the subject is a non-human (e.g., a cow, a horse, a sheep, a pig, a goat, a dog, or a cat). In one embodiment, the subject is a non-pregnant human and the method is used to diagnose a propensity to develop a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, prior to a pregnancy. In additional embodiments, the BMI or GA or both is also measured.

Also disclosed is a kit for the diagnosis of a pregnancy related hypertensive disorder, or a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, in a subject that includes at least one nucleic acid sequence, or a sequence complementary

thereto, that is selected from nucleic acids that encode the following group of polypeptides: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450–family 11. The kit may also include directions for the use of the nucleic acid sequence, or sequence complementary thereto, for the diagnosis of a pregnancy related hypertensive disorder, or a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. In preferred embodiments, the kit includes at least two, at least three, at least four, or at least five or more of the nucleic acid sequences.

Also disclosed is a kit for the diagnosis of a pregnancy related hypertensive disorder, or a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, in a subject comprising a component or reagent used to detect a polypeptide that is selected from the following group of polypeptides: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein,

alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor– alternatively spliced transcript H, chemokine receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11. The kit may also include directions for the use of the components to detect the polypeptide for the diagnosis of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. In preferred embodiments, the kit includes components or reagents used to detect at least two, at least three, at least four, or at least five or more of the polypeptides of the invention. Preferred polypeptides or nucleic acids include follistatin related protein, inhibin-A, beta fertilin, insulin-like growth factor binding protein-5, or secreted frizzled related protein. In preferred embodiments, the components or reagents used to detect a polypeptide include a binding molecule, such as an antibody or antigen binding fragment that is specific for the polypeptide and the polypeptide is detected by any one of the following assays: an immunological assay, an enzymatic assay, or a colorimetric assay. The component or reagent can also be a polypeptide, or fragment thereof, that can bind to an antibody that specifically binds the polypeptide. Such a kit can be used to detect antibodies present in a bodily fluid sample from a subject that are indicative of levels of the protein in the subject.

In additional preferred embodiments of any of the kits defined herein, the kit also includes a reference sample, standard, or level. The reference sample, standard, or level can be a normal reference sample, standard

or level taken from a subject not having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or a subject that is not pregnant. The reference sample can also be a purified polypeptide at a known normal concentration.

In preferred embodiments, the diagnostic kit is labeled or includes instructions for use in the diagnosis of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or a predisposition to a pregnancy related hypertensive disorder, in a subject. In yet another embodiment, the diagnostic kit is labeled or includes instructions for use in therapeutic monitoring or therapeutic dosage determination. Desirably, the diagnostic kit includes a label or instructions for the use of the kit to determine the levels of a polypeptide of the invention of the subject sample and to compare those subject sample levels to a reference sample value or a standard curve of reference sample values, where the standard curve shows values indicative of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, and normal values. It will be understood that the reference sample values will depend on the intended use of the kit. For example, in a kit used for diagnostic purposes, the subject sample can be compared to a reference value or reference sample for a polypeptide of the invention taken from a subject that does not have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or is not pregnant. In another example, a kit used for therapeutic monitoring can have a reference value or reference sample that is a positive reference indicative of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, wherein an alteration (increase or decrease) in the value of the subject sample relative to the reference sample can be used to indicate an improvement in the pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or effective dosages of therapeutic compounds.

Disclosed is a device for diagnosing a subject as having or a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The device can include a component useful for comparing the levels of a polypeptide of the invention or a nucleic acid encoding a polypeptide of the invention, wherein an alteration (increase or decrease) in the levels of a polypeptide of the invention is a diagnostic indicator of a pregnancy related hypertensive disorder, or a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, in the subject. In preferred embodiments, the device includes a membrane in a lateral flow or dipstick format used to measure and compare polypeptide levels in urine sample. The device can also include components for comparing the levels of one or more polypeptides of the invention or nucleic acid molecules encoding the polypeptides of the invention and at least one of soluble endoglin sFlt-1, VEGF, and PlGF nucleic acid molecules or polypeptides in a sample from a subject, relative to a reference sample, wherein an alteration (increase or decrease) diagnoses a pregnancy related hypertensive disorder or a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia in the subject. In a preferred embodiment the device includes a component or components for use with a metric to compare the levels of one or more polypeptides of the invention and at least one, and preferably two, of soluble endoglin, sFlt-1, VEGF, and PlGF polypeptides.

Disclosed is a nucleic acid array comprising one or more substrate supports which are stably associated with a plurality of polynucleotide probes, wherein the polynucleotide probes are capable of hybridizing under highly stringent conditions to RNA transcripts, or the complements thereof, of nucleic acids encoding any of the polypeptides of the invention.

Also disclosed is a polypeptide array comprising one or more substrate supports which are stably associated with a plurality of polypeptides of the invention; variants of the polypeptides; antibodies specific for the polypeptides or variants; or any combination of the polypeptides, variants, or antibodies.

Each of the arrays described above can also include instructions for the use of the array for the diagnosis of a pregnancy related hypertensive disorder or a predisposition thereto.

Any of the diagnostic methods, kits, or arrays described herein can also be used to monitor a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, in a subject. In preferred embodiments, the diagnostic methods are used to monitor the subject during therapy or to determine effective therapeutic dosages. The level of a polypeptide of the invention or a nucleic acid encoding a polypeptide of the invention is measured alone or in combination with the levels of soluble endoglin, sFlt-1, VEGF, or PlGF protein or nucleic acids, or any combination thereof. In preferred embodiments the levels of are measured on two or more occasions and an alteration (increase or decrease) in the levels is a diagnostic indicator of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. In additional preferred embodiments, the levels are compared to a reference sample and an alteration (increase or decrease) in the levels of any of the polypeptides relative to the reference sample is a diagnostic indicator of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. In one embodiment, the level of at least one of the following polypeptides or nucleic acids encoding the following secreted or intracellular polypeptides, or fragments thereof, is measured during or after administering therapy and compared to the value before therapy: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein (#AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing

factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, and beta-glucosidase. In this embodiment, a decrease in the level of any one or more of the above polypeptides, or fragments thereof, as compared to the value before therapy indicates an improvement in the pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.

In another embodiment, the level of at least one of the following secreted or intracellular polypeptides or nucleic acid encoding the secreted polypeptides, or fragments thereof is measured during or after administering therapy and compared to the value before therapy: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor – alternatively spliced transcript H, chemokine receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450 –family 11. In this embodiment, an increase in the level of any one or more of the above polypeptides, or fragments thereof, as compared to the value before therapy indicates an improvement in the pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.

In preferred embodiments of the diagnostic monitoring methods of the disclosure that include the measurement of sFlt-1, VEGF, or PlGF, the method can include calculating the relationship between the levels of sFlt-1, VEGF, or PlGF using a metric, wherein an alteration in the relationship between said levels in the subject sample relative to a reference sample, is a diagnostic indicator of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. One example of such a metric is the PAAI. In this example, a

decrease in the PAAI value of a subject (e.g., less than 20, preferably less than 10) indicates an improvement in the pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. A decrease in the PAAI (e.g., less than 20, preferably less than 10) can also indicate an effective dosage of a therapeutic compound. In preferred embodiments of the aspects relating to diagnosis or monitoring of therapeutic treatments, polypeptides are measured using an immunological assay, such as ELISA or western blot, or a protein array or antibody array for the measurement of expression levels of more than one polypeptide. For any of the monitoring methods, the measuring of levels can be done on two or more occasions and a change in the levels between measurements is a diagnostic indicator of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.

Further disclosed is a method of treating or preventing a pregnancy related hypertensive disorder, or a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, in a subject by administering to the subject a compound capable of decreasing the biological activity or the expression level of a polypeptide or nucleic acid molecule encoding a polypeptide selected from the group of secreted polypeptides consisting of: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, and galectin-3, where the administering is for a time and in an amount sufficient to treat or prevent a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, in a subject. In preferred embodiments, the compound is a nucleobase oligomer that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% complementary to at least a portion of the nucleic acid sequence

encoding any of the polypeptides listed above. The nucleobase oligomer can be an antisense nucleobase oligomer, preferably at least 90%, 95%, 96%, 97%, 98%, 99% or 100% complementary to at least 8 to 30 nucleotides of the desired nucleic acid sequence. The nucleobase oligomer can also be a double stranded RNA (dsRNA), preferably a small interfering RNA (siRNA) that is preferably at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to at least 18, 19, 20, 21, 22, 23, 24, 25, 35, 45, or 50 nucleotides of the desired nucleic acid sequence.

In additional preferred embodiments, the compound is an antibody or antigen-binding fragment, preferably a monoclonal antibody, that specifically binds any one of the following polypeptides, or fragments thereof: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, and galectin–3. In preferred embodiments, the antibody or antigen-binding fragment thereof is a human or humanized antibody.

Also disclosed is a method of treating or preventing a pregnancy related hypertensive disorder, or a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, in a subject by administering to the subject a compound capable of increasing the biological activity or the expression level of a polypeptide or nucleic acid molecule encoding a secreted polypeptide selected from the group consisting of: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, and azurocidin, where the administering is for a time and in an amount sufficient to treat or prevent a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, in

a subject. In a preferred embodiment, the compound is a purified polypeptide selected from the group consisting of: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, and azurocidin. In various embodiments, the method further involves the step of administering to a subject an anti-hypertensive compound (e.g., adenosine, nifedipine, minoxidil, and magnesium sulfate). In other embodiments, the subject is a pregnant human, a post-partum human, a non-pregnant human, or a non-human (e.g., a cow, a horse, a sheep, a pig, a goat, a dog, or a cat). The therapeutic methods of the disclosure can be used to treat or prevent a pregnancy related hypertensive disorder that includes pre-eclampsia, eclampsia, gestational hypertension, chronic hypertension, HELLP syndrome, and pregnancy with an SGA infant. Preferred disorders are pre-eclampsia and eclampsia. In various embodiments of the above aspects, the method can be combined with the diagnostic methods of the disclosure, described below, to monitor the subject during therapy or to determine effective therapeutic dosages.

Any of the therapeutic aspects of the disclosure can also include administering one ore more additional compounds, such as a purified sFlt-1 antibody, a sFlt-1 antigen-binding fragment, nicotine, theophylline, adenosine, nifedipine, minoxidil, magnesium sulfate, vascular endothelial growth factor (VEGF), including all isoforms such as VEGF189, VEGF121, or VEGF165, or fragments thereof; placental growth factor (PlGF), including all isoforms and fragments thereof; a purified soluble endoglin antibody or soluble endoglin antigen-binding fragment; where the administering is for a time and in an amount sufficient to treat or prevent the pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, in a subject. Preferred examples of such compounds are described in U.S. Patent Application Publication Numbers 20040126828, 20050025762, and 20050170444; PCT Publication

Numbers WO 2004/008946 and WO 2005/077007; and U.S Patent Application Serial Number 11/235,577. Desirably, the compound will be a compound capable of binding to sFlt-1 or decreasing sFlt-1 expression.

Any of the therapeutic aspects of the disclosure can be used alone or in combination with one or more additional methods (diagnostic or treatment) of the disclosure.

Also disclosed is a method of identifying a compound that ameliorates a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, that includes contacting a cell that expresses a polypeptide of the invention or a nucleic acid molecule encoding a polypeptide of the invention with a candidate compound, and comparing the level of expression or biological activity of the polypeptide of the invention or the nucleic acid molecule encoding the polypeptide of the invention in the cell contacted by the candidate compound with the level of expression or biological activity in a control cell not contacted by the candidate compound, where an alteration in expression or biological activity of the polypeptide of the invention or the nucleic acid molecule encoding the polypeptide of the invention identifies the candidate compound as a compound that ameliorates the pregnancy related hypertensive disorder.

In one embodiment, the method is used to identify a compound that decreases the expression of a polypeptide, or fragment thereof, or a nucleic acid molecule encoding the polypeptide, or fragment thereof, selected from the following group of polypeptides: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein (#AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein -5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, and galectin-3, sperminine oxidase, UDP

glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, and beta-glucosidase. In another embodiment, the method is used to identify a compound that promotes an increase in the expression of a polypeptide, or fragment thereof, or a nucleic acid molecule encoding the polypeptide, or fragment thereof, selected from the following group of polypeptides: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, and azurocidin, or the level of any one of the following intracellular polypeptides, or fragments thereof, in a sample from the subject: lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11. The alteration can be, for example, in transcription, translation, protein stability, production, or biological activity.

For the purpose of the present disclosure, the following abbreviations and terms are defined below.

By "alteration" is meant a change (increase or decrease) in the expression levels of a gene or polypeptide as detected by standard art known methods such as those described below. As used herein, an alteration includes a 10% change in expression levels, preferably a 25% change, more preferably a 40% change, and most preferably a 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or greater change in expression levels. "Alteration" can also indicate a change (increase or decrease) in the biological activity of any of the polypeptides of the invention. Examples of biological activities include ligand binding, enzymatic activity, cell migration, cell proliferation, induction of endothelial dysfunction, or induction of an anti-angiogenic state. Biological activities can be measured, for example, by ligand binding assays; cell migration assays; assays for enzymatic activity (e.g., kinase activity); Scatchard plot analysis; immunoassays; cell proliferation assays such as BrdU labeling,

cell counting experiments, or quantitative assays for DNA synthesis such as ^{3}H thymidine incorporation; and angiogenesis assays that are standard in the art or are described herein. As used herein, an alteration includes a 10% change in biological activity, preferably a 25% change, more preferably a 40% change, and most preferably a 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or greater change in biological activity.

By "antisense nucleobase oligomer" is meant a nucleobase oligomer, regardless of length, that is complementary to the coding strand or mRNA of a nucleic acid encoding a polypeptide of the invention. The antisense nucleobase oligomer can also be targeted to the translational start and stop sites. Preferably the antisense nucleobase oligomer comprises from about 8 to 30 nucleotides. The antisense nucleobase oligomer can also contain at least 40, 60, 85, 120, or more consecutive nucleotides that are complementary to mRNA or DNA encoding the polypeptide of the invention, and may be as long as the full-length mRNA or gene.

By "body mass index" is meant a number, derived by using height and weight measurements, that gives a general indication of whether or not weight falls within a healthy range. The formula generally used to determine the body mass index is a person's weight in kilograms divided by a person's height in meters squared or weight (kg)/ (height (m))^{2}.

By "compound" is meant any small molecule chemical compound, antibody, nucleic acid molecule, polypeptide, or fragments thereof.

By "chimeric antibody" is meant a polypeptide comprising at least the antigen-binding portion of an antibody molecule linked to at least part of another protein (typically an immunoglobulin constant domain).

By "decrease" is meant the ability to cause an overall reduction, preferably of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or greater, in the level of polypeptide or nucleic acid, detected

by the assays described herein (see "expression") or the biological activity of the polypeptide, detected by the assays described herein (see "biological activity"), as compared to a reference sample.

By "double-stranded RNA (dsRNA)" is meant a ribonucleic acid molecule comprised of both a sense and an anti-sense strand. dsRNAs can be used to mediate RNA interference.

By "expression" is meant the detection of a gene or polypeptide by standard art known methods. For example, polypeptide expression is often detected by immunoassays (e.g., ELISA or western blotting), DNA expression is often detected by Southern blotting or polymerase chain reaction (PCR), and RNA expression is often detected by northern blotting, PCR, or RNAse protection assays.

By "fragment" is meant a portion of a polypeptide or nucleic acid molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more amino acids or nucleotides up to the entire length of the polypeptide or nucleic acid molecule.

By "gestational age" is meant a reference to the age of the fetus, counting from the first day of the mother's last menstrual period usually referred to in weeks.

By "gestational hypertension" is meant the development of high blood pressure without proteinuria after 20 weeks of pregnancy.

By a "history of pre-eclampsia or eclampsia" is meant a previous diagnosis of pre-eclampsia or eclampsia or pregnancy induced hypertension in the subject themselves or in a related family member.

By "homologous" is meant any gene or polypeptide sequence that bears at least 30% homology, more preferably 40%, 50%, 60%, 70%, 80%, and most preferably 90% or more homology to a known gene or polypeptide sequence

over the length of the comparison sequence. A "homologous" polypeptide can also have at least one biological activity of the comparison polypeptide. For polypeptides, the length of comparison sequences will generally be at least 6 amino acids, preferably at least 10 or 20 amino acids, more preferably at least 25 amino acids, and most preferably 50, 100, 150, 200 amino acids or more, up to the entire length of the polypeptide. For nucleic acids, the length of comparison sequences will generally be at least 18 nucleotides, preferably at least 25 or 50 nucleotides, more preferably at least 75 nucleotides, and most preferably from at least 100, 150, 200, 250, 300 nucleotides or more up to the entire length of the nucleic acid. "Homology" can also refer to a substantial similarity between an epitope used to generate antibodies and the polypeptide or fragment thereof to which the antibodies are directed. In this case, homology refers to a similarity sufficient to elicit the production of antibodies that can specifically recognize the polypeptide at issue.

By "humanized antibody" is meant an immunoglobulin amino acid sequence variant or fragment thereof that is capable of binding to a predetermined antigen. Ordinarily, the antibody will contain both the light chain as well as at least the variable domain of a heavy chain. The antibody also may include the CH1, hinge, CH2, CH3, or CH4 regions of the heavy chain. The humanized antibody comprises a framework region (FR) having substantially the amino acid sequence of a human immunoglobulin and a complementarity determining region (CDR) having substantially the amino acid sequence of a non-human immunoglobulin (the "import" sequences).

Generally, a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains (Fab, Fab', $F(ab')_2$, Fabc, Fv) in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally will comprise at least

a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. By "complementarity determining region (CDR)" is meant the three hypervariable sequences in the variable regions within each of the immunoglobulin light and heavy chains. By "framework region (FR)" is meant the sequences of amino acids located on either side of the three hypervariable sequences (CDR) of the immunoglobulin light and heavy chains.

The FR and CDR regions of the humanized antibody need not correspond precisely to the parental sequences, e.g., the import CDR or the consensus FR may be mutagenized by substitution, insertion or deletion of at least one residue so that the CDR or FR residue at that site does not correspond to either the consensus or the import antibody. Such mutations, however, will not be extensive. Usually, at least 75%, preferably 90%, and most preferably at least 95%, 96%, 97%, 98%, 99% or 100% of the humanized antibody residues will correspond to those of the parental FR and CDR sequences.

By "hybridize" is meant pair to form a double-stranded molecule between complementary polynucleotide sequences, or portions thereof, under various conditions of stringency. (See, e.g., Wahl and Berger (1987) *Methods Enzymol.* 152:399; Kimmel, *Methods Enzymol.* 152:507, 1987.) For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and most preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and most preferably at least about 50% formamide. Stringent temperature conditions will ordinarily include temperatures of at least about 30°C, more preferably of at least about 37°C, and most preferably of at least about 42°C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of

stringency are accomplished by combining these various conditions as needed. In a preferred embodiment, hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37°C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 μg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42°C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 μg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

For most applications, washing steps that follow hybridization will also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash steps will ordinarily include a temperature of at least about 25°C, more preferably of at least about 42°C, and most preferably of at least about 68°C. In a preferred embodiment, wash steps will occur at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 42°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a most preferred embodiment, wash steps will occur at 68°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art. Hybridization techniques are well known to those skilled in the art and are described, for example, in Benton and Davis (*Science* 196:180, 1977); Grunstein and Hogness (*Proc. Natl. Acad. Sci.*, USA 72:3961, 1975); Ausubel et al. (*Current Protocols in Molecular Biology*, Wiley Interscience, New York,

2001); Berger and Kimmel (*Guide to Molecular Cloning Techniques*, 1987, Academic Press, New York); and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, New York.

By "increase" is meant the ability to cause an overall increase preferably of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or greater, in the level of polypeptide or nucleic acid, detected by the aforementioned assays (see "expression") or the biological activity of the polypeptide, detected by the aforementioned assays (see "biological activity"), as compared to a reference sample.

By "intrauterine growth retardation (IUGR)" is meant a syndrome resulting in a birth weight which is less that 10 percent of the predicted fetal weight for the gestational age of the fetus. The current World Health Organization criterion for low birth weight is a weight less than 2,500 gm (5 lbs. 8 oz.) or below the 10^{th} percentile for gestational age according to U.S. tables of birth weight for gestational age by race, parity, and infant sex (Zhang and Bowes, *Obstet. Gynecol.* 86:200-208, 1995). These low birth weight babies are also referred to as "small for gestational age (SGA)." Pre-eclampsia is a condition known to be associated with IUGR or SGA.

By "metric" is meant a measure. A metric may be used, for example, to compare the levels of a polypeptide or nucleic acid molecule of the invention. Exemplary metrics include, but are not limited to, mathematical formulas or algorithms, such as ratios. Depending on the metric that is used, the diagnostic indicator of eclampsia or pre-eclampsia may be significantly above or below a value using the same metric with a reference sample or level (e.g., from a control subject not having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia). The metric to be used is that which best discriminates between levels of a polypeptide or nucleic acid molecule of the invention, and/or soluble endoglin, sFlt-1, VEGF, PlGF, or any combination thereof, in a subject having pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, and a reference sample or level. For example, the

metric can be a pre-eclampsia anti-angiogenic index (PAAI): [sFlt-1/VEGF + PlGF], a soluble endoglin anti-angiogenic index: (sFlt-1 + 0.25(soluble endoglin polypeptide))/PlGF, sFlt1/PLGF, (sFlt1+soluble endoglin)/PlGF, (sFlt1+soluble endoglin+follistatin related protein)/PlGF, or any combination thereof. Some examples of metrics that are useful are described in U.S. Patent Application Publication Numbers 20040126828, 20050025762, and 20050170444; PCT Publication Numbers WO 2004/008946 and WO 2005/077007; and U.S Patent Application Serial Number 11/235,577.

By a "nucleobase oligomer" is meant a compound that includes a chain of at least eight nucleobases, preferably at least twelve, and most preferably at least sixteen bases, joined together by linkage groups. Included in this definition are natural and non-natural oligonucleotides, both modified and unmodified, as well as oligonucleotide mimetics such as Protein Nucleic Acids, locked nucleic acids, and arabinonucleic acids. Examples of numerous nucleobases and linkage groups that may be used in the nucleobase oligomers of the invention, can be found in U.S. Patent Application Publication Nos. 20030114412, paragraphs [0030] to [0046] and 20030114407, paragraphs [0036] to [0055], and 20030190659, paragraphs [0083] to [0106], herein incorporated by reference.

By "operably linked" is meant that a gene and a regulatory sequence(s) are connected in such a way as to permit gene expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequence(s).

By "pharmaceutically acceptable carrier" is meant a carrier that is physiologically acceptable to the treated mammal while retaining the therapeutic properties of the compound with which it is administered. One exemplary pharmaceutically acceptable carrier substance is physiological saline. Other physiologically acceptable carriers and their formulations are

known to one skilled in the art and described, for example, in Remington's Pharmaceutical Sciences, (20th edition), ed. A. Gennaro, 2000, Lippincott, Williams & Wilkins, Philadelphia, PA.

By "polymorphism" is meant a genetic variation, mutation, deletion or addition in a nucleic acid molecule encoding a polypeptide of the invention that is indicative of a predisposition to develop a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. A polymorphism may be present in the promoter sequence, an open reading frame, intronic sequence, or untranslated 3' region of a gene.

By "pregnancy related hypertensive disorder" is meant any condition or disease or pregnancy that is associated with or characterized by an increase in blood pressure. Included among these conditions are pre-eclampsia (including premature pre-eclampsia, severe pre-eclampsia), eclampsia, gestational hypertension, HELLP syndrome, (hemolysis, elevated liver enzymes, low platelets), abruption placenta, chronic hypertension, pregnancy with intra uterine growth restriction, and pregnancy with a small for gestational age (SGA) infant. It should be noted that although pregnancy with a SGA infant is not often associated with hypertension, it is included in this definition.

By "pre-eclampsia" is meant the multi-system disorder that is characterized by hypertension with proteinuria or edema, or both, glomerular dysfunction, brain edema, liver edema, or coagulation abnormalities due to pregnancy or the influence of a recent pregnancy. Pre-eclampsia generally occurs after the 20th week of gestation. Pre-eclampsia is generally defined as some combination of the following symptoms: (1) a systolic blood pressure (BP) >140 mmHg and a diastolic BP >90 mmHg after 20 weeks gestation (generally measured on two occasions, 4-168 hours apart), (2) new onset proteinuria (1+ by dipstik on urinanaysis, >300mg of protein in a 24-hour urine collection, or a single random urine sample having a protein/creatinine ratio >0.3), and (3) resolution of hypertension and proteinuria by 12 weeks postpartum. Severe pre-eclampsia is generally defined as (1) a diastolic BP >

110 mmHg (generally measured on two occasions, 4-168 hours apart) or (2) proteinuria characterized by a measurement of 3.5 g or more protein in a 24-hour urine collection or two random urine specimens with at least 3+ protein by dipstick. In pre-eclampsia, hypertension and proteinuria generally occur within seven days of each other. In severe pre-eclampsia, severe hypertension, severe proteinuria and HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) or eclampsia can occur simultaneously or only one symptom at a time. Occasionally, severe pre-eclampsia can lead to the development of seizures. This severe form of the syndrome is referred to as "eclampsia." Eclampsia can also include dysfunction or damage to several organs or tissues such as the liver (e.g., hepatocellular damage, periportal necrosis) and the central nervous system (e.g., cerebral edema and cerebral hemorrhage). The etiology of the seizures is thought to be secondary to the development of cerebral edema and focal spasm of small blood vessels in the kidney.

By "pre-eclampsia anti-angiogenesis index (PAAI)" is meant the ratio of sFlt-1/VEGF + PlGF used as an indicator of anti-angiogenic activity. A PAAI greater than 10, more preferably greater than 20, is considered to be indicative of pre-eclampsia or risk of pre-eclampsia.

By "premature pre-eclampsia" is meant pre-eclampsia with onset of symptoms <37 weeks or <34 weeks.

By "protein" or "polypeptide" or "polypeptide fragment" is meant any chain of more than two amino acids, regardless of post-translational modification (e.g., glycosylation or phosphorylation), constituting all or part of a naturally occurring polypeptide or peptide, or constituting a non-naturally occurring polypeptide or peptide.

By "polypeptide of the invention" is meant any of the following secreted polypeptides where the number in parenthesis indicates the GenBank accession number for the polypeptide: follistatin related protein (FLRG, U76702), interleukin 8 (IL-8, M28130), inhibin A (M13981), VEGF-C (U43142), angiogenin (M11567), beta fertilin (U38805), hypothetical protein

(AL039458), leukocyte associated Ig-like receptor secreted protein (LAIR-2, AF013250), erythroid differentiation protein (J03634), adipogenesis inhibitory factor (X58377), corticotropin releasing factor binding protein (CRF-BP, X58022), alpha-1 anti-chymotrypsin (X68733), insulin-like growth factor binding protein-5 (IGFBP-5, L27559), CD33L (D86358), cytokine receptor like factor 1 (CRLF1, AF059293), platelet derived endothelial growth factor (ECGF-1, NP_001953), lysyl hydroxylase isoform 2 (PLOD2, U84573), stanniocalcin precursor (U25997), secreted frizzled related protein (AF056087), galectin -3 (NM_002306), alpha defensin (L12691), ADAM-TS3 (AB002364), cholecystokinin precursor (AW043690), interferon stimulated T-cell alpha chemoattractant precursor (AF030514), and azurocidin (M96326); or any of the following intracellular polypeptides sperminine oxidase (U01134), UDP glycosyltransferase 2 family polypeptide B28 (AF091582), neurotrophic tyrosine kinase receptor 2 (X63759), neutral endopeptidase (J03779), CDC28 protein kinase regulatory subunit 2 (X54942) and beta glucosidase (J03060), lanosterol synthase (U22526), calcium/calmodulin-dependent serine protein kinase (AI688589), estrogen receptor –alternatively spliced transcript H (X86816), chemokine (CX3C motif) receptor 1 (U27699), tyrosinase-related protein 1 (M20681), hydoxy-delta-5-steroid dehydrogenase (AL080151), dihydropyramidinase-like-4 (J03634) and cytochrome P450–family 11 (D84361). Included in this definition are splice variants, isoforms, homologs, degradation products, and fragments of any of the above polypeptides.

By "reference sample" is meant any sample, standard, or level that is used for comparison purposes. A "normal reference sample" can be a prior sample taken from the same subject, a sample from a pregnant subject not having any pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, a sample from a pregnant subject not having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, a subject that is pregnant but the sample was taken early in pregnancy (e.g., in the first or second trimester or before the detection of a pregnancy related hypertensive

disorder, such as pre-eclampsia or eclampsia), a subject that is pregnant and has no history of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, a subject that is not pregnant, a sample of a purified reference polypeptide at a known normal concentration (i.e., not indicative of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia). By "reference standard or level" is meant a value or number derived from a reference sample. A normal reference standard or level can be a value or number derived from a normal subject that is matched to the sample subject by at least one of the following criteria: gestational age of the fetus, maternal age, maternal blood pressure prior to pregnancy, maternal blood pressure during pregnancy, BMI of the mother, weight of the fetus, prior diagnosis of pre-eclampsia or eclampsia, and a family history of pregnancy related hypertensive disorders, such as pre-eclampsia or eclampsia. A "positive reference" sample, standard or value is a sample or value or number derived from a subject that is known to have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, that is matched to the sample subject by at least one of the following criteria: gestational age of the fetus, maternal age, maternal blood pressure prior to pregnancy, maternal blood pressure during pregnancy, BMI of the mother, weight of the fetus, prior diagnosis of a pregnancy related hypertensive disorder, and a family history of a pregnancy related hypertensive disorder

By "reduce or inhibit" is meant the ability to cause an overall decrease preferably of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more in the level of polypeptide or nucleic acid, detected by the aforementioned assays (see "expression") or the biological activity of the polypeptide, detected by the aforementioned assays (see "biological activity"), as compared to a reference sample or a sample not treated with antisense nucleobase oligomers, dsRNA, or siRNA used for RNA interference.

By "sample" is meant a tissue biopsy, cell, bodily fluid (e.g., blood, serum, plasma, urine, saliva, amniotic fluid, or cerebrospinal fluid) or other specimen obtained from a subject. Desirably, the biological sample includes polypeptides of the invention or nucleic acid molecules encoding polypeptides of the invention or both.

By "small interfering RNAs (siRNAs)" is meant a nucleobase oligomer that is preferably a dsRNA molecule, and is preferably greater than 10 nucleotides (nt) in length, more preferably greater than 15 nucleotides in length, and most preferably greater than 19 nucleotides in length that is used to identify the target gene or mRNA to be degraded. Desirably, the siRNA is at least 90%, 95%, 96%, 97%, 98%, 99%, 100% complementary to 18, 19, 20, 21, 22, 23, 24, 25, 35, 45, 50 nucleotides of the desired nucleic acid sequence. A range of 19-25 nucleotides is the most preferred size for siRNAs. siRNAs can also include short hairpin RNA (shRNA) in which both strands of an siRNA duplex are included within a single RNA molecule. siRNA includes any form of dsRNA (proteolytically cleaved products of larger dsRNA, partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA) as well as altered RNA that differs from naturally occurring RNA by the addition, deletion, substitution, and/or alteration of one or more nucleotides. Such alterations can include the addition of non-nucleotide material, such as to the end(s) of the 21 to 23 nt RNA or internally (at one or more nucleotides of the RNA). In a preferred embodiment, the RNA molecules contain a 3' hydroxyl group. Nucleotides in the RNA molecules of the present invention can also comprise non-standard nucleotides, including non-naturally occurring nucleotides or deoxyribonucleotides. Collectively, all such altered RNAs are referred to as analogs of RNA. siRNAs of the present invention need only be sufficiently similar to natural RNA that it has the ability to mediate RNA interference (RNAi). As used herein, RNAi refers to the ATP-dependent targeted cleavage and degradation of a specific mRNA molecule through the

introduction of small interfering RNAs or dsRNAs into a cell or an organism. As used herein "mediate RNAi" refers to the ability to distinguish or identify which RNAs are to be degraded.

By "specifically binds" is meant a compound or antibody which recognizes and binds a polypeptide of the invention but that does not substantially recognize and bind other molecules in a sample, for example, a biological sample, which naturally includes a polypeptide of the invention.

By "subject" is meant a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, ovine, or feline. Included in this definition are pregnant, post-partum, and non-pregnant mammals.

By "substantially identical" is meant a nucleic acid or amino acid sequence that, when optimally aligned, for example using the methods described below, share at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with a second nucleic acid or amino acid sequence, e.g., an endoglin or soluble endoglin sequence. "Substantial identity" may be used to refer to various types and lengths of sequence, such as full-length sequence, epitopes or immunogenic peptides, functional domains, coding and/or regulatory sequences, exons, introns, promoters, and genomic sequences. Percent identity between two polypeptides or nucleic acid sequences is determined in various ways that are within the skill in the art, for instance, using publicly available computer software such as Smith Waterman Alignment (Smith, T. F. and M. S. Waterman (1981) *J. Mol. Biol.* 147:195-7); "Best Fit" (Smith and Waterman, Advances in Applied Mathematics, 482-489 (1981)) as incorporated into GeneMatcher Plus™, Schwarz and Dayhof (1979) Atlas of Protein Sequence and Structure, Dayhof, M.O., Ed pp 353-358; BLAST program (Basic Local Alignment Search Tool; (Altschul, S. F., W. Gish, et al. (1990) *J. Mol. Biol.* 215: 403-10), BLAST-2, BLAST-P, BLAST-N, BLAST-X, WU-BLAST-2, ALIGN, ALIGN-2, CLUSTAL, or Megalign (DNASTAR) software. In addition, those skilled in

the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the length of the sequences being compared. In general, for proteins, the length of comparison sequences will be at least 6 amino acids, preferably 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 200, 250, 300, 350, 400, or 500 amino acids or more up to the entire length of the protein. For nucleic acids, the length of comparison sequences will generally be at least 18, 25, 50, 100, 125, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 800, 900, 1000, 1100, 1200, or at least 1500 nucleotides or more up to the entire length of the nucleic acid molecule. It is understood that for the purposes of determining sequence identity when comparing a DNA sequence to an RNA sequence, a thymine nucleotide is equivalent to a uracil nucleotide. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

By "substrate" or "solid support is meant any material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes, polypeptides, or polypeptide binding molecules of the invention and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, Teflon, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silica-based materials including silicon and modified silicon, carbon, metals, etc. In general, the substrates allow optical detection and have low background fluorescence.

By "symptoms of pre-eclampsia" is meant any of the following: (1) a systolic blood pressure (BP) >140 mmHg and a diastolic BP >90 mmHg after

20 weeks gestation, (2) new onset proteinuria (1+ by dipstik on urinanaysis, >300mg of protein in a 24 hour urine collection, or random urine protein/creatinine ratio >0.3), and (3) resolution of hypertension and proteinuria by 12 weeks postpartum. The symptoms of pre-eclampsia can also include renal dysfunction and glomerular endotheliosis or hypertrophy. By "symptoms of eclampsia" is meant the development of any of the following symptoms due to pregnancy or the influence of a recent pregnancy: seizures, coma, thrombocytopenia, liver edema, pulmonary edema, and cerebral edema.

By "therapeutic amount" is meant an amount that when administered to a patient suffering from a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, is sufficient to cause a qualitative or quantitative reduction in the symptoms of the pregnancy related hypertensive disorder as described herein. A therapeutic amount can also mean an amount that when administered to a patient suffering from a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, is sufficient to cause a reduction in the expression levels of any one or more of the following: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein (#AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein -5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, and beta glucosidase. A therapeutic amount can also mean an amount that when administered to a patient suffering from a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, is sufficient to cause an increase in the expression levels of any one or more of the following: alpha defensin,

ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehyrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11. Assays for the measurement of the expression levels of polypeptides or a nucleic acid encoding the above polypeptides are known in the art, some of which are described herein.

By "treating" is meant administering a compound or a pharmaceutical composition for prophylactic and/or therapeutic purposes. To "treat disease" or use for "therapeutic treatment" refers to administering treatment to a subject already suffering from a disease to improve the subject's condition. Preferably, the subject is diagnosed as suffering from a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, based on identification of any of the characteristic symptoms described below or the use of the diagnostic methods described herein. To "prevent disease" refers to prophylactic treatment of a subject who is not yet ill, but who is susceptible to, or otherwise at risk of, developing a particular disease. Preferably a subject is determined to be at risk of developing a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, using the diagnostic methods described herein. Thus, in the claims and embodiments, treating is the administration to a mammal either for therapeutic or prophylactic purposes.

By "trophoblast" is meant the mesectodermal cell layer covering the blastocyst that erodes the uterine mucosa and through which the embryo receives nourishment from the mother; the cells contribute to the formation of the placenta.

By "vector" is meant a DNA molecule, usually derived from a plasmid or bacteriophage, into which fragments of DNA may be inserted or cloned. A recombinant vector will contain one or more unique restriction sites, and may

be capable of autonomous replication in a defined host or vehicle organism such that the cloned sequence is reproducible. A vector contains a promoter operably linked to a gene or coding region such that, upon transfection into a recipient cell, an RNA is expressed.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

Brief Description of the Drawings

Figure 1 is a graph showing the cumulative distribution function (CDF) for expression ratio greater than 1.0. Software BADGE (Bayesian Analysis of Gene Expression) v1.0 implements a Bayesian approach to identify differentially expressed genes across different experimental conditions. The genes are ranked in order of the conditional probability of increased fold expression given the expression data; the null probability value is 0.5. The ideal CDF has most genes near the null probability value, and few genes have high or low probabilities. For an expected false positive rate of 0.5%, we selected 78 genes, 42 upregulated and 36 downregulated.

Figure 2 is a colormap showing a predictive gene set in normal versus preeclamptic placenta based on mRNA expression using the BADGE program. Rows represent predictive genes for pre-eclampsia while columns represent expression levels for a given patient relative to the average gene expression. The expected false positive rate of 1.0% yields a predictive gene set of 127 genes, with 65 upregulated and 62 downregulated respectively. Significantly upregulated genes include soluble fms-like tyrosine kinase 1 and follistatin-related protein. mRNA expression profile from 3 pre-term placentas are also shown as additional controls.

Figure 3 shows a hierarchical clustering of the affymetrix patient data using Cluster and Treeview, (by Michael Eisen, Stanford University). The samples labeled as P are preeclamptic patients and the samples labeled as N are normal pregnant patients. The dataset was filtered from 12625 to 3564 genes using presence and expression criteria, and the resulting set was median-centered and normalized for genes and arrays. We used hierarchical clustering to analyze possible classes in genes. The cluster includes sFlt1 along with other genes confirmed in literature.

Figure 4 is an autoradiogram showing mRNA expression of Flt-1 and sFlt-1 in pre-eclampsia. mRNA expression of placental sFlt-1 from 3 patients with pre-eclampsia (P1, P2, P3) and three normotensive term pregnancies (N1, N2, N3) were determined by northern blot analysis. The higher band (7.5 kb) is the full length Flt-1 mRNA and the lower, more abundant band (3.4 kb) is the alternatively spliced sFlt-1 mRNA. Actin is included as a control and 28S is shown as arrowhead.

Figure 5 is a set of images showing the immunohistochemistry of Flt-1 expression in normal and preeclamptic placentas. A monoclonal antibody against human Flt-1 was used for these experiments. The data shown here demonstrates increased expression of Flt-1 by the syncitiotrophoblasts of the preeclamptic placenta.

Figure 6A shows the amino acid sequence of follistatin related protein (FLRG) (SEQ ID NO: 1). Figure 6B shows the DNA sequence of follistatin related protein (FLRG) (SEQ ID NO: 2).

Figure 7A shows the amino acid sequence of interleukin 8 (SEQ ID NO: 3). Figure 7B shows the DNA sequence of interleukin 8 (SEQ ID NO: 4).

Figure 8A shows the amino acid sequence of inhibin A (SEQ ID NO: 5). Figure 8B shows the DNA sequence of inhibin A (SEQ ID NO: 6).

Figure 9A shows the amino acid sequence of VEGF-C (SEQ ID NO: 7). Figure 9B shows the DNA sequence of VEGF-C (SEQ ID NO: 8).

Figure 10A shows the amino acid sequence of angiogenin (SEQ ID NO: 9). Figure 10B shows the DNA sequence of angiogenin (SEQ ID NO: 10).

Figure 11A shows the amino acid sequence of beta fertilin (SEQ ID NO: 11). Figure 11B shows the DNA sequence of beta fertilin (SEQ ID NO: 12).

Figure 12 shows the DNA sequence of hypothetical protein (SEQ ID NO: 13).

Figure 13A shows the amino acid sequence of leukocyte associated Ig-like receptor secreted protein (SEQ ID NO: 14). Figure 13B shows the DNA sequence of leukocyte associated Ig-like receptor secreted protein (SEQ ID NO: 15).

Figure 14A shows the amino acid sequence of erythroid differentiation protein (SEQ ID NO: 16). Figure 14B shows the DNA sequence of erythroid differentiation prtoein (SEQ ID NO: 17).

Figure 15A shows the amino acid sequence of adipogenesis inhibitory factor (SEQ ID NO: 18). Figure 15B shows the DNA sequence of adipogenesis inhibitory factor (SEQ ID NO: 19).

Figure 16A shows the amino acid sequence of corticotropin releasing factor binding protein (SEQ ID NO: 20). Figure 16B shows the DNA sequence of corticotropin releasing factor binding protein (SEQ ID NO: 21).

Figure 17A shows the amino acid sequence of alpha-1 anti-chymotrypsin (SEQ ID NO: 22). Figure 17B shows the DNA sequence of alpha-1 anti-chymotrypsin (SEQ ID NO: 23).

Figure 18A shows the amino acid sequence of insulin-like growth factor binding protein-5 (SEQ ID NO: 24). Figure 18B shows the DNA sequence of insulin-like growth factor binding protein-5 (SEQ ID NO: 25).

Figure 19 shows the amino acid sequence of CD33L (SEQ ID NO: 26).

Figure 20A shows the amino acid sequence of cytokine receptor like factor 1 (SEQ ID NO: 27). Figure 20B shows the DNA sequence of cytokine receptor like factor 1 (SEQ ID NO: 28).

Figure 21 shows the amino acid sequence of platelet derived endothelial growth factor (SEQ ID NO: 29).

Figure 22A shows the amino acid sequence of lysyl hydroxylase isoform 2 (SEQ ID NO: 30). Figure 22B shows the DNA sequence of lysyl hydroxylase isoform 2 (SEQ ID NO: 31).

Figure 23A shows the amino acid sequence of stanniocalcin precursor (SEQ ID NO: 32). Figure 23B shows the DNA sequence of stanniocalcin precursor (SEQ ID NO: 33).

Figure 24A shows the amino acid sequence of secreted frizzled related protein (SEQ ID NO: 34). Figure 24B shows the DNA sequence of secreted frizzled related protein (SEQ ID NO: 35).

Figure 25A shows the amino acid sequence of galectin-3 (SEQ ID NO: 36). Figure 25B shows the DNA sequence of galectin-3 (SEQ ID NO: 37).

Figure 26A shows the amino acid sequence of alpha defensin (SEQ ID NO: 38). Figure 26B shows the DNA sequence of alpha defensin (SEQ ID NO: 39).

Figure 27A shows the amino acid sequence of ADAM-TS3 (SEQ ID NO: 40). Figure 27B shows the DNA sequence of ADAM-TS3 (SEQ ID NO: 41).

Figure 28 shows the DNA sequence of cholecystokinin precursor (SEQ ID NO: 42).

Figure 29A shows the amino acid sequence of interferon stimulated T-cell alpha chemoattractant precursor (SEQ ID NO: 43). Figure 29B shows the DNA sequence of interferon stimulated T-cell alpha chemoattractant precursor (SEQ ID NO: 44).

Figure 30A shows the amino acid sequence of azurocidin (SEQ ID NO: 45). Figure 30B shows the DNA sequence of azurocidin (SEQ ID NO: 46).

Figure 31A shows the amino acid sequence of spermine oxidase (SEQ ID NO: 47). Figure 31B shows the DNA sequence of spermine oxidase (SEQ ID NO: 48).

Figure 32A shows the amino acid sequence of UDP glycosyltransferase 2 family polypeptide B28 (SEQ ID NO: 49). Figure 32B shows the DNA sequence of UDP glycosyltransferase 2 family polypeptide B28 (SEQ ID NO: 50).

Figure 33A shows the amino acid sequence of neurotrophic tyrosine kinase receptor 2 (SEQ ID NO: 51). Figure 33B shows the DNA sequence of neurotrophic tyrosine kinase receptor 2 (SEQ ID NO: 52).

Figure 34A shows the amino acid sequence of neutral endopeptidase (SEQ ID NO: 53). Figure 34B shows the DNA sequence of neutral endopeptidase (SEQ ID NO: 54).

Figure 35A shows the amino acid sequence of CDC28 protein kinase regulatory subunit 2 (SEQ ID NO: 55). Figure 35B shows the DNA sequence of CDC28 protein kinase regulatory subunit 2 (SEQ ID NO: 56).

Figure 36 shows the DNA sequence of beta glucosidase (SEQ ID NO: 57).

Figure 37A shows the amino acid sequence of lanosterol synthase (SEQ ID NO: 58). Figure 37B shows the DNA sequence of lanosterol synthase (SEQ ID NO: 59).

Figure 38 shows the DNA sequence of calcium/calmodulin-dependent serine protein kinase (SEQ ID NO: 60).

Figure 39 shows the DNA sequence of estrogen receptor-alternatively spliced transcript H (SEQ ID NO: 61).

Figure 40A shows the amino acid sequence of chemokine (CX3C motif) receptor 1 (SEQ ID NO: 62). Figure 40B shows the DNA sequence of chemokine (CX3C motif) receptor 1 (SEQ ID NO: 63).

Figure 41A shows the amino acid sequence of tyrosinase-related protein 1 (SEQ ID NO: 64). Figure 41B shows the DNA sequence of tyrosinase-related protein 1 (SEQ ID NO: 65).

Figure 42 shows the DNA sequence of hydroxy-delta-5-steroid dehydrogenase (SEQ ID NO: 66).

Figure 43A shows the amino acid sequence of dihydropyramidinase-like-4 (SEQ ID NO: 67). Figure 43B shows the DNA sequence of dihydropyramidinase-like-4 (SEQ ID NO: 68).

Figure 44 shows the amino acid sequence of cytochrome P450 family 11 (SEQ ID NO: 69).

Detailed Description

In order to identify secreted factors involved in the pathogenesis of pregnancy related hypertensive disorders, such as pre-eclampsia, we performed gene expression profiling of placental tissue from 19 women with pre-eclampsia and 15 nomotensive pregnant women using Affymetrix U95A microarray chips. Data were analyzed using the computer program BADGE (Bayesian Analysis of Differential Gene Expression version 1.0) (http://genomethods.org/badge) (see Ramoni and Sebastiani, in Berthold and Hand eds. *Intelligent Data Analysis: An Introduction*, Springer, New York,NY (1999)) and hierarchical clustering analysis (Eisen et al., *Proc. Natl. Acad. Sci.*, 95:14863-8 (1998)) to identify differentially expressed genes across experimental conditions. We discovered that the gene encoding the following secreted polypeptides showed increased expression in blood samples taken from women with pre-eclampsia: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein (#AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein -5, CD33L, cytokine receptor like factor 1, platelet derived

endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, and galectin-3. We also discovered that expression levels of the genes encoding the following secreted polypeptides were decreased in blood samples taken from women with pre-eclampsia: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, and azurocidin. In addition, we also discovered that genes encoding the following intracellular polypeptides or enzymes showed increased expression in placentas from women with pre-eclampsia: sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, and beta glucosidase. Genes encoding the following intracellular gene polypeptides showed decreased expression in placentas from women with pre-eclampsia: lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11.

For the purposes of the descriptions below, all of the polypeptides described above are collectively referred to as "the polypeptides of the invention." While the detailed description presented herein refers specifically to polypeptides associated with specific GenBank accession numbers, it will be clear to one skilled in the art that the detailed description can also apply to family members, isoforms, homologs, fragments, and/or variants or the specified polypeptides.

We have also discovered therapeutic agents that reduce the expression or biological activity of any one or more of the following polypeptides: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein (#AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-

chymotrypsin, insulin-like growth factor binding protein -5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, and galectin -3, or agents that increase the expression levels or biological activity of any one or more of the following polypeptides: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, or azurocidin, can be used to treat or prevent pregnancy related hypertensive disorders, such as pre-eclampsia or eclampsia in a subject. Such agents include, but are not limited to, antibodies, nucleobase oligomers for antisense or RNAi, purified natural or synthetic compounds, chemical compounds, and small molecules.

The invention also features methods for measuring levels of any one or more of the polypeptides of the invention or a nucleic acid encoding a polypeptide of the invention as a detection tool for early diagnosis and management of pregnancy related hypertensive disorders, such as pre-eclampsia or eclampsia.

Diagnostics

The present invention features assays based on the detection of at least one of the polypeptides of the invention to diagnose pregnancy related hypertensive disorders, such as pre-eclampsia, eclampsia, or the propensity to develop such conditions. The present invention also features diagnostic assays based on the detection of at least two, at least three, at least four, or at least five or more polypeptides of the invention to diagnose pregnancy related hypertensive disorders, such as pre-eclampsia, eclampsia, or a predisposition to such conditions. Levels of any one or more of the polypeptides of the invention (either free, bound, or total levels) are measured in a subject sample and used as an indicator of a pregnancy related hypertensive disorder, such as pre-eclampsia, eclampsia, or a predisposition to such conditions. The diagnostic methods can also be combined with methods to detect levels of any

additional markers of pregnancy related hypertensive disorders, such as pre-eclampsia or eclampsia, such as soluble endoglin, sFlt-1, VEGF, or PlGF. In one embodiment, a metric incorporating the levels of any one or more of the polypeptides of the invention, soluble endoglin, sFlt-1, VEGF, or PlGF, or any combination thereof, is used to determine whether a relationship between levels of at least two of the polypeptides is indicative of pre-eclampsia or eclampsia.

Standard methods may be used to measure levels of any one or more of the polypeptides of the invention in any bodily fluid, including, but not limited to, urine, blood, serum, plasma, saliva, amniotic fluid, or cerebrospinal fluid. Such methods include immunoassay, ELISA, western blotting using antibodies directed to the polypeptide of the invention and quantitative enzyme immunoassay techniques such as those described in Ong et al. (*Obstet. Gynecol.* 98:608-611, 2001) and Su et al. (*Obstet. Gynecol.*, 97:898-904, 2001). ELISA assays are the preferred method for measuring levels of a polypeptide of the invention. In preferred embodiments, the level of follistatin related protein, inhibin-A, beta fertilin, or insulin-like growth factor binding protein –5 is measured. In additional preferred embodiments, the body mass index (BMI) and gestational age of the fetus is also measured and included the diagnostic metric. For example, if the level of any of the following polypeptides: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein (#AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, and galectin-3 is increased (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more), relative to a reference sample, this is considered a positive indicator of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. In another example, if the levels of any one of the

following proteins: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, and azurocidin is decreased (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more), relative to a reference sample, this is considered a positive indicator of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.

Metrics measuing the levels of sFlt-1, VEGF, PlGF, and/or soluble endoglin can also be used in combination with any of the diagnostic methods of the invention. For example, the PAAI (sFlt-1/ VEGF + PlGF) is used, in combination with measurement of any one or more polypeptides of the invention, as an anti-angiogenic index that is diagnostic of pregnancy related hypertensive disorders, such as pre-eclampsia, eclampsia, or the propensity to develop such conditions. The PAAI (sFlt-1/ VEGF + PlGF) ratio is merely one example of a useful metric that may be used as a diagnostic indicator. It is not intended to limit the invention. Another example is the following soluble endoglin anti-angiogenic index: (sFlt-1 + 0.25(soluble endoglin polypeptide))/PlGF. Virtually any metric that detects an alteration in the levels of any polypeptide of the invention, soluble endoglin, sFlt-1, PlGF, or VEGF, or any combination thereof, in a subject relative to a reference sample may be used as a diagnostic indicator. One example of a metric that can be used in the diagnostic methods of the invention is (sFlt1+soluble endoglin+follistatin related protein)/PlGF.

Expression levels of particular nucleic acids or polypeptides may be correlated with a particular disease state (e.g., pregnancy related hypertensive disorders, such as pre-eclampsia or eclampsia), and thus are useful in diagnosis. Oligonucleotides or longer fragments derived from a nucleic acid sequence encoding a polypeptide of the invention may be used as a probe not only to monitor expression, but also to identify subjects having a genetic variation, mutation, or polymorphism in a nucleic acid molecule, encoding a polypeptide of the invention, that is indicative of a predisposition to develop the conditions.

These polymorphisms may affect nucleic acid or polypeptide expression levels or biological activity. Detection of genetic variation, mutation, or polymorphism relative to a normal, reference sample can be used as a diagnostic indicator of a pregnancy related hypertensive disorder, such as pre-eclampsia, eclampsia, or a predisposition to develop such disorders.

Such genetic alterations may be present in the promoter sequence, an open reading frame, intronic sequence, or untranslated 3' region of a gene. Information related to genetic alterations can be used to diagnose a subject as having a pregnancy related hypertensive disorder, such as pre-eclampsia, eclampsia, or a predisposition to develop such conditions. As noted throughout, specific alterations in the levels of biological activity of any polypeptide of the invention or any combination thereof, can be correlated with the likelihood of developing a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or the predisposition to the same. As a result, one skilled in the art, having detected a given mutation, can then assay one or more of the biological activities of the polypeptide to determine if the mutation causes or increases the likelihood of pre-eclampsia or eclampsia.

In one embodiment, a subject having pre-eclampsia, eclampsia, or a propensity to develop such conditions will show an alteration in the expression of a nucleic acid encoding a polypeptide of the invention. Methods for detecting such alterations in nucleic acids are standard in the art and are described in Ausubel et al., *supra*. In one example northern blotting or real-time PCR is used to detect mRNA levels for a nucleic acid encoding any polypeptide of the invention.

In another embodiment, hybridization with PCR probes that are capable of detecting a nucleic acid molecule encoding a polypeptide of the invention, including genomic sequences, or closely related molecules, may be used to hybridize to a nucleic acid sequence derived from a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or at risk of developing such conditions. The specificity of the probe, whether it is made

from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low), determine whether the probe hybridizes to a naturally occurring sequence, allelic variants, or other related sequences. Hybridization techniques may be used to identify mutations indicative of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or may be used to monitor expression levels of a gene encoding a polypeptide of the invention (for example, by Northern analysis, Ausubel et al., *supra*).

A subject having a pregnancy related hypertensive disorder, such as pre-eclampsia, eclampsia, or a propensity to develop such conditions will show an increase relative to a reference sample or level (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more) in the expression of a secreted or intracellular polypeptide or a nucleic acid encoding a secreted or intracellular polypeptide selected from the group consisting of: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein (#AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, and beta glucosidase, relative to a reference sample. In another example, a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia, eclampsia, or a propensity to develop such conditions will show a decrease (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more) relative to a reference sample or level in the expression of

a secreted or intracellular polypeptide or a nucleic acid encoding a secreted or intracellular polypeptide selected from the group consisting of: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11, relative to a reference sample.

A variety of protocols for measuring an alteration in the expression of such polypeptides are known, including immunological methods (such as ELISAs and RIAs), and provide a basis for diagnosing a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or a risk of developing such conditions.

In one embodiment, the level of at least one polypeptide or nucleic acid encoding a polypeptide of the invention is measured in combination with the level of soluble endoglin, sFlt-1, VEGF, or PlGF polypeptide or nucleic acid, or any combination thereof. Methods for the measurement of sFlt-1, VEGF, PlGF, and soluble endoglin are described in U.S. Patent Application Publication Numbers U.S. Patent Application Publication Numbers 20040126828, 20050025762, and 20050170444; PCT Publication Numbers WO 2004/008946 and WO 2005/077007; and U.S Patent Application Serial Number 11/235,577, each of which is hereby incorporated by reference in its entirety.

In one example, the measurement of any of the nucleic acids or polypeptides described herein preferably occurs on at least two different occasions and an alteration in the levels over time is used as an indicator of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or the propensity to develop such conditions. In another example, the measurement of any of the nucleic acids or polypeptides described herein is compared to a reference sample and an alteration as compared to normal

reference levels is used as an indicator of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or the propensity to develop such conditions.

The level of any polypeptide of the invention in the bodily fluids of a subject having pre-eclampsia, eclampsia, or the propensity to develop such conditions may be altered by as little as 10%, 20%, 30%, or 40%, or by as much as 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more relative to the level of the same polypeptide in a reference sample. The level of any polypeptide of the invention in the bodily fluids of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or the propensity to develop such conditions may be altered by as little as 10%, 20%, 30%, or 40%, or by as much as 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more over time from one measurement to the next.

In one embodiment, a subject sample of a bodily fluid (e.g., urine, plasma, serum, amniotic fluid, or cerebrospinal fluid) is collected early in pregnancy prior to the onset of symptoms of the pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. In another example, the sample can be a tissue or cell collected early in pregnancy prior to the onset of symptoms of the pregnancy related hypertensive disorder. Non-limiting examples include placental tissue, placental cells, endothelial cells, and leukocytes such as monocytes. In humans, for example, maternal blood serum samples are collected from the antecubital vein of pregnant women during the first, second, or third trimesters of the pregnancy. Preferably, the assay is carried out during the first trimester, for example, at 4, 6, 8, 10, or 12 weeks, or during the second trimester, for example at 14, 16, 18, 20, 22, or 24 weeks. Such assays may also be conducted at the end of the second trimester or the third trimester, for example at 26, 28, 30, 32, 34, 36, 38, or 40 weeks. It is preferable that levels of one or more polypeptides of the invention be measured twice during this period of time. For the diagnosis of post-partum pre-eclampsia or eclampsia, the assay is carried out postpartum. For the diagnosis

of a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, the assay may be carried out prior to the onset of pregnancy. In one example, for the monitoring and management of therapy, the assay is carried out after the diagnosis of pre-eclampsia but during the pregnancy.

In one particular example, a sample of bodily fluid (e.g., (blood, serum, plasma, urine, amniotic fluid, and cerebrospinal fluid) is collected during pregnancy and the levels of at least one polypeptide of the invention determined by ELISA. In another example, a sample is collected during the second trimester and early in the third trimester and in increase or decrease in the level of a polypeptide of the invention from the first sampling to the next is indicative of pre-eclampsia or eclampsia, or the propensity to develop either. In another particular example, serial blood samples can be collected during pregnancy and the levels of any one or more of the polypeptides of the invention determined by ELISA. In another example, a sample is collected during the second trimester and early in the third trimester and an alteration in the levels of any one or more of the polypeptides of the invention from the first sampling to the next is indicative of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or a predisposition thereto.

In veterinary practice, assays may be carried out at any time during the pregnancy but are preferably carried out early in pregnancy, prior to the onset of symptoms of the pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. Given that the term of pregnancies varies widely between species, the timing of the assay will be determined by a veterinarian, but will generally correspond to the timing of assays during a human pregnancy.

The diagnostic methods described herein can be used individually or in combination with any other diagnostic method described herein for a more accurate diagnosis of the presence of, severity of, or estimated time of onset of the pregnancy related hypertensive disorder, such as pre-eclampsia or

eclampsia. For example, the diagnostic methods using the nucleic acids that encode the polypeptides of the invention can be used initially and then increased expression of the polypeptide can be confirmed using standard immunological methods (e.g., western blooting or ELISA). In addition, the diagnostic methods described herein can be used in combination with any other diagnostic methods determined to be useful for the accurate diagnosis of the presence of, severity of, or estimated time of onset of the pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The diagnostic methods described herein can also be used to monitor and manage pregnancy related hypertensive disorders, such as pre-eclampsia or eclampsia in a subject.

Expression level of each polypeptide or nucleic acids encoding polypeptides of the invention may be considered individually, although it is within the scope of the invention to provide combinations of two or more polypeptides of the invention or nucleic acids encoding polypeptides of the invention for use in the methods and compositions of the invention to increase the confidence of the analysis. A panel comprises two or more polypeptides of the invention, or fragments thereof, two or more, 2-5, 5-10, 10-15, 15-20, 20-25 or more than 25 nucleic acid molecules, or fragments thereof or complementary nucleic acid molecules, or two or more binding molecules, such as antibodies, that recognize a polypeptide of the invention. In one embodiment, these panels of polypeptides of the invention are selected such that the polypeptides of the invention within any one panel share certain features, such as polypeptides that are shown herein to be increased in samples from pre-eclamptic women. Similarly, different panels of polypeptides of the invention may be composed of polypeptides of the invention representing different stages of a pregnancy related hypertensive disorder, for example separate panels for mild-pre-eclampsia, to severe pre-eclampsia, to eclampsia.

Panels of the polypeptides of the invention can also include binding molecules (e.g., antibodies) that specifically bind sFlt-1, VEGF, PlGF, and soluble endoglin, and may further be provided on biochips, as discussed below.

Diagnostic Kits

The invention also provides for a diagnostic test kit. The diagnostic test kit includes the components or reagents required to carry out any of the diagnostic assays described above and instructions for the use of the components or reagents to diagnose a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or a predisposition to a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. For example, a diagnostic test kit can include antibodies to any polypeptide of the invention and components required to detect, and more preferably to evaluate, binding between the antibodies and the polypeptide of the invention. Non-lmiting examples of antibodies useful in the diagnostic methods and kits of the invention include human FLRG antibody, catalog number AF1288, R&D systems, Minneapolis, MN and human secreted frizzled related protein antibody, catalog number AF1384, R&D systems, Minneapolis, MN. For detection, either the antibody or the polypeptide of the invention is labeled, and either the antibody or the polypeptide of the invention is substrate-bound, such that polypeptide of the invention-antibody interaction can be established by determining the amount of label attached to the substrate following binding between the antibody and the polypeptide of the invention. A conventional ELISA is a common, art-known method for detecting antibody-substrate interaction and can be provided with the kit of the invention. Polypeptides of the invention can be detected in virtually any bodily fluid including, but not limited to urine, serum, plasma, saliva, amniotic fluid, or cerebrospinal fluid. The invention also provides for a diagnostic test kit that includes a nucleic acid encoding a polypeptide of the invention that can be used to detect and determine levels of nucleic acids encoding a polypeptide of the invention. A

kit that determines an alteration in the level of a polypeptide of the invention relative to a reference, such as the level present in a normal control, is useful as a diagnostic kit in the methods of the invention.

The diagnostic kits of the invention can also include antibodies or nucleic acids for the detection of soluble endoglin, sFlt-1, VEGF, or PlGF polypeptides or nucleic acids as described in U.S. Patent Application Publication Numbers 20040126828, 20050025762, and 20050170444; PCT Publication Numbers WO 2004/008946 and WO 2005/077007; and U.S. Patent Application Serial Number 11/235,577.

Desirably, the kit includes any of the components needed to perform any of the diagnostic methods described above. In one embodiment of the invention, such a kit includes a solid support (e.g., a membrane or a microtiter plate) coated with a primary agent (e.g., an antibody or protein that recognizes the antigen), standard solutions of purified protein for preparation of a standard curve, a body fluid (e.g. serum or urine) control for quality testing of the analytical run, a secondary agent (e.g., a second antibody reactive with a second epitope in the antigen to be detected or an antibody or protein that recognizes the primary antibody) conjugated to a label or an enzyme such as horse radish peroxidase or otherwise labeled, a substrate solution, a stopping solution, a washing buffer and an instruction manual. The membrane can be supported on a dipstick structure where the sample is deposited on the membrane by placing the dipstick structure into the sample or the membrane can be supported in a lateral flow cassette where the sample is deposited on the membrane through an opening in the cassette. The kit can also be in an array format and can include an array of polypeptides of the invention or binding molecules that specifically bind polypeptides of the invention arranged on a biochip, such as, for example, a GeneChip™.

The diagnostic kits also generally include a label or instructions for the intended use of the kit components and a reference sample or purified proteins to be used to establish a standard curve. In one example, the kit contains

instructions for the use of the kit for the diagnosis of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or the propensity to develop pre-eclampsia or eclampsia. In yet another example, the kit contains instructions for the use of the kit to monitor therapeutic treatment or dosage regimens for the treatment of pregnancy related hypertensive disorders, such as pre-eclampsia or eclampsia. It will be understood that the reference sample values will depend on the intended use of the kit. For example, the sample can be compared to a normal reference value, wherein an alteration in the levels of one or more of the polypeptides of the invention or a metric using levels of one or more of the polypeptides of the invention is indicative of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or a predisposition to pre-eclampsia or eclampsia. In another example, a kit used for therapeutic monitoring can have a reference value that is indicative of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, wherein an alteration in the level of one or more of the polypeptides of the invention or a metric using levels of one or more of the polypeptides of the invention relative to the reference sample can be used to indicate therapeutic efficacy or effective dosages of therapeutic compounds.

Arrays and Biochips

The invention also includes an array comprising a panel of polypeptides of the invention. The array can be used to assay expression of one or more genes or polypeptides in the array.

It will be appreciated by one skilled in the art that the panels of polypeptides of the invention of the invention may be provided on solid supports, as a biochip. For example, polynucleotides may be coupled to an array (e.g., a biochip using GeneChip™ for hybridization analysis), to a resin (e.g., a resin which can be packed into a column for column chromatography), or a matrix (e.g., a nitrocellulose matrix for northern blot analysis). The immobilization of nucleic acid molecules complementary to nucleic acid

molecules encoding any of the polypeptides of the invention, either covalently or noncovalently, permits a discrete analysis of the presence or activity of each of the nucleic acid molecules encoding the polypeptides of the invention in a sample. In an array, for example, polynucleotides complementary to each member of a panel of nucleic acid molecules encoding polypeptides of the invention may individually be attached to different, known locations on the array. The array may be hybridized with, for example, polynucleotides extracted from a bodily fluid, tissue, or cell sample from a subject. The hybridization of polynucleotides from the sample with the array at any location on the array can be detected, and thus the presence or quantity of the nucleic acids or transcripts encoding polypeptides of the invention in the sample can be ascertained. In one embodiment, an array based on a biochip is employed. Similarly, immunological analyses may be performed using protein arrays or antibody arrays that include immobilized antibodies or other binding molecules specific for polypeptides of the invention. Such protein arrays can be hybridized with a bodily fluid, tissue, or cell sample, which contains polypeptides of the invention or antibodies to polypeptides of the invention, from a subject. Additional details on examples of arrays and biochips can be found, for example, in U.S. Patent Application Publication No. 20050266409, herein incorporated by reference.

Exemplary binding molecules and antibodies

Examples of antibodies and binding proteins that can be used in the diagnostic methods and kits of the invention are described below. The antibodies described below can also be used in the therapeutic methods of the invention and can be modified to increase potency or stability or to reduce reactivity to the antibodies. These examples are intended to illustrate the invention and not to limit the invention in anyway.

Follistatin related protein

Follistatin related protein, also known as FLRG, FSRP, FRP, FLS-1, and FSTL1, is a protein related to follistatin. Follistatin is a secreted glycoprotein that binds activin in vitro and in vivo and inhibits the biological functions of activin. Follistatin related protein also binds to activin with high affinity and is expressed in the basement membrane between the dermis and the epidermis and around blood vessels. The gene encoding follistatin related protein, FLRG, was induced during the wound healing process (Wankell et al., *J. Endocrin.* 171:385-395 (2001) and Tortoriello et al., *Endocrinology* 142:3426-3434 (2001)).

Activin and other TGFβ superfamily members, or fragments thereof, can be used as specific binding molecules to detect follistatin related protein in a biological sample. Exemplary antibodies that specifically bind follistatin related protein that can also be used to detect follistatin related protein in a biological sample include the polyclonal FSRP antibody described in Tortorielle et al., *supra*, and antibodies available from Abnova Corporation (e.g., catalog no. H00010468-A01) and human FLRG antibody, R&D systems (e.g., catalog nos. AF1288 and AF1694).

Inhibin A

Inhibin is a disulfide-linked, dimeric glycoprotein composed of an α-subunit and one of two β-subunits. Inhibin is a member of the TGFβ superfamily and is expressed in the adrenal cortex. One hypothesis regarding inhibin action is that inhibin binds the membrane bound serine-threonine kinase ActRII subunit, and blocks the signal generating subunit (ActRI) phosphorylation, thereby antagonizing activin activation. One example of a protein that specifically binds to inhibin A is betaglycan (Vale et al., *Ann. N. Y. Acad. Sci.* 1038:142-147 (2004). Betaglycan, or fragments thereof, can be used as specific binding molecules to detect follistatin related protein in a biological sample. Examples of antibodies, or antigen binding fragments thereof, that

specifically bind inhibin A that can also be used to detect inhibin A in a biological sample include antibodies available from Abnova Corp. (e.g., catalog no. H00003624-A01), Abcam (e.g., catalog no. Ab10599, Ab724), and Genetex (e.g., catalog no. GTX10599 and GTX20724), and the antibody described in Rishi et al., *Am. J. Surg. Pathol.* 21:583-589 (1997).

Beta fertilin

Beta fertilin, also known as fertilin beta, is a sperm protein that is a candidate molecule fro mediating the binding and fusion of the sperm and egg plasma membranes. Fertilin is a heterodimer with a beta subunit that has a region of homology to the disintegrin family of integrin ligands and an alpha subunit that has a region of homology to viral fusion peptides. Fertilin alpha and beta have also been shown to interact with the heat shock protein calmegin. (Ikawa et al., *Dev. Biol.* 240:254-261 (2001) and Evans et al., *Dev. Biol.* 187:94-106 (1997)).

Calmegin, or fragments thereof, can be used as specific binding molecules to detect beta fertilin in a biological sample. Examples of antibodies, or antigen binding fragments thereof, that specifically bind beta fertilin that can also be used to detect beta fertilin in a biological sample include the antibodies described in Ikawa et al., supra, and antibodies commercially available from Chemicon (e.g., catalog nos. MAB 19292 and 19030) and United States Biological (e.g., catalog no. A0858-070).

Insulin like growth factor binding protein-5

Insulin like growth factor binding protein-5, also known as IGFBP-5 or ILGFBP-5, is a member of the superfamily of insulin-like growth factor binding proteins, which are cysteine-rich proteins with conserved cysteine residues clustered in the amino-terminal and the carboxy-terminal regions of the molecule. IGFBP-5 interacts with IGF-I and functions to inhibit the survival effect of IGF-I (Tonner et al., *Development* 129:4547-4557 (2002))

and modulate IGF-I ligand-receptor interactions (Tonner et al., *Adv. Exp. Med. Biol.* 480:45-53 (2000)). Additional IGFBP-5 binding proteins include plasminogen activator inhibitor-1 (Tonner et al., *J. Endocrinol.* 167:265-73 (2000)) and alphas2-casein (Tonner et al., *Adv. Exp. Med. Biol.* 480:45-53 (2000)).

IGF, plasminogen activator inhibitor-1, alpha s2-casein, or any fragments thereof, can be used as specific binding molecules to detect IGFBP-5 in a biological sample. Examples of antibodies, or antigen binding fragments thereof, that specifically bind IGFBP-5 that can also be used to detect IGFBP-5 in a biological sample include the antibodies from Diagnostic Systems Laboratories Inc. (e.g., catalog no. R00737), Alpha Diagnostic International (e.g., catalog no. IGFBP5-1s) and Abcam (e.g., catalog no. Ab4257).

Secreted frizzled related protein

The secreted frizzled related proteins are a family of secreted proteins that contain an N-terminal signal peptide, a frizzled-related CRD, and a C-terminal hydrophilic region with some homology to the netrins, but lack evidence of any transmembrane domains.

The secreted frizzled related proteins appear to act as soluble modulators of Wnt signaling, presumably by competing with membrane frizzled receptors for the binding of secreted Wnt ligands.

Any Wnt family member protein, or any fragments thereof, can be used as specific binding molecules to detect secreted frizzled related protein in a biological sample. One example of an antibody that specifically binds secreted frizzled related protein and can be used to detect secreted frizzled related protein in a biological sample is the human secreted frizzled related protein antibody, (catalog no. AF1384) from R&D systems.

Screening Assays

As discussed above, the expression level of one ore more polypeptides of the invention or nucleic acids encoding a polypeptide of the invention is altered in a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or a propensity to develop such conditions. Based on these discoveries, polypeptides of the invention (both intracellular and secreted) are useful for the high-throughput low-cost screening of candidate compounds to identify those that modulate the expression of a polypeptide of the invention or nucleic acid molecule encoding a polypeptide of the invention whose expression is altered in a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.

Any number of methods are available for carrying out screening assays to identify new candidate compounds that alter the expression of a nucleic acid molecule encoding a polypeptide of the invention. In one working example, candidate compounds are added at varying concentrations to the culture medium of cultured cells expressing a nucleic acid sequence encoding a polypeptide of the invention. Exemplary cell cultures include any mammalian, yeast, insect, or bacterial cell cultures. Preferred cell cultures include mammalian cell cultures such as trophoblasts (e.g., BEWO, JAR, and JEG cells) and HUVECs. These cells can then be used to screen for new candidate compounds. Gene expression is then measured, for example, by microarray analysis, Northern blot analysis (Ausubel et al., *supra*), or RT-PCR, using any appropriate fragment prepared from the nucleic acid molecule as a hybridization probe. The level of gene expression in the presence of the candidate compound is compared to the level measured in a control culture medium lacking the candidate compound. A compound considered to be useful in the invention is one that promotes a decrease in the expression of a polypeptide, or fragment thereof, or a nucleic acid molecule encoding the polypeptide, or fragment thereof, selected from the following group of polypeptides: follistatin related protein, interleukin 8, inhibin A, VEGF-C,

angiogenin, beta fertilin, hypothetical protein (#AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein -5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, and galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, and beta-glucosidase. Additional useful compounds are compounds that promote an increase in the expression of a polypeptide, or fragment thereof, or a nucleic acid molecule encoding the polypeptide, or fragment thereof, selected from the following group of polypeptides: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, and azurocidin, or the level of any one of the following intracellular polypeptides, or fragments thereof, in a sample from the subject: lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11. Such compounds may be used, for example, as a therapeutic to treat pregnancy related hypertensive disorders, such as pre-eclampsia or eclampsia, in a subject.

In another working example, the effect of candidate compounds may be measured at the level of polypeptide production using the same general approach and standard immunological techniques, such as Western blotting or immunoprecipitation with an antibody specific for a polypeptide of the invention. For example, immunoassays may be used to detect or monitor the expression of at least one of the polypeptides of the invention in an organism. Polyclonal or monoclonal antibodies (produced as described above) that are capable of binding to such a polypeptide may be used in any standard

immunoassay format (e.g., ELISA, western blot, or RIA assay) to measure the level of the polypeptide. In some embodiments, a compound that promotes a decrease in the expression or biological activity of a polypeptide of the invention is considered particularly useful. Again, such a molecule may be used, for example, as a therapeutic to delay, ameliorate, or treat the pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or the symptoms of the pregnancy related hypertensive disorder in a subject.

In yet another working example, candidate compounds may be screened to identify those that specifically bind to a polypeptide of the invention. The efficacy of such a candidate compound is dependent upon its ability to interact with such a polypeptide or a functional equivalent thereof. Such an interaction can be readily assayed using any number of standard binding techniques and functional assays (e.g., those described in Ausubel et al., *supra*). In one embodiment, a candidate compound may be tested *in vitro* for its ability to specifically bind a polypeptide of the invention.

In another working example, a nucleic acid encoding a polypeptide of the invention is expressed as a transcriptional or translational fusion protein with a detectable reporter, and expressed in an isolated cell (e.g., mammalian or insect cell) under the control of a heterologous promoter, such as an inducible promoter. The cell expressing the fusion protein is then contacted with a candidate compound, and the expression of the detectable reporter in that cell is compared to the expression of the detectable reporter in an untreated control cell. A candidate compound that alters (e.g., increases or decreases) the expression of a polypeptide of the invention fused to a detectable reporter is a compound that is useful for the treatment of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.

In one particular working example, a candidate compound that binds to a polypeptide of the invention may be identified using a chromatography-based technique. For example, a recombinant polypeptide of the invention may be purified by standard techniques from cells engineered to express the

polypeptide (e.g., those described above) and may be immobilized on a column. A solution of candidate compounds is then passed through the column, and a compound specific for the immobilized polypeptide of the invention is identified on the basis of its ability to bind to the polypeptide and be immobilized on the column. To isolate the compound, the column is washed to remove non-specifically bound molecules, and the compound of interest is then released from the column and collected. Similar methods may be used to isolate a compound bound to a polypeptide microarray. Compounds isolated by this method (or any other appropriate method) may, if desired, be further purified (e.g., by high performance liquid chromatography). In addition, these candidate compounds may be tested for their ability to alter (e.g., increase or decrease) the activity of a polypeptide of the invention. Compounds isolated by this approach may also be used, for example, as therapeutics to treat a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, in a human subject. Compounds that are identified as binding to a polypeptide of the invention with an affinity constant less than or equal to 10 mM are considered particularly useful in the invention. Alternatively, any *in vivo* protein interaction detection system, for example, any two-hybrid assay may be utilized to identify compounds or proteins that bind to a polypeptide of the invention.

Potential antagonists include organic molecules, peptides, peptide mimetics, polypeptides, nucleic acids, and antibodies that bind to a polypeptide of the invention or a nucleic acid sequence encoding a polypeptide of the invention.

DNA sequences encoding a polypeptide of the invention may also be used in the discovery and development of a therapeutic compound for the treatment of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The encoded polypeptide, upon expression, can be used as a target for the screening of drugs. Additionally, the DNA sequences encoding

the amino terminal regions of the encoded polypeptide or Shine-Delgarno or other translation facilitating sequences may be isolated by standard techniques (Ausubel et al., *supra*).

Optionally, compounds identified in any of the above-described assays may be confirmed as useful in an assay for compounds that alter (e.g., increase or decrease) the biological activity of a polypeptide of the invention using standard assays such as those described herein.

Small molecules of the invention preferably have a molecular weight below 2,000 daltons, more preferably between 300 and 1,000 daltons, and most preferably between 400 and 700 daltons. It is preferred that these small molecules are organic molecules.

Test compounds and extracts

In general, compounds capable of altering (e.g., increasing or decreasing) the activity of a polypeptide of the invention are identified from large libraries of both natural product or synthetic (or semi-synthetic) extracts or chemical libraries or from polypeptide or nucleic acid libraries, according to methods known in the art. Those skilled in the field of drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the screening procedure(s) of the invention. Compounds used in screens may include known compounds (for example, known therapeutics used for other diseases or disorders). Alternatively, virtually any number of unknown chemical extracts or compounds can be screened using the methods described herein. Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds. Numerous methods are also available for generating random or directed synthesis (e.g., semi-synthesis or total synthesis) of any number of chemical compounds, including, but not limited to, saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic compound libraries are commercially available from Brandon Associates

(Merrimack, NH) and Aldrich Chemical (Milwaukee, WI). Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceangraphics Institute (Ft. Pierce, FL), and PharmaMar, U.S.A. (Cambridge, MA). In addition, natural and synthetically produced libraries are produced, if desired, according to methods known in the art, e.g., by standard extraction and fractionation methods. Furthermore, if desired, any library or compound is readily modified using standard chemical, physical, or biochemical methods.

In addition, those skilled in the art of drug discovery and development readily understand that methods for dereplication (e.g., taxonomic dereplication, biological dereplication, and chemical dereplication, or any combination thereof) or the elimination of replicates or repeats of materials already known for their molt-disrupting activity should be employed whenever possible.

When a crude extract is found to alter (e.g., increase or decrease) the activity of a polypeptide of the invention by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more, or to bind to a polypeptide of the invention, further fractionation of the positive lead extract is necessary to isolate chemical constituents responsible for the observed effect. Thus, the goal of the extraction, fractionation, and purification process is the careful characterization and identification of a chemical entity within the crude extract that alters (e.g., increases or decreases) the activity of a polypeptide of the invention. Methods of fractionation and purification of such heterogeneous extracts are known in the art. If desired, compounds shown to be useful as therapeutics for the treatment of a pregnancy related hypertensive disorder in a human are chemically modified according to methods known in the art.

Therapeutics

The present invention features methods and compositions for treating or preventing pregnancy related hypertensive disorders, such as pre-eclampsia or eclampsia, in a subject. We have discovered that levels of follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein (#AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, and galectin-3 are increased in subjects having pregnancy related hypertensive disorders, such as pre-eclampsia or eclampsia, or predisposition thereto. Therefore, the invention includes methods and agents that decrease the expression levels or biological activity of any one or more of these polypeptides or nucleic acid molecules. Such agents include compounds that downregulate or inhibit the biological activity of any one or more of the above polypeptides; a purified antibody or antigen-binding fragment that specifically binds any one of the above polypeptides; antisense nucleobase oligomers; and dsRNAs targeting any of the above polypeptides. These methods are described in detail below.

We have also discovered that the levels of alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, and azurocidin are decreased in subjects having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or a predisposition to develop such conditions. Therefore, the invention also includes any methods and agents that increase the expression levels or biological activity of any one or more of these polypeptides or nucleic acid molecules. Such agents include

compounds that upregulate or increase the biological activity of any one or more of the above polypeptides or purified forms of the polypeptides themselves.

These methods and agents can be combined with any additional therapies for pregnancy related hypertensive disorders such as therapeutics aimed at decreasing sFlt-1 or soluble endoglin levels or increasing VEGF or PlGF levels as described in U.S. Patent Application Publication Numbers 20040126828, 20050025762, and 20050170444; PCT Publication Numbers WO 2004/008946 and WO 2005/077007; and U.S Patent Application Serial Number 11/235,577.

In addition to the use of compounds that can increase the levels of any of the above polypeptides in a subject sample, the invention provides for the use of any chronic hypertension medications used in combination with any of the therapeutic methods described herein. Medications used for the treatment of hypertension during pregnancy include methyldopa, hydralazine hydrochloride, or labetalol. For each of these medications, modes of administration and dosages are determined by the physician and by the manufacturer's instructions.

Purified proteins

In a preferred embodiment of the present invention, purified forms of any one or more of the following polypeptides: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, and azurocidin are administered to the subject in order to treat or prevent pregnancy related hypertensive disorders, such as pre-eclampsia or eclampsia.

Purified alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, and azurocidin polypeptides include any polypeptide with an amino acid sequence that is homologous, more desirably, substantially identical to the amino acid sequence

of alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, and azurocidin, that can induce angiogenesis or that is capable of promoting selective growth of vascular endothelial cells or umbilical vein endothelial cells.

Therapeutic nucleic acids

Recent work has shown that the delivery of nucleic acid molecules (e.g., DNA or RNA) capable of expressing an endothelial cell mitogen such as VEGF to the site of a blood vessel injury will induce proliferation and reendothelialization of the injured vessel. While the present invention does not relate to blood vessel injury, these general techniques for the delivery of nucleic acid to endothelial cells can be used in the present invention for the delivery of nucleic acids encoding alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, or azurocidin. These general techniques are described in U.S. Patent Nos. 5,830,879 and 6,258,787 and are incorporated herein by reference.

In the present invention, the nucleic acid molecule may be any nucleic acid (e.g., DNA or RNA) including genomic DNA, cDNA, and mRNA, encoding any of the following: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, or azurocidin. The nucleic acids encoding the desired protein may be obtained using routine procedures in the art, e.g. recombinant DNA, PCR amplification.

Modes for delivering nucleic acids

For any of the nucleic acid applications described herein, standard methods for administering nucleic acids can be used. For example, to simplify the manipulation and handling of the nucleic acid encoding any of the following polypeptides: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, or azurocidin; the nucleic acid is preferably inserted into a cassette where it is

operably linked to a promoter. The promoter must be capable of driving expression of the polypeptide in the desired target host cell. The selection of appropriate promoters can readily be accomplished. Preferably, one would use a high expression promoter. An example of a suitable promoter is the 763-base-pair cytomegalovirus (CMV) promoter. The Rous sarcoma virus (RSV) (Davis, et al., *Hum. Gene Ther.* 4:151-159, 1993) and mouse mammary tumor virus (MMTV) promoters may also be used. Certain proteins can be expressed using their native promoter. Other elements that can enhance expression can also be included (e.g., enhancers or a system that results in high levels of expression such as a tat gene and tar element). The recombinant vector can be a plasmid vector such as pUC118, pBR322, or other known plasmid vectors, that includes, for example, an *E. coli* origin of replication (see, Sambrook, et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory press, 1989). The plasmid vector may also include a selectable marker such as the β lactamase gene for ampicillin resistance, provided that the marker polypeptide does not adversely affect the metabolism of the organism being treated. The cassette can also be bound to a nucleic acid binding moiety in a synthetic delivery system, such as the system disclosed in PCT Publication No. WO95/22618.

The nucleic acid can be introduced into the cells by any means appropriate for the vector employed. Many such methods are well known in the art (Sambrook et al., *supra*, and Watson et al., "Recombinant DNA", Chapter 12, 2d edition, Scientific American Books, 1992). Recombinant vectors can be transferred by methods such as calcium phosphate precipitation, electroporation, liposome-mediated transfection, gene gun, microinjection, viral capsid-mediated transfer, polybrene-mediated transfer, or protoplast fusion. For a review of the procedures for liposome preparation, targeting and delivery of contents, see Mannino and Gould-Fogerite, (*Bio Techniques*, 6:682-690, 1988), Felgner and Holm, (*Bethesda Res. Lab. Focus*, 11:21, 1989) and Maurer (*Bethesda Res. Lab. Focus,* 11:25, 1989).

Transfer of the recombinant vector (either plasmid vector or viral vectors) can be accomplished through direct injection into the amniotic fluid or intravenous delivery.

Gene delivery using adenoviral vectors or adeno-associated vectors (AAV) can also be used. Adenoviruses are present in a large number of animal species, are not very pathogenic, and can replicate equally well in dividing and quiescent cells. As a general rule, adenoviruses used for gene delivery are lacking one or more genes required for viral replication. Replication-defective recombinant adenoviral vectors used for the delivery of a nucleic acid encoding a desired protein, can be produced in accordance with art-known techniques (see Quantin et al., *Proc. Natl. Acad. Sci. USA*, 89:2581-2584, 1992; Stratford-Perricadet et al., *J. Clin. Invest.*, 90:626-630, 1992; and Rosenfeld et al., *Cell*, 68:143-155, 1992). For an example of the use of gene therapy *in utero* see U.S. Patent No. 6,399,585.

Once transferred, the nucleic acid is expressed by the cells at the site of injury for a period of time sufficient to increase blood serum levels of the desired protein. Because the vectors containing the nucleic acid are not normally incorporated into the genome of the cells, expression of the protein of interest takes place for only a limited time. Typically, the protein is expressed at therapeutic levels for about two days to several weeks, preferably for about one to two weeks. Re-application of the DNA can be utilized to provide additional periods of expression of the therapeutic protein.

Therapeutic nucleobase oligomers that inhibit protein expression

The present invention also features the use of nucleobase oligomers to downregulate expression of any of the following: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein (#AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth

factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, and galectin-3.

In one example, the nucleobase oligomer is an antisense nucleobase oligomer. By binding to the complementary nucleic acid sequence (the sense or coding strand), antisense nucleobase oligomers are able to inhibit protein expression presumably through the enzymatic cleavage of the RNA strand by RNAse H. Preferably the antisense nucleobase oligomer is capable of reducing expression of one or more of the above polypeptides or nucleic acids encoding one or more of the above polypeptides in a cell that expresses increased levels of that protein. Preferably the decrease in protein expression is at least 10% relative to cells treated with a control nucleobase oligomer, more preferably 25%, and most preferably 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or greater. Methods for selecting and preparing antisense nucleobase oligomers are well known in the art. For an example of the use of antisense nucleobase oligomers to downregulate VEGF expression see U.S. Patent No. 6,410,322. Methods for assaying levels of protein expression are also well known in the art and include western blotting, immunoprecipitation, and ELISA.

The present invention also features the use of RNA interference (RNAi) to inhibit expression of any one or more of the following: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein (#AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, and galectin-3. RNA interference (RNAi) is a mechanism of post-transcriptional gene silencing (PTGS) in which double-stranded RNA (dsRNA)

corresponding to a gene or mRNA of interest is introduced into an organism resulting in the degradation of the corresponding mRNA. In the RNAi reaction, both the sense and anti-sense strands of a dsRNA molecule are processed into small RNA fragments or segments ranging in length from 18 to 25 nucleotides, preferably 21 to 23 nucleotides (nt), and having 2-nucleotide 3' tails. Alternatively, synthetic dsRNAs, which are 21 to 23 nt in length and have 2-nucleotide 3' tails, can be synthesized, purified and used in the reaction. These 21 to 23 nt dsRNAs are known as "guide RNAs" or "short interfering RNAs" (siRNAs). dsRNAs or siRNAs that are useful in the present invention are substantially complementary (e.g., at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) to at least 18, 19, 20, 21, 22, 23, 24, or 25 consecutive nucleotides of a gene encoding any one or more of the following polypeptides: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein (#AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, and galectin-3.

The siRNA duplexes then bind to a nuclease complex composed of proteins that target and destroy endogenous mRNAs having homology to the siRNA within the complex. Although the identity of the proteins within the complex remains unclear, the function of the complex is to target the homologous mRNA molecule through base pairing interactions between one of the siRNA strands and the endogenous mRNA. The mRNA is then cleaved approximately 12 nt from the 3' terminus of the siRNA and degraded. In this manner, specific genes can be targeted and degraded, thereby resulting in a loss

of protein expression from the targeted gene. siRNAs can also be chemically synthesized or obtained from a company that chemically synthesizes siRNAs (e.g., Dharmacon Research Inc., Pharmacia, or ABI).

General descriptions of the specific requirements and modifications of dsRNA are described in PCT Publication No. WO01/75164. While dsRNA molecules can vary in length, it is most preferable to use siRNA molecules which are 21- to 23- nucleotide dsRNAs with characteristic 2- to 3- nucleotide 3' overhanging ends typically either (2'-deoxy) thymidine or uracil. The siRNAs typically comprise a 3' hydroxyl group. Single stranded siRNA as well as blunt ended forms of dsRNA and shRNA can also be used. In order to further enhance the stability of the RNA, the 3' overhangs can be stabilized against degradation. In one such embodiment, the RNA is stabilized by including purine nucleotides, such as adenosine or guanosine. Alternatively, substitution of pyrimidine nucleotides by modified analogs, e.g., substitution of uridine 2-nucleotide overhangs by (2'-deoxy) thymidine is tolerated and does not affect the efficiency of RNAi. The absence of a 2' hydroxyl group significantly enhances the nuclease resistance of the overhang in tissue culture medium.

Alternatively siRNA can be prepared using any of the methods set forth in PCT Publication No. WO01/75164 or using standard procedures for *in vitro* transcription of RNA and dsRNA annealing procedures as described in Elbashir et al. (*Genes & Dev.*, 15:188-200, 2001). siRNAs are also obtained as described in Elbashir et al. by incubation of dsRNA that corresponds to a sequence of the target gene in a cell-free Drosophila lysate from syncytial blastoderm Drosophila embryos under conditions in which the dsRNA is processed to generate siRNAs of about 21 to about 23 nucleotides, which are then isolated using techniques known to those of skill in the art. For example, gel electrophoresis can be used to separate the 21-23 nt RNAs and the RNAs

can then be eluted from the gel slices. In addition, chromatography (e.g., size exclusion chromatography), glycerol gradient centrifugation, and affinity purification with antibody can be used to isolate the 21 to 23 nt RNAs.

A variety of methods are available for transfection, or introduction, of dsRNA or oligonucleotides into mammalian cells. For example, there are several commercially available transfection reagents including but not limited to: TransIT-TKO™ (Mirus, Cat. # MIR 2150), Transmessenger™ (Qiagen, Cat. # 301525), and Oligofectamine™ (Invitrogen, Cat. # MIR 12252-011). Protocols for each transfection reagent are available from the manufacturer.

In the present invention, the dsRNA, or siRNA, is substantially complementary (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) to at least a portion of the mRNA sequence of any one of the following proteins: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein (#AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein -5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, and galectin –3 and can reduce or inhibit the expression of the protein. Preferably, the decrease in protein expression is at least 10% relative to cells treated with a control dsRNA or siRNA, more preferably 25%, and most preferably at least 50%. Methods for assaying levels of protein expression are also well known in the art and include western blotting, immunoprecipitation, and ELISA.

In the present invention, the nucleobase oligomers used include any modification that enhances the stability or function of the nucleic acid in any way. Examples include modifications to the phosphate backbone, the internucleotide linkage, or to the sugar moiety. Examples of modifications that may be used in the nucleobase oligomers of the invention, can be found in U.S.

Patent Application Publication Nos. 20030114412, paragraphs [0030] to [0046] and 20030114407, paragraphs [0036] to [0055], and 20030190659, paragraphs [0083] to [0106].

Assays for gene and protein expression

The following methods can be used to evaluate protein or gene expression and determine efficacy for any of the above-mentioned methods for increasing or decreasing the expression of any one or more polypeptides of the invention.

A sample from the subject (e.g., a bodily fluid such as blood, serum, plasma, urine, amniotic fluid, and cerebrospinal fluid, a cell, or a tissue) is measured for levels of a desired polypeptide, using methods such as ELISA, western blotting, or immunoassays using specific antibodies. Methods used to measure serum levels of polypeptides include ELISA, western blotting, or immunoassays using specific antibodies. A positive result is considered an alteration of at least 20%, preferably 30%, more preferably at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more in the serum levels of a polypeptide of the invention as compared to a reference sample.

In addition, *in vitro* angiogenesis assays can be performed to determine if the subject's blood has converted from an anti-angiogenic state to a pro-angiogenic state. One example of such an *in vitro* assay for angiogenesis is the endothelial tube assay. In this assay, growth factor reduced Matrigel (7 mg/mL, Collaborative Biomedical Products, Bedford, MA) is placed in wells (100 µl/well) of a pre-chilled 48-well cell culture plate and is incubated at 37° C for 25-30 minutes to allow polymerization. Human umbilical vein endothelial cells (30,000 + in 300 µl of endothelial basal medium with no serum, Clonetics, Walkersville, MD) at passages 3-5 are treated with 10% patient serum, plated onto the Matrigel coated wells, and are incubated at 37° C for 12-16 hours. Tube formation is then assessed through an inverted phase contrast microscope at 4X (Nikon Corporation, Tokyo, Japan) and is analyzed

(tube area and total length) using the Simple PCI imaging analysis software. A positive result can be considered conversion from an anti-angiogenic state to a pro-angiogenic state using the *in vitro* angiogenesis assay.

Bodily fluid samples from the subject can also be measured for levels of nucleic acid encoding a polypeptide of the invention. There are several art-known methods to assay for gene expression. Some examples include the preparation of RNA from the blood samples of the subject and the use of the RNA for northern blotting, PCR based amplification, or RNAse protection assays.

Use of antibodies for therapeutic treatment

The use of compounds, such as antibodies, to bind to and neutralize the activity of any one or more of the following polypeptides: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein (#AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein -5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, and galectin –3, can be used to prevent or treat pre-eclampsia or eclampsia.

The present invention provides antibodies that bind specifically to the any of the above proteins. The antibodies are used to neutralize the activity of any one or more of the above proteins. Methods for the preparation and use of antibodies for therapeutic purposes are described in several patents including U.S. Patent Numbers 6,054,297; 5,821,337; 6,365,157; and 6,165,464 and are incorporated herein by reference. Antibodies can be polyclonal or monoclonal;

monoclonal antibodies are preferred. Some examples of antibodies to some of the polypeptides of the invention are described above under "Exemplary binding molecules and antibodies."

Monoclonal antibodies, particularly those derived from rodents including mice, have been used for the treatment of various diseases; however, there are limitations to their use including the induction of a human anti-mouse immunoglobulin response that causes rapid clearance and a reduction in the efficacy of the treatment. For example, a major limitation in the clinical use of rodent monoclonal antibodies is an anti-globulin response during therapy (Miller et al., *Blood*, 62:988-995 1983; Schroff et al., *Cancer Res.*, 45:879-885, 1985).

The art has attempted to overcome this problem by constructing "chimeric" antibodies in which an animal antigen-binding variable domain is coupled to a human constant domain (U.S. Pat. No. 4,816,567; Morrison et al., *Proc. Natl. Acad. Sci. USA,* 81:6851-6855, 1984; Boulianne et al., *Nature,* 312:643-646, 1984; Neuberger et al., *Nature,* 314:268-270, 1985). The production and use of such chimeric antibodies are described below.

A cocktail of the monoclonal antibodies of the present invention can be used as an effective treatment for pregnancy related hypertensive disorders, such as pre-eclampsia or eclampsia. The cocktail may include as few as two, three, or four different antibodies or as many as six, eight, or ten different antibodies. In addition, the antibodies of the present invention can be combined with an anti-hypertensive drug (e.g., methyldopa, hydralazine hydrochloride, or labetalol) or any other medication used to treat pregnancy related hypertensive disorders, such as pre-eclampsia or eclampsia, or the symptoms associated with pregnancy related hypertensive disorders.

Non-limiting examples of antibodies that are useful in the methods of the invention are as follows: anti-interleukin 8 (see Leong et al. *Cytokine* 16:106-119, 2001 and Mian et al., *Clin. Cancer Res.* 9:3167-3175, 2003); anti-

inhibin A (Verotec Catalog No. MCA951S, see Rishi et al. *Am. J. Surg. Pathol.* 21:582-589, 1997); and anti-VEFG-C (e.g., Alitalo et al., U.S. Patent No. 6,361,946).

Preparation of Antibodies

Monoclonal antibodies that specifically bind to any of the polypeptides of the invention may be produced by methods known in the art. These methods include the immunological method described by Kohler and Milstein (*Nature,* 256: 495-497, 1975) and Campbell ("Monoclonal Antibody Technology, The Production and Characterization of Rodent and Human Hybridomas" in Burdon et al., Eds., Laboratory Techniques in Biochemistry and Molecular Biology, Volume 13, Elsevier Science Publishers, Amsterdam, 1985), as well as by the recombinant DNA method described by Huse et al. (*Science*, 246, 1275-1281, 1989).

Monoclonal antibodies may be prepared from supernatants of cultured hybridoma cells or from ascites induced by intra-peritoneal inoculation of hybridoma cells into mice. The hybridoma technique described originally by Kohler and Milstein (*Eur. J. Immunol*, 6, 511-519, 1976) has been widely applied to produce hybrid cell lines that secrete high levels of monoclonal antibodies against many specific antigens.

The route and schedule of immunization of the host animal or cultured antibody-producing cells therefrom are generally in keeping with established and conventional techniques for antibody stimulation and production. Typically, mice are used as the test model, however, any mammalian subject including human subjects or antibody producing cells therefrom can be manipulated according to the processes of this invention to serve as the basis for production of mammalian, including human, hybrid cell lines.

After immunization, immune lymphoid cells are fused with myeloma cells to generate a hybrid cell line that can be cultivated and subcultivated indefinitely, to produce large quantities of monoclonal antibodies. For

purposes of this invention, the immune lymphoid cells selected for fusion are lymphocytes and their normal differentiated progeny, taken either from lymph node tissue or spleen tissue from immunized animals. The use of spleen cells is preferred, since they offer a more concentrated and convenient source of antibody producing cells with respect to the mouse system. The myeloma cells provide the basis for continuous propagation of the fused hybrid. Myeloma cells are tumor cells derived from plasma cells. Murine myeloma cell lines can be obtained, for example, from the American Type Culture Collection (ATCC; Manassas, VA). Human myeloma and mouse-human heteromyeloma cell lines have also been described (Kozbor et al., *J. Immunol.*, 133:3001-3005, 1984; Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, pp. 51-63, 1987).

The hybrid cell lines can be maintained *in vitro* in cell culture media. Once the hybridoma cell line is established, it can be maintained on a variety of nutritionally adequate media such as hypoxanthine-aminopterin-thymidine (HAT) medium. Moreover, the hybrid cell lines can be stored and preserved in any number of conventional ways, including freezing and storage under liquid nitrogen. Frozen cell lines can be revived and cultured indefinitely with resumed synthesis and secretion of monoclonal antibody. The secreted antibody is recovered from tissue culture supernatant by conventional methods such as precipitation, ion exchange chromatography, affinity chromatography, or the like.

The antibody may be prepared in any mammal, including mice, rats, rabbits, goats, and humans. The antibody may be a member of one of the following immunoglobulin classes: IgG, IgM, IgA, IgD, or IgE, and the subclasses thereof, and preferably is an IgG antibody.

While the preferred animal for producing monoclonal antibodies is mouse, the invention is not so limited; in fact, human antibodies may be used and may prove to be preferable. Such antibodies can be obtained by using human hybridomas (Cole et al., "Monoclonal Antibodies and Cancer Therapy",

Alan R. Liss Inc., p. 77-96, 1985). In the present invention, techniques developed for the production of chimeric antibodies by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule can be used (Morrison et al., *Proc. Natl. Acad. Sci.* 81, 6851-6855, 1984; Neuberger et al., *Nature* 312, 604-608, 1984; Takeda et al., *Nature* 314, 452-454, 1985); such antibodies are within the scope of this invention and are described below.

As another alternative to the cell fusion technique, Epstein-Barr virus (EBV) immortalized B cells are used to produce the monoclonal antibodies of the present invention (Crawford D. et al., *J. of Gen. Virol.,* 64:697-700, 1983; Kozbor and Roder, *J. Immunol.*, 4:1275-1280, 1981; Kozbor et al., *Methods in Enzymology,* 121:120-140, 1986). In general, the procedure consists of isolating Epstein-Barr virus from a suitable source, generally an infected cell line, and exposing the target antibody secreting cells to supernatants containing the virus. The cells are washed, and cultured in an appropriate cell culture medium. Subsequently, virally transformed cells present in the cell culture can be identified by the presence of the Epstein-Barr viral nuclear antigen, and transformed antibody secreting cells can be identified using standard methods known in the art. Other methods for producing monoclonal antibodies, such as recombinant DNA, are also included within the scope of the invention.

Preparation of immunogens

Any of the polypeptides of the invention may be used alone as an immunogen, or may be attached to a carrier protein or to other objects, such as sepharose beads. Any of the proteins of the invention may be purified from cells known to express the endogenous protein such as human umbilical vein endothelial cells (trophoblasts or HUVEC; Burrows et al., *Clin. Cancer Res.* 1:1623-1634, 1995; Fonsatti et al., *Clin. Cancer Res.* 6:2037-2043, 2000). Additionally, nucleic acid molecules that encode any of the polypeptides of the invention, or portions thereof, can be inserted into known vectors for

expression in host cells using standard recombinant DNA techniques. Suitable host cells for protein expression include baculovirus cells (e.g., Sf9 cells), bacterial cells (e.g., *E. coli*), and mammalian cells (e.g., NIH3T3 cells).

In addition, peptides derived from any of the polypeptides of the invention can be synthesized and used as immunogens. The methods for making antibody to peptides are well known in the art and generally require coupling the peptide to a suitable carrier molecule, such as serum albumin. Peptides can be any length, preferably 10 amino acids or greater, more preferably 25 amino acids or greater, and most preferably 40, 50, 60, 70, 80, or 100 amino acids or greater. Preferably, the amino acid sequences are at least 60%, more preferably 85%, and, most preferably 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence of any of the nucleic acid sequences encoding the polypeptides of the invention. The peptides can be commercially obtained or made using techniques well known in the art, such as, for example, the Merrifield solid-phase method (*Science*, 232:341-347, 1985). The procedure may use commercially available synthesizers such as a Biosearth 9500 automated peptide machine, with cleavage of the blocked amino acids being achieved with hydrogen fluoride, and the peptides purified by preparative HPLC using a Waters Delta Prep 3000 instrument, on a 15-20 μm Vydac C4 PrepPAK column.

Functional equivalents of antibodies

The invention also includes functional equivalents of the antibodies described in this specification. Functional equivalents include polypeptides with amino acid sequences substantially identical to the amino acid sequence of the variable or hypervariable regions of the antibodies of the invention. Functional equivalents have binding characteristics comparable to those of the antibodies, and include, for example, chimerized, humanized and single chain antibodies as well as fragments thereof. Methods of producing such functional equivalents are disclosed, for example, in PCT Publication No. WO93/21319;

European Patent Application No. 239,400; PCT Publication No. WO89/09622; European Patent Application No. 338,745; European Patent Application No. 332424; and U.S. Patent No. 4,816,567; each of which is herein incorporated by reference.

Chimerized antibodies preferably have constant regions derived substantially or exclusively from human antibody constant regions and variable regions derived substantially or exclusively from the sequence of the variable region from a mammal other than a human. Such humanized antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', $F(ab')_2$ or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Methods for humanizing non-human antibodies are well known in the art (for reviews see Vaswani and Hamilton, *Ann Allergy Asthma Immunol.,* 81:105-119, 1998 and Carter, *Nature Reviews Cancer*, 1:118-129, 2001). Generally, a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the methods known in the art (Jones et al., *Nature*, 321:522-525, 1986; Riechmann et al., *Nature,* 332:323-329, 1988; and Verhoeyen et al., *Science*, 239:1534-1536 1988), by substituting rodent CDRs or other CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species (see for example, U.S. Patent No. 4,816,567). In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies (Presta, *Curr. Op. Struct. Biol.,* 2:593-596, 1992).

Additional methods for the preparation of humanized antibodies can be found in U.S. Patent Nos. 5,821,337, 6,054,297, 6,639,055, and Carter, (*supra*) which are all incorporated herein by reference. The humanized antibody is selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA and IgE, and any isotype, including IgG_1, IgG_2, IgG_3, and IgG_4. Where cytotoxic activity is not needed, such as in the present invention, the constant domain is preferably of the IgG_2 class. The humanized antibody may comprise sequences from more than one class or isotype, and selecting particular constant domains to optimize desired effector functions is within the ordinary skill in the art.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries (Marks et al., *J. Mol. Biol.,* 222:581-597, 1991 and Winter et al. *Annu. Rev. Immunol.,* 12:433-455, 1994). The techniques of Cole et al. and Boerner et al. are also useful for the preparation of human monoclonal antibodies (Cole et al., *supra*; Boerner et al., *J. Immunol.,* 147: 86-95, 1991).

Suitable mammals other than a human include any mammal from which monoclonal antibodies may be made. Examples of mammals other than a human include, for example a rabbit, rat, mouse, horse, goat, or primate; a mouse is preferred.

Functional equivalents of antibodies also include single-chain antibody fragments, also known as single-chain antibodies (scFvs). Single-chain antibody fragments are recombinant polypeptides which typically bind antigens or receptors; these fragments contain at least one fragment of an antibody variable heavy-chain amino acid sequence (V_H) tethered to at least one fragment of an antibody variable light-chain sequence (V_L) with or without one or more interconnecting linkers. Such a linker may be a short, flexible peptide selected to assure that the proper three-dimensional folding of the V_L and V_H domains occurs once they are linked so as to maintain the target molecule binding-specificity of the whole antibody from which the single-chain antibody fragment is derived. Generally, the carboxyl terminus of the V_L or V_H

sequence is covalently linked by such a peptide linker to the amino acid terminus of a complementary V_L and V_H sequence. Single-chain antibody fragments can be generated by molecular cloning, antibody phage display library or similar techniques. These proteins can be produced either in eukaryotic cells or prokaryotic cells, including bacteria.

Single-chain antibody fragments contain amino acid sequences having at least one of the variable regions or CDRs of the whole antibodies described in this specification, but are lacking some or all of the constant domains of those antibodies. These constant domains are not necessary for antigen binding, but constitute a major portion of the structure of whole antibodies. Single-chain antibody fragments may therefore overcome some of the problems associated with the use of antibodies containing part or all of a constant domain. For example, single-chain antibody fragments tend to be free of undesired interactions between biological molecules and the heavy-chain constant region, or other unwanted biological activity. Additionally, single-chain antibody fragments are considerably smaller than whole antibodies and may therefore have greater capillary permeability than whole antibodies, allowing single-chain antibody fragments to localize and bind to target antigen-binding sites more efficiently. Also, antibody fragments can be produced on a relatively large scale in prokaryotic cells, thus facilitating their production. Furthermore, the relatively small size of single-chain antibody fragments makes them less likely than whole antibodies to provoke an immune response in a recipient.

Functional equivalents further include fragments of antibodies that have the same or comparable binding characteristics to those of the whole antibody. Such fragments may contain one or both Fab fragments or the $F(ab')_2$ fragment. Preferably the antibody fragments contain all six CDRs of the whole antibody, although fragments containing fewer than all of such regions, such as three, four or five CDRs, are also functional.

Further, the functional equivalents may be or may combine members of any one of the following immunoglobulin classes: IgG, IgM, IgA, IgD, or IgE, and the subclasses thereof.

Preparation of Functional Equivalents of Antibodies

Equivalents of antibodies are prepared by methods known in the art. For example, fragments of antibodies may be prepared enzymatically from whole antibodies. Preferably, equivalents of antibodies are prepared from DNA encoding such equivalents. DNA encoding fragments of antibodies may be prepared by deleting all but the desired portion of the DNA that encodes the full-length antibody.

DNA encoding chimerized antibodies may be prepared by recombining DNA substantially or exclusively encoding human constant regions and DNA encoding variable regions derived substantially or exclusively from the sequence of the variable region of a mammal other than a human. DNA encoding humanized antibodies may be prepared by recombining DNA encoding constant regions and variable regions other than the CDRs derived substantially or exclusively from the corresponding human antibody regions and DNA encoding CDRs derived substantially or exclusively from a mammal other than a human.

Suitable sources of DNA molecules that encode fragments of antibodies include cells, such as hybridomas, that express the full-length antibody. The fragments may be used by themselves as antibody equivalents, or may be recombined into equivalents, as described above.

The DNA deletions and recombinations described in this section may be carried out by known methods, such as those described in the published patent applications listed above.

Antibody Screening and Selection

Monoclonal antibodies are isolated and purified using standard art-known methods. For example, antibodies can be screened using standard art-known methods such as ELISA or western blot analysis. Non-limiting examples of such techniques are described in Examples II and III of U.S. Patent No. 6,365,157, herein incorporated by reference.

Therapeutic Uses of Antibodies

When used *in vivo* for the treatment or prevention of a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, the antibodies of the subject invention are administered to the subject in therapeutically effective amounts. Preferably, the antibodies are administered parenterally or intravenously by continuous infusion. The dose and dosage regimen depends upon the severity of the disease, and the overall health of the subject. The amount of antibody administered is typically in the range of about 0.001 to about 10 mg/kg of subject weight, preferably 0.01 to about 5 mg/kg of subject weight.

For parenteral administration, the antibodies are formulated in a unit dosage injectable form (solution, suspension, emulsion) in association with a pharmaceutically acceptable parenteral vehicle. Such vehicles are inherently nontoxic, and non-therapeutic. Examples of such vehicles are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils and ethyl oleate may also be used. Liposomes may be used as carriers. The vehicle may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, e.g., buffers and preservatives. The antibodies typically are formulated in such vehicles at concentrations of about 1 mg/ml to 10 mg/ml.

Combination therapies

Optionally, a therapeutic of the invention may be administered in combination with any other standard pregnancy related hypertensive disorder therapeutic; such methods are known to the skilled artisan.

Dosages and Modes of Administration

Preferably, the therapeutic compound of the invention is administered during pregnancy for the treatment or prevention of the pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or after pregnancy to treat post-partum pre-eclampsia or eclampsia. Techniques and dosages for administration vary depending on the type of compound (e.g., chemical compound, antibody, antisense, or nucleic acid vector) and are well known to those skilled in the art or are readily determined.

Therapeutic compounds of the present invention may be administered with a pharmaceutically acceptable diluent, carrier, or excipient, in unit dosage form. Administration may be parenteral, intravenous, subcutaneous, oral or local by direct injection into the amniotic fluid. Intravenous delivery by continuous infusion is the preferred method for administering the therapeutic compounds of the present invention.

The composition can be in the form of a pill, tablet, capsule, liquid, or sustained release tablet for oral administration; or a liquid for intravenous, subcutaneous or parenteral administration; or a polymer or other sustained release vehicle for local administration.

Methods well known in the art for making formulations are found, for example, in "Remington: The Science and Practice of Pharmacy" (20th ed., ed. A.R. Gennaro AR., 2000, Lippincott Williams & Wilkins, Philadelphia, PA). Formulations for parenteral administration may, for example, contain excipients, sterile water, saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or

polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Nanoparticulate formulations (e.g., biodegradable nanoparticles, solid lipid nanoparticles, liposomes) may be used to control the biodistribution of the compounds. Other potentially useful parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. The concentration of the compound in the formulation varies depending upon a number of factors, including the dosage of the drug to be administered, and the route of administration.

The compound may be optionally administered as a pharmaceutically acceptable salt, such as non-toxic acid addition salts or metal complexes that are commonly used in the pharmaceutical industry. Examples of acid addition salts include organic acids such as acetic, lactic, pamoic, maleic, citric, malic, ascorbic, succinic, benzoic, palmitic, suberic, salicylic, tartaric, methanesulfonic, toluenesulfonic, or trifluoroacetic acids or the like; polymeric acids such as tannic acid, carboxymethyl cellulose, or the like; and inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid phosphoric acid, or the like. Metal complexes include zinc, iron, and the like.

Formulations for oral use include tablets containing the active ingredient(s) in a mixture with non-toxic pharmaceutically acceptable excipients. These excipients may be, for example, inert diluents or fillers (e.g., sucrose and sorbitol), lubricating agents, glidants, and anti-adhesives (e.g., magnesium stearate, zinc stearate, stearic acid, silicas, hydrogenated vegetable oils, or talc).

Formulations for oral use may also be provided as chewable tablets, or as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium.

The dosage and the timing of administering the compound depends on various clinical factors including the overall health of the subject and the

severity of the symptoms of the pregnancy related hypertensive disorder, such as pre-eclampsia. In general, once the pregnancy related hypertensive disorder, such as pre-eclampsia or a propensity to develop pre-eclampsia, is detected, continuous infusion of the purified protein is used to treat or prevent further progression of the condition. Treatment can be continued for a period of time ranging from 1 to 100 days, more preferably 1 to 60 days, and most preferably 1 to 20 days, or until the completion of pregnancy. Dosages vary depending on each compound and the severity of the condition and are titrated to achieve a steady-state blood serum concentration.

Subject monitoring

The diagnostic methods described herein can also be used to monitor the pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, during therapy or to determine the dosages of therapeutic compounds. In one example, a therapeutic compound is administered and the level of expression of a polypeptide of the invention is determined during the course of therapy.

Therapeutics that modulate the expression of any one or more nucleic acids or polypeptides of the invention are taken as particularly useful in the invention.

In one example, a therapeutic agent or method that decreases, by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more, the level of any of the following polypeptides or nucleic acids encoding the polypeptides: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein (#AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2

family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, and beta glucosidase during the course of therapy, is considered to be an effective therapeutic agent or an effective dosage of a therapeutic agent. In another example, a therapeutic agent or method that increases, by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more, the level of any of the following polypeptides or nucleic acids encoding the polypeptides: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11 during the course of therapy, is considered to be an effective therapeutic agent or an effective dosage of a therapeutic agent.

The disease state or treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia, or a propensity to develop such a condition, can be monitored using the methods and compositions of the invention. In one embodiment, the expression of a polypeptide of the invention present in a bodily fluid, such as urine, plasma, amniotic fluid, or CSF, is monitored. Such monitoring may be useful, for example, in assessing the efficacy of a particular drug in a subject or in assessing disease progression.

Examples

Example 1. Gene expression profiling of placental tissue from pre-eclamptic and normotensive women.

In order to identify novel secreted factors involved in the pathogenesis of pre-eclampsia, we performed gene expression profiling of placental tissue from 19 women with pre-eclampsia and 15 nomotensive pregnant women using Affymetrix U95A microarray chips (see Table 1).

Table 1: Clinical characteristics of the study patients

	Normal (n=15)	Pre-eclampsia (n=19)
Maternal Age (years)	35.2	31.9
Gestational Age (wks)	39.0	31.1*
Primiparous (%)	19	81*
Systolic BP (mm Hg)	107	167.2**
Diastolic BP (mm Hg)	83	101.8**
Proteinuria (g protein/g creat)	<0.3	5.2**
Serum Uric Acid (mg/dl)	NA	6.8
Hematocrit (%)	35.7	33.9
Platelet Count (K/μl)	217	198
Serum Creatinine (mg/dl)	0.5	0.6

Data shown are mean values. * $p<0.05$, ** $p<0.005$

Data were analyzed using the computer program BADGE (Bayesian Analysis of Differential Gene Expression version 1.0) (http://genomethods.org/badge) (see Ramoni and Sebastiani, in Berthold and Hand eds. *Intelligent Data Analysis: An Introduction*, Springer, New York,NY (1999)) and hierarchical clustering analysis (Eisen et al., *Proc. Natl. Acad. Sci.*, 95:14863-8 (1998)) to identify differentially expressed genes across experimental conditions (Figure 1). The software BADGE (Bayesian Analysis of Gene Expression) v1.0 implements a Bayesian approach to identify differentially expressed genes across different experimental conditions.

Cumulative distribution function (CDF) for expression ratio greater than 1.0. The genes are ranked in order of the conditional probability of increased fold expression given the expression data; the null probability value is 0.5.

A predictive gene set in normal versus pre-eclampsia placenta mRNA expression was discovered using the BADGE program. A colormap of the predictive gene set is shown in Figure 2. Rows represent predictive genes for pre-eclampsia while columns represent expression levels for a given patient relative to the average gene expression. The expected false positive rate of 1.0% yields a predictive gene set of 127 genes, with 65 upregulated and 62 downregulated respectively (Table 2). (See Figures 6A – 44 for amino acid and nucleic acid sequences for the polypeptides of the invention).

Table 2. Summary of predictive genes

Affy Probe	Genbank	Probability	Fold	Gene Symbol	Gene Name
33900_at	U76702	0.99992	3.849	FSTL3	follistatin-like 3 (secreted glycoprotein)
990_at	X51602	0.99990	3.233	FLT1	fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
991_g_at	X51602	0.99989	2.727	FLT1	fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
1601_s_at	M11567	0.99986	3.254	IGFBP5	insulin-like growth factor binding protein 5
36317_at	U57057	0.99982	3.767	CORO2A	coronin, actin binding protein, 2A
1389_at	J03779	0.99982	2.299	MME	membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD10)
501_g_at	U37143	0.99980	2.293	CYP2J2	cytochrome P450, family 2, subfamily J, polypeptide 2
37657_at	Y16270	0.99979	3.089	PALM	paralemmin
HUMGAPDH	L27559	0.99978	3.647	GAPD	glyceraldehyde-3-phosphate dehydrogenase
159_at	U61836	0.99969	3.343	VEGFC	vascular endothelial growth factor C
31754_at	AI950015	0.99966	3.737	ABCA12	ATP-binding cassette, sub-family A (ABC1), member 12
1149_at	D16154	0.99960	3.241	---	Transcription Factor Eb
1545_g_at	U43142	0.99959	2.692	FLT1	fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
34129_at	D86358	0.99953	2.211	STXBP5L	syntaxin binding protein 5-like
1103_at	HG4740	0.99952	3.141	ANG	angiogenin, ribonuclease, RNase A family, 5

Affy Probe	Genbank	Probability	Fold	Gene Symbol	Gene Name
255_s_at	X52009	0.99950	2.761	INHA	inhibin, alpha
1650_g_at	U01134	0.99948	2.745	SMOX	spermine oxidase
1964_g_at	M74297	0.99946	2.331	FLT1	fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
32298_at	L35848	0.99940	2.894	ADAM2	a disintegrin and metalloproteinase domain 2 (fertilin beta)
33995_at	M77144	0.99939	5.997	GUCA2A	guanylate cyclase activator 2A (guanylin)
32892_at	AF058989	0.99937	2.014	RPS6KA2	ribosomal protein S6 kinase, 90kDa, polypeptide 2
41577_at	W27723	0.99910	2.361	PPP1R16B	protein phosphatase 1, regulatory (inhibitor) subunit 16B
40790_at	X53004	0.99903	2.169	BHLHB2	basic helix-loop-helix domain containing, class B, 2
41024_f_at	AF055033	0.99891	2.617	GYPE	glycophorin E
36426_g_at	AF052095	0.99879	1.981	NEBL	nebulette
34800_at	L37362	0.99868	2.943	LRIG1	leucine-rich repeats and immunoglobulin-like domains 1
36979_at	L26953	0.99868	2.389	SLC2A3	solute carrier family 2 (facilitated glucose transporter), member 3
31382_f_at	AF091582	0.99851	2.065	UGT2B28	UDP glycosyltransferase 2 family, polypeptide B28
40357_at	U20350	0.99831	3.380	INHBA	inhibin, beta A (activin A, activin AB alpha polypeptide)
1963_at	U01134	0.99822	2.714	FLT1	fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
35865_at	AB001915	0.99815	2.632	NR5A2	nuclear receptor subfamily 5, group A, member 2
39051_at	X86400	0.99814	1.805	NNAT	neuronatin
33642_s_at	X68733	0.99807	3.236	SLC6A8	solute carrier family 6 (neurotransmitter transporter, creatine), member 8
33182_at	X63759	0.99804	2.698	NTRK2	neurotrophic tyrosine kinase, receptor, type 2
33639_g_at	U17986	0.99802	1.694	ERBB3	v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)
34483_at	AL039458	0.99793	2.234	SIGLEC6	sialic acid binding Ig-like lectin 6
1511_at	S77812	0.99793	1.771	SHC3	src homology 2 domain containing transforming protein C3
38280_s_at	U43753	0.99787	3.286	NTRK2	neurotrophic tyrosine kinase, receptor, type 2
41420_at	AB020630	0.99785	2.479	IGFBP5	insulin-like growth factor binding protein 5
34088_at	AB023223	0.99783	2.009	NXPH4	neurexophilin 4
36284_at	Y17673	0.99781	2.978	LY6D	lymphocyte antigen 6 complex, locus D
33825_at	M97496	0.99777	2.575	SERPINA3	serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3
36533_at	D83402	0.99742	2.354	PTGIS	prostaglandin I2 (prostacyclin) synthase

Affy Probe	Genbank	Probability	Fold	Gene Symbol	Gene Name
37813_at	AL079273	0.99735	2.073	DDX51	DEAD (Asp-Glu-Ala-Asp) box polypeptide 51
39202_at	W26403	0.99731	1.667	TRAF3IP1	TNF receptor-associated factor 3 interacting protein 1
368_at	Z29083	0.99721	1.904	TPBG	trophoblast glycoprotein
500_at	U37143	0.99716	1.751	CYP2J2	cytochrome P450, family 2, subfamily J, polypeptide 2
38078_at	AF042166	0.99699	1.774	FLNB	filamin B, beta (actin binding protein 278)
41608_at	X58022	0.99693	2.906	CRHBP	corticotropin releasing hormone binding protein
1734_at	M60556	0.99656	2.200	---	Human transforming growth factor beta-3 gene, 5 end
1945_at	M25753	0.99644	1.747	CCNB1	cyclin B1
31990_at	AF009624	0.99636	1.496	KIF17	kinesin family member 17
36933_at	D87953	0.99618	2.050	NDRG1	N-myc downstream regulated gene 1
32562_at	X72012	0.99610	1.941	ENG	endoglin (Osler-Rendu-Weber syndrome 1)
32565_at	U66619	0.99606	2.098	SMARCD3	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 3
1369_s_at	M28130	0.99601	3.111	IL8	interleukin 8
1678_g_at	M65062	0.99589	2.334	IGFBP5	insulin-like growth factor binding protein 5
37887_at	AF086904	0.99572	1.887	CHEK2	CHK2 checkpoint homolog (S. pombe)
40690_at	X54942	0.99568	1.913	CKS2	CDC28 protein kinase regulatory subunit 2
40926_at	U52111	0.99559	2.068	SLC6A8	solute carrier family 6 (neurotransmitter transporter, creatine), member 8
34898_at	M30704	0.99558	2.179	AREG	amphiregulin (schwannoma-derived growth factor)
33748_at	D86976	0.99546	2.523	HA-1	minor histocompatibility antigen HA-1
35940_at	X64624	0.99536	2.086	POU4F1	POU domain, class 4, transcription factor 1
32632_g_at	J03060	0.99526	2.108	GBAP	glucosidase, beta; acid, pseudogene
33792_at	AF043498	0.99518	2.318	PSCA	prostate stem cell antigen
38566_at	X60382	0.00495	0.730	COL10A1	collagen, type X, alpha 1(Schmid metaphyseal chondrodysplasia)
31740_s_at	AB008913	0.00488	0.637	PAX4	paired box gene 4
33359_at	AB018311	0.00485	0.547	LPHN3	latrophilin 3
38519_at	U68233	0.00476	0.483	NR1H4	nuclear receptor subfamily 1, group H, member 4
33046_f_at	X68879	0.00473	0.492	EMX1	empty spiracles homolog 1 (Drosophila)
39108_at	U22526	0.00472	0.616	LSS	lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase)
33693_at	M76482	0.00451	0.499	DSG3	desmoglein 3 (pemphigus vulgaris antigen)
834_at	U40462	0.00436	0.615	ZNFN1A1	zinc finger protein, subfamily 1A, 1 (Ikaros)
34575_f_at	U10689	0.00416	0.480	MAGEA5	melanoma antigen, family A, 5

Affy Probe	Genbank	Probability	Fold	Gene Symbol	Gene Name
33379_at	AB023140	0.00407	0.432	SSX2IP	synovial sarcoma, X breakpoint 2 interacting protein
31599_f_at	U10691	0.00390	0.420	MAGEA3	melanoma antigen, family A, 3
32935_at	AL080157	0.00389	0.512	WDR21	WD repeat domain 21
33072_at	AF041245	0.00361	0.809	HCRTR2	hypocretin (orexin) receptor 2
36777_at	AJ001687	0.00357	0.525	KLRK1	killer cell lectin-like receptor subfamily K, member 1
36269_at	AB002364	0.00356	0.538	ADAMTS3	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 3
38095_i_at	M83664	0.00351	0.596	HLA-DPB1	major histocompatibility complex, class II, DP beta 1
36272_r_at	X62167	0.00319	0.335	PMP2	peripheral myelin protein 2
494_at	U31120	0.00307	0.610	IL13	interleukin 13
34698_at	M60165	0.00300	0.522	GNAO1	guanine nucleotide binding protein (G protein), alpha activating activity polypeptide O
39646_at	S60415	0.00291	0.414	CACNB2	calcium channel, voltage-dependent, beta 2 subunit
36049_at	W27899	0.00278	0.497	---	CDNA clone IMAGE:4940887, partial cds
37039_at	J00194	0.00277	0.602	HLA-DRA	major histocompatibility complex, class II, DR alpha
37588_s_at	U62317	0.00262	0.621	MAPK8IP2	mitogen-activated protein kinase 8 interacting protein 2
33846_at	AA620377	0.00260	0.522	---	Cluster Incl. AA620377:ae57a07.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-950964
36416_g_at	AI688589	0.00259	0.512	CASK	calcium/calmodulin-dependent serine protein kinase (MAGUK family)
1298_at	X86816	0.00256	0.447	---	Human estrogen receptor mRNA, alternatively spliced transcript H, partial cds.
40646_at	U27699	0.00235	0.562	CX3CR1	chemokine (C-X3-C motif) receptor 1
37108_at	X72755	0.00229	0.529	---	MRNA; cDNA DKFZp779B1535 (from clone DKFZp779B1535)
32997_at	AI018523	0.00228	0.363	GAGEB1	G antigen, family B, 1 (prostate associated)
35028_at	AB002314	0.00227	0.438	GABRB1	gamma-aminobutyric acid (GABA) A receptor, beta 1
40679_at	AB004066	0.00213	0.458	SLC6A12	solute carrier family 6 (neurotransmitter transporter, betaine/GABA), member 12
39498_at	AA044910	0.00213	0.497	---	Cluster Incl. X86400:H.sapiens mRNA for gamma subunit of sodium potassium ATPase
38833_at	U31767	0.00199	0.670	HLA-DPA1	major histocompatibility complex, class II, DP alpha 1
35031_r_at	AF030514	0.00183	0.281	KIAA0316	KIAA0316 gene product
36911_at	M20681	0.00180	0.433	TYRP1	tyrosinase-related protein 1
31494_at	L12691	0.00175	0.434	---	Cluster Incl. D25272:Homo sapiens mRNA, clone-RES4-16
37782_at	AB000381	0.00170	0.654	SST	somatostatin
36767_at	X51420	0.00164	0.302	CYP1A1	cytochrome P450, family 1,

Affy Probe	Genbank	Probability	Fold	Gene Symbol	Gene Name
					subfamily A, polypeptide 1
35539_at	AB019246	0.00159	0.386	IMPG1	interphotoreceptor matrix proteoglycan 1
38330_at	X00457	0.00159	0.371	FRDA	Friedreich ataxia
35061_at	AF047492	0.00152	0.272	CXCL11	chemokine (C-X-C motif) ligand 11
34002_at	AL080151	0.00139	0.627	HSD3B2	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2
32017_at	U38805	0.00139	0.531	PARD6B	par-6 partitioning defective 6 homolog beta (C. elegans)
31398_at	D25272	0.00132	0.440	ABCB11	ATP-binding cassette, sub-family B (MDR/TAP), member 11
32451_at	X96744	0.00131	0.556	MS4A3	membrane-spanning 4-domains, subfamily A, member 3 (hematopoietic cell-specific)
34045_at	AF043469	0.00131	0.503	LOC196993	hypothetical protein LOC196993
36428_at	K03191	0.00130	0.569	VMD2	vitelliform macular dystrophy (Best disease, bestrophin)
AFFX-DapX-3_a	M33197	0.00122	0.469	---	L38424 B subtilis dapB, jojF, jojG genes corresponding to nucleotides 1358-3197 of L38424
31324_at	AF016492	0.00116	0.484	---	U82303:Homo sapiens unknown protein mRNA
32474_at	X85106	0.00111	0.644	PAX7	paired box gene 7
37219_at	AI636761	0.00098	0.395	CXCL9	chemokine (C-X-C motif) ligand 9
31506_s_at	AL080207	0.00097	0.288	DEFA1	defensin, alpha 1, myeloid-related sequence
378_s_at	W28432	0.00075	0.529	GML	GPI anchored molecule like protein
41820_s_at	D85376	0.00073	0.570	CDC2L5	cell division cycle 2-like 5 (cholinesterase-related cell division controller)
31310_at	U82303	0.00061	0.523	GLRA1	glycine receptor, alpha 1 (startle disease/hyperekplexia, stiff man syndrome)
39502_at	J03634	0.00046	0.553	DPYSL4	dihydropyrimidinase-like 4
35024_at	X14767	0.00031	0.272	OPRK1	opioid receptor, kappa 1
36220_at	Y12642	0.00030	0.346	DDAH1	dimethylarginine dimethylaminohydrolase 1
204_at	M13981	0.00022	0.601	HOXA4	homeo box A4
750_at	L38424	0.00021	0.389	TRHR	thyrotropin-releasing hormone receptor
33478_at	AA584202	0.00009	0.296	TNP2	transition protein 2 (during histone to protamine replacement)
1412_g_at	D84361	0.00008	0.560	CYP11B1	cytochrome P450, family 11, subfamily B, polypeptide 1

*Genes selected with a 1.0% false positive error rate for a total of 127 gene, 65 of these upregulated. Genes with no Locuslink classification are labeled with Genbank accession numbers

A hierarchical clustering of the Affymetrix patient data was performed using Cluster and Treeview, (by Michael Eisen, Stanford University) (Figure 3). The samples labeled as P are preeclamptic patients and the samples labeled as N are normal pregnant patients. The dataset was filtered from 12625 to 3564 genes using presence and expression criteria, and the resulting set was median-centered and normalized for genes and arrays. We used hierarchical clustering to analyze possible classes in genes. The above cluster includes sFlt1 along with other genes confirmed in literature.

From the predictive gene set, we found that expression of the gene for the following secreted polypeptides was upregulated in blood samples taken from women with pre-eclampsia: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein (#AL039458), leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, and galectin-3. We have also discovered that expression levels of the gene for the following secreted polypeptides were decreased in blood samples taken from women with pre-eclampsia: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, and azurocidin. In addition we also found the following intracellular polypeptides or enzymes that are increased in preeclamptic placenta sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2 and beta glucosidase. The following intracellular gene products/enzymes are decreased in preeclamptic placentas are: lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced

transcript H , chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11.

Example 2. mRNA expression of Flt-1 and sFlt-1 in pre-eclampsia.

As the above cluster identified sFlt1 along with other genes confirmed in the literature, we chose to confirm the ability of the array to identify predictive markers of pre-eclampsia using sFlt-1. For these experiments, mRNA expression of placental sFlt-1 from 3 patients with pre-eclampsia (P1, P2, P3) and three normotensive term pregnancies (N1, N2, N3) were determined by northern blot analysis (Figure 4). The higher band (7.5 kb) is the full length Flt-1 mRNA and the lower, more abundant band (3.4 kb) is the alternatively spliced sFlt-1 mRNA. Actin is included as a control and 28S is shown as arrowhead. These results show the increased expression of the gene for sFlt-1 in pre-eclamptic patients and confirm the use of the predictive gene set identified by the array as markers for pre-eclampsia or eclampsia or the propensity to develop pre-eclampsia or eclampsia.

Example 3. Immunohistochemistry analysis of Flt-1 expression in normal and pre-eclamptic patients.

In order to visualize Flt-1 expression in placental samples from normal and pre-eclamptic patients, a monoclonal antibody against human Flt-1 was used for immunohistochemistry analysis. Increased expression of Flt-1 by the syncitiotrophoblasts of the preeclamptic placenta was detected (Figure 5), further confirming the ability of the array to identify genes that can be used as markers for pre-eclampsia or eclampsia or the propensity to develop pre-eclampsia or eclampsia.

Other Embodiments

The description of the specific embodiments of the invention is presented for the purposes of illustration. It is not intended to be exhaustive or to limit the scope of the invention to the specific forms described herein. Although the invention has been described with reference to several embodiments, it will be understood by one of ordinary skill in the art that various modifications can be made without departing from the spirit and the scope of the invention, as set forth in the claims. All patents, patent applications, and publications referenced herein are hereby incorporated by reference. Other embodiments are in the claims.

What is claimed is:

Claims

1. A method of diagnosing a subject as having, or having a predisposition to, a pregnancy related hypertensive disorder, said method comprising measuring the level of at least one polypeptide, or a fragment thereof, in a sample from said subject, wherein said at least one polypeptide, or fragment thereof, is selected from the group consisting of follistatin related protein, interleukin 8, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, and beta glucosidase, and wherein an increase in the level of said at least one polypeptide, or fragment thereof, as compared to the level in a normal reference, is a diagnostic indicator of said pregnancy related hypertensive disorder or a predisposition to said pregnancy related hypertensive disorder.

2. The method of claim 1, wherein said increase is at least 20%.

3. The method of claim 1, wherein said polypeptide is selected from the group consisting of follistatin related protein, beta fertilin, insulin-like growth factor binding protein-5, and secreted frizzled related protein.

4. A method of diagnosing a subject as having, or having a predisposition to, a pregnancy related hypertensive disorder, said method comprising measuring the level of at least one polypeptide, or a fragment thereof, in a sample from said subject, wherein said polypeptide, or fragment thereof, is selected from the group consisting of alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11, and wherein a decrease in the level of said polypeptide, or fragment thereof, as compared to a normal reference is a diagnostic indicator of said pregnancy related hypertensive disorder or a predisposition to said pregnancy related hypertensive disorder.

5. The method of claim 4, wherein said decrease is at least 20%.

6. The method of claim 1 or 4, wherein said pregnancy related hypertensive disorder is selected from the group consisting of pre-eclampsia, eclampsia, gestational hypertension, chronic hypertension, HELLP syndrome, and pregnancy with a small for gestational age (SGA) infant.

7. The method of claim 6, wherein said pregnancy related hypertensive disorder is pre-eclampsia or eclampsia.

8. The method of claim 1 or 4, wherein the normal reference is a sample previously taken from said subject.

9. The method of claim 1 or 4, further comprising measuring the level of at least one polypeptide, or fragment thereof, selected from the group consisting of soluble endoglin, sFlt-1, VEGF, and PlGF in a sample from said subject.

10. The method of claim 9, further comprising calculating the relationship between said levels of soluble endoglin, sFlt-1, VEGF, or PlGF using a metric, wherein an alteration in the relationship between said levels in the subject sample relative to said levels in a reference sample is a diagnostic indicator of a pregnancy related hypertensive disorder or a predisposition to a pregnancy related hypertensive disorder in said subject.

11. The method of claim 1 or 4, wherein said measuring is done using an immunological assay.

12. The method of claim 11, wherein said immunological assay is an ELISA.

13. The method of claim 1, wherein said method comprises measuring the level of at least two polypeptides or fragments thereof.

14. A method of diagnosing a subject as having, or having a predisposition to, a pregnancy related hypertensive disorder, said method comprising measuring the level of a nucleic acid molecule in a sample from said subject, said nucleic acid molecule selected from the group consisting of nucleic acids encoding follistatin related protein, interleukin 8, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, insulin-like growth factor binding protein-5, CD33L, cytokine

receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, and beta glucosidase, wherein an increase in the level of said nucleic acid molecule, as compared to the level in a normal reference, is a diagnostic indicator of said pregnancy related hypertensive disorder or a predisposition to said pregnancy related hypertensive disorder.

15. A method of diagnosing a subject as having, or having a predisposition to, a pregnancy related hypertensive disorder, said method comprising measuring the level of a nucleic acid molecule in a sample from said subject, said nucleic acid molecule selected from the group consisting of nucleic acids encoding alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11, wherein a decrease in the level of said nucleic acid molecule, as compared to the level in a normal reference is a diagnostic indicator of said pregnancy related hypertensive disorder or a predisposition to said pregnancy related hypertensive disorder.

16. The method of claim 14 or 15, wherein the normal reference is a sample previously taken from said subject.

17. The method of claim 14 or 15, wherein said pregnancy related hypertensive disorder is selected from the group consisting of pre-eclampsia, eclampsia, gestational hypertension, chronic hypertension, HELLP syndrome, and pregnancy with a small for gestational age (SGA) infant.

18. The method of claim 17, wherein said pregnancy related hypertensive disorder is pre-eclampsia or eclampsia.

19. The method of claim 14 or 15, further comprising measuring the level of a nucleic acid molecule encoding a polypeptide selected from the group consisting of soluble endoglin, sFlt-1, VEGF, or PlGF in a sample from said subject.

20. The method of claim 1, 4, 14, or 15, wherein said subject is a non-pregnant human, a pregnant human, a post-partum human, or a non-human.

21. The method of claim 20, wherein said non-human is selected from the group consisting of a cow, a horse, a sheep, a pig, a goat, a dog, or a cat.

22. The method of claim 1, 4, 14, or 15, wherein said method is used to diagnose a pregnancy related hypertensive disorder, or a predisposition to a pregnancy related hypertensive disorder, at least 4 weeks prior to the onset of symptoms.

23. The method of claim 1, 4, 14, or 15, wherein said sample is a bodily fluid, a tissue, or a cell in which said polypeptide or nucleic acid molecule is normally detectable.

24. The method of claim 23, wherein said bodily fluid is selected from the group consisting of blood, urine, amniotic fluid, saliva, serum, plasma, and cerebrospinal fluid.

25. A method of diagnosing a subject as having, or having a predisposition to, a pregnancy related hypertensive disorder, said method comprising determining the nucleic acid sequence of a gene encoding a polypeptide selected from the group consisting of follistatin related protein, interleukin 8, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, and beta glucosidase, wherein an alteration in the subject's nucleic acid sequence that is an alteration that increases the expression level or biological activity of the gene product in said subject diagnoses the subject with said pregnancy related hypertensive disorder or a predisposition to said pregnancy related hypertensive disorder.

26. A method of diagnosing a subject as having, or having a predisposition to a pregnancy related hypertensive disorder, said method comprising determining the nucleic acid sequence of a gene encoding a polypeptide selected from the group consisting of: alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-

alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11, wherein an alteration in the subject's nucleic acid sequence that is an alteration that decreases the expression level or biological activity of the gene product in said subject diagnoses the subject with said pregnancy related hypertensive disorder or a predisposition to said pregnancy related hypertensive disorder.

27. The method of claim 25 or 26, wherein said pregnancy related hypertensive disorder is selected from the group consisting of pre-eclampsia, eclampsia, gestational hypertension, chronic hypertension, HELLP syndrome, and pregnancy with a small for gestational age (SGA) infant.

28. The method of claim 27, wherein said pregnancy related hypertensive disorder is pre-eclampsia or eclampsia.

29. A kit for the diagnosis of a pregnancy related hypertensive disorder, or a predisposition to a pregnancy related hypertensive disorder in a subject comprising the following:

(a) a nucleic acid sequence or a sequence complementary thereto selected from the group consisting of nucleic acids sequences that encode any of the following polypeptides: follistatin related protein, interleukin 8, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral

endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11; and

(b) instructions for the use of said nucleic acid sequence or sequence complementary thereto for the diagnosis of a pregnancy related hypertensive disorder in a subject.

30. The kit of claim 29, further comprising a reference sample, standard, or level.

31. The kit of claim 30, wherein said reference sample is sample from a subject not having a pregnancy related disorder or a subject that is not pregnant.

32. A kit for the diagnosis of a pregnancy related hypertensive disorder in a subject comprising the following:

(a) a component useful for detecting a polypeptide selected from the group consisting of follistatin related protein, interleukin 8, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral

endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11; and

(b) instructions for the use of said component for the diagnosis of a pregnancy related hypertensive disorder in said subject.

33. The kit of claim 32, wherein said component is a binding molecule that specifically binds said polypeptide.

34. The kit of claim 33, wherein said binding molecule is an antibody, or antigen-binding fragment thereof, that specifically binds said polypeptide.

35. The kit of claim 32, further comprising a reference sample, standard, or level.

36. The kit of claim 35, wherein said reference sample is a sample from a subject not having a pregnancy related disorder or a subject that is not pregnant.

37. The kit of claim 32, wherein said polypeptide is detected by an assay selected from the group consisting of an immunological assay, an enzymatic assay, and a colorimetric assay.

38. A nucleic acid array comprising one or more substrate supports that are stably associated with a plurality of polynucleotide probes, wherein said polynucleotide probes are capable of hybridizing under highly stringent conditions to RNA transcripts, or the complements thereof, of genes encoding proteins selected from the group consisting of follistatin related protein, interleukin 8, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11.

39. A polypeptide array comprising one or more substrate supports that are stably associated with a plurality of polypeptides selected from the group consisting of follistatin related protein, interleukin 8, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related

protein, galectin-3, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehydrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11; variants of said polypeptides; antibodies specific for said polypeptides or variants; or any combination of said polypeptides, variants, or antibodies.

40. The array of claim 38 or 39, further comprising instructions for the use of said array for the diagnosis of a pregnancy related hypertensive disorder in said subject.

41. The method of claims 1, 14, 15, 25, 26, or the kits of claims 29, 32 wherein said polypeptide is selected from insulin-like growth factor binding protein-5, and secreted frizzled related protein.

42. The nucleic acid array of claim 38 or polypeptide array of claim 39 wherein said polypeptide is selected from insulin-like growth factor binding protein-5, and secreted frizzled related protein.

SEQUENCE LISTING

<110> Beth Israel Deaconess Medical Center et al.

<120> Nucleic Acids and Polypeptides Useful For Diagnosing and Treating Complications of Pregnancy

<130> 01948/108WO2

<140> PCT/US2005/045805
<141> 2005-12-15

<150> US 60/636,275
<151> 2004-12-15

<160> 69

<170> PatentIn version 3.3

<210> 1
<211> 263
<212> PRT
<213> Homo sapiens

<400> 1

Met Arg Pro Gly Ala Pro Gly Pro Leu Trp Pro Leu Pro Trp Gly Ala
1 5 10 15

Leu Ala Trp Ala Val Gly Phe Val Ser Ser Met Gly Ser Gly Asn Pro
20 25 30

Ala Pro Gly Gly Val Cys Trp Leu Gln Gln Gly Gln Glu Ala Thr Cys
35 40 45

Ser Leu Val Leu Gln Thr Asp Val Thr Arg Ala Glu Cys Cys Ala Ser
50 55 60

Gly Asn Ile Asp Thr Ala Trp Ser Asn Leu Thr His Pro Gly Asn Lys
65 70 75 80

Ile Asn Leu Leu Gly Phe Leu Gly Leu Val His Cys Leu Pro Cys Lys
85 90 95

Asp Ser Cys Asp Gly Val Glu Cys Gly Pro Gly Lys Ala Cys Arg Met
100 105 110

Leu Gly Gly Arg Pro Arg Cys Glu Cys Ala Pro Asp Cys Ser Gly Leu
115 120 125

Pro Ala Arg Leu Gln Val Cys Gly Ser Asp Gly Ala Thr Tyr Arg Asp
130 135 140

Glu Cys Glu Leu Arg Ala Ala Arg Cys Arg Gly His Pro Asp Leu Ser
145 150 155 160

Val Met Tyr Arg Gly Arg Cys Arg Lys Ser Cys Glu His Val Val Cys
165 170 175

Pro Arg Pro Gln Ser Cys Val Val Asp Gln Thr Gly Ser Ala His Cys
180 185 190

Val Val Cys Arg Ala Ala Pro Cys Pro Val Pro Ser Ser Pro Gly Gln
195 200 205

Glu Leu Cys Gly Asn Asn Asn Val Thr Tyr Ile Ser Ser Cys His Met
210 215 220

Arg Gln Ala Thr Cys Phe Leu Gly Arg Ser Ile Gly Val Arg His Ala
225 230 235 240

Gly Ser Cys Ala Gly Thr Pro Glu Glu Pro Pro Gly Gly Glu Ser Ala
245 250 255

Glu Glu Glu Glu Asn Phe Val
260

<210> 2
<211> 2500
<212> DNA
<213> Homo sapiens

<400> 2
gttcgccatg cgtcccgggg cgccagggcc actctggcct ctgccctggg gggccctggc 60

ttgggccgtg ggcttcgtga gctccatggg ctcggggaac cccgcgcccg gtggtgtttg 120

ctggctccag cagggccagg aggccacctg cagcctggtg ctccagactg atgtcacccg 180

ggccgagtgc tgtgcctccg gcaacattga caccgcctgg tccaacctca cccacccggg 240

gaacaagatc aacctcctcg gcttcttggg ccttgtccac tgccttccct gcaaagattc 300

gtgcgacggc gtggagtgcg gcccgggcaa ggcgtgccgc atgctggggg gccgcccgcg 360

ctgcgagtgc gcgcccgact gctcggggct cccggcgcgg ctgcaggtct gcggctcaga 420

cggcgccacc taccgcgacg agtgcgagct gcgcgccgcg cgctgccgcg gccacccgga 480

cctgagcgtc atgtaccggg gccgctgccg caagtcctgt gagcacgtgg tgtgcccgcg 540

gccacagtcg tgcgtcgtgg accagacggg cagcgcccac tgcgtggtgt gtcgagcggc 600

gccctgccct gtgccctcca gccccggcca ggagctttgc ggcaacaaca acgtcaccta 660

catctcctcg tgccacatgc gccaggccac ctgcttcctg ggccgctcca tcggcgtgcg 720

ccacgcgggc agctgcgcag gcacccctga ggagccgcca ggtggtgagt ctgcagaaga 780

ggaagagaac ttcgtgtgag cctgcaggac aggcctgggc ctggtgcccg aggcccccca 840

tcatcccctg ttatttattg ccacagcaga gtctaattta tatgccacgg acactcctta 900

gagcccggat tcggaccact tggggatccc agaacctccc tgacgatatc ctggaaggac 960

tgaggaaggg aggcctgggg gccggctggt gggtgggata gacctgcgtt ccggacactg 1020

agcgcctgat ttagggccct tctctaggat gccccagccc ctaccctaag acctattgcc 1080

ggggaggatt ccacacttcc gctcctttgg ggataaacct attaattatt gctactatca 1140

agagggctgg gcattctctg ctggtaattc ctgaagaggc atgactgctt ttctcagccc 1200

caagcctcta gtctgggtgt gtacggaggg tctagcctgg gtgtgtacgg agggtctagc 1260

ctgggtgagt acggagggtc tagcctgggt gagtacggag ggtctagcct gggtgagtac 1320

ggagagtcta gcctgggtgt gtatggagga tctagcctgg gtgagtatgg agggtctagc 1380

ctgggtgagt atggagggtc tagcctgggt gtgtatggag ggtctagcct gggtgagtat 1440

ggagggtcta gcctgggtgt gtatggaggg tctagcctgg gtgagtatgg agggtctagc 1500

ctgggtgtgt acggagggtc tagtctgagt gcgtgtgggg acctcagaac actgtgacct 1560

tagcccagca agccaggccc ttcatgaagg ccaagaaggc tgccaccatt ccctgccagc 1620

ccaagaactc cagcttcccc actgcctctg tgtgcccctt tgcgtcctgt gaaggccatt 1680

gagaaatgcc cagtgtgccc cctgggaaag ggcacggcct gtgctcctga cacgggctgt 1740

gcttggccac agaaccaccc agcgtctccc ctgctgctgt ccacgtcagt tcatgaggca 1800

acgtcgcgtg gtctcagacg tggagcagcc agcggcagct cagagcaggg cactgtgtcc 1860

ggcggagcca agtccactct gggggagctc tggcggggac cacgggccac tgctcaccca 1920

ctggccccga gggggggtgta gacgccaaga ctcacgcatg tgtgacatcc ggagtcctgg 1980

agccgggtgt cccagtggca ccactaggtg cctgctgcct ccacagtggg gttcacaccc 2040

agggctcctt ggtcccccac aacctgcccc ggccaggcct gcagacccag actccagcca 2100

gacctgcctc acccaccaat gcagccgggg ctggcgacac cagccaggtg ctggtcttgg 2160

gccagttctc ccacgacggc tcaccctccc ctccatctgc gttgatgctc agaatcgcct 2220

acctgtgcct gcgtgtaaac cacagcctca gaccagctat ggggagagga caacacggag 2280

gatatccagc ttccccggtc tggggtgagg agtgtgggga gcttgggcat cctcctccag 2340

cctcctccag cccccaggca gtgccttacc tgtggtgccc agaaaagtgc ccctaggttg 2400

gtgggtctac aggagcctca gccaggcagc ccaccccacc ctggggccct gcctcaccaa 2460

ggaaataaag actcaaagaa gccttttttt ttttttttt 2500

<210> 3
<211> 99
<212> PRT
<213> Homo sapiens

<400> 3

Met Thr Ser Lys Leu Ala Val Ala Leu Leu Ala Ala Phe Leu Ile Ser
1 5 10 15

Ala Ala Leu Cys Glu Gly Ala Val Leu Pro Arg Ser Ala Lys Glu Leu
20 25 30

Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro Lys Phe
35 40 45

Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala Asn Thr
50 55 60

Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu Asp Pro
65 70 75 80

Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys Arg Ala
85 90 95

Glu Asn Ser

<210> 4
<211> 5191
<212> DNA
<213> Homo sapiens

<400> 4

gaattcagta acccaggcat tattttatcc tcaagtctta ggttggttgg agaaagataa 60

caaaaagaaa catgattgtg cagaaacaga caaacctttt tggaaagcat ttgaaaatgg 120

cattcccccc ccacagtgtg ttcacagtgt gggcaaattc actgctctgt cgtactttct 180

gaaaatgaag aactgttaca ccaaggtgaa ttatttataa attatgtact tgcccagaag 240

cgaacagact tttactatca taagaaccct tccttggtgt gctctttatc tacagaatcc 300

aagacctttc aagaaaggtc ttggattctt ttcttcagga cactaggaca taaagccacc 360

tttttatgat ttgttgaaat ttctcactcc atccctttg ctgatgatca tgggtcctca 420

gaggtcagac ttggtgtcct tggataaaga gcatgaagca acagtggctg aaccagagtt 480

ggaacccaga tgctctttcc actaagcata caactttcca ttagataaca cctccctccc 540

accccaacca agcagctcca gtgcaccact ttctggagca taaacatacc ttaactttac 600

aacttgagtg gccttgaata ctgttcctat ctggaatgtg ctgttctctt tcatcttcct 660

ctattgaagc cctcctattc ctcaatgcct tgctccaact gcctttggaa gattctgctc 720

ttatgcctcc actggaatta atgtcttagt accacttgtc tattctgcta tatagtcagt 780

ccttacattg ctttcttctt ctgatagacc aaactcttta aggacaagta cctagtctta 840

tctatttcta gatcccccac attactcaga aagttactcc ataaatgttt gtggaactga 900

tttctatgtg aagacatgtg ccccttcact ctgttaacta gcattagaaa aacaaatctt 960

ttgaaaagtt gtagtatgcc cctaagagca gtaacagttc ctagaaactc tctaaaatgc 1020

ttagaaaaag atttatttta aattacctcc ccaataaaat gattggctgg cttatcttca 1080

ccatcatgat agcatctgta attaactgaa aaaaaataat tatgccatta aaagaaaatc 1140

atccatgatc ttgttctaac acctgccact ctagtactat atctgtcaca tggtctatga 1200

taaagttatc tagaaataaa aaagcataca attgataatt caccaaattg tggagcttca 1260

gtattttaaa tgtatattaa aattaaatta ttttaaagat caaagaaaac tttcgtcata 1320

ctccgtattt gataaggaac aaataggaag tgtgatgact caggtttgcc ctgaggggat 1380

gggccatcag ttgcaaatcg tggaatttcc tctgacataa tgaaaagatg agggtgcata 1440

agttctctag tagggtgatg atataaaaag ccaccggagc actccataag gcacaaactt 1500

tcagagacag cagagcacac aagcttctag gacaagagcc aggaagaaac caccggaagg 1560

aaccattctc actgtgtgta aacatgactt ccaagctggc cgtggctctc ttggcagcct 1620

tcctgatttc tgcagctctg tgtgaaggta agcacatctt tctgacctac agcgttttcc 1680

tatgtctaaa tgtgatcctt agatagcaaa gctattcttg atgctttggt aacaaacatc 1740

ctttttattc agaaacagaa tataatctta gcagtcaatt aatgttaaat tgaagattta 1800

gaaaaaacta tatataacac ttaggaaata taaaggtttg atcaatatag atattctgct 1860

tttataattt ataccaggta gcatgcatat atttaacgta aataagtaat ttatagtatg 1920

tcctattgag aaccacggtt acctatatta tgtattaata ttgagttgag caaggtaact 1980

cagacaattc cactccttgt agtatttcat tgacaagcct cagatttgtc attaattcct 2040

gtctggttta aagataccct gattatagac caggcatgta taacttattt atatatttct 2100

gttaattctt tctgaaggca atttctatgc tggagagtct tagcttgcct actataaata 2160

acactgtggt atcacagagg attatgcaat attgaccaga taaaaatacc atgaagatgt 2220

tgatattgta caaaaagaac tctaactctt atataggaag ttgttcaatg ttgtcagtta 2280

tgactgtttt ttaaaacaaa gaactaactg aggtcaaggg ctaggagata ttcaggaatg 2340

agttcactag aaacatgatg ccttccatag tctccaaata atcatattgg aattagaagg 2400

aagtagctgg cagagctgtg cctgttgata aaatcaatcc ttaatcactt tttcccccaa 2460

caggtgcagt tttgccaagg agtgctaaag aacttagatg tcagtgcata aagacatact 2520

ccaaaccttt ccaccccaaa tttatcaaag aactgagagt gattgagagt ggaccacact 2580

gcgccaacac agaaattatg taagtacttt aaaaaagatt agatattttg ttttagcaaa 2640

cttaaaatta aggaaggtgg aaatatttag gaaagttcca ggtgttagga ttacagtagt 2700

aaatgaaaca aaacaaaata aaaatatttg tctacatgac atttaaatat ggtagcttcc 2760

acaactacta taaatgttat tttggactta gactttatgc ctgacttaag gaatcatgat 2820

ttgaatgcaa aaactaaata ttaatctgaa ccatttcttt cttatttcag tgtaaagctt 2880

tctgatggaa gagagctctg tctggacccc aaggaaaact gggtgcagag ggttgtggag 2940

aagtttttga agaggtaagt tatatatttt ttaatttaaa tttttcattt atcctgagac 3000

atataatcca aagtcagcct ataaatttct ttctgttgct aaaaatcgtc attaggtatc 3060

tgccttttttg gttaaaaaaa aaggaatagc atcaatagtg agtttgttgt acttatgacc 3120

agaaagacca tacatagttt gcccaggaaa ttctgggttt aagcttgtgt cctatactct 3180

tagtaaagtt ctttgtcact cccagtagtg tcctatttta gatgataatt tctttgatct 3240

ccctatttat agttgagaat atagagcatt tctaacacat gaatgtcaaa gactatattg 3300

actttttcaag aaccctactt tccttcttat taaacatagc tcatctttat atttttaatt 3360

ttattttagg gctgagaatt cataaaaaaa ttcattctct gtggtatcca agaatcagtg 3420

aagatgccag tgaaacttca agcaaatcta cttcaacact tcatgtattg tgtgggtctg 3480

ttgtagggtt gccagatgca atacaagatt cctggttaaa tttgaatttc agtaaacaat 3540

gaatagtttt tcattgtacc atgaaatatc cagaacatac ttatatgtaa agtattattt 3600

atttgaatct acaaaaaaca acaaataatt tttaaatata aggattttcc tagatattgc 3660

acgggagaat atacaaatag caaaattggg ccaagggcca agagaatatc cgaactttaa 3720

tttcaggaat tgaatgggtt tgctagaatg tgatatttga agcatcacat aaaaatgatg 3780

ggacaataaa ttttgccata aagtcaaatt tagctggaaa tcctggattt ttttctgtta 3840

aatctggcaa ccctagtctg ctagccagga tccacaagtc cttgttccac tgtgccttgg 3900

tttctccttt atttctaagt ggaaaaagta ttagccacca tcttacctca cagtgatgtt 3960

gtgaggacat gtggaagcac tttaagtttt ttcatcataa cataaattat tttcaagtgt 4020

aacttattaa cctatttatt atttatgtat ttatttaagc atcaaatatt tgtgcaagaa 4080

tttggaaaaa tagaagatga atcattgatt gaatagttat aaagatgtta tagtaaattt 4140

attttatttt agatattaaa tgatgtttta ttagataaat ttcaatcagg gtttttagat 4200

taaacaaaca aacaattggg tacccagtta aattttcatt tcagatatac aacaaataat 4260

tttttagtat aagtacatta ttgtttatct gaaattttaa ttgaactaac aatcctagtt 4320

tgatactccc agtcttgtca ttgccagctg tgttggtagt gctgtgttga attacggaat 4380

aatgagttag aactattaaa acagccaaaa ctccacagtc aatattagta atttcttgct 4440

ggttgaaact tgtttattat gtacaaatag attcttataa tattatttaa atgactgcat 4500

ttttaaatac aaggctttat atttttaact ttagtgtttt tatgtgctct ccaaattttt 4560

tttactgttt ctgattgtat ggaaatataa aagtaaatat gaaacattta aaatataatt 4620

tgttgtcaaa gtaatcaagt gtttgtcttt tttttagttt tagcttattg ggattctctt 4680

tgtttatatt taaaattata ctttgattta gaaaacataa atgcttcccc ttagcatttt 4740

gttatggaaa attacaaact tttatttttа gaaaacagaa ctcctttcca gaaataggtt 4800

acaaacagta gtgtcctcca cagaatgttg gaaatgtttt caactcccca ctgtatacta 4860

tcttgctaat aagtctgtct tcagatttcg attaaccggt ttgtatgtct gtgcacttta 4920

gcatagctgg acattaaaga ggaaagagag tacatattat aagttgctta tcagtaactg 4980

aggagtaaaa ctgataaatg tgaggcaaag aagtttaaaa tatggttaaa gcctaagcat 5040

atttgcaaac aaatcaaaca atactctgag aagtaaaaac ataattattt aattaacaaa 5100

tttcagtgga taaattttat aacaaattag acacagttga aaataaaatt agaaaactag 5160

aaaatagaac aaaagaaact tctggaattc a 5191

<210> 5
<211> 366
<212> PRT
<213> Homo sapiens

<400> 5

Met Val Leu His Leu Leu Leu Phe Leu Leu Leu Thr Pro Gln Gly Gly
1 5 10 15

His Ser Cys Gln Gly Leu Glu Leu Ala Arg Glu Leu Val Leu Ala Lys
20 25 30

Val Arg Ala Leu Phe Leu Asp Ala Leu Gly Pro Pro Ala Val Thr Arg
35 40 45

Glu Gly Gly Asp Pro Gly Val Arg Arg Leu Pro Arg Arg His Ala Leu
50 55 60

Gly Gly Phe Thr His Arg Gly Ser Glu Pro Glu Glu Glu Glu Asp Val
65 70 75 80

Ser Gln Ala Ile Leu Phe Pro Ala Thr Asp Ala Ser Cys Glu Asp Lys
85 90 95

Ser Ala Ala Arg Gly Leu Ala Gln Glu Ala Glu Glu Gly Leu Phe Arg
100 105 110

Tyr Met Phe Arg Pro Ser Gln His Thr Arg Ser Arg Gln Val Thr Ser
115 120 125

Ala Gln Leu Trp Phe His Thr Gly Leu Asp Arg Gln Gly Thr Ala Ala
130 135 140

Ser Asn Ser Ser Glu Pro Leu Leu Gly Leu Leu Ala Leu Ser Pro Gly
145 150 155 160

```
Gly Pro Val Ala Val Pro Met Ser Leu Gly His Ala Pro Pro His Trp
                165                 170                 175

Ala Val Leu His Leu Ala Thr Ser Ala Leu Ser Leu Leu Thr His Pro
            180                 185                 190

Val Leu Val Leu Leu Leu Arg Cys Pro Leu Cys Thr Cys Ser Ala Arg
        195                 200                 205

Pro Glu Ala Thr Pro Phe Leu Val Ala His Thr Arg Thr Arg Pro Pro
    210                 215                 220

Ser Gly Gly Glu Arg Ala Arg Arg Ser Thr Pro Leu Met Ser Trp Pro
225                 230                 235                 240

Trp Ser Pro Ser Ala Leu Arg Leu Leu Gln Arg Pro Pro Glu Glu Pro
                245                 250                 255

Ala Ala His Ala Asn Cys His Arg Val Ala Leu Asn Ile Ser Phe Gln
            260                 265                 270

Glu Leu Gly Trp Glu Arg Trp Ile Val Tyr Pro Pro Ser Phe Ile Phe
        275                 280                 285

His Tyr Cys His Gly Gly Cys Gly Leu His Ile Pro Pro Asn Leu Ser
    290                 295                 300

Leu Pro Val Pro Gly Ala Pro Pro Thr Pro Ala Gln Pro Tyr Ser Leu
305                 310                 315                 320

Leu Pro Gly Ala Gln Pro Cys Cys Ala Ala Leu Pro Gly Thr Met Arg
                325                 330                 335

Pro Leu His Val Arg Thr Thr Ser Asp Gly Gly Tyr Ser Phe Lys Tyr
            340                 345                 350

Glu Thr Val Pro Asn Leu Leu Thr Gln His Cys Ala Cys Ile
        355                 360                 365
```

<210> 6
<211> 1338
<212> DNA
<213> Homo sapiens

<400> 6
gaaggactgg ggaagactgg atgagaaggg tagaagaggg tgggtgtggg atggggaggg 60

gagagtggaa aggccctggg cagaccctgg cagaaggggc acggggcagg gtgtgagttc 120

cccactagca gggccaggtg agctatggtg ctgcacctac tgctcttctt gctgctgacc 180

ccacagggtg ggcacagctg ccaggggctg gagctggccc gggaacttgt tctggccaag 240

gtgagggccc tgttcttgga tgccttgggg ccccccgcgg tgaccaggga aggtggggac 300

cctggagtca ggcggctgcc ccgaagacat gccctggggg gcttcacaca caggggctct 360

gagcccgagg aagaggagga tgtctcccaa gccatccttt tcccagccac agatgccagc 420

tgtgaggaca agtcagctgc cagagggctg gcccaggagg ctgaggaggg cctcttcaga 480

tacatgttcc ggccatccca gcatacacgc agccgccagg tgacttcagc ccagctgtgg 540

ttccacaccg ggctggacag gcagggcaca gcagcctcca atagctctga gcccctgcta 600

ggcctgctgg cactgtcacc gggaggaccc gtggctgtgc ccatgtcttt gggccatgct 660

ccccctcact gggccgtgct gcacctggcc acctctgctc tctctctgct gacccacccc 720

gtcctggtgc tgctgctgcg ctgtcccctc tgtacctgct cagcccggcc tgaggccacg 780

cccttcctgg tggcccacac tcggaccaga ccacccagtg gaggggagag agcccgacgc 840

tcaactcccc tgatgtcctg gccttggtct ccctctgctc tgcgcctgct gcagaggcct 900

ccggaggaac cggctgccca tgccaactgc cacagagtag cactgaacat ctccttccag 960

gagctgggct gggaacggtg gatcgtgtac cctcccagtt tcatcttcca ctactgtcat 1020

ggtggttgtg ggctgcacat cccaccaaac ctgtcccttc cagtccctgg ggctcccccc 1080

accccagccc agccctactc cttgctgcca ggggcccagc cctgctgtgc tgctctccca 1140

gggaccatga ggcccctaca tgtccgcacc acctcggatg gaggttactc tttcaagtat 1200

gagacagtgc ccaaccttct cacgcagcac tgtgcttgta tctaagggtg gggggtcttc 1260

cttcttaatc ccatggctgg tggccacgcc cccaccatca tcagctggga ggaaaggcag 1320

agttgggaaa tagatggc 1338

<210> 7
<211> 419
<212> PRT
<213> Homo sapiens

<400> 7

Met His Leu Leu Gly Phe Phe Ser Val Ala Cys Ser Leu Leu Ala Ala
1 5 10 15

Ala Leu Leu Pro Gly Pro Arg Glu Ala Pro Ala Ala Ala Ala Ala Phe
20 25 30

Glu Ser Gly Leu Asp Leu Ser Asp Ala Glu Pro Asp Ala Gly Glu Ala
35 40 45

Thr Ala Tyr Ala Ser Lys Asp Leu Glu Glu Gln Leu Arg Ser Val Ser
50 55 60

Ser Val Asp Glu Leu Met Thr Val Leu Tyr Pro Glu Tyr Trp Lys Met
65 70 75 80

Tyr Lys Cys Gln Leu Arg Lys Gly Gly Trp Gln His Asn Arg Glu Gln
85 90 95

Ala Asn Leu Asn Ser Arg Thr Glu Glu Thr Ile Lys Phe Ala Ala Ala
100 105 110

His Tyr Asn Thr Glu Ile Leu Lys Ser Ile Asp Asn Glu Trp Arg Lys
115 120 125

Thr Gln Cys Met Pro Arg Glu Val Cys Ile Asp Val Gly Lys Glu Phe
130 135 140

Gly Val Ala Thr Asn Thr Phe Phe Lys Pro Pro Cys Val Ser Val Tyr
145 150 155 160

Arg Cys Gly Gly Cys Cys Asn Ser Glu Gly Leu Gln Cys Met Asn Thr
165 170 175

Ser Thr Ser Tyr Leu Ser Lys Thr Leu Phe Glu Ile Thr Val Pro Leu
180 185 190

Ser Gln Gly Pro Lys Pro Val Thr Ile Ser Phe Ala Asn His Thr Ser
195 200 205

Cys Arg Cys Met Ser Lys Leu Asp Val Tyr Arg Gln Val His Ser Ile
210 215 220

```
Ile Arg Arg Ser Leu Pro Ala Thr Leu Pro Gln Cys Gln Ala Ala Asn
225                 230                 235                 240

Lys Thr Cys Pro Thr Asn Tyr Met Trp Asn Asn His Ile Cys Arg Cys
                245                 250                 255

Leu Ala Gln Glu Asp Phe Met Phe Ser Ser Asp Ala Gly Asp Asp Ser
            260                 265                 270

Thr Asp Gly Phe His Asp Ile Cys Gly Pro Asn Lys Glu Leu Asp Glu
        275                 280                 285

Glu Thr Cys Gln Cys Val Cys Arg Ala Gly Leu Arg Pro Ala Ser Cys
    290                 295                 300

Gly Pro His Lys Glu Leu Asp Arg Asn Ser Cys Gln Cys Val Cys Lys
305                 310                 315                 320

Asn Lys Leu Phe Pro Ser Gln Cys Gly Ala Asn Arg Glu Phe Asp Glu
                325                 330                 335

Asn Thr Cys Gln Cys Val Cys Lys Arg Thr Cys Pro Arg Asn Gln Pro
            340                 345                 350

Leu Asn Pro Gly Lys Cys Ala Cys Glu Cys Thr Glu Ser Pro Gln Lys
        355                 360                 365

Cys Leu Leu Lys Gly Lys Lys Phe His His Gln Thr Cys Ser Cys Tyr
    370                 375                 380

Arg Arg Pro Cys Thr Asn Arg Gln Lys Ala Cys Glu Pro Gly Phe Ser
385                 390                 395                 400

Tyr Ser Glu Glu Val Cys Arg Cys Val Pro Ser Tyr Trp Lys Arg Pro
                405                 410                 415

Gln Met Ser
```

<210> 8
<211> 2015
<212> DNA
<213> Homo sapiens

<400> 8
cgcggggtgt tctggtgtcc cccgccccgc ctctccaaaa agctacaccg acgcggaccg 60

cggcggcgtc ctccctcgcc ctcgcttcac ctcgcgggct ccgaatgcgg ggagctcgga 120

tgtccggttt cctgtgaggc ttttacctga cacccgccgc ctttccccgg cactggctgg 180

gagggcgccc tgcaaagttg ggaacgcgga gccccggacc cgctcccgcc gcctccggct 240

cgcccagggg gggtcgccgg gaggagcccg ggggagaggg accaggaggg gcccgcggcc 300

tcgcaggggc gcccgcgccc ccacccctgc ccccgccagc ggaccggtcc cccacccccg 360

gtccttccac catgcacttg ctgggcttct tctctgtggc gtgttctctg ctcgccgctg 420

cgctgctccc gggtcctcgc gaggcgcccg ccgccgccgc cgccttcgag tccggactcg 480

acctctcgga cgcggagccc gacgcgggcg aggccacggc ttatgcaagc aaagatctgg 540

aggagcagtt acggtctgtg tccagtgtag atgaactcat gactgtactc tacccagaat 600

attggaaaat gtacaagtgt cagctaagga aaggaggctg gcaacataac agagaacagg 660

ccaacctcaa ctcaaggaca gaagagacta taaaatttgc tgcagcacat tataatacag 720

agatcttgaa aagtattgat aatgagtgga gaaagactca atgcatgcca cgggaggtgt 780

gtatagatgt ggggaaggag tttggagtcg cgacaaacac cttctttaaa cctccatgtg 840

tgtccgtcta cagatgtggg ggttgctgca atagtgaggg gctgcagtgc atgaacacca 900

gcacgagcta cctcagcaag acgttatttg aaattacagt gcctctctct caaggcccca 960

aaccagtaac aatcagtttt gccaatcaca cttcctgccg atgcatgtct aaactggatg 1020

tttacagaca agttcattcc attattagac gttccctgcc agcaacacta ccacagtgtc 1080

aggcagcgaa caagacctgc cccaccaatt acatgtggaa taatcacatc tgcagatgcc 1140

tggctcagga agattttatg ttttcctcgg atgctggaga tgactcaaca gatggattcc 1200

atgacatctg tggaccaaac aaggagctgg atgaagagac ctgtcagtgt gtctgcagag 1260

cggggcttcg gcctgccagc tgtggacccc acaaagaact agacagaaac tcatgccagt 1320

gtgtctgtaa aaacaaactc ttccccagcc aatgtggggc caaccgagaa tttgatgaaa 1380

acacatgcca gtgtgtatgt aaaagaacct gccccagaaa tcaaccccta aatcctggaa 1440

aatgtgcctg tgaatgtaca gaaagtccac agaaatgctt gttaaaagga aagaagttcc 1500

accaccaaac atgcagctgt tacagacggc catgtacgaa ccgccagaag gcttgtgagc 1560

caggattttc atatagtgaa gaagtgtgtc gttgtgtccc ttcatattgg aaaagaccac 1620

aaatgagcta agattgtact gttttccagt tcatcgattt tctattatgg aaaactgtgt 1680

tgccacagta gaactgtctg tgaacagaga gacccttgtg ggtccatgct aacaaagaca 1740

aaagtctgtc tttcctgaac catgtggata actttacaga aatggactgg agctcatctg 1800

caaaaggcct cttgtaaaga ctggttttct gccaatgacc aaacagccaa gattttcctc 1860

ttgtgatttc tttaaaagaa tgactatata atttatttcc actaaaaata ttgtttctgc 1920

attcattttt atagcaacaa caattggtaa aactcactgt gatcaatatt tttatatcat 1980

gcaaaatatg tttaaaataa aatgaaaatt gtatt 2015

<210> 9
<211> 147
<212> PRT
<213> Homo sapiens

<400> 9

Met Val Met Gly Leu Gly Val Leu Leu Leu Val Phe Val Leu Gly Leu
1 5 10 15

Gly Leu Thr Pro Pro Thr Leu Ala Gln Asp Asn Ser Arg Tyr Thr His
20 25 30

Phe Leu Thr Gln His Tyr Asp Ala Lys Pro Gln Gly Arg Asp Asp Arg
35 40 45

Tyr Cys Glu Ser Ile Met Arg Arg Arg Gly Leu Thr Ser Pro Cys Lys
50 55 60

Asp Ile Asn Thr Phe Ile His Gly Asn Lys Arg Ser Ile Lys Ala Ile
65 70 75 80

Cys Glu Asn Lys Asn Gly Asn Pro His Arg Glu Asn Leu Arg Ile Ser
85 90 95

Lys Ser Ser Phe Gln Val Thr Thr Cys Lys Leu His Gly Gly Ser Pro
100 105 110

Trp Pro Pro Cys Gln Tyr Arg Ala Thr Ala Gly Phe Arg Asn Val Val
115 120 125

Val Ala Cys Glu Asn Gly Leu Pro Val His Leu Asp Gln Ser Ile Phe
130 135 140

Arg Arg Pro
145

<210> 10
<211> 4668
<212> DNA
<213> Homo sapiens

<400> 10
tgtttgcatt aagttcatag attataattt gtaatggaat caacaccaaa tgcaaattag 60

aaagagagcc cactttgctc acccagtcac gtcttcccat gtaaccatag aacgttgggg 120

tcctgtgtct ttctagatcc acagtcttgc tctcagaaca ggctagccac accacaggcc 180

tagtgccagg acccatggcc tttttttaag ctcagactcc cttctgtgaa cagcaatatc 240

cccacaactt gtacaacatt ggtgcttcct gcaagggcta cagaactatt tgatacgaaa 300

atgttcattg acttacacac aagagaagca caaaataaaa aattaataat taatttaatg 360

tctttgaaaa tgtaccattt atttttacat ttggggtcat aagaattgta ttacacttaa 420

gaatgcaata caatttgaag atcagatttt tctccctttg tgagaatttc tcagtatgtg 480

tgatgactac caagaaatca tagccagtca taaattcagt gagttactca taaacgaaca 540

agaaccacct acttcttggg gaggtaggtc tgcttccctt caactcagga tacaactgct 600

ttcaactgct ttcttcacat tagctgacta attagctaga agcctgtcgt aaacaatttt 660

atggttgact ccttccctgg gctcagggtt ccctagaaca gagaggtccc caaatcccgg 720

tctgtggcct gtccgcctaa gctctgcctc ctgccagatc agcaggcagc attagattct 780

cataggagct ggacgcctat tgtgaactgc gcatgtgcgg gatccagatt gtgcactctt 840

tatgagaatc taactaatgc ttgatgatct atctgaacca gaacaatttc atcctgaaac 900

catcccccac caatccatag aaatactgtc ttccacaaaa atgatccctg gtgccaaaaa 960

tgttagagac cactccccta aaactctctt cttagctctc acctcctgta ttactatctc 1020

atctcagtac attgaagccc ccatcttttc cccatggatg cctcatttcc tattagggag 1080

gcatttttt attttttgtt tttatttttt tccgagacgg agtctcgctc tgtcgccaag 1140

gctggagtgc agtggcgcga tctcggctca ctgcaagctc cgcctcccgg gttcacgcca 1200

ttctcctgcc tcagcctccc aagtagctgg gactacaggc gcccgcacta cgcccggcta 1260

atttttgta ttttagtag agacggggtt tcaccgtggt agccaggatg gtctcgatct 1320

cctgacctcg tgatccgccc gccttggcct cccaaagtgc tgggattaca ggcgtgagac 1380

cgcgcccggc cgtcatttgg tatgtcttaa tgtgcctcag gacctagcac agtccctggt 1440

acccagtaga gacctatgta atgttcgtta ttcaataata aatacatgaa ttaaagagtg 1500

agagtggatt ttgtaatgtt acgactgata gagaaatact cagtgattct aagggatggg 1560

gaagaacggt tggagctaga ggttgtgctc aggaaactat taaatagacg ttccgcagga 1620

agggattgac gaagtgtgag gttaatgagg aagggaaaat agaatataaa atttggtggt 1680

ggaaaagatc tgattcatga tgccgtgtca gagagcaaag ctcctgtcct tttggcctaa 1740

tttggtgatg ctgttcttgg gtctaccaca cctccttttg ccctccgcag gagcctgtgt 1800

tggaagagat ggtgatgggc ctgggcgttt tgttgttggt cttcgtgctg ggtctgggtc 1860

tgaccccacc gaccctggct caggataact ccaggtacac acacttcctg acccagcact 1920

atgatgccaa accacagggc cgggatgaca gatactgtga aagcatcatg aggagacggg 1980

gcctgacctc accctgcaaa gacatcaaca catttattca tggcaacaag cgcagcatca 2040

aggccatctg tgaaaacaag aatggaaacc ctcacagaga aaacctaaga ataagcaagt 2100

cttctttcca ggtcaccact tgcaagctac atggaggttc cccctggcct ccatgccagt 2160

accgagccac agcggggttc agaaacgttg ttgttgcttg tgaaaatggc ttacctgtcc 2220

acttggatca gtcaattttc cgtcgtccgt aaccagcggg cccctggtca agtgctggct 2280

ctgctgtcct tgccttccat ttcccctctg cacccagaac agtggtggca acattcattg 2340

ccaagggccc aaagaaagag ctacctggac cttttgtttt ctgtttgaca acatgtttaa 2400

taaataaaaa tgtcttgata tcagtaagaa tcagagtctt ctcactgatt ctgggcatat 2460

tgatctttcc cccattttct ctacttggct gctccctgag aggactgcat aggatagaaa 2520

tgccttttttc ttttcttttc gttttttttt ttttttttttt ttgagatgga gtctcactct 2580

gtcgcccagg cttaagtgca atggcacaat ctcggctcac tgcaacctct ctctcctggg 2640

ttcaagtgat tctcctgcct cagcctccca aatagctgag attacaggca tgcaccacca 2700

cacctggcta atttttgtgt ttttagtaga gacagggttt caccgttttg gccaggttgg 2760

tcttgaactc ctgacctcgg gagatccgcc caccttggcc tctctttgtg ctgggattac 2820

aggcatgagc cactgagccg ggccactttt tccttatcag tcagttttta caagtcatta 2880

gggaggtaga ctttacctct ctgtgaagga aagtatggta tgttgatcta cagagagaga 2940

tggaaaaatt ccagggctcg tagctactaa gcagaatttc caagataggc aaattgtttt 3000

ttctgtcaaa taataagcta atattacttc tacaaatatg agaccttgga gagaagtttc 3060

caaggaccaa gtaccaacat accaacagat tattatagtt tctctcactc ttacacacac 3120

acacacacat atacacatat gtaatccagc atgaatacca aaattcattc agggtagcca 3180

ccttttgtct taatcgagag ataattttga tgtttgaatg gaatgctccc aggatattct 3240

cttgtcatgg ttattttata taaaattcaa aaaccaatta cattatttcc tctgtaatct 3300

tttactttat caactaatgt ctggcaagtg tgatgttttg gggaagttat agaagattcc 3360

ggccaggcgc ttatctcacg cttgtaatcc agcactttgg gaagctgagg cggacagatc 3420

acgaggtcaa gagatcaaga ccatcctgga caacatggtg aaaccttgtc tctactaaaa 3480

atgtgaaaat tagctgggcg tggtggcaca cacctatagt cccagctact cgggaggctg 3540

aggcaggaga atcgcttgaa cctaggaggc ggaggttgca ctgagccgag atcacgccac 3600

tgcactccag cctgggcgac agagcgagac tccatctcaa aaaaaaaaaa aaaagaaaga 3660

tcccagttta tcccagttta tcccttattc ttcctcaatt ctcaagattt gtttttaagt 3720

taacataact taggttaaca cactctttgt aaaatacact gttcaatcta cagactcagt 3780

ggttagcttc ctgttaacta atttctgttg acaggtactt ggatatttta tttagaaagt 3840

ggttgccaat aaattagtta taagtcgcca gtttcactgc cttgtgaaca cataattatt 3900

gtggtctcag tattccctat ggtggcttct cctgctcctg gtattgccct gaaatgggcc 3960

aaaagccgtg gctccccaat gctcaggtta tagaacattg tccaggtacc acctaggaga 4020

gcccagcctc actgaaagta ttcaaattta ggaatgggtt tgagaagtag gtagctggta 4080

tgtgcttagc acaagaatct ctcttccttg ggttagtctg tttcaaaact gaaaacactg 4140

tcattcctta agaaaatagg aaaaagtatt ccaaacctct gtcactagaa aatttgccat 4200

attaccaaat ctcaaaaacc tctcaggaaa tgagaaagtc ccagtttctg gtaaactatt 4260

tgggcccttt tctcaagttc tccttccagt gctatttcct tgaggtgagg caaagttact 4320

caagatcatc gctgccactc aaggccttga tagggcaagt gaaaggcatg gaccattatt 4380

atattgatca cagcataagc tgtgaaaacc cacatcttct ccaaacatct gcttggagca 4440

ttatcatcgc atagtttgct ctggtgttca gggaaatcgc tgtttcatag gaaatcacat 4500

ggcagtggga tgggagtgtt tcctgacctg ccgatggtac tggcacctga gcaagcattc 4560

ctagtccttt ttggtctggg cctcttgttc tatcacaacc acaagctgtt taaaataaaa 4620

acgtcaagtc acaggcaggt cattttatcc tgcgtgaatc aattgaag 4668

<210> 11
<211> 734
<212> PRT
<213> Homo sapiens

<400> 11

Met Trp Val Leu Phe Leu Leu Ser Gly Leu Gly Gly Leu Arg Met Asp
1 5 10 15

Ser Asn Phe Asp Ser Leu Pro Val Gln Ile Thr Val Pro Glu Lys Ile
20 25 30

Arg Ser Ile Ile Lys Glu Gly Ile Glu Ser Gln Ala Ser Tyr Lys Ile
35 40 45

Val Ile Glu Gly Lys Pro Tyr Thr Val Asn Leu Met Gln Lys Asn Phe
50 55 60

Leu Pro His Asn Phe Arg Val Tyr Ser Tyr Ser Gly Thr Gly Ile Met
65 70 75 80

Lys Pro Leu Asp Gln Asp Phe Gln Asn Phe Cys His Tyr Gln Gly Tyr
85 90 95

Ile Glu Gly Tyr Pro Lys Ser Val Val Met Val Ser Thr Cys Thr Gly
100 105 110

Leu Arg Gly Val Leu Gln Phe Glu Asn Val Ser Tyr Gly Ile Glu Pro
115 120 125

Leu Glu Ser Ser Val Gly Phe Glu His Val Ile Tyr Gln Val Lys His
130 135 140

Lys Lys Ala Asp Val Ser Leu Tyr Asn Glu Lys Asp Ile Glu Ser Arg
145 150 155 160

Asp Leu Ser Phe Lys Leu Gln Ser Ala Glu Pro Gln Gln Asp Phe Ala
165 170 175

Lys Tyr Ile Glu Met His Val Ile Val Glu Lys Gln Leu Tyr Asn His
180 185 190

Met Gly Ser Asp Thr Thr Val Val Ala Gln Lys Val Phe Gln Leu Ile
195 200 205

Gly Leu Thr Asn Ala Ile Phe Val Ser Phe Asn Ile Thr Ile Ile Leu
210 215 220

Ser Ser Leu Glu Leu Trp Ile Asp Glu Asn Lys Ile Ala Thr Thr Gly
225 230 235 240

Glu Ala Asn Glu Leu Leu His Thr Phe Leu Arg Trp Lys Thr Ser Tyr
245 250 255

Leu Val Leu Arg Pro His Asp Val Ala Phe Leu Leu Val Tyr Arg Glu
260 265 270

Lys Ser Asn Tyr Val Gly Ala Thr Phe Gln Gly Lys Met Cys Asp Ala
275 280 285

Asn Tyr Ala Gly Gly Val Val Leu His Pro Arg Thr Ile Ser Leu Glu
290 295 300

Ser Leu Ala Val Ile Leu Ala Gln Leu Leu Ser Leu Ser Met Gly Ile
305 310 315 320

Thr Tyr Asp Asp Ile Asn Lys Cys Gln Cys Ser Gly Ala Val Cys Ile
325 330 335

Met Asn Pro Glu Ala Ile His Phe Ser Gly Val Lys Ile Phe Ser Asn
340 345 350

Cys Ser Phe Glu Asp Phe Ala His Phe Ile Ser Lys Gln Lys Ser Gln
355 360 365

Cys Leu His Asn Gln Pro Arg Leu Asp Pro Phe Phe Lys Gln Gln Ala
370 375 380

Val Cys Gly Asn Ala Lys Leu Glu Ala Gly Glu Glu Cys Asp Cys Gly
385 390 395 400

Thr Glu Gln Asp Cys Ala Leu Ile Gly Glu Thr Cys Cys Asp Ile Ala
405 410 415

Thr Cys Arg Phe Lys Ala Gly Ser Asn Cys Ala Glu Gly Pro Cys Cys
420 425 430

Glu Asn Cys Leu Phe Met Ser Lys Glu Arg Met Cys Arg Pro Ser Phe
435 440 445

Glu Glu Cys Asp Leu Pro Glu Tyr Cys Asn Gly Ser Ser Ala Ser Cys
450 455 460

Pro Glu Asn His Tyr Val Gln Thr Gly His Pro Cys Gly Leu Asn Gln
465 470 475 480

Trp Ile Cys Ile Asp Gly Val Cys Met Ser Gly Asp Lys Gln Cys Thr
485 490 495

Asp Thr Phe Gly Lys Glu Val Glu Phe Gly Pro Ser Glu Cys Tyr Ser
500 505 510

His Leu Asn Ser Lys Thr Asp Val Ser Gly Asn Cys Gly Ile Ser Asp
515 520 525

Ser Gly Tyr Thr Gln Cys Glu Ala Asp Asn Leu Gln Cys Gly Lys Leu
530 535 540

Ile Cys Lys Tyr Val Gly Lys Phe Leu Leu Gln Ile Pro Arg Ala Thr
545 550 555 560

Ile Ile Tyr Ala Asn Ile Ser Gly His Leu Cys Ile Ala Val Glu Phe
565 570 575

Ala Ser Asp His Ala Asp Ser Gln Lys Met Trp Ile Lys Asp Gly Thr
580 585 590

Ser Cys Gly Ser Asn Lys Val Cys Arg Asn Gln Arg Cys Val Ser Ser
595 600 605

Ser Tyr Leu Gly Tyr Asp Cys Thr Thr Asp Lys Cys Asn Asp Arg Gly
610 615 620

Val Cys Asn Asn Lys Lys His Cys His Cys Ser Ala Ser Tyr Leu Pro
625 630 635 640

```
Pro Asp Cys Ser Val Gln Ser Asp Leu Trp Pro Gly Gly Ser Ile Asp
                645                 650                 655

Ser Gly Asn Phe Pro Pro Val Ala Ile Pro Ala Arg Leu Pro Glu Arg
            660                 665                 670

Arg Tyr Ile Glu Asn Ile Tyr His Ser Lys Pro Met Arg Trp Pro Phe
        675                 680                 685

Phe Leu Phe Ile Pro Phe Phe Ile Ile Phe Cys Val Leu Ile Ala Ile
    690                 695                 700

Met Val Lys Val Asn Phe Gln Arg Lys Lys Trp Arg Thr Glu Asp Tyr
705                 710                 715                 720

Ser Ser Asp Glu Gln Pro Glu Ser Glu Ser Glu Pro Lys Gly
                725                 730
```

<210> 12
<211> 2650
<212> DNA
<213> Homo sapiens

<400> 12

```
catctcgcac ttccaactgc cctgtaacca ccaactgccc ttattccggc tgggacccag     60

gacttcaagc catgtgggtc ttgtttctgc tcagcgggct cggcgggctg cggatggaca    120

gtaattttga tagtttacct gtgcaaatta cagttccgga gaaaatacgg tcaataataa    180

aggaaggaat tgaatcgcag gcatcctaca aaattgtaat tgaagggaaa ccatatactg    240

tgaatttaat gcaaaaaaac tttttacccc ataattttag agtttacagt tatagtggca    300

caggaattat gaaaccactt gaccaagatt ttcagaattt ctgccactac caagggtata    360

ttgaaggtta tccaaaatct gtggtgatgg ttagcacatg tactggactc aggggcgtac    420

tacagtttga aaatgttagt tatggaatag aacccctgga gtcttcagtt ggctttgaac    480

atgtaattta ccaagtaaaa cataagaaag cagatgtttc cttatataat gagaaggata    540

ttgaatcaag agatctgtcc tttaaattac aaagcgcaga gccacagcaa gattttgcaa    600

agtatataga aatgcatgtt atagttgaaa aacaattgta taatcatatg gggtctgata    660

caactgttgt cgctcaaaaa gttttccagt tgattggatt gacgaatgct atttttgttt    720

catttaatat tacaattatt ctgtcttcat tggagctttg gatagatgaa aataaaattg    780
```

caaccactgg agaagctaat gagttattac acacattttt aagatggaaa acatcttatc 840

ttgttttacg tcctcatgat gtggcatttt tacttgttta cagagaaaag tcaaattatg 900

ttggtgcaac ctttcaaggg aagatgtgtg atgcaaacta tgcaggaggt gttgttctgc 960

accccagaac cataagtctg gaatcacttg cagttatttt agctcaatta ttgagcctta 1020

gtatggggat cacttatgat gacattaaca aatgccagtg ctcaggagct gtctgcatta 1080

tgaatccaga agcaattcat ttcagtggtg tgaagatctt tagtaactgc agcttcgaag 1140

actttgcaca ttttatttca aagcagaagt cccagtgtct tcacaatcag cctcgcttag 1200

atccttttt caaacagcaa gcagtgtgtg gtaatgcaaa gctggaagca ggagaggagt 1260

gtgactgtgg gactgaacag gattgtgccc ttattggaga aacatgctgt gatattgcca 1320

catgtagatt taaagccggt tcaaactgtg ctgaaggacc atgctgcgaa aactgtctat 1380

ttatgtcaaa agaaagaatg tgtaggcctt cctttgaaga atgcgacctc cctgaatatt 1440

gcaatggatc atctgcatca tgcccagaaa accactatgt tcagactggg catccgtgtg 1500

gactgaatca atggatctgt atagatggag tttgtatgag tggggataaa caatgtacag 1560

acacatttgg caaagaagta gagtttggcc cttcagaatg ttattctcac cttaattcaa 1620

agactgatgt atctggaaac tgtggtataa gtgattcagg atacacacag tgtgaagctg 1680

acaatctgca gtgcggaaaa ttaatatgta aatatgtagg taaattttta ttacaaattc 1740

caagagccac tattatttat gccaacataa gtggacatct ctgcattgct gtggaatttg 1800

ccagtgatca tgcagacagc caaaagatgt ggataaaaga tggaacttct tgtggttcaa 1860

ataaggtttg caggaatcaa agatgtgtga gttcttcata cttgggttat gattgtacta 1920

ctgacaaatg caatgataga ggtgtatgca ataacaaaaa gcactgtcac tgtagtgctt 1980

catatttacc tccagattgc tcagttcaat cagatctatg gcctggtggg agtattgaca 2040

gtggcaattt tccacctgta gctataccag ccagactccc tgaaaggcgc tacattgaga 2100

acatttacca ttccaaacca atgagatggc cattttttctt attcattcct ttctttatta 2160

ttttctgtgt actgattgct ataatggtga aagttaattt ccaaaggaaa aaatggagaa 2220

ctgaggacta ttcaagcgat gagcaacctg aaagtgagag tgaacctaaa gggtagtctg 2280

gacaacagag atgccatgat atcacttctt ctagagtaat tatctgtgat ggatggacac 2340

aaaaaaatgg aaagaaaaga atgtacatta cctggtttcc tgggattcaa acctgcatat 2400

tgtgatttta atttgaccag aaaatatgat atatatgtat aatttcacag ataatttact 2460

tatttaaaaa tgcatgataa tgagttttac attacaaatt tctgtttttt taaagttatc 2520

ttacgctatt tctgttggtt agtagacact aattctgtca gtaggggcat ggtataagga 2580

aatatcataa tgtaatgagg tggtactatg attaaaagcc actgttacat ttcaaaaaaa 2640

aaaaaaaaaa 2650

<210> 13
<211> 718
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (5)..(5)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (102)..(102)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (206)..(206)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (385)..(385)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (420)..(420)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (423)..(423)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (463)..(463)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (557)..(557)
<223> n is a, c, g, or t

<220>

<221> misc_feature
<222> (568)..(568)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (582)..(582)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (627)..(627)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (640)..(640)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (649)..(649)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (671)..(671)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (696)..(696)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (700)..(700)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (708)..(708)
<223> n is a, c, g, or t

<400> 13
agagngtcgc ccctttttt ttttttttt ttttttttt ttttttttt ttgacattta 60

taaatgaacc tttattaaag acacttcaat gccatttgtt anacacttca atattttaca 120

tggttttcaa tgtacactgt accaaaattt ctataaataa ataactttgt acataaaagt 180

aatactccct ctttcacatt gcctcncaga agcagcaaat tcatatattt tgtggaagta 240

agattagtca gttaactgtc aagaacaaaa ttctaaatgt gcttaccttt tgaacagtga 300

tgacacctga cagtaattgt taactatttt ctcagtaact cccttcagct tttggccaaa 360

ggaacatttg aaggaccttg tttcnattta agttttacta aatgacacat tggcactcan 420

aanatggtta gctaccagtc tcaaaagtgc aaattatacc canaacccag gtcaagggct 480

gtcctttcca agtcccagct cagtttcatc tggtgcgaag gaatggcatg gacaggcctg 540

ctccgggtcc ttaatanaaa taaggtancc ctgaaaagtc anaacttcct cctttctgtc 600

ccccaagggc aatgtaatac tcattanatt gggcaaaacn aaaacatcng tatagtaaaa 660

atccacaggt nccaacacca gcagccttta ccttantttn aaaggccnca aaatagca 718

<210> 14
<211> 135
<212> PRT
<213> Homo sapiens

<400> 14

Met Ser Pro His Leu Thr Ala Leu Leu Gly Leu Val Leu Cys Leu Ala
1 5 10 15

Gln Thr Ile His Thr Gln Glu Gly Ala Leu Pro Arg Pro Ser Ile Ser
20 25 30

Ala Glu Pro Gly Thr Val Ile Ser Pro Gly Ser His Val Thr Phe Met
35 40 45

Cys Arg Gly Pro Val Gly Val Gln Thr Phe Arg Leu Glu Arg Glu Asp
50 55 60

Arg Ala Lys Tyr Lys Asp Ser Tyr Asn Val Phe Arg Leu Gly Pro Ser
65 70 75 80

Glu Ser Glu Ala Arg Phe His Ile Asp Ser Val Ser Glu Gly Asn Ala
85 90 95

Gly Leu Tyr Arg Cys Leu Tyr Tyr Lys Pro Pro Gly Trp Ser Glu His
100 105 110

Ser Asp Phe Leu Glu Leu Leu Val Lys Gly Thr Val Pro Gly Thr Glu
115 120 125

Ala Ser Gly Phe Asp Ala Pro
130 135

<210> 15
<211> 568
<212> DNA
<213> Homo sapiens

<400> 15
ccacgcgtcc ggggaccggg gccatgtctc cacacctcac tgctctcctg ggcctagtgc 60

tctgcctggc ccagaccatc cacacgcagg agggggccct tcccagaccc tccatctcgg 120

ctgagccagg cactgtgatc tccccgggga gccatgtgac tttcatgtgc cggggcccgg 180

ttggggttca aacattccgc ctggagaggg aggatagagc caagtacaaa gatagttata 240

atgtgtttcg acttggtcca tctgagtcag aggccagatt ccacattgac tcagtaagtg 300

aaggaaatgc cgggctttat cgctgcctct attataagcc ccctggatgg tctgagcaca 360

gtgacttcct ggagctgctg gtgaaaggga ctgtgccagg cactgaagcc tccggatttg 420

atgcaccatg aatgaggaga aatggcctcc cgtcttgtga acttcaatgg ggagaaataa 480

ttagaatgag caatagaaat gcacagatgc ctatacatac atatacaaat aaaaagatac 540

gattcgcaaa aaaaaaaaaa aaaagggc 568

<210> 16
<211> 426
<212> PRT
<213> Homo sapiens

<400> 16

Met Pro Leu Leu Trp Leu Arg Gly Phe Leu Leu Ala Ser Cys Trp Ile
1 5 10 15

Ile Val Arg Ser Ser Pro Thr Pro Gly Ser Glu Gly His Ser Ala Ala
20 25 30

Pro Asp Cys Pro Ser Cys Ala Leu Ala Ala Leu Pro Lys Asp Val Pro
35 40 45

Asn Ser Gln Pro Glu Met Val Glu Ala Val Lys Lys His Ile Leu Asn
50 55 60

Met Leu His Leu Lys Lys Arg Pro Asp Val Thr Gln Pro Val Pro Lys
65 70 75 80

Ala Ala Leu Leu Asn Ala Ile Arg Lys Leu His Val Gly Lys Val Gly

```
                85                  90                  95

Glu Asn Gly Tyr Val Glu Ile Glu Asp Asp Ile Gly Arg Arg Ala Glu
            100                 105                 110

Met Asn Glu Leu Met Glu Gln Thr Ser Glu Ile Ile Thr Phe Ala Glu
        115                 120                 125

Ser Gly Thr Ala Arg Lys Thr Leu His Phe Glu Ile Ser Lys Glu Gly
    130                 135                 140

Ser Asp Leu Ser Val Val Glu Arg Ala Glu Val Trp Leu Phe Leu Lys
145                 150                 155                 160

Val Pro Lys Ala Asn Arg Thr Arg Thr Lys Val Thr Ile Arg Leu Phe
                165                 170                 175

Gln Gln Gln Lys His Pro Gln Gly Ser Leu Asp Thr Gly Glu Glu Ala
            180                 185                 190

Glu Glu Val Gly Leu Lys Gly Glu Arg Ser Glu Leu Leu Leu Ser Glu
        195                 200                 205

Lys Val Val Asp Ala Arg Lys Ser Thr Trp His Val Phe Pro Val Ser
    210                 215                 220

Ser Ser Ile Gln Arg Leu Leu Asp Gln Gly Lys Ser Ser Leu Asp Val
225                 230                 235                 240

Arg Ile Ala Cys Glu Gln Cys Gln Glu Ser Gly Ala Ser Leu Val Leu
                245                 250                 255

Leu Gly Lys Lys Lys Lys Lys Glu Glu Glu Gly Glu Gly Lys Lys Lys
            260                 265                 270

Gly Gly Gly Glu Gly Gly Ala Gly Ala Asp Glu Glu Lys Glu Gln Ser
        275                 280                 285

His Arg Pro Phe Leu Met Leu Gln Ala Arg Gln Ser Glu Asp His Pro
    290                 295                 300

His Arg Arg Arg Arg Arg Gly Leu Glu Cys Asp Gly Lys Val Asn Ile
```

305 310 315 320

Cys Cys Lys Lys Gln Phe Phe Val Ser Phe Lys Asp Ile Gly Trp Asn
325 330 335

Asp Trp Ile Ile Ala Pro Ser Gly Tyr His Ala Asn Tyr Cys Glu Gly
340 345 350

Glu Cys Pro Ser His Ile Ala Gly Thr Ser Gly Ser Ser Leu Ser Phe
355 360 365

His Ser Thr Val Ile Asn His Tyr Arg Met Arg Gly His Ser Pro Phe
370 375 380

Ala Asn Leu Lys Ser Cys Cys Val Pro Thr Lys Leu Arg Pro Met Ser
385 390 395 400

Met Leu Tyr Tyr Asp Asp Gly Gln Asn Ile Ile Lys Lys Asp Ile Gln
405 410 415

Asn Met Ile Val Glu Glu Cys Gly Cys Ser
420 425

<210> 17
<211> 1840
<212> DNA
<213> Homo sapiens

<400> 17
tccacacaca caaaaaacct gcgcgtgagg ggggaggaaa agcagggcct ttaaaaaggc 60

aatcacaaca acttttgctg ccaggatgcc cttgctttgg ctgagaggat ttctgttggc 120

aagttgctgg attatagtga ggagttcccc caccccagga tccgaggggc acagcgcggc 180

ccccgactgt ccgtcctgtg cgctggccgc cctcccaaag gatgtaccca actctcagcc 240

agagatggtg gaggccgtca agaagcacat tttaaacatg ctgcacttga agaagagacc 300

cgatgtcacc cagccggtac ccaaggcggc gcttctgaac gcgatcagaa agcttcatgt 360

gggcaaagtc ggggagaacg ggtatgtgga gatagaggat gacattggaa ggagggcaga 420

aatgaatgaa cttatggagc agacctcgga gatcatcacg tttgccgagt caggaacagc 480

caggaagacg ctgcacttcg agatttccaa ggaaggcagt gacctgtcag tggtggagcg 540

tgcagaagtc tggctcttcc taaaagtccc caaggccaac aggaccagga ccaaagtcac 600

catccgcctc ttccagcagc agaagcaccc gcagggcagc ttggacacag gggaagaggc 660

cgaggaagtg ggcttaaagg gggagaggag tgaactgttg ctctctgaaa aagtagtaga 720

cgctcggaag agcacctggc atgtcttccc tgtctccagc agcatccagc ggttgctgga 780

ccagggcaag agctccctgg acgttcggat tgcctgtgag cagtgccagg agagtggcgc 840

cagcttggtt ctcctgggca agaagaagaa gaaagaagag gaggggggaag ggaaaaagaa 900

gggcggaggt gaaggtgggg caggagcaga tgaggaaaag gagcagtcgc acagaccttt 960

cctcatgctg caggcccggc agtctgaaga ccaccctcat cgccggcgtc ggcggggctt 1020

ggagtgtgat ggcaaggtca acatctgctg taagaaacag ttctttgtca gtttcaagga 1080

catcggctgg aatgactgga tcattgctcc ctctggctat catgccaact actgcgaggg 1140

tgagtgcccg agccatatag caggcacgtc cgggtcctca ctgtccttcc actcaacagt 1200

catcaaccac taccgcatgc ggggccatag ccccttttgcc aacctcaaat cgtgctgtgt 1260

gcccaccaag ctgagaccca tgtccatgtt gtactatgat gatggtcaaa acatcatcaa 1320

aaaggacatt cagaacatga tcgtggagga gtgtgggtgc tcatagagtt gcccagccca 1380

gggggaaagg gagcaagagt tgtccagaga agacagtggc aaaatgaaga aatttttaag 1440

gtttctgagt taaccagaaa aatagaaatt aaaaacaaaa caaaacaaaa aaaaaaacaa 1500

aaaaaaacaa aagtaaatta aaaacaaacc tgatgaaaca gatgaaacag atgaaggaag 1560

atgtggaaat cttagcctgc cttagccagg gctcagagat gaagcagtga agagacagat 1620

tgggagggaa agggagaatg gtgtaccctt tatttcttct gaaatcacac tgatgacatc 1680

agttgtttaa acggggtatt gtcctttccc cccttgaggt tcccttgtga gcttgaatca 1740

accaatctga tctgcagtag tgtggactag aacaacccaa atagcatcta gaaagccatg 1800

agtttgaaag ggcccatcac aggcactttc ctagcctaat 1840

<210> 18
<211> 199
<212> PRT
<213> Homo sapiens

<400> 18

Met Asn Cys Val Cys Arg Leu Val Leu Val Val Leu Ser Leu Trp Pro
1 5 10 15

Asp Thr Ala Val Ala Pro Gly Pro Pro Pro Gly Pro Pro Arg Val Ser

20 25 30

Pro Asp Pro Arg Ala Glu Leu Asp Ser Thr Val Leu Leu Thr Arg Ser
35 40 45

Leu Leu Ala Asp Thr Arg Gln Leu Ala Ala Gln Leu Arg Asp Lys Phe
50 55 60

Pro Ala Asp Gly Asp His Asn Leu Asp Ser Leu Pro Thr Leu Ala Met
65 70 75 80

Ser Ala Gly Ala Leu Gly Ala Leu Gln Leu Pro Gly Val Leu Thr Arg
85 90 95

Leu Arg Ala Asp Leu Leu Ser Tyr Leu Arg His Val Gln Trp Leu Arg
100 105 110

Arg Ala Gly Gly Ser Ser Leu Lys Thr Leu Glu Pro Glu Leu Gly Thr
115 120 125

Leu Gln Ala Arg Leu Asp Arg Leu Leu Arg Arg Leu Gln Leu Leu Met
130 135 140

Ser Arg Leu Ala Leu Pro Gln Pro Pro Pro Asp Pro Pro Ala Pro Pro
145 150 155 160

Leu Ala Pro Pro Ser Ser Ala Trp Gly Gly Ile Arg Ala Ala His Ala
165 170 175

Ile Leu Gly Gly Leu His Leu Thr Leu Asp Trp Ala Val Arg Gly Leu
180 185 190

Leu Leu Leu Lys Thr Arg Leu
195

<210> 19
<211> 2281
<212> DNA
<213> Homo sapiens

<400> 19
gaagggttaa aggccccccgg ctccctgccc cctgccctgg ggaacccctg gccctgtggg 60

gacatgaact gtgtttgccg cctggtcctg gtcgtgctga gcctgtggcc agatacagct 120

gtcgcccctg ggccaccacc tggcccccct cgagtttccc cagaccctcg ggccgagctg 180

gacagcaccg tgctcctgac ccgctctctc ctggcggaca cgcggcagct ggctgcacag 240

ctgagggaca aattcccagc tgacggggac cacaacctgg attccctgcc caccctggcc 300

atgagtgcgg gggcactggg agctctacag ctcccaggtg tgctgacaag gctgcgagcg 360

gacctactgt cctacctgcg gcacgtgcag tggctgcgcc gggcaggtgg ctcttccctg 420

aagaccctgg agcccgagct gggcaccctg caggcccgac tggaccggct gctgcgccgg 480

ctgcagctcc tgatgtcccg cctggccctg ccccagccac ccccggaccc gccggcgccc 540

ccgctggcgc ccccctcctc agcctggggg ggcatcaggg ccgcccacgc catcctgggg 600

gggctgcacc tgacacttga ctgggccgtg aggggactgc tgctgctgaa gactcggctg 660

tgacccgggg cccaaagcca ccaccgtcct tccaaagcca gatcttattt atttatttat 720

ttcagtactg ggggcgaaac agccaggtga tccccccgcc attatctccc cctagttaga 780

gacagtcctt ccgtgaggcc tgggggacat ctgtgcctta tttatactta tttatttcag 840

gagcaggggt gggaggcagg tggactcctg ggtccccgag gaggagggga ctggggtccc 900

ggattcttgg gtctccaaga agtctgtcca cagacttctg ccctggctct tccccatcta 960

ggcctgggca ggaacatata ttatttattt aagcaattac ttttcatgtt ggggtgggga 1020

cggaggggaa agggaagcct gggtttttgt acaaaaatgt gagaaacctt tgtgagacag 1080

agaacaggga attaaatgtg tcatacatat ccacttgagg gcgatttgtc tgagagctgg 1140

ggctggatgc ttgggtaact ggggcagggc aggtggaggg gagacctcca ttcaggtgga 1200

ggtcccgagt gggcggggca gcgactggga gatgggtcgg tcacccagac agctctgtgg 1260

aggcagggtc tgagccttgc ctggggcccc gcactgcata gggccgtttg tttgtttttt 1320

gagatggagt ctcgctctgt tgcctaggct ggagtgcagt gaggcaatct aaggtcactg 1380

caagctccac ctcccgggtt caagcaattc tcctgcctca gcctcccgat tagctgggat 1440

cacaggtgtg caccaccatg cccagctaat tatttatttc ttttgtattt ttagtagaga 1500

cagggtttca ccatgttggc caggctggtt tcgaactcct gacctcaggt gatcctcctg 1560

cctcggcctc ccaaagtgct gggattacag gtgtgagcca ccacacctga cccataggtc 1620

ttcaataaat atttaatgga aggttccaca agtcaccctg tgatcaacag tacccgtatg 1680

ggacaaagct gcaaggtcaa gatggttcat tatggctgtg ttcaccatag caaactggaa 1740

agaatctaga tatccaacag tgagggttaa gcaacatggt gcatctgtgg atagaacacc 1800

acccagccgc ccggagcagg gactgtcatt cagggaggct aaggagagag gcttgcttgg 1860

gatatagaaa gatatcctga cattggccag gcatggtggc tcacgcctgt aatcctggca 1920

ctttgggagg acgaagcgag tggatcactg aagtccaaga gtttgagacc ggcctgcgag 1980

acatggcaaa accctgtctc aaaaaagaaa gaatgatgtc ctgacatgaa acagcaggct 2040

acaaaaccac tgcatgctgt gatcccaatt ttgtgttttt ctttctatat atggattaaa 2100

acaaaaatcc taaagggaaa tacgccaaaa tgttgacaat gactgtctcc aggtcaaagg 2160

agagaggtgg gattgtgggt gacttttaat gtgtatgatt gtctgtattt tacagaattt 2220

ctgccatgac tgtgtatttt gcatgacaca ttttaaaaat aataaacact atttttagaa 2280

t 2281

<210> 20
<211> 322
<212> PRT
<213> Homo sapiens

<400> 20

Met Ser Pro Asn Phe Lys Leu Gln Cys His Phe Ile Leu Ile Phe Leu
1 5 10 15

Thr Ala Leu Arg Gly Glu Ser Arg Tyr Leu Glu Leu Arg Glu Ala Ala
20 25 30

Asp Tyr Asp Pro Phe Leu Leu Phe Ser Ala Asn Leu Lys Arg Asp Val
35 40 45

Ala Gly Glu Gln Pro Tyr Arg Arg Ala Leu Arg Cys Leu Asp Met Leu
50 55 60

Ser Leu Gln Gly Gln Phe Thr Phe Thr Ala Asp Arg Pro Gln Leu His
65 70 75 80

Cys Ala Ala Phe Phe Ile Ser Glu Pro Glu Glu Phe Ile Thr Ile His
85 90 95

Tyr Asp Gln Val Ser Ile Asp Cys Gln Gly Gly Asp Phe Leu Lys Val
100 105 110

Phe Asp Gly Trp Ile Leu Lys Gly Glu Lys Phe Pro Ser Ser Gln Asp

115 120 125

His Pro Leu Pro Ser Ala Glu Arg Tyr Ile Asp Phe Cys Glu Ser Gly
130 135 140

Leu Ser Arg Arg Ser Ile Arg Ser Ser Gln Asn Val Ala Met Ile Phe
145 150 155 160

Phe Arg Val His Glu Pro Gly Asn Gly Phe Thr Leu Thr Ile Lys Thr
165 170 175

Asp Pro Asn Leu Phe Pro Cys Asn Val Ile Ser Gln Thr Pro Asn Gly
180 185 190

Lys Phe Thr Leu Val Val Pro His Gln His Arg Asn Cys Ser Phe Ser
195 200 205

Ile Ile Tyr Pro Val Val Ile Lys Ile Ser Asp Leu Thr Leu Gly His
210 215 220

Val Asn Gly Leu Gln Leu Lys Lys Ser Ser Ala Gly Cys Glu Gly Ile
225 230 235 240

Gly Asp Phe Val Glu Leu Leu Glu Gly Thr Gly Leu Asp Pro Ser Lys
245 250 255

Met Thr Pro Leu Ala Asp Leu Cys Tyr Pro Phe His Gly Pro Ala Gln
260 265 270

Met Lys Val Gly Cys Asp Asn Thr Val Val Arg Met Val Ser Ser Gly
275 280 285

Lys His Val Asn Arg Val Thr Phe Glu Tyr Arg Gln Leu Glu Pro Tyr
290 295 300

Glu Leu Glu Asn Pro Asn Gly Asn Ser Ile Gly Glu Phe Cys Leu Ser
305 310 315 320

Gly Leu

<210> 21

<211> 1248
<212> DNA
<213> Homo sapiens

<400> 21
ggacctccgg agcagacagc acagcagctg cagaggcaag gccagcatgt cgcccaactt 60

caaacttcag tgtcacttca ttctcatctt cctgacggct ctaagagggg aaagccggta 120

cctagagctg agggaagcgg cggactacga tcctttcctg ctcttcagcg ccaacctgaa 180

gcgggacgtg gctggggagc agccgtaccg ccgcgctctg cggtgcctgg acatgctgag 240

cctccagggc cagttcacct tcaccgccga ccggccgcag ctgcactgcg cagccttctt 300

catcagcgag cccgaggagt tcattaccat ccactacgac caggtctcca tcgactgtca 360

gggcggcgac ttcctgaagg tatttgatgg ttggattctc aaggggggaga agttccccag 420

ttcccaggat catcctctcc cctcagctga gcggtacata gatttctgtg agagtggtct 480

tagcaggagg agcatcagat cttcccagaa tgtggccatg atcttcttcc gagtccatga 540

accaggaaat ggattcacat taaccataaa gacagacccc aacctctttc cttgcaatgt 600

catttctcag actccaaatg gaaagtttac cctggtagtt ccacaccagc atcgaaactg 660

cagcttctcc ataatttatc ctgtggtgat caaaatatct gatcttaccc tgggacacgt 720

aaatggtctt cagttaaaga aatcctcagc aggttgcgag ggaataggag actttgtgga 780

gctgctggag ggaactggat tggacccttc caagatgacg cctttagctg atctctgcta 840

ccccttttcat ggcccggccc agatgaaagt tggctgtgac aacactgtgg tgcgcatggt 900

ctccagtgga aaacacgtaa atcgtgtgac ttttgagtat cgtcagctgg agccgtacga 960

gctggaaaac ccaaatggaa acagtatcgg ggaattctgt ttgtctggtc tttgaataac 1020

caacccagtg atttacatgc tgatagctaa gtgagttttt aatggccatt gtgtatgatt 1080

ttgatgcaca actagttaaa agcctttcat accagtcagt atttcccagc cttgagcgca 1140

cgcacacacc acacacatac acacacgcat tatttttgtt actttgcttc tttttatgtt 1200

tgtaatctgt aaatgaacac atggcagaaa ataaccctga ttggtagg 1248

<210> 22
<211> 442
<212> PRT
<213> Homo sapiens

<400> 22

Thr Thr Pro Asp Arg Arg Leu Trp Asn Pro Pro Ala Thr Ser Ser Ser

1 5 10 15

Leu Arg Gln Met Glu Arg Met Leu Pro Leu Leu Thr Leu Gly Leu Leu
20 25 30

Ala Ala Gly Phe Cys Pro Ala Val Leu Cys His Pro Asn Ser Pro Leu
35 40 45

Asp Glu Glu Asn Leu Thr Gln Glu Asn Gln Asp Arg Gly Thr His Val
50 55 60

Asp Leu Gly Leu Ala Ser Ala Asn Val Asp Phe Ala Phe Ser Leu Tyr
65 70 75 80

Lys Gln Leu Val Leu Lys Ala Pro Asp Lys Asn Val Ile Phe Ser Pro
85 90 95

Leu Ser Ile Ser Thr Ala Leu Ala Phe Leu Ser Leu Gly Ala His Asn
100 105 110

Thr Thr Leu Thr Glu Ile Leu Lys Gly Leu Lys Phe Asn Leu Thr Glu
115 120 125

Thr Ser Glu Ala Glu Ile His Gln Ser Phe Gln His Leu Leu Arg Thr
130 135 140

Leu Asn Gln Ser Ser Asp Glu Leu Gln Leu Ser Met Gly Asn Ala Met
145 150 155 160

Phe Val Lys Glu Gln Leu Ser Leu Leu Asp Arg Phe Thr Glu Asp Ala
165 170 175

Lys Arg Leu Tyr Gly Ser Glu Ala Phe Ala Thr Asp Phe Gln Asp Ser
180 185 190

Ala Ala Ala Lys Lys Leu Ile Asn Asp Tyr Val Lys Asn Gly Thr Arg
195 200 205

Gly Lys Ile Thr Asp Leu Ile Lys Asp Leu Asp Ser Gln Thr Met Met
210 215 220

Val Leu Val Asn Tyr Ile Phe Phe Lys Ala Lys Trp Glu Met Pro Phe

225 230 235 240

Asp Pro Gln Asp Thr His Gln Ser Arg Phe Tyr Leu Ser Lys Lys Lys
245 250 255

Trp Val Met Val Pro Met Met Ser Leu His His Leu Thr Ile Pro Tyr
260 265 270

Phe Arg Asp Glu Glu Leu Ser Cys Thr Val Val Glu Leu Lys Tyr Thr
275 280 285

Gly Asn Ala Ser Ala Leu Phe Ile Leu Pro Asp Gln Asp Lys Met Glu
290 295 300

Glu Val Glu Ala Met Leu Leu Pro Glu Thr Leu Lys Arg Trp Arg Asp
305 310 315 320

Ser Leu Glu Phe Arg Glu Ile Gly Glu Leu Tyr Leu Pro Lys Phe Ser
325 330 335

Ile Ser Arg Asp Tyr Asn Leu Asn Asp Ile Leu Leu Gln Leu Gly Ile
340 345 350

Glu Glu Ala Phe Thr Ser Lys Ala Asp Leu Ser Gly Ile Thr Gly Ala
355 360 365

Arg Asn Leu Ala Val Ser Gln Val Val His Lys Ala Val Leu Asp Val
370 375 380

Phe Glu Glu Gly Thr Glu Ala Ser Ala Ala Thr Ala Val Lys Ile Thr
385 390 395 400

Leu Leu Ser Ala Leu Val Glu Thr Arg Thr Ile Val Arg Phe Asn Arg
405 410 415

Pro Phe Leu Met Ile Ile Val Pro Thr Asp Thr Gln Asn Ile Phe Phe
420 425 430

Met Ser Lys Val Thr Asn Pro Lys Gln Ala
435 440

<210> 23

<211> 561
<212> DNA
<213> Homo sapiens

<400> 23
ctgtctcaaa ataaaaataa aaaataaaaa gaaataaaaa agaaatatac caaaatgtta 60

gctggggtct tctctgggta gtaaagtgct gggggatatt ttccaaagtc cttctttaca 120

ttctctgagt ttttccatgt tcttcaatga gtatttaata agcagataaa aactaataca 180

acaaaggatt ttttctgtgt gctttttga cctttggagg aagagattag agctagtccc 240

ataaccaggt tatttgagta ggtctaataa gcccgtatta ccagaaatta tcatctggtc 300

atttccagtc cgagaacaga acacttggtt gtcctggcat ttcccaagca gtgggaggag 360

ttctctgcag gaataaataa gcctcagcat tcatgaaaat ccactactcc agacagacgg 420

ctttggaatc caccagctac atccagctcc ctgaggcagg taatccatga tgttttacat 480

cctgggagcg gaggaatctg tttttccagg agagttttag gcagcagcct ggagtgtgtg 540

gagtgtgagg ggtaagcaga g 561

<210> 24
<211> 272
<212> PRT
<213> Homo sapiens

<400> 24

Met Val Leu Leu Thr Ala Val Leu Leu Leu Ala Ala Tyr Ala Gly
1 5 10 15

Pro Ala Gln Ser Leu Gly Ser Phe Val His Cys Glu Pro Cys Asp Glu
20 25 30

Lys Ala Leu Ser Met Cys Pro Pro Ser Pro Leu Gly Cys Glu Leu Val
35 40 45

Lys Glu Pro Gly Cys Gly Cys Cys Met Thr Cys Ala Leu Ala Glu Gly
50 55 60

Gln Ser Cys Gly Val Tyr Thr Glu Arg Cys Ala Gln Gly Leu Arg Cys
65 70 75 80

Leu Pro Arg Gln Asp Glu Glu Lys Pro Leu His Ala Leu Leu His Gly
85 90 95

```
Arg Gly Val Cys Leu Asn Glu Lys Ser Tyr Arg Glu Gln Val Lys Ile
            100                 105                 110

Glu Arg Asp Ser Arg Glu His Glu Glu Pro Thr Thr Ser Glu Met Ala
        115                 120                 125

Glu Glu Thr Tyr Ser Pro Lys Ile Phe Arg Pro Lys His Thr Arg Ile
    130                 135                 140

Ser Glu Leu Lys Ala Glu Ala Val Lys Lys Asp Arg Arg Lys Lys Leu
145                 150                 155                 160

Thr Gln Ser Lys Phe Val Gly Gly Ala Glu Asn Thr Ala His Pro Arg
                165                 170                 175

Ile Ile Ser Ala Pro Glu Met Arg Gln Glu Ser Glu Gln Gly Pro Cys
            180                 185                 190

Arg Arg His Met Glu Ala Ser Leu Gln Glu Leu Lys Ala Ser Pro Arg
        195                 200                 205

Met Val Pro Arg Ala Val Tyr Leu Pro Asn Cys Asp Arg Lys Gly Phe
    210                 215                 220

Tyr Lys Arg Lys Gln Cys Lys Pro Ser Arg Gly Arg Lys Arg Gly Ile
225                 230                 235                 240

Cys Trp Cys Val Asp Lys Tyr Gly Met Lys Leu Pro Gly Met Glu Tyr
                245                 250                 255

Val Asp Gly Asp Phe Gln Cys His Thr Phe Asp Ser Ser Asn Val Glu
            260                 265                 270
```

<210> 25
<211> 1303
<212> DNA
<213> Homo sapiens

<400> 25
tgaaaaaaaa aaaaggaaag aaagggattg aaggagcttg ccaagggtag gctgcctaaa 60

ttcacatttt ccctgggtct ttccgtgaaa tggggacacc agaaacccaa gggtcgggtc 120

tagtgccctc aactctctgg ggatgagagt cttgccttgg ggtagacaag aggcagggca 180

gggaggagca gagccctggg gtgcggccgt cctcaccgcc tgttgctcta ctcaccccag 240

tgcaaacctt cccgtggccg caagcgtggc atctgctggt gcgtggacaa gtacgggatg 300

aagctgccag gcatggagta cgttgacggg gactttcagt gccacacctt cgacagcagc 360

aacgttgagt gatgcgtccc cccccaacct ttccctcacc ccctcccacc cccagccccg 420

actccagcca gcgcctcccc ccaccccagg acgccactca tttcatctca tttaagggaa 480

aaatatatat ctatctattt gaggaaactg aggacctcgg aatctctagc aagggctcaa 540

cttcgaaaat ggcaacaaca gagatgcaaa aagctaaaaa gacacccccc ccctttaaat 600

ggttttcttt ttgaggcaag ttggatgaac agagaaggga agagaggaag aacgagagga 660

agagaaggga aggaagtgtt tgtgtagaag agagagaaag acgaatagag ttaggaaaag 720

gaagacaagc aggtgggcag gaaggacatg caccgagacc aggcaggggc ccaactttca 780

cgtccagccc tggcctgggg tcgggagagg tgggcgctag aagatgcagc ccaggatgtg 840

gcaatcaatg acactattgg ggtttcccag gatggattgg tcaggggggag aaaggaaaag 900

gcaaaaacact ccaggacctc tcccggatct gtctcctcct ctagccagca gtatggacag 960

ctggacccct gaacttcctc tcctcttacc tgggcagagt gttgtctctc cccaaattta 1020

taaaaactaa aatgcattcc attcctctga aagcaaaaca aattcataat tgagtgatat 1080

taaatagaga ggttttcgga agcagatctg tgaatatgaa atacatgtgc atatttcatt 1140

ccccaggcag acatttttta gaaatcaata catgccccaa tattggaaag acttgttctt 1200

ccacggtgac tacagtacat gctgaagcgt gccgtttcag ccctcattta attcaatttg 1260

taagtagcgc acgagcctct gtgggggagg ataggctgaa aaa 1303

<210> 26
<211> 448
<212> PRT
<213> Homo sapiens

<400> 26

Met Val Leu Ile Gln Ile Pro Met Tyr Asn Glu Lys Glu Val Cys Gln
1 5 10 15

Leu Ser Ile Gly Ala Ala Cys Arg Leu Ser Trp Pro Leu Asp Arg Met
20 25 30

Ile Val Gln Val Leu Asp Asp Ser Thr Asp Pro Ala Ser Lys Glu Leu

```
        35                  40                  45

Val Asn Ala Glu Cys Asp Lys Trp Ala Arg Lys Gly Ile Asn Ile Met
    50                  55                  60

Ser Glu Ile Arg Asp Asn Arg Ile Gly Tyr Lys Ala Gly Ala Leu Lys
65                  70                  75                  80

Ala Gly Met Met His Asn Tyr Val Lys Gln Cys Glu Phe Val Ala Ile
                85                  90                  95

Phe Asp Ala Asp Phe Gln Pro Asp Pro Asp Phe Leu Glu Arg Thr Ile
            100                 105                 110

Pro Phe Leu Ile His Asn His Glu Ile Ser Leu Val Gln Cys Arg Trp
        115                 120                 125

Lys Phe Val Asn Ala Asn Glu Cys Leu Met Thr Arg Met Gln Glu Met
    130                 135                 140

Ser Leu Asn Tyr His Phe Val Ala Glu Gln Glu Ser Gly Ser Ser Ile
145                 150                 155                 160

His Ala Phe Phe Gly Phe Asn Gly Thr Ala Gly Val Trp Arg Ile Ala
                165                 170                 175

Ala Leu Asn Glu Ala Gly Gly Trp Lys Asp Arg Thr Thr Val Glu Asp
            180                 185                 190

Met Asp Leu Ala Val Arg Ala Cys Leu His Gly Trp Lys Phe Val Tyr
        195                 200                 205

Val His Asp Val Glu Val Lys Asn Glu Leu Pro Ser Thr Phe Lys Ala
    210                 215                 220

Tyr Arg Phe Gln Gln His Arg Trp Ser Cys Gly Pro Ala Asn Leu Trp
225                 230                 235                 240

Arg Lys Met Thr Met Glu Ile Leu Gln Asn Lys Lys Val Ser Ala Trp
                245                 250                 255

Lys Lys Leu Tyr Leu Ile Tyr Asn Phe Phe Phe Ile Arg Lys Ile Val
```

260 265 270

Val His Ile Phe Thr Phe Val Phe Tyr Cys Leu Ile Leu Pro Thr Thr
275 280 285

Val Leu Phe Pro Glu Leu Gln Val Pro Lys Trp Ala Thr Val Tyr Phe
290 295 300

Pro Thr Thr Ile Thr Ile Leu Asn Ala Ile Ala Thr Pro Arg Met Ile
305 310 315 320

Lys Ser Leu Thr Tyr Ile Val Tyr Cys Arg Ser Leu His Leu Leu Val
325 330 335

Phe Trp Ile Leu Phe Glu Asn Val Met Ser Met His Arg Thr Lys Ala
340 345 350

Thr Phe Ile Gly Leu Leu Glu Ala Gly Arg Val Asn Glu Trp Val Val
355 360 365

Thr Glu Lys Leu Gly Asp Thr Leu Lys Ser Lys Leu Ile Gly Lys Ala
370 375 380

Thr Thr Lys Leu Tyr Thr Arg Phe Gly Gln Arg Leu Asn Trp Arg Glu
385 390 395 400

Leu Val Val Gly Leu Tyr Ile Phe Phe Cys Gly Cys Tyr Asp Phe Ala
405 410 415

Tyr Gly Gly Ser Tyr Phe Tyr Val Tyr Leu Phe Leu Gln Ser Cys Ala
420 425 430

Phe Phe Val Ala Gly Val Gly Tyr Ile Gly Thr Phe Val Pro Thr Val
435 440 445

<210> 27
<211> 422
<212> PRT
<213> Homo sapiens

<400> 27

Met Pro Ala Gly Arg Arg Gly Pro Ala Ala Gln Ser Ala Arg Arg Pro
1 5 10 15

```
Pro Pro Leu Leu Pro Leu Leu Leu Leu Leu Cys Val Leu Gly Ala Pro
            20                  25                  30

Arg Ala Gly Ser Gly Ala His Thr Ala Val Ile Ser Pro Gln Asp Pro
        35                  40                  45

Thr Leu Leu Ile Gly Ser Ser Leu Leu Ala Thr Cys Ser Val His Gly
    50                  55                  60

Asp Pro Pro Gly Ala Thr Ala Glu Gly Leu Tyr Trp Thr Leu Asn Gly
65                  70                  75                  80

Arg Arg Leu Pro Pro Glu Leu Ser Arg Val Leu Asn Ala Ser Thr Leu
                85                  90                  95

Ala Leu Ala Leu Ala Asn Leu Asn Gly Ser Arg Gln Arg Ser Gly Asp
            100                 105                 110

Asn Leu Val Cys His Ala Arg Asp Gly Ser Ile Leu Ala Gly Ser Cys
        115                 120                 125

Leu Tyr Val Gly Leu Pro Pro Glu Lys Pro Val Asn Ile Ser Cys Trp
    130                 135                 140

Ser Lys Asn Met Lys Asp Leu Thr Cys Arg Trp Thr Pro Gly Ala His
145                 150                 155                 160

Gly Glu Thr Phe Leu His Thr Asn Tyr Ser Leu Lys Tyr Lys Leu Arg
                165                 170                 175

Trp Tyr Gly Gln Asp Asn Thr Cys Glu Glu Tyr His Thr Val Gly Pro
            180                 185                 190

His Ser Cys His Ile Pro Lys Asp Leu Ala Leu Phe Thr Pro Tyr Glu
        195                 200                 205

Ile Trp Val Glu Ala Thr Asn Arg Leu Gly Ser Ala Arg Ser Asp Val
    210                 215                 220

Leu Thr Leu Asp Ile Leu Asp Val Val Thr Thr Asp Pro Pro Pro Asp
225                 230                 235                 240
```

Val His Val Ser Arg Val Gly Gly Leu Glu Asp Gln Leu Ser Val Arg
245 250 255

Trp Val Ser Pro Pro Ala Leu Lys Asp Phe Leu Phe Gln Ala Lys Tyr
260 265 270

Gln Ile Arg Tyr Arg Val Glu Asp Ser Val Asp Trp Lys Val Val Asp
275 280 285

Asp Val Ser Asn Gln Thr Ser Cys Arg Leu Ala Gly Leu Lys Pro Gly
290 295 300

Thr Val Tyr Phe Val Gln Val Arg Cys Asn Pro Phe Gly Ile Tyr Gly
305 310 315 320

Ser Lys Lys Ala Gly Ile Trp Ser Glu Trp Ser His Pro Thr Ala Ala
325 330 335

Ser Thr Pro Arg Ser Glu Arg Pro Gly Pro Gly Gly Gly Ala Cys Glu
340 345 350

Pro Arg Gly Gly Glu Pro Ser Ser Gly Pro Val Arg Arg Glu Leu Lys
355 360 365

Gln Phe Leu Gly Trp Leu Lys Lys His Ala Tyr Cys Ser Asn Leu Ser
370 375 380

Phe Arg Leu Tyr Asp Gln Trp Arg Ala Trp Met Gln Lys Ser His Lys
385 390 395 400

Thr Arg Asn Gln Asp Glu Gly Ile Leu Pro Ser Gly Arg Arg Gly Thr
405 410 415

Ala Arg Gly Pro Ala Arg
420

<210> 28
<211> 1716
<212> DNA
<213> Homo sapiens

<400> 28

cgcccagcga cgtgcgggcg gcctggcccg cgccctcccg cgcccggcct gcgtcccgcg 60

ccctgcgcca ccgccgccga gccgcagccc gccgcgcgcc cccggcagcg ccggccccat 120

gcccgccggc cgccggggcc ccgccgccca atccgcgcgg cggccgccgc cgttgctgcc 180

cctgctgctg ctgctctgcg tcctcggggc gccgcgagcc ggatcaggag cccacacagc 240

tgtgatcagt ccccaggatc ccacgcttct catcggctcc tccctgctgg ccacctgctc 300

agtgcacgga gacccaccag gagccaccgc cgagggcctc tactggaccc tcaacgggcg 360

ccgcctgccc cctgagctct cccgtgtact caacgcctcc accttggctc tggccctggc 420

caacctcaat gggtccaggc agcggtcggg ggacaacctc gtgtgccacg cccgtgacgg 480

cagcatcctg gctggctcct gcctctatgt tggcctgccc ccagagaaac ccgtcaacat 540

cagctgctgg tccaagaaca tgaaggactt gacctgccgc tggacgccag gggcccacgg 600

ggagaccttc ctccacacca actactccct caagtacaag cttaggtggt atggccagga 660

caacacatgt gaggagtacc acacagtggg gccccactcc tgccacatcc ccaaggacct 720

ggctctcttt acgccctatg agatctgggt ggaggccacc aaccgcctgg gctctgcccg 780

ctccgatgta ctcacgctgg atatcctgga tgtggtgacc acggaccccc cgcccgacgt 840

gcacgtgagc cgcgtcgggg gcctggagga ccagctgagc gtgcgctggg tgtcgccacc 900

cgccctcaag gatttcctct ttcaagccaa ataccagatc cgctaccgag tggaggacag 960

tgtggactgg aaggtggtgg acgatgtgag caaccagacc tcctgccgcc tggccggcct 1020

gaaacccggc accgtgtact tcgtgcaagt gcgctgcaac ccctttggca tctatggctc 1080

caagaaagcc gggatctgga gtgagtggag ccaccccaca gccgcctcca ctccccgcag 1140

tgagcgcccg ggcccgggcg gcggggcgtg cgaaccgcgg ggcggagagc cgagctcggg 1200

gccggtgcgg cgcgagctca agcagttcct gggctggctc aagaagcacg cgtactgctc 1260

caacctcagc ttccgcctct acgaccagtg gcgagcctgg atgcagaagt cgcacaagac 1320

ccgcaaccag gacgagggga tcctgccctc gggcagacgg ggcacggcga gaggtcctgc 1380

cagataagct gtaggggctc aggccaccct ccctgccacg tggagacgca gaggccgaac 1440

ccaaactggg gccacctctg taccctcact tcagggcacc tgagccaccc tcagcaggag 1500

ctggggtggc ccctgagctc caacggccat aacagctctg actcccacgt gaggccacct 1560

ttgggtgcac cccagtgggt gtgtgtgtgt gtgtgagggt tggttgagtt gcctagaacc 1620

cctgccaggg ctgggggtga gaaggggagt cattactccc cattacctag ggcccctcca 1680

aaagagtcct tttaaataaa tgagctattt aggtgc 1716

<210> 29
<211> 228
<212> PRT
<213> Homo sapiens

<400> 29

Met Leu His Val Glu Met Leu Thr Leu Val Phe Leu Val Leu Trp Met
1 5 10 15

Cys Val Phe Ser Gln Asp Pro Gly Ser Lys Ala Val Ala Asp Arg Tyr
20 25 30

Ala Val Tyr Trp Asn Ser Ser Asn Pro Arg Phe Gln Arg Gly Asp Tyr
35 40 45

His Ile Asp Val Cys Ile Asn Asp Tyr Leu Asp Val Phe Cys Pro His
50 55 60

Tyr Glu Asp Ser Val Pro Glu Asp Lys Thr Glu Arg Tyr Val Leu Tyr
65 70 75 80

Met Val Asn Phe Asp Gly Tyr Ser Ala Cys Asp His Thr Ser Lys Gly
85 90 95

Phe Lys Arg Trp Glu Cys Asn Arg Pro His Ser Pro Asn Gly Pro Leu
100 105 110

Lys Phe Ser Glu Lys Phe Gln Leu Phe Thr Pro Phe Ser Leu Gly Phe
115 120 125

Glu Phe Arg Pro Gly Arg Glu Tyr Phe Tyr Ile Ser Ser Ala Ile Pro
130 135 140

Asp Asn Gly Arg Arg Ser Cys Leu Lys Leu Lys Val Phe Val Arg Pro
145 150 155 160

Thr Asn Ser Cys Met Lys Thr Ile Gly Val His Asp Arg Val Phe Asp
165 170 175

Val Asn Asp Lys Val Glu Asn Ser Leu Glu Pro Ala Asp Asp Thr Val
180 185 190

```
His Glu Ser Ala Glu Pro Ser Arg Gly Glu Asn Ala Ala Gln Thr Pro
        195                 200                 205

Arg Ile Pro Ser Arg Leu Leu Ala Ile Leu Leu Phe Leu Leu Ala Met
    210                 215                 220

Leu Leu Thr Leu
225
```

<210> 30
<211> 737
<212> PRT
<213> Homo sapiens

<400> 30

```
Met Gly Gly Cys Thr Val Lys Pro Gln Leu Leu Leu Leu Ala Leu Val
1               5                   10                  15

Leu His Pro Trp Asn Pro Cys Leu Gly Ala Asp Ser Glu Lys Pro Ser
            20                  25                  30

Ser Ile Pro Thr Asp Lys Leu Leu Val Ile Thr Val Ala Thr Lys Glu
        35                  40                  45

Ser Asp Gly Phe His Arg Phe Met Gln Ser Ala Lys Tyr Phe Asn Tyr
    50                  55                  60

Thr Val Lys Val Leu Gly Gln Gly Glu Glu Trp Arg Gly Gly Asp Gly
65                  70                  75                  80

Ile Asn Ser Ile Gly Gly Gly Gln Lys Val Arg Leu Met Lys Glu Val
                85                  90                  95

Met Glu His Tyr Ala Asp Gln Asp Asp Leu Val Val Met Phe Thr Glu
            100                 105                 110

Cys Phe Asp Val Ile Phe Ala Gly Gly Pro Glu Glu Val Leu Lys Lys
        115                 120                 125

Phe Gln Lys Ala Asn His Lys Val Val Phe Ala Ala Asp Gly Ile Leu
    130                 135                 140
```

```
Trp Pro Asp Lys Arg Leu Ala Asp Lys Tyr Pro Val Val His Ile Gly
145                 150                 155                 160

Lys Arg Tyr Leu Asn Ser Gly Gly Phe Ile Gly Tyr Ala Pro Tyr Val
                165                 170                 175

Asn Arg Ile Val Gln Gln Trp Asn Leu Gln Asp Asn Asp Asp Asp Gln
            180                 185                 190

Leu Phe Tyr Thr Lys Val Tyr Ile Asp Pro Leu Lys Arg Glu Ala Ile
        195                 200                 205

Asn Ile Thr Leu Asp His Lys Cys Lys Ile Phe Gln Thr Leu Asn Gly
    210                 215                 220

Ala Val Asp Glu Val Val Leu Lys Phe Glu Asn Gly Lys Ala Arg Ala
225                 230                 235                 240

Lys Asn Thr Phe Tyr Glu Thr Leu Pro Val Ala Ile Asn Gly Asn Gly
                245                 250                 255

Pro Thr Lys Ile Leu Leu Asn Tyr Phe Gly Asn Tyr Val Pro Asn Ser
            260                 265                 270

Trp Thr Gln Asp Asn Gly Cys Thr Leu Cys Glu Phe Asp Thr Val Asp
        275                 280                 285

Leu Ser Ala Val Asp Val His Pro Asn Val Ser Ile Gly Val Phe Ile
    290                 295                 300

Glu Gln Pro Thr Pro Phe Leu Pro Arg Phe Leu Asp Ile Leu Leu Thr
305                 310                 315                 320

Leu Asp Tyr Pro Lys Glu Ala Leu Lys Leu Phe Ile His Asn Lys Glu
                325                 330                 335

Val Tyr His Glu Lys Asp Ile Lys Val Phe Phe Asp Lys Ala Lys His
            340                 345                 350

Glu Ile Lys Thr Ile Lys Ile Val Gly Pro Glu Glu Asn Leu Ser Gln
        355                 360                 365
```

```
Ala Glu Ala Arg Asn Met Gly Met Asp Phe Cys Arg Gln Asp Glu Lys
    370                 375                 380

Cys Asp Tyr Tyr Phe Ser Val Asp Ala Asp Val Val Leu Thr Asn Pro
385                 390                 395                 400

Arg Thr Leu Lys Ile Leu Ile Glu Gln Asn Arg Lys Ile Ile Ala Pro
                405                 410                 415

Leu Val Thr Arg His Gly Lys Leu Trp Ser Asn Phe Trp Gly Ala Leu
            420                 425                 430

Ser Pro Asp Gly Tyr Tyr Ala Arg Ser Glu Asp Tyr Val Asp Ile Val
        435                 440                 445

Gln Gly Asn Arg Val Gly Val Trp Asn Val Pro Tyr Met Ala Asn Val
    450                 455                 460

Tyr Leu Ile Lys Gly Lys Thr Leu Arg Ser Glu Met Asn Glu Arg Asn
465                 470                 475                 480

Tyr Phe Val Arg Asp Lys Leu Asp Pro Asp Met Ala Leu Cys Arg Asn
                485                 490                 495

Ala Arg Glu Met Gly Val Phe Met Tyr Ile Ser Asn Arg His Glu Phe
            500                 505                 510

Gly Arg Leu Leu Ser Thr Ala Asn Tyr Asn Thr Ser His Tyr Asn Asn
        515                 520                 525

Asp Leu Trp Gln Ile Phe Glu Asn Pro Val Asp Trp Lys Glu Lys Tyr
    530                 535                 540

Ile Asn Arg Asp Tyr Ser Lys Ile Phe Thr Glu Asn Ile Val Glu Gln
545                 550                 555                 560

Pro Cys Pro Asp Val Phe Trp Phe Pro Ile Phe Ser Glu Lys Ala Cys
                565                 570                 575

Asp Glu Leu Val Glu Glu Met Glu His Tyr Gly Lys Trp Ser Gly Gly
            580                 585                 590
```

Lys His His Asp Ser Arg Ile Ser Gly Gly Tyr Glu Asn Val Pro Thr
595 600 605

Asp Asp Ile His Met Lys Gln Val Asp Leu Glu Asn Val Trp Leu Asp
610 615 620

Phe Ile Arg Glu Phe Ile Ala Pro Val Thr Leu Lys Val Phe Ala Gly
625 630 635 640

Tyr Tyr Thr Lys Gly Phe Ala Leu Leu Asn Phe Val Val Lys Tyr Ser
645 650 655

Pro Glu Arg Gln Arg Ser Leu Arg Pro His His Asp Ala Ser Thr Phe
660 665 670

Thr Ile Asn Ile Ala Leu Asn Asn Val Gly Glu Asp Phe Gln Gly Gly
675 680 685

Gly Cys Lys Phe Leu Arg Tyr Asn Cys Ser Ile Glu Ser Pro Arg Lys
690 695 700

Gly Trp Ser Phe Met His Pro Gly Arg Leu Thr His Leu His Glu Gly
705 710 715 720

Leu Pro Val Lys Asn Gly Thr Arg Tyr Ile Ala Val Ser Phe Ile Asp
725 730 735

Pro

<210> 31
<211> 3503
<212> DNA
<213> Homo sapiens

<400> 31
atgggggat gcacggtgaa gcctcagctg ctgctcctgg cgctcgtcct ccacccctgg 60

aatccctgtc tgggtgcgga ctcggagaag ccctcgagca tccccacaga taaattatta 120

gtcataactg tagcaacaaa agaaagtgat ggattccatc gatttatgca gtcagccaaa 180

tatttcaatt atactgtgaa ggtccttggt caaggagaag aatggagagg tggtgatgga 240

attaatagta ttggaggggg ccagaaagtg agattaatga aagaagtcat ggaacactat 300

gctgatcaag atgatctggt tgtcatgttt actgaatgct ttgatgtcat atttgctggt 360

ggtccagaag aagttctaaa aaaattccaa aaggcaaacc acaaagtggt ctttgcagca 420

gatggaattt tgtggccaga taaaagacta gcagacaagt atcctgttgt gcacattggg 480

aaacgctatc tgaattcagg aggatttatt ggctatgctc catatgtcaa ccgtatagtt 540

caacaatgga atctccagga taatgatgat gatcagctct tttacactaa agtttacatt 600

gatccactga aaagggaagc tattaacatc acattggatc acaaatgcaa aattttccag 660

accttaaatg gagctgtaga tgaagttgtt ttaaaatttg aaaatggcaa agccagagct 720

aagaatacat tttatgaaac attaccagtg gcaattaatg gaaatggacc caccaagatt 780

ctcctgaatt attttggaaa ctatgtaccc aattcatgga cacaggataa tggctgcact 840

ctttgtgaat tcgatacagt cgacttgtct gcagtagatg tccatccaaa cgtatcaata 900

ggtgttttta ttgagcaacc aacccctttt ctacctcggt ttctggacat attgttgaca 960

ctggattacc caaaagaagc acttaaactt tttattcata acaaagaagt ttatcatgaa 1020

aaggacatca aggtattttt tgataaagct aagcatgaaa tcaaaactat aaaaatagta 1080

ggaccagaag aaaatctaag tcaagcggaa gccagaaaca tgggaatgga cttttgccgt 1140

caggatgaaa agtgtgatta ttactttagt gtggatgcag atgttgtttt gacaaatcca 1200

aggactttaa aaattttgat tgaacaaaac agaaagatca ttgctcctct tgtaactcgt 1260

catggaaagc tgtggtccaa tttctgggga gcattgagtc ctgatggata ctatgcacga 1320

tctgaagatt atgtggatat tgttcaaggg aatagagtag gagtatggaa tgtcccatat 1380

atggctaatg tgtacttaat taaaggaaag acactccgat cagagatgaa tgaaaggaac 1440

tattttgttc gtgataaact ggatcctgat atggctcttt gccgaaatgc tagagaaatg 1500

ggtgtattta tgtacatttc taatagacat gaatttggaa ggctattatc cactgctaat 1560

tacaatactt cccattataa caatgacctc tggcagattt ttgaaaatcc tgtggactgg 1620

aaggaaaagt atataaaccg tgattattca aagattttca ctgaaaatat agttgaacag 1680

ccctgtccag atgtcttttg gttccccata ttttctgaaa aagcctgtga tgaattggta 1740

gaagaaatgg aacattacgg caaatggtct gggggaaaac atcatgatag ccgtatatct 1800

ggtggttatg aaaatgtccc aactgatgat atccacatga agcaagttga tctggagaat 1860

gtatggcttg attttatccg ggagttcatt gcaccagtta cactgaaggt ctttgcaggc 1920

tattatacga agggatttgc actactgaat tttgtagtaa aatactcccc tgaacgacag 1980

cgttctcttc gtcctcatca tgatgcttct acatttacca taaacattgc acttaataac 2040

gtgggagaag actttcaggg aggtggttgc aaatttctaa ggtacaattg ctctattgag 2100

tcaccacgaa aaggctggag cttcatgcat cctgggagac tcacacattt gcatgaagga 2160

cttcctgtta aaaatggaac aagatacatt gcagtgtcat ttatagatcc ctaagttatt 2220

tacttttcat tgaattgaaa tttattttgg gtgaatgact ggcatgaaca cgtctttgaa 2280

gttgtggctg agaagatgag aggaatattt aaataacatc aacagaacaa cttcactttg 2340

ggccaaacat ttgaaaaact ttttataaaa aattgtttga tatttcttaa tgtctgctct 2400

gagccttaaa acacagattg aagaagaaaa gaaagaaaaa acttaaatat ttatttctat 2460

gctttgttgc ctctgagaat aatgacaatt tatgaatttg tgtttcaaat tgataaaata 2520

tttaggtaca aataacaaga ctaataatat tttcttattt aaaaaaagca tgggaagatt 2580

tttatttatc aaaatataga ggaaatgtag acaaaatgga tataaatgaa aattaccatg 2640

ttgtaaaacc ttgaaaatca gattctaact gattgtatgc aactaagtat ttctgaacac 2700

ctatgcaggt cttatttaca gtgttactaa gggaacacac aaagaattac acaacgtttt 2760

cctcaagaaa atggtacaaa acacaaccga ggagcgtata cagttgaaaa cattttgtt 2820

ttgattggaa ggcagattat tttatattag tattaaaaat caaaccctat gtttctttca 2880

gatgaatctt ccaaagtgga ttatattaag caggtattag atttagaaaa cctttccatt 2940

tcttaaagta ttatcaagtg tcaagatcag caagtgtcct taagtcaaat aggttttttt 3000

ttgttggtgg ttgtgcttgc tttccttttt tagaaagttc tagaaaatag gaaaacgaaa 3060

aatttcattg agatgagtag tgcatttaat tatttttaa aaaacttttt aagtacttga 3120

attttatatc aggaaaacaa agttgttgag ccttgcttct tccgttttgc cctttgtctc 3180

gctccttatt ctttttgggg gggagggtta tttgcttttt tatcttcctg gcataatttc 3240

cattttattc ttctgagtgt ctatgttaac ttccctctat cccgcttata aaaaaattct 3300

ccaacaaaaa tacttgttga cttgatgttt tatcacttct ctaagtaagg ttgaaatatc 3360

cttattgtag ctactgtttt taatgtaaag gttaaacttg aaaagaaatt cttaatcacg 3420

gtgccaaaat tcattttcta acaccatgtg ttagaaaatt ataaaaaata aaataatttt 3480

aaaaaaaaaa aaaaaaaaaa aaa 3503

<210> 32
<211> 247

<212> PRT
<213> Homo sapiens

<400> 32

Met Leu Gln Asn Ser Ala Val Leu Leu Val Leu Val Ile Ser Ala Ser
1 5 10 15

Ala Thr His Glu Ala Glu Gln Asn Asp Ser Val Ser Pro Arg Lys Ser
20 25 30

Arg Val Ala Ala Gln Asn Ser Ala Glu Val Val Arg Cys Leu Asn Ser
35 40 45

Ala Leu Gln Val Gly Cys Gly Ala Phe Ala Cys Leu Glu Asn Ser Thr
50 55 60

Cys Asp Thr Asp Gly Met Tyr Asp Ile Cys Lys Ser Phe Leu Tyr Ser
65 70 75 80

Ala Ala Lys Phe Asp Thr Gln Gly Lys Ala Phe Val Lys Glu Ser Leu
85 90 95

Lys Cys Ile Ala Asn Gly Val Thr Ser Lys Val Phe Leu Ala Ile Arg
100 105 110

Arg Cys Ser Thr Phe Gln Arg Met Ile Ala Glu Val Gln Glu Glu Cys
115 120 125

Tyr Ser Lys Leu Asn Val Cys Ser Ile Ala Lys Arg Asn Pro Glu Ala
130 135 140

Ile Thr Glu Val Val Gln Leu Pro Asn His Phe Ser Asn Arg Tyr Tyr
145 150 155 160

Asn Arg Leu Val Arg Ser Leu Leu Glu Cys Asp Glu Asp Thr Val Ser
165 170 175

Thr Ile Arg Asp Ser Leu Met Glu Lys Ile Gly Pro Asn Met Ala Ser
180 185 190

Leu Phe His Ile Leu Gln Thr Asp His Cys Ala Gln Thr His Pro Arg
195 200 205

Ala Asp Phe Asn Arg Arg Arg Thr Asn Glu Pro Gln Lys Leu Lys Val
210 215 220

Leu Leu Arg Asn Leu Arg Gly Glu Glu Asp Ser Pro Ser His Ile Lys
225 230 235 240

Arg Thr Ser His Glu Ser Ala
245

<210> 33
<211> 3901
<212> DNA
<213> Homo sapiens

<400> 33
cagtttgcaa aagccagagg tgcaagaagc agcgactgca gcagcagcag cagcagcggc 60

ggtggcagca gcagcagcag cggcggcagc agcagcagca gcggaggcac cggtggcagc 120

agcagcatca ccagcaacaa caacaaaaaa aaatcctcat caaatcctca cctaagcttt 180

cagtgtatcc agatccacat cttcactcaa gccaggagag ggaaagagga aaggggggca 240

ggaaaaaaaa aaaacccaac aacttagcgg aaacttctca gagaatgctc caaaactcag 300

cagtgcttct ggtgctggtg atcagtgctt ctgcaaccca tgaggcggag cagaatgact 360

ctgtgagccc caggaaatcc cgagtggcgg ctcaaaactc agctgaagtg gttcgttgcc 420

tcaacagtgc tctacaggtc ggctgcgggg cttttgcatg cctggaaaac tccacctgtg 480

acacagatgg gatgtatgac atctgtaaat ccttcttgta cagcgctgct aaatttgaca 540

ctcagggaaa agcattcgtc aaagagagct taaaatgcat cgccaacggg gtcacctcca 600

aggtcttcct cgccattcgg aggtgctcca ctttccaaag gatgattgct gaggtgcagg 660

aagagtgcta cagcaagctg aatgtgtgca gcatcgccaa gcggaaccct gaagccatca 720

ctgaggtcgt ccagctgccc aatcacttct ccaacagata ctataacaga cttgtccgaa 780

gcctgctgga atgtgatgaa gacacagtca gcacaatcag agacagcctg atggagaaaa 840

ttgggcctaa catggccagc ctcttccaca tcctgcagac agaccactgt gcccaaacac 900

acccacgagc tgacttcaac aggagacgca ccaatgagcc gcagaagctg aaagtcctcc 960

tcaggaacct ccgaggtgag gaggactctc cctcccacat caaacgcaca tcccatgaga 1020

gtgcataacc agggagaggt tattcacaac ctcaccaaac tagtatcatt ttaggggtgt 1080

tgacacacca attttgagtg tactgtgcct ggtttgattt ttttaaagta gttcctattt 1140

tctatccccc ttaaagaaaa ttgcatgaaa ctaggcttct gtaatcaata tcccaacatt 1200

ctgcaatggc agcattccca ccaacaaaat ccatgtgatc attctgcctc tcctcaggag 1260

aaagtaccct cttttaccaa cttcctctgc catgtctttt cccctgctcc cctgagacca 1320

cccccaaaca caaaacattc atgtaactct ccagccattg taatttgaag atgtggatcc 1380

ctttagaacg gttgccccag tagagttagc tgataaggaa actttattta aatgcatgtc 1440

ttaaatgctc ataaagatgt taaatggaat tcgtgttatg aatctgtgct ggccatggac 1500

gaatatgaat gtcacatttg aattcttgat ctctaatgag ctagtgtctt atggtcttga 1560

tcctccaatg tctaattttc tttccgacac atttaccaaa ttgcttgagc ctggctgtcc 1620

aaccagactt tgagcctgca tcttcttgca tctaatgaaa aacaaaaagc taacatcttt 1680

acgtactgta actgctcaga gctttaaaag tatctttaac aattgtctta aaaccagaga 1740

atcttaaggt ctaactgtgg aatataaata gctgaaaact aatgtactgt acataaattc 1800

cagaggactc tgcttaaaca aagcagtata taataacttt attgcatata gatttagttt 1860

tgtaacttag ctttatttttt cttttcctgg gaatggaata actatctcac ttccagatat 1920

ccacataaat gctccttgtg gccttttta taactaaggg ggtagaagta gttttaattc 1980

aacatcaaaa cttaagatgg gcctgtatga gacaggaaaa accaacaggt ttatctgaag 2040

gaccccaggt aagatgttaa tctcccagcc cacctcaacc cagaggctac tcttgactta 2100

gacctatact gaaagatctc tgtcacatcc aactggaaat tccaggaacc aaaaagagca 2160

tccctatggg cttggaccac ttacagtgtg ataaggccta ctatacatta ggaagtggta 2220

gttctttact cgtccccttt catcggtgcc tggtactctg gcaaatgatg atggggtggg 2280

agactttcca ttaaatcaat caggaatgag tcaatcagcc tttaggtctt tagtccgggg 2340

gacttggggc tgagagagta taaataaccc tgggctgtcc agccttaata gacttctctt 2400

acattttcgt cctgtagcac gctgcctgcc aaagtagtcc tggcagctgg accatctctg 2460

taggatcgta aaaaaataga aaaaaagaaa aaaaaaagaa agaaagaggg aaaaagagct 2520

ggtggtttga tcatttctgc catgatgttt acaagatggc gaccaccaaa gtcaaacgac 2580

taacctatct atgaacaaca gtagtttctc agggtcactg tccttgaacc caacagtccc 2640

ttatgagcgt cactgcccac caaaggtcaa tgtcaagaga ggaagagagg gaggaggggt 2700

aggactgcag gggccactcc aaactcgctt aggtagaaac tattggtgct cgactctcac 2760

taggctaaac tcaagatttg accaaatcga gtgataggga tcctggtggg aggagagagg 2820

gcacatctcc agaaaaatga aaagcaatac aactttacca taaagccttt aaaaccagta 2880

acgtgctgct caaggaccaa gagcaattgc agcagaccca gcagcagcag cagcagcaca 2940

aacattgctg cctttgtccc cacacagcct ctaagcgtgc tgacatcaga ttgttaaggg 3000

catttttata ctcagaactg tcccatcccc aggtccccaa acttatggac actgccttag 3060

cctcttggaa atcaggtaga ccatattcta agttagactc ttcccctccc tcccacactt 3120

cccacccccа ggcaaggctg acttctctga atcagaaaag ctattaaagt ttgtgtgttg 3180

tgtccatttt gcaaacccaa ctaagccagg accccaatgc gacaagtagt tcatgagtat 3240

tcctagcaaa tttctctctt tcttcagttc agtagatttc ctttttttctt ttctttttttt 3300

ttttttttttt tttttggctg tgacctcttc aaaccgtggt acccccccctt ttctccccac 3360

gatgatatct atatatgtat ctacaataca tatatctaca catacagaaa gaagcagttc 3420

tcacatgttg ctagtttttt gcttctcttt cccccaccct actccctcca attccccccct 3480

taaacttcca aagcttcgtc ttgtgtttgc tgcagagtga ttcgggggct gacctagacc 3540

agtttgcatg attcttctct tgtgatttgg ttgcacttta gacatttttg tgccattata 3600

tttgcattat gtatttataa tttaaatgat atttaggttt ttggctgagt actggaataa 3660

acagtgagca tatctggtat atgtcattat ttattgttaa attacatttt ttaagctcca 3720

tgtgcatata aaggttatga aacatatcat ggtaatgaca gatgcaagtt attttatttg 3780

cttatttttt ataattaaag atgccatagc ataatatgaa gcctttggtg aattccttct 3840

aagataaaaa taataataaa gtgttacgtt ttattggttt caaaaaaaaa aaaaaaaaaa 3900

a 3901

<210> 34
<211> 313
<212> PRT
<213> Homo sapiens

<400> 34

Met Gly Ile Gly Arg Ser Glu Gly Gly Arg Arg Gly Ala Leu Gly Val
1 5 10 15

Leu Leu Ala Leu Gly Ala Ala Leu Leu Ala Val Gly Ser Ala Ser Glu
20 25 30

Tyr Asp Tyr Val Ser Phe Gln Ser Asp Ile Gly Pro Tyr Gln Ser Gly

35 40 45

Arg Phe Tyr Thr Lys Pro Pro Gln Cys Val Asp Ile Pro Ala Asp Leu
50 55 60

Arg Leu Cys His Asn Val Gly Tyr Lys Lys Met Val Leu Pro Asn Leu
65 70 75 80

Leu Glu His Glu Thr Met Ala Glu Val Lys Gln Gln Ala Ser Ser Trp
85 90 95

Val Pro Leu Leu Asn Lys Asn Cys His Ala Gly Thr Gln Val Phe Leu
100 105 110

Cys Ser Leu Phe Ala Pro Val Cys Leu Asp Arg Pro Ile Tyr Pro Cys
115 120 125

Arg Trp Leu Cys Glu Ala Val Arg Asp Ser Cys Glu Pro Val Met Gln
130 135 140

Phe Phe Gly Phe Tyr Trp Pro Glu Met Leu Lys Cys Asp Lys Phe Pro
145 150 155 160

Glu Gly Asp Val Cys Ile Ala Met Thr Pro Pro Asn Ala Thr Glu Ala
165 170 175

Ser Lys Pro Gln Gly Thr Thr Val Cys Pro Pro Cys Asp Asn Glu Leu
180 185 190

Lys Ser Glu Ala Ile Ile Glu His Leu Cys Ala Ser Glu Phe Ala Leu
195 200 205

Arg Met Lys Ile Lys Glu Val Lys Lys Glu Asn Gly Asp Lys Lys Ile
210 215 220

Val Pro Lys Lys Lys Lys Pro Leu Lys Leu Gly Pro Ile Lys Lys Lys
225 230 235 240

Asp Leu Lys Lys Leu Val Leu Tyr Leu Lys Asn Gly Ala Asp Cys Pro
245 250 255

Cys His Gln Leu Asp Asn Leu Ser His His Phe Leu Ile Met Gly Arg

260 265 270

Lys Val Lys Ser Gln Tyr Leu Leu Thr Ala Ile His Lys Trp Asp Lys
275 280 285

Lys Asn Lys Glu Phe Lys Asn Phe Met Lys Lys Met Lys Asn His Glu
290 295 300

Cys Pro Thr Phe Gln Ser Val Phe Lys
305 310

<210> 35
<211> 4469
<212> DNA
<213> Homo sapiens

<400> 35
cctgcagcct ccggagtcag tgccgcgcgc ccgccgcccc gcgccttcct gctcgccgca 60

cctccgggag ccggggcgca cccagcccgc agcgccgcct ccccgcccgc gccgcctccg 120

accgcaggcc gagggccgcc actggccggg gggaccgggc agcagcttgc ggccgcggag 180

ccgggcaacg ctggggactg cgccttttgt ccccggaggt ccctggaagt ttgcggcagg 240

acgcgcgcgg ggaggcggcg gaggcagccc cgacgtcgcg gagaacaggg cgcagagccg 300

gcatgggcat cgggcgcagc gaggggggcc gccgcggggc cctgggcgtg ctgctggcgc 360

tgggcgcggc gcttctggcc gtgggctcgg ccagcgagta cgactacgtg agcttccagt 420

cggacatcgg cccgtaccag agcgggcgct tctacaccaa gccacctcag tgcgtggaca 480

tccccgcgga cctgcggctg tgccacaacg tgggctacaa gaagatggtg ctgcccaacc 540

tgctggagca cgagaccatg gcggaggtga agcagcaggc cagcagctgg gtgcccctgc 600

tcaacaagaa ctgccacgcc gggacccagg tcttcctctg ctcgctcttc gcgcccgtct 660

gcctggaccg gcccatctac ccgtgtcgct ggctctgcga ggccgtgcgc gactcgtgcg 720

agccggtcat gcagttcttc ggcttctact ggcccgagat gcttaagtgt gacaagttcc 780

cggaggggga cgtctgcatc gccatgacgc cgcccaatgc caccgaagcc tccaagcccc 840

aaggcacaac ggtgtgtcct ccctgtgaca acgagttgaa atctgaggcc atcattgaac 900

atctctgtgc cagcgagttt gcactgagga tgaaaataaa agaagtgaaa aaagaaaatg 960

gcgacaagaa gattgtcccc aagaagaaga agcccctgaa gttggggccc atcaagaaga 1020

aggacctgaa gaagcttgtg ctgtacctga agaatggggc tgactgtccc tgccaccagc 1080

tggacaacct cagccaccac ttcctcatca tgggccgcaa ggtgaagagc cagtacttgc 1140

tgacggccat ccacaagtgg gacaagaaaa acaaggagtt caaaaacttc atgaagaaaa 1200

tgaaaaacca tgagtgcccc acctttcagt ccgtgtttaa gtgattctcc cgggggcagg 1260

gtggggaggg agcctcgggt ggggtgggag cgggggggac agtgcccggg aacccgtggt 1320

cacacacacg cactgccctg tcagtagtgg acattgtaat ccagtcggct tgttcttgca 1380

gcattcccgc tccctttccc tccatagcca cgctccaaac cccagggtag ccatggccgg 1440

gtaaagcaag ggccatttag attaggaagg tttttaagat ccgcaatgtg gagcagcagc 1500

cactgcacag gaggaggtga caaaccattt ccaacagcaa cacagccact aaaacacaaa 1560

aaggggggatt gggcggaaag tgagagccag cagcaaaaac tacattttgc aacttgttgg 1620

tgtggatcta ttggctgatc tatgcctttc aactagaaaa ttctaatgat tggcaagtca 1680

cgttgttttc aggtccagag tagtttcttt ctgtctgctt taaatggaaa cagactcata 1740

ccacacttac aattaaggtc aagcccagaa agtgataagt gcagggagga aaagtgcaag 1800

tccattatct aatagtgaca gcaaagggac caggggagag gcattgcctt ctctgcccac 1860

agtctttccg tgtgattgtc tttgaatctg aatcagccag tctcagatgc cccaaagttt 1920

cggttcctat gagcccgggg catgatctga tccccaagac atgtggaggg gcagcctgtg 1980

cctgcctttg tgtcagaaaa aggaaaccac agtgagcctg agagagacgg cgattttcgg 2040

gctgagaagg cagtagtttt caaaacacat agttaaaaaa gaaacaaatg aaaaaaattt 2100

tagaacagtc cagcaaattg ctagtcaggg tgaattgtga aattgggtga agagcttagg 2160

attctaatct catgtttttt ccttttcaca tttttaaaag aacaatgaca aacacccact 2220

tatttttcaa ggttttaaaa cagtctacat tgagcatttg aaaggtgtgc tagaacaagg 2280

tctcctgatc cgtccgaggc tgcttcccag aggagcagct ctccccaggc atttgccaag 2340

ggaggcggat ttccctggta gtgtagctgt gtggctttcc ttcctgaaga gtccgtggtt 2400

gccctagaac ctaacacccc ctagcaaaac tcacagagct ttccgttttt ttctttcctg 2460

taaagaaaca tttcctttga acttgattgc ctatggatca aagaaattca gaacagcctg 2520

cctgttcccc cgcacttttt acatatattt gtttcatttc tgcagatgga aagttgacat 2580

gggtggggtg tccccatcca gcgagagagt ttcaaaagca aaacatctct gcagtttttc 2640

ccaagtaccc tgagatactt cccaaagccc ttatgtttaa tcagcgatgt atataagcca 2700

gttcacttag acaactttac ccttcttgtc caatgtacag gaagtagttc taaaaaaaat 2760

gcatattaat ttcttccccc aaagccggat tcttaattct ctgcaacact ttgaggacat 2820

ttatgattgt ccctctgggc caatgcttat acccagtgag gatgctgcag tgaggctgta 2880

aagtggcccc ctgcggccct agcctgaccc ggagaaagga tggtagattc tgttaactct 2940

tgaagactcc agtatgaaaa tcagcatgcc cgcctagtta cctaccggag agttatcctg 3000

ataaattaac ctctcacagt tagtgatcct gtccttttaa caccttttt gtggggttct 3060

ctctgacctt tcatcgtaaa gtgctgggga ccttaagtga tttgcctgta attttggatg 3120

attaaaaaat gtgtatatat attagctaat tagaaatatt ctacttctct gttgtcaaac 3180

tgaaattcag agcaagttcc tgagtgcgtg gatctgggtc ttagttctgg ttgattcact 3240

caagagttca gtgctcatac gtatctgctc attttgacaa agtgcctcat gcaaccgggc 3300

cctctctctg cggcagagtc cttagtggag gggtttacct ggaacataag tagttaccac 3360

agaatacgga agagcaggtg actgtgctgt gcagctctct aaatgggaat tctcaggtag 3420

gaagcaacag cttcagaaag agctcaaaat aaattggaaa tgtgaatcgc agctgtgggt 3480

tttaccaccg tctgtctcag agtcccagga ccttgagtgt cattagttac tttattgaag 3540

gttttagacc catagcagct ttgtctctgt cacatcagca atttcagaac caaaagggag 3600

gctctctgta ggcacagagc tgcactatca cgagcctttg tttttctcca caaagtatct 3660

aacaaaacca atgtgcagac tgattggcct ggtcattggt ctccgagaga ggaggtttgc 3720

ctgtgatttg cctgtgattt cctaattatc gctagggcca aggtgggatt tgtaaagctt 3780

tacaataatc attctggata gagtcctggg aggtccttgg cagaactcag ttaaatcttt 3840

gaagaatatt tgtagttatc ttagaagata gcatgggagg tgaggattcc aaaaacattt 3900

tatttttaaa atatcctgtg taacacttgg ctcttggtac ctgtgggtta gcatcaagtt 3960

ctccccaggg tagaattcaa tcagagctcc agtttgcatt tggatgtgta aattacagta 4020

atcccatttc ccaaacctaa aatctgtttt tctcatcaga ctctgagtaa ctggttgctg 4080

tgtcataact tcatagatgc aggaggctca ggtgatctgt ttgaggagag cacctaggc 4140

agcctgcagg gaataacata ctggccgttc tgacctgttg ccagcagata cacaggacat 4200

ggatgaaatt cccgtttcct ctagtttctt cctgtagtac tcctctttta gatcctaagt 4260

ctcttacaaa agctttgaat actgtgaaaa tgttttacat tccatttcat ttgtgttgtt 4320

tttttaactg cattttacca gatgttttga tgttatcgct tatgttaata gtaattcccg 4380

tacgtgttca ttttattttc atgcttttc agccatgtat caatattcac ttgactaaaa 4440

tcactcaatt aatcaatgaa aaaaaaaaa 4469

<210> 36
<211> 250
<212> PRT
<213> Homo sapiens

<400> 36

Met Ala Asp Asn Phe Ser Leu His Asp Ala Leu Ser Gly Ser Gly Asn
1 5 10 15

Pro Asn Pro Gln Gly Trp Pro Gly Ala Trp Gly Asn Gln Pro Ala Gly
20 25 30

Ala Gly Gly Tyr Pro Gly Ala Ser Tyr Pro Gly Ala Tyr Pro Gly Gln
35 40 45

Ala Pro Pro Gly Ala Tyr Pro Gly Gln Ala Pro Pro Gly Ala Tyr His
50 55 60

Gly Ala Pro Gly Ala Tyr Pro Gly Ala Pro Ala Pro Gly Val Tyr Pro
65 70 75 80

Gly Pro Pro Ser Gly Pro Gly Ala Tyr Pro Ser Ser Gly Gln Pro Ser
85 90 95

Ala Pro Gly Ala Tyr Pro Ala Thr Gly Pro Tyr Gly Ala Pro Ala Gly
100 105 110

Pro Leu Ile Val Pro Tyr Asn Leu Pro Leu Pro Gly Gly Val Val Pro
115 120 125

Arg Met Leu Ile Thr Ile Leu Gly Thr Val Lys Pro Asn Ala Asn Arg
130 135 140

Ile Ala Leu Asp Phe Gln Arg Gly Asn Asp Val Ala Phe His Phe Asn
145 150 155 160

Pro Arg Phe Asn Glu Asn Asn Arg Arg Val Ile Val Cys Asn Thr Lys
165 170 175

Leu Asp Asn Asn Trp Gly Arg Glu Glu Arg Gln Ser Val Phe Pro Phe

180 185 190

Glu Ser Gly Lys Pro Phe Lys Ile Gln Val Leu Val Glu Pro Asp His
195 200 205

Phe Lys Val Ala Val Asn Asp Ala His Leu Leu Gln Tyr Asn His Arg
210 215 220

Val Lys Lys Leu Asn Glu Ile Ser Lys Leu Gly Ile Ser Gly Asp Ile
225 230 235 240

Asp Leu Thr Ser Ala Ser Tyr Thr Met Ile
245 250

<210> 37
<211> 914
<212> DNA
<213> Homo sapiens

<400> 37
ccagccaacg agcggaaaat ggcagacaat ttttcgctcc atgatgcgtt atctgggtct 60

ggaaacccaa accctcaagg atggcctggc gcatggggga accagcctgc tggggcaggg 120

ggctacccag gggcttccta tcctggggcc taccccgggc aggcaccccc aggggcttat 180

cctggacagg cacctccagg cgcctaccat ggagcacctg gagcttatcc cggagcacct 240

gcacctggag tctacccagg gccacccagc ggccctgggg cctacccatc ttctggacag 300

ccaagtgccc ccggagccta ccctgccact ggcccctatg gcgcccctgc tgggccactg 360

attgtgcctt ataacctgcc tttgcctggg ggagtggtgc ctcgcatgct gataacaatt 420

ctgggcacgg tgaagcccaa tgcaaacaga attgctttag atttccaaag agggaatgat 480

gttgccttcc actttaaccc acgcttcaat gagaacaaca ggagagtcat tgtttgcaat 540

acaaagctgg ataataactg gggaagggaa gaaagacagt cggttttccc atttgaaagt 600

gggaaaccat tcaaaataca agtactggtt gaacctgacc acttcaaggt tgcagtgaat 660

gatgctcact tgttgcagta caatcatcgg gttaaaaaac tcaatgaaat cagcaaactg 720

ggaatttctg gtgacataga cctcaccagt gcttcatata ccatgatata atctgaaagg 780

ggcagattaa aaaaaaaaaa aaagaatcta aaccttacat gtgtaaaggt ttcatgttca 840

ctgtgagtga aaatttttac attcatcaat atccctcttg taagtcatct acttaataaa 900

tattacagtg aaag 914

<210> 38
<211> 94
<212> PRT
<213> Homo sapiens

<400> 38

Met Arg Thr Leu Ala Ile Leu Ala Ala Ile Leu Leu Val Ala Leu Gln
1 5 10 15

Ala Gln Ala Glu Pro Leu Gln Ala Arg Ala Asp Glu Val Ala Ala Ala
20 25 30

Pro Glu Gln Ile Ala Ala Asp Ile Pro Glu Val Val Val Ser Leu Ala
35 40 45

Trp Asp Glu Ser Leu Ala Pro Lys His Pro Gly Ser Arg Lys Asn Met
50 55 60

Asp Cys Tyr Cys Arg Ile Pro Ala Cys Ile Ala Gly Glu Arg Arg Tyr
65 70 75 80

Gly Thr Cys Ile Tyr Gln Gly Arg Leu Trp Ala Phe Cys Cys
85 90

<210> 39
<211> 3710
<212> DNA
<213> Homo sapiens

<400> 39
gaattccctg taagccctgt tacaggggct gcaccccaga tacaacctga cctgtgtcca 60

aggcgggcaa ctcaaccctt agatattgaa tgggtcccat ggcaccaatg cttaaacacc 120

agcagccctc acaaccacag atcgtgtttt aaggatgagg aggtagttct ctggatgcac 180

aggcttcaat ccaaatgggc tcatgacgcc gcagcacaca cccagtctgc agcctgaaga 240

gttggagcat tgcattcaca gaaagcatcc agacatgatc atgggctcag ggatacacct 300

gttctccgat gtgtaccagt gaaggatgga aactcctatg cctcccagaa agcaccactc 360

aagcttttgc tgaatgcttc tctgaaggcc cacaaggctg agaggctgtg caacaccagc 420

agtaaagtga atgcccagac tcccacctcc tttcttgggt ggccatctgg aaaggccact 480

cccaccctga tggctaatgc ctcagaccag ttcttggccc agatgatcct agacaattgt 540

ttaagcttaa actgttcatt ggccaagcaa acaggtgata gtacctctgg ggaaccacat 600

gccgcgtgta catccagatc tcaggagaac ccaaaaatgt ctgttccaca tagcaacaga 660

agcccaggta gcactcagtc tcacctgggt gttctccaac atcccagctc agccaaatgg 720

ctttcattag tttttatggt tagaccccag gtcctcggga cactgcttta gaaacacatt 780

ccaaatcctc ctctgtgtgc aggtggcatt cctatcccaa tctctttgca gggcgtatac 840

tgtgatacgc agccaggctg tcccagaggc cttaaatatt cccttggtgc aggtagttca 900

gcttagccac agccaatgca tcacagggtc aactgtgtta ggagccattg agaatccata 960

gttggttgct gcctgggcct ggccagggct gaccaaggta gatgagaggt tcctctgtgg 1020

agttctactt taacctcacc ttcccaccaa atttctcaac tgtccttgcc accacaatta 1080

tttaatggac ccaacagaaa gtaaccccgg aaattaggac acctcatccc aaaagacctt 1140

taaatagggg aagtccactt gtgcacggct gctccttgct atagaagacc tgggacagag 1200

gactgctgtc tgccctctct ggtcaccctg cctagctaga ggatctgtaa gtactacaaa 1260

acttaaactt tacactgagt tttcatcatt gaagctatgc ctccaatctg acctctgact 1320

gtggggccgc cccagaggga cccagcgggt gaatccctgc taggaacgtc tgtccggacc 1380

tctggtgact gctggggacg atggcttcca gctaacttaa tagagaaact caagcagttt 1440

ccttctaaat acacatgtca catgtcctgg ttgacatgtc cagtaagaag actatcacag 1500

gtctttggaa cattcttttg agagaaacct atttaggtcc ttggtctgtt tttcaatcag 1560

gttgtttgat ttttgctatt gagttgttgg aattccttat gtattcagat atttgcccct 1620

tctgccatgt aggttttgca aatatttttct ctcattttct gggttatctt ttcactcggt 1680

tgattgtttc ctttgctgtg cagatgcttt agcgttaaat gaagccacac ttgtctattt 1740

tccctttttat tgcctgtgcc tttggtgtca tagccaagaa atcattacct acatcaatgt 1800

caaaagcttt atccttctat acacttctag tagtttatgg tttcagttgt tacatttagg 1860

ttttcaattc attctgagtt gatgttccta catggtgtga gataaagatt taaatacata 1920

catatataaa atcatgaggt agtgtacact ataaatatac aattgttaat tgttactcaa 1980

gtctaagtag aggtggaaat aataaacttt ctttttttta cttaaaccac tctgtgtcac 2040

tgagctgatt tcacctttag cctgataaaa tcattgtcct ctccaccctg attcctacag 2100

gagactactc accccataac ctcaaaaacc tcttcatgag gatggtaagt cacctgaatc 2160

ctgaagtgaa ttactcgcta ttccattgga actcatatag gacaccagaa tctagacctc 2220

cagagaacag caggacccat cttcagaaaa taagaagcat ttgttccctg agcctgttga 2280

atcaaagtgc aatttctatt ctttttggaa tgttaaaaag tgaatcataa tatttaagca 2340

ggtgaaccca cgagtaacat agcagggtct ttcttgtcat tattagctcc aacctagcac 2400

agacattaaa ggtacagatg tatactagca tgaaactggg agaacaggag cattcgagca 2460

accttgagac caatgggcct ctcttataaa atgcacacct cctctcactg agattgagga 2520

aggtttcttg tctccgagcc ttctcccagt agagctataa atccaggctg gctcctccct 2580

ccccacacag ctgctcctgc tctccctcct ccaggtgacc ccagccatga ggaccctcgc 2640

catccttgct gccattctcc tggtggccct gcaggcccag gctgagccac tccaggcaag 2700

agctgatgag gttgctgcag ccccggagca gattgcagcg gacatcccag aagtggttgt 2760

ttcccttgca tgggacgaaa gcttggctcc aaagcatcca ggtgagagag gcaggcatgc 2820

agagctgcta agtctagagg gaaggacggg agagaggttc cagagttggg tctcagcagt 2880

ctatgtcact gaggtggctt cacttagaat ctctgggcat tgattttctc atctagaaat 2940

tgaacagaga gccaaataaa cctgagaaac tttatttctc caaagacttg attccaagaa 3000

acatctgtga aattcactaa gtttaagata tgaagagaca gactagttat ttctggatct 3060

aaacaagtag acttagttgt aaagagaaca ttttactcta tctacagaag agcttttaaa 3120

aactgcagcc aagcctgagg gtaagttcag gtgtgtgtgt gatggggcag gaatgcaaaa 3180

atgagagcaa aggagaatga gtctcaaatt ctgtgtgaca agcactgctc tgcgtgttta 3240

ttcctatcga ctgaggttgt tcgtgctacc ggctgcaatg cagccagcat cacctgtcag 3300

ctagcatgtg acttccccga gattcttttt cttacccact gctaactcca tactcaattt 3360

ctcatgctct ccctgtccca ggctcaagga aaaacatgga ctgctattgc agaataccag 3420

cgtgcattgc aggagaacgt cgctatggaa cctgcatcta ccagggaaga ctctgggcat 3480

tctgctgctg agcttgcaga aaaagaaaaa tgagctcaaa atttgctttg agagctacag 3540

ggaattgcta ttactcctgt accttctgct caatttcctt tcctcatctc aaataaatgc 3600

cttgttacaa gatttctgtg tttccacctc tttaatgtgt gatatgtgtc tgtgtcaaga 3660

cacttgggat acacgtacca aaacgcaaaa tcaaattttt gaacaatata 3710

<210> 40
<211> 1201
<212> PRT
<213> Homo sapiens

<400> 40

Ser Leu Trp Leu Ile Ala Ala Ala Leu Val Glu Val Arg Thr Ser Ala
1 5 10 15

Asp Gly Gln Ala Gly Asn Glu Glu Met Val Gln Ile Asp Leu Pro Ile
20 25 30

Lys Arg Tyr Arg Glu Tyr Glu Leu Val Thr Pro Val Ser Thr Asn Leu
35 40 45

Glu Gly Arg Tyr Leu Ser His Thr Leu Ser Ala Ser His Lys Lys Arg
50 55 60

Ser Ala Arg Asp Val Ser Ser Asn Pro Glu Gln Leu Phe Phe Asn Ile
65 70 75 80

Thr Ala Phe Gly Lys Asp Phe His Leu Arg Leu Lys Pro Asn Thr Gln
85 90 95

Leu Val Ala Pro Gly Ala Val Val Glu Trp His Glu Thr Ser Leu Val
100 105 110

Pro Gly Asn Ile Thr Asp Pro Ile Asn Asn His Gln Pro Gly Ser Ala
115 120 125

Thr Tyr Arg Ile Arg Lys Thr Glu Pro Leu Gln Thr Asn Cys Ala Tyr
130 135 140

Val Gly Asp Ile Val Asp Ile Pro Gly Thr Ser Val Ala Ile Ser Asn
145 150 155 160

Cys Asp Gly Leu Ala Gly Met Ile Lys Ser Asp Asn Glu Glu Tyr Phe
165 170 175

Ile Glu Pro Leu Glu Arg Gly Lys Gln Met Glu Glu Glu Lys Gly Arg
180 185 190

Ile His Val Val Tyr Lys Arg Ser Ala Val Glu Gln Ala Pro Ile Asp
195 200 205

Met Ser Lys Asp Phe His Tyr Arg Glu Ser Asp Leu Glu Gly Leu Asp

210 215 220

Asp Leu Gly Thr Val Tyr Gly Asn Ile His Gln Gln Leu Asn Glu Thr
225 230 235 240

Met Arg Arg Arg Arg His Ala Gly Glu Asn Asp Tyr Asn Ile Glu Val
245 250 255

Leu Leu Gly Val Asp Asp Ser Val Val Arg Phe His Gly Lys Glu His
260 265 270

Val Gln Asn Tyr Leu Leu Thr Leu Met Asn Ile Val Asn Glu Ile Tyr
275 280 285

His Asp Glu Ser Leu Gly Val His Ile Asn Val Val Leu Val Arg Met
290 295 300

Ile Met Leu Gly Tyr Ala Lys Ser Ile Ser Leu Ile Glu Arg Gly Asn
305 310 315 320

Pro Ser Arg Ser Leu Glu Asn Val Cys Arg Trp Ala Ser Gln Gln Gln
325 330 335

Arg Ser Asp Leu Asn His Ser Glu His His Asp His Ala Ile Phe Leu
340 345 350

Thr Arg Gln Asp Phe Gly Pro Ala Gly Met Gln Gly Tyr Ala Pro Val
355 360 365

Thr Gly Met Cys His Pro Val Arg Ser Cys Thr Leu Asn His Glu Asp
370 375 380

Gly Phe Ser Ser Ala Phe Val Val Ala His Glu Thr Gly His Val Leu
385 390 395 400

Gly Met Glu His Asp Gly Gln Gly Asn Arg Cys Gly Asp Glu Thr Ala
405 410 415

Met Gly Ser Val Met Ala Pro Leu Val Gln Ala Ala Phe His Arg Tyr
420 425 430

His Trp Ser Arg Cys Ser Gly Gln Glu Leu Lys Arg Tyr Ile His Ser

435 440 445

Tyr Asp Cys Leu Leu Asp Asp Pro Phe Asp His Asp Trp Pro Lys Leu
450 455 460

Pro Glu Leu Pro Gly Ile Asn Tyr Ser Met Asp Glu Gln Cys Arg Phe
465 470 475 480

Asp Phe Gly Val Gly Tyr Lys Met Cys Thr Ala Phe Arg Thr Phe Asp
485 490 495

Pro Cys Lys Gln Leu Trp Cys Ser His Pro Asp Asn Pro Tyr Phe Cys
500 505 510

Lys Thr Lys Lys Gly Pro Pro Leu Asp Gly Thr Glu Cys Ala Ala Gly
515 520 525

Lys Trp Cys Tyr Lys Gly His Cys Met Trp Lys Asn Ala Asn Gln Gln
530 535 540

Lys Gln Asp Gly Asn Trp Gly Ser Trp Thr Lys Phe Gly Ser Cys Ser
545 550 555 560

Arg Thr Cys Gly Thr Gly Val Arg Phe Arg Thr Arg Gln Cys Asn Asn
565 570 575

Pro Met Pro Ile Asn Gly Gly Gln Asp Cys Pro Gly Val Asn Phe Glu
580 585 590

Tyr Gln Leu Cys Asn Thr Glu Glu Cys Gln Lys His Phe Glu Asp Phe
595 600 605

Arg Ala Gln Gln Cys Gln Gln Arg Asn Ser His Phe Glu Tyr Gln Asn
610 615 620

Thr Lys His His Trp Leu Pro Tyr Glu His Pro Asp Pro Lys Lys Arg
625 630 635 640

Cys His Leu Tyr Cys Gln Ser Lys Glu Thr Gly Asp Val Ala Tyr Met
645 650 655

Lys Gln Leu Val His Asp Gly Thr His Cys Ser Tyr Lys Asp Pro Tyr

660 665 670

Ser Ile Cys Val Arg Gly Glu Cys Val Lys Val Gly Cys Asp Lys Glu
675 680 685

Ile Gly Ser Asn Lys Val Glu Asp Lys Cys Gly Val Cys Gly Gly Asp
690 695 700

Asn Ser His Cys Arg Thr Val Lys Gly Thr Phe Thr Arg Thr Pro Arg
705 710 715 720

Lys Leu Gly Tyr Leu Lys Met Phe Asp Ile Pro Pro Gly Ala Arg His
725 730 735

Val Leu Ile Gln Glu Asp Glu Ala Ser Pro His Ile Leu Ala Ile Lys
740 745 750

Asn Gln Ala Thr Gly His Tyr Ile Leu Asn Gly Lys Gly Glu Glu Ala
755 760 765

Lys Ser Arg Thr Phe Ile Asp Leu Gly Val Glu Trp Asp Tyr Asn Ile
770 775 780

Glu Asp Asp Ile Glu Ser Leu His Thr Asp Gly Pro Leu His Asp Pro
785 790 795 800

Val Ile Val Leu Ile Ile Pro Gln Glu Asn Asp Thr Arg Ser Ser Leu
805 810 815

Thr Tyr Lys Tyr Ile Ile His Glu Asp Ser Val Pro Thr Ile Asn Ser
820 825 830

Asn Asn Val Ile Gln Glu Glu Leu Asp Thr Phe Glu Trp Ala Leu Lys
835 840 845

Ser Trp Ser Gln Val Ser Lys Pro Cys Gly Gly Gly Phe Gln Tyr Thr
850 855 860

Lys Tyr Gly Cys Arg Arg Lys Ser Asp Asn Lys Met Val His Arg Ser
865 870 875 880

Phe Cys Glu Ala Asn Lys Lys Pro Lys Pro Ile Arg Arg Met Cys Asn

885 890 895

Ile Gln Glu Cys Thr His Pro Leu Trp Val Ala Glu Glu Trp Glu His
900 905 910

Cys Thr Lys Thr Cys Gly Ser Ser Gly Tyr Gln Leu Arg Thr Val Arg
915 920 925

Cys Leu Gln Pro Leu Leu Asp Gly Thr Asn Arg Ser Val His Ser Lys
930 935 940

Tyr Cys Met Gly Asp Arg Pro Glu Ser Arg Arg Pro Cys Asn Arg Val
945 950 955 960

Pro Cys Pro Ala Gln Trp Lys Thr Gly Pro Trp Ser Glu Cys Ser Val
965 970 975

Thr Cys Gly Glu Gly Thr Glu Val Arg Gln Val Leu Cys Arg Ala Gly
980 985 990

Asp His Cys Asp Gly Glu Lys Pro Glu Ser Val Arg Ala Cys Gln Leu
995 1000 1005

Pro Pro Cys Asn Asp Glu Pro Cys Leu Gly Asp Lys Ser Ile Phe
1010 1015 1020

Cys Gln Met Glu Val Leu Ala Arg Tyr Cys Ser Ile Pro Gly Tyr
1025 1030 1035

Asn Lys Leu Cys Cys Glu Ser Cys Ser Lys Arg Ser Ser Thr Leu
1040 1045 1050

Pro Pro Pro Tyr Leu Leu Glu Ala Ala Glu Thr His Asp Asp Val
1055 1060 1065

Ile Ser Asn Pro Ser Asp Leu Pro Arg Ser Leu Val Met Pro Thr
1070 1075 1080

Ser Leu Val Pro Tyr His Ser Glu Thr Pro Ala Lys Lys Met Ser
1085 1090 1095

Leu Ser Ser Ile Ser Ser Val Gly Gly Pro Asn Ala Tyr Ala Ala

1100 1105 1110

Phe Arg Pro Asn Ser Lys Pro Asp Gly Ala Asn Leu Arg Gln Arg
1115 1120 1125

Ser Ala Gln Gln Ala Gly Ser Lys Thr Val Arg Leu Val Thr Val
1130 1135 1140

Pro Ser Ser Pro Pro Thr Lys Arg Val His Leu Ser Ser Ala Ser
1145 1150 1155

Gln Met Ala Ala Ala Ser Phe Phe Ala Ala Ser Asp Ser Ile Gly
1160 1165 1170

Ala Ser Ser Gln Ala Arg Thr Ser Lys Lys Asp Gly Lys Ile Ile
1175 1180 1185

Asp Asn Arg Arg Pro Thr Arg Ser Ser Thr Leu Glu Arg
1190 1195 1200

<210> 41
<211> 5774
<212> DNA
<213> Homo sapiens

<400> 41
gtcactttgg ttgatagcag ccgctctggt agaggttagg acttcagctg atggacaagc 60

tggtaatgaa gaaatggtgc aaatagattt accaataaag agatatagag agtatgagct 120

ggtgactcca gtcagcacaa atctagaagg acgctatctc tcccatactc tttctgcgag 180

tcacaaaaag aggtcagcga gggacgtgtc ttccaaccct gagcagttgt tctttaacat 240

cacggcattt ggaaaagatt ttcatctgcg actaaagccc aacactcaac tagtagctcc 300

tggggctgtt gtggagtggc atgagacatc tctggtgcct gggaatataa ccgatcccat 360

taacaaccat caaccaggaa gtgctacgta tagaatccgg aaaacagagc ctttgcagac 420

taactgtgct tatgttggtg acatcgtgga cattccagga acctctgttg ccatcagcaa 480

ctgtgatggt ctggctggaa tgataaaaag tgataatgaa gagtatttca ttgaaccctt 540

ggaaagaggt aaacagatgg aggaagaaaa aggaaggatt catgttgtct acaagagatc 600

agctgtagaa caggctccca tagacatgtc caaagacttc cactacagag agtcggacct 660

ggaaggcctt gatgatctag gtactgttta tggcaacatc caccagcagc tgaatgaaac 720

aatgagacgc cgcagacacg cgggagaaaa cgattacaat atcgaggtac tgctgggagt 780

ggatgactct gtggtccgtt tccatggcaa agagcacgtc caaaactacc tcctgaccct 840

aatgaacatt gtgaatgaaa tttaccatga tgagtccctc ggagtgcata taaatgtggt 900

cctggtgcgc atgataatgc tgggatatgc aaagtccatc agcctcatag aaaggggaaa 960

cccatccaga agcttggaga atgtgtgtcg ctgggcgtcc caacagcaaa gatctgatct 1020

caaccactct gaacaccatg accatgcaat ttttttaacc aggcaagact ttggacctgc 1080

tggaatgcaa ggatatgctc cagtcaccgg catgtgtcat ccagtgagaa gttgtaccct 1140

gaatcatgag gatggttttt catctgcttt tgtagtagcc catgaaacgg gccatgtgtt 1200

gggaatggag catgatggac aaggcaacag gtgtggtgat gagactgcta tgggaagtgt 1260

catggctccc ttggtacaag cagcattcca tcgttaccac tggtcccgat gcagtggtca 1320

agaactgaaa agatatatcc attcctatga ctgtctcctt gatgaccctt ttgatcatga 1380

ttggcctaaa ctcccagaac ttcctggaat caattattct atggatgagc aatgtcgttt 1440

tgattttggt gttggctata aaatgtgcac cgcgttccga acctttgacc catgtaaaca 1500

gctgtggtgt agccatcctg ataatcccta cttttgtaag actaaaaagg gacctccact 1560

tgatgggact gaatgtgctg ctggaaaatg gtgctataag ggtcattgca tgtggaagaa 1620

tgctaatcag caaaaacaag atggcaattg ggggtcatgg actaaatttg gctcctgttc 1680

tcggacatgt ggaactggtg ttcgtttcag aacacgccag tgcaataatc ccatgcccat 1740

caatggtggt caggattgtc ctggtgttaa ttttgagtac cagctttgta acacagaaga 1800

atgccaaaaa cactttgagg acttcagagc acagcagtgt cagcagcgaa actcccactt 1860

tgaataccag aataccaaac accactggtt gccatatgaa catcctgacc ccaagaaaag 1920

atgccacctt tactgtcagt ccaaggagac tggagatgtt gcttacatga aacaactggt 1980

gcatgatgga acgcactgtt cttacaaaga tccatatagc atatgtgtgc gaggagagtg 2040

tgtgaaagtg ggctgtgata aagaaattgg ttctaataag gttgaggata agtgtggtgt 2100

ctgtggagga gataattccc actgccgaac cgtgaagggg acatttacca gaactcccag 2160

gaagcttggg taccttaaga tgtttgatat acccccctggg gctagacatg tgttaatcca 2220

agaagacgag gcttctcctc atattcttgc tattaagaac caggctacag gccattatat 2280

tttaaatggc aaaggggagg aagccaagtc gcggaccttc atagatcttg gtgtggagtg 2340

ggattataac attgaagatg acattgaaag tcttcacacc gatggacctt tacatgatcc 2400

tgttattgtt ttgattatac ctcaagaaaa tgatacccgc tctagcctga catataagta 2460

catcatccat gaagactctg tacctacaat caacagcaac aatgtcatcc aggaagaatt 2520

agatactttt gagtgggctt tgaagagctg gtctcaggtt tccaaaccct gtggtggagg 2580

tttccagtac actaaatatg gatgccgtag gaaaagtgat aataaaatgg tccatcgcag 2640

cttctgtgag gccaacaaaa agccgaaacc tattagacga atgtgcaata ttcaagagtg 2700

tacacatcca ctctgggtag cagaagaatg ggaacactgc accaaaacct gtggaagttc 2760

tggctatcag cttcgcactg tacgctgcct tcagccactc cttgatggca ccaaccgctc 2820

tgtgcacagc aaatactgca tgggtgaccg tcccgagagc cgccggccct gtaacagagt 2880

gccctgccct gcacagtgga aaacaggacc ctggagtgag tgttcagtga cctgcggtga 2940

aggaacggag gtgaggcagg tcctctgcag ggctggggac cactgtgatg gtgaaaagcc 3000

tgagtcggtc agagcctgtc aactgcctcc ttgtaatgat gaaccatgtt tgggagacaa 3060

gtccatattc tgtcaaatgg aagtgttggc acgatactgc tccataccag gttataacaa 3120

gttatgttgt gagtcctgca gcaagcgcag tagcaccctg ccaccaccat accttctaga 3180

agctgctgaa actcatgatg atgtcatctc taaccctagt gacctcccta gatctctagt 3240

gatgcctaca tctttggttc cttatcattc agagacccct gcaaagaaga tgtctttgag 3300

tagcatctct tcagtgggag gtccaaatgc atatgctgct ttcaggccaa acagtaaacc 3360

tgatggtgct aatttacgcc agaggagtgc tcagcaagca ggaagtaaga ctgtgagact 3420

ggtcaccgta ccatcctccc cacccaccaa gagggtccac ctcagttcag cttcacaaat 3480

ggctgctgct tccttctttg cagccagtga ttcaataggt gcttcttctc aggcaagaac 3540

ctcaaagaaa gatggaaaga tcattgacaa cagacgtccg acaagatcat ccaccttaga 3600

aagatgagaa agtgaaccaa aaaggctaga aaccagagga aaacctggac aacctctctc 3660

ttcccatggt gcatatgctt gtttaaagtg gaaatctcta tagatcgtca gctcatttta 3720

tctgtaattg gaagaacaga aagtgctggc tcactttcta gttgctttca tcctcctttt 3780

gttctgcatt gactcattta ccagaattca ttggaagaaa tcaccaaaga ttattacaaa 3840

agaaaaatat gttgctaaga ttgtgttggt cgctctctga agcagaaaag ggactggaac 3900

caattgtgca tatcagctga ctttttgttt gttttagaaa agttacagta aaaattaaaa 3960

agagatacca atggtttaca ctttaacaag aaattttgga tatggaacaa agaattctta 4020

gacttgtatt cctatttatc tatattagaa atattgtatg agcaaatttg cagctgttgt 4080

gtaaatactg tatattgcaa aaatcagtat tattttaaga gatgtgttct caaatgattg 4140

tttactatat tacatttctg gatgttctag gtgcctgtcg ttgagtattg ccttgtttga 4200

cattctatag gttaattttc aaagcagagt attacaaaag agaagttaga attacagcta 4260

ctgacaatat aaagggtttt gttgaatcaa caatgtgata cgtaaattat agaaaaagaa 4320

aagaaacaca aaagctatag atatacagat atcagcttac ctattgcctt ctatacttat 4380

aatttaaagg attggtgtct tagtacactt gtggtcacag ggatcaacga atagtaaata 4440

atgaactcgt gcaagacaaa actgaaaccc tctttccagg acctcagtag gcaccgttga 4500

ggtgtccttt gtttttgtgt gtgtgtgttc ttttttaatt ttcgcattgt tgacagatac 4560

aaacagttat actcaatgta ctgtaataat cgcaaaggaa aaagttttgg gataacttat 4620

ttgtatgttg gtagctgaga aaaatatcat cagtctagaa ttgatatttg agtatagtag 4680

agctttgggg ctttgaaggc aggttcaaga aagcatatgt cgatggttga gatatttatt 4740

ttccatatgg ttcatgttca aatgttcaca accacaatgc atctgactgc aataatgtgc 4800

taataattta tgtcagtagt caccttgctc acagcaaagc cagaaatgct ctctccaggg 4860

agtagatgta aagtacttgt acatagaatt cagaactgaa gatatttatt aaaagttgat 4920

tttttttttct tgatagtatt tttatgtact aaatatttac actaatatca attacatatt 4980

ttggtaaact agagagacat aattagagat gcatgctttg ttctgtgcat agagaccttt 5040

aagcaaacta ctacagccaa ctcaaaagct aaaactgaac aaatttgatg ttatgcaaac 5100

atcttgcatt tttagtagtt gatattaagt tgatgacttg tttcccttca aggaaacatt 5160

aaattgtatg gactcagcta gctgttcaat gaaattgtga attagaaaca tttttaaaag 5220

tttttgaaag agataagtgc atcatgaatt acatgtacat gagaggagat agtgatatca 5280

gcataatgat tttgaggtca gtacctgagc tgtctaaaaa tatattatac aaactaaaat 5340

gtagatgaat taacctctca aagcacagaa tgtgcaagaa cttttgcatt ttaatcgttg 5400

taaactaaca gcttaaacta ttgactctat acctctaaag aattgctgct actttgtgca 5460

agaactttga aggtcaaatt aggcaaattc cagatagtaa aacaatccct aagccttaag 5520

tctttttttt ttcctaaaaa ttcccataga ataaaattct ctctagttta cttgtgtgtg 5580

catacatctc atccacaggg gaagataaag atggtcacac aaacagtttc cataaagatg 5640

tacatattca ttatacttct gacctttggg ctttcttttc tactaagcta aaaattcctt 5700

tttatcaaag tgtacactac tgatgctgtt tgttgtactg agagcacgta ccaataaaaa 5760

tgttaacaaa atat 5774

<210> 42
<211> 629
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (596)..(596)
<223> n is a, c, g, or t

<400> 42
ttttttttttc agattgaaat cactttaata gcataacaac attttcagac caggagtcac 60

agatgaagaa aacattttgt cttccatttg cacaattctg gtgaggtgtg tggttgcact 120

ggacaatctt acagacacat ttttcacatt gagaacttaa taaatagata catacaatgt 180

caaactccac agacaatgag ttatgagtgt gattgttttc ttattctgcc tcctctgggt 240

tgggaggttg cttcccgttg ggctgatggc ggctgggtcc tctaggaggg gtactcatac 300

tcctcggcac tgcgacggcc aaaatccatc cagcccatgt agtcccggtc acttatcctg 360

tggctggggt ccaggttctg caggttctta acgatggaca ttcgtccaga aggagctttc 420

cgggcctgct ggatgtatct tgccagcagg gcgcccaggt gcgctcggga ctcgccatcc 480

gttctctgcg ataccctcag ctgcctacgg ggcgcctcct ctgcccgctg cagcccggag 540

cccgcgggat ctgcgggagg caccggctgc gtcagggcgc cagccgccag taccgncatc 600

agcacgcaca ggcacacgcc gctgttcat 629

<210> 43
<211> 94
<212> PRT
<213> Homo sapiens

<400> 43

Met Ser Val Lys Gly Met Ala Ile Ala Leu Ala Val Ile Leu Cys Ala
1 5 10 15

Thr Val Val Gln Gly Phe Pro Met Phe Lys Arg Gly Arg Cys Leu Cys
20 25 30

Ile Gly Pro Gly Val Lys Ala Val Lys Val Ala Asp Ile Glu Lys Ala
35 40 45

Ser Ile Met Tyr Pro Ser Asn Asn Cys Asp Lys Ile Glu Val Ile Ile
50 55 60

Thr Leu Lys Glu Asn Lys Gly Gln Arg Cys Leu Asn Pro Lys Ser Lys
65 70 75 80

Gln Ala Arg Leu Ile Ile Lys Lys Val Glu Arg Lys Asn Phe
85 90

<210> 44
<211> 1371
<212> DNA
<213> Homo sapiens

<400> 44
ctccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa 60

aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgctaca 120

gttgttcaag gcttccccat gttcaaaaga ggacgctgtc tttgcatagg ccctggggta 180

aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtacccaag taacaactgt 240

gacaaaatag aagtgattat taccctgaaa gaaaataaag gacaacgatg cctaaatccc 300

aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaattt ttaaaaatat 360

caaaacatat gaagtcctgg aaaagggcat ctgaaaaacc tagaacaagt ttaactgtga 420

ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg ttttgtgact 480

ttcaactttt gtacagttat gtgaaggatg aaaggtgggt gaaaggacca aaaacagaaa 540

tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta 600

aatggatttc taggaaaagc taccttaaga aaggctggtt accatcggag tttacaaagt 660

gctttcacgt tcttacttgt tgtattatac attcatgcat ttctaggcta gagaaccttc 720

tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt 780

tatctgtctg tattgatctt tatgctatat tactatctgt ggttacagtg gagacattga 840

cattattact ggagtcaagc ccttataagt caaaagcatc tatgtgtcgt aaagcattcc 900

tcaaacattt tttcatgcaa atacacaytt ctttccccaa atatcatgta gcacatcaat 960

atgtagggaa acattcttat gcatcatttg gtttgtttta taaccaattc attaaatgta 1020

attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat 1080

atttcataac caaattagca gcaccggtct taatttgatg tttttcaact tttattcatt 1140

gagatgtttt gaagcaatta ggatatgtgt gtttactgta ctttttgttt tgatccgttt 1200

gtataaatga tagcaatatc ttggacacat ttgaaataca aaatgttttt gtctaccaaa 1260

gaaaaatgtt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc 1320

tgtctcttag aaaaatacat aatctaatca aaaaaaaaaa aaaaaaaaaa a 1371

<210> 45
<211> 251
<212> PRT
<213> Homo sapiens

<400> 45

Met Thr Arg Leu Thr Val Leu Ala Leu Leu Ala Gly Leu Leu Ala Ser
1 5 10 15

Ser Arg Ala Gly Ser Ser Pro Leu Leu Asp Ile Val Gly Gly Arg Lys
20 25 30

Ala Arg Pro Arg Gln Phe Pro Phe Leu Ala Ser Ile Gln Asn Gln Gly
35 40 45

Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe Val Met Thr
50 55 60

Ala Ala Ser Cys Phe Gln Ser Gln Asn Pro Gly Val Ser Thr Val Val
65 70 75 80

Leu Gly Ala Tyr Asp Leu Arg Arg Arg Glu Arg Gln Ser Arg Gln Thr
85 90 95

Phe Ser Ile Ser Ser Met Ser Glu Asn Gly Tyr Asp Pro Gln Gln Asn
100 105 110

Leu Asn Asp Leu Met Leu Leu Gln Leu Asp Arg Glu Ala Asn Leu Thr
115 120 125

Ser Ser Val Thr Ile Leu Pro Leu Pro Leu Gln Asn Ala Thr Val Glu
130 135 140

Ala Gly Thr Arg Cys Gln Val Ala Gly Trp Gly Ser Gln Arg Ser Gly
145 150 155 160

```
Gly Arg Leu Ser Arg Phe Pro Arg Phe Val Asn Val Thr Val Thr Pro
                165                 170                 175

Glu Asp Gln Cys Arg Pro Asn Asn Val Cys Thr Gly Val Leu Thr Arg
            180                 185                 190

Arg Gly Gly Ile Cys Asn Gly Asp Gly Gly Thr Pro Leu Val Cys Glu
        195                 200                 205

Gly Leu Ala His Gly Val Ala Ser Phe Ser Leu Gly Pro Cys Gly Arg
    210                 215                 220

Gly Pro Asp Phe Phe Thr Arg Val Ala Leu Phe Arg Asp Trp Ile Asp
225                 230                 235                 240

Gly Val Leu Asn Asn Pro Gly Pro Gly Pro Ala
                245                 250
```

<210> 46
<211> 5002
<212> DNA
<213> Homo sapiens

<400> 46

```
ggatccactg gttcctgaca ccctcacctg cccctggggg tgtggccatc ttctagagag     60

ggaaactgag gatcagtgca gaatgtaggg ggagcccagg ctggcccagg gagcagttgg    120

cggtggaggc cttgggcaat ttcccgtgtt cccactgagt ggggctgtcc ctgggcctgg    180

gcggggacgc caccaactgc caaggcctgt gtataagggc agccgccgcc ttagccacag    240

acctgccccg ccatgacccg gctgacagtc ctggccctgc tggctggtct gctggcatcc    300

tcgagggccg gtgagtgcct ctctgtgccg gtggtccccc atctgtgcta gggcccggct    360

gccagggcag aactcagact taaagcacag agaaggcaag cggcttggcc tgggtcacac    420

agccagcccg gcctggacga tcccgcgaaa ggcgtgaggg cggacggtgt gcgggactca    480

ggggcccccc gtcctcttag ggagtgggac gatgggggag ggtgggtccc cccgcagccc    540

cactgggtgg atagagctga ggctgcagct tcacacgccc tcccggccac tgtgtggatt    600

cttggggatc tcagagctgt ctcccccccga cccaggctcc agccccctttt tggacatcgt    660

tggcggccgg aaggcgaggc cccgccagtt cccgttcctg gcctccattc agaatcaagg    720
```

caggcacttc tgcgggggtg ccctgatcca tgcccgcttc gtgatgaccg cggccagctg 780

cttccaaagc cagtgagggg tcctggggag ggggcctagg gggcattggg gctcagagaa 840

ggggcttggg gggcttaggc attcagtggg ggtgcttggt aggtgaggag gggaggggat 900

tgcaaaagga ggggctcagg gaaaggaggg ggcttggaga gggaaatggg gactgagttg 960

aggagggacc caaggatatt ggggggctca gatggaggag gcccagagaa gggaaggggg 1020

tcagatggag gaggcccaga gaaaggaaga ggctcagatg gaggaggtgc agtgaaggaa 1080

aggggtcag atgggggagg cccagagaag ggaaggggct cagatggagg agggggccca 1140

gagaaaggaa ggggctcaga tggaggaggt gcagagaagg gaaggggtc agatgggggg 1200

aggcccagag aagggaaggg gctcagatgg aggaggtgca gagaagggaa ggggctcaga 1260

tggaggaggt gcagagaaga gaagggcctc agatggagga ggtgcagaga agagaagggc 1320

ctcagatgga ggaggtgcag agaagggaag ggcctcagat ggaggaggtg cggagaaggg 1380

aaggggtca gatggaggag gtgcagagaa gggaaggggg tcagatgggg gaggcccagg 1440

gaagggaagg ggctcagatg gaggaggggc agagaaggga aggggtcag atgggggagg 1500

cccagggaag ggaaggggct cagatggggg aggcgcagag aagggaaggg ggtcagatgg 1560

aggaggtgca gagaagggaa gggggtcaga tgggggaggc ccagataagg gaatggggtc 1620

agatggggga ggtgcagaga agggaagggg gtcagatggg ggaggcccag ataagggaag 1680

gggctcagat ggaggaggtg cagagaaggg gaggggtca gatggaggag gctcagagaa 1740

gggaagggac tcagatggag gaggggcgc agagaagaga aggggctcag atggaggagg 1800

aggcgcagag aagggaaggg gctcaagatg ggaaggggc cctggaaagt ctcggctctg 1860

cttctgtaaa agcgggggag ttttcagggt gaaggattgc agtctgcagg ctgggatccc 1920

ccctaatttg caagccggct tgctctgtgc ccaggcccca gcctggtgtc ctccctctgc 1980

cctttcctcc gctactctca ggaaccccgg ggttagcacc gtggtgctgg gtgcctatga 2040

cctgaggcgg cgggagaggc agtcccgcca gacgttttcc atcagcagca tgagcgagaa 2100

tggctacgac ccccagcaga acctgaacga cctgatgctg cttcaggtga gaggatggtg 2160

ccacctgtga tcccagcacc tcgggaggcc gacgttagcc agggaaacaa gtccaaactt 2220

ggtctctaca aaaaaataca aaaattagcc gggagtggtg gcgcgcacct gtggcccctg 2280

tgcttcagga ggccgaggcg gaaggacggc ttgaggtcag gagttcgaga ccagcctggg 2340

caacatggcc aaactcagtc tctacaaaaa tatatatgtg tgtgtgtgtg tgtgtgtgtg 2400

tgtgtgtgtg tgtgtatctt gccgggtgag gtggctcatg cctgtaatcc cagcattttg 2460

ggaggccgag gtgggcggat cacgaggtca ggagattgag accagcctgg ccaacatggt 2520

gaaaccccat ctctactaaa aatacaaaaa ttagccaggc atggcagcgg gcgcctctag 2580

tcccagctac tcaggaggct gaggcaggag aatcgcttga acccgggagg cggagcttgc 2640

agtgagccga gatcgcgccc ctgcactcca gcctgggtaa cagagccaga ccctatctca 2700

aaaaaaactt ccaaaaacaa tacagcaaca catacagatg taccacggtt cgcgtatgga 2760

gcctcctgtt ggtggagact gacgtcgttt tcaaatgctt ttgctatgac agaatcatgt 2820

gaatgttttt catgtttggt ttttttcttt gagaaaatga taaaattatc tcaaaaatat 2880

cattaaaaaa tttaaaaaag tagagacggg ggtttcacct tgttggccag tttggtctcg 2940

aactcctggc ctcaagtgat ccacccacct tggcctcgca acgtgctggg aatacaggcg 3000

tgagccaccg cacccggccc ctgccgggaa ttaaacgcaa accacttaca gactacagtt 3060

aatgtcgctg acacttctgc tcccaggggt ccccatgagg ctccagtccc cagggccacc 3120

ctcccctgac tccatttcct tccccagctg gaccgtgagg ccaacctcac cagcagcgtg 3180

acgatactgc cactgcctct gcagaacgcc acggtggaag ccggcaccag atgccaggtg 3240

gccggctggg ggagccagcg cagtgggggg cgtctctccc gttttcccag gtttgtcaac 3300

gtgactgtga cccccgagga ccagtgtcgc cccaacaacg tgtgcaccgg tgtgctcacc 3360

cgccgcggtg gcatctgcaa tgtgagtgct ccctgtggcg ggaggagggg tcctgagagg 3420

tactgagctc tccgtggcag gagaaagcaa gtgcaggctg agggcggcac agcaggggg 3480

ccccaggatt gagcattttc acggtaggag aaacagtatc ttttttttt ttttgagac 3540

agagtctcgc tctgtcgccc aggctggagt gtagtggcgt gatctcggcg gctcactgca 3600

acctccgcct cctgggttca agcgattctc ctgcctcagc ctcctaagta gctgggatta 3660

caggcatgcg ccaccacgcc cggctaattt tgtattttta gtagagacag ggtttctcca 3720

tgtgggtcag gctggtctcg aactcctgac ctcatgatcg acccaccttg gcctcccaaa 3780

gtgttaggat aacaggcatg agccaccgtg cctggctgag aaacagtagc tatcaaacgc 3840

cggctgtgag ccacgtctgt gctgggggtt ggggacccag caggcatggt agagccggtc 3900

actgagggac tcaggcgtgt gattgccagg ggaggggcac ctggcccagc ctggaggtgc 3960

caggaagctc cagaaagcaa ctgatcccaa agtccactag cagttaacca gggcagagaa 4020

agagaagagc catgcaaagg ccctggggct ggatcaggac ttgtaggttc caggggcagc 4080

aagaggcctc tgcagttctg gggtggcgtg ggagccaggc cctgggacgc cctgacacag 4140

ctgctgcctg cccaggggga cgggggcacc cccctcgtct gcgagggcct ggcccacggc 4200

gtggcctcct tttccctggg gccctgtggc cgaggccctg acttcttcac ccgagtggcg 4260

ctcttccgag actggatcga tggtgttctc aacaacccgg gaccggggcc agcctagggg 4320

ggcctgtgac ctcccatgga gcccagcccc cgccctccac acctccggcg ctccgcaccc 4380

acctcccacg gccccgcccc tgcccccgct ccggccagag gggccctggc tgtaataaag 4440

aagccgatct ctcctctgct cctggtttct gttcattggt gggggagggg gctgtgggga 4500

cgcgtgagtg gcaccttcac cggccttagg ggcacccacc gcaggtgcac tgcctgtgca 4560

gatgtcagat gttcagagat tccctcaaag cccggggaag caggggctgg tgttatctgc 4620

acccgacagc ggggtgttgg ggggaggccc aggttcagag aggttgggtg gctgcccaga 4680

ggtcacacag tgaatgccgc ccagcacttt gggaggccga ggtgggcgga tcacctgagg 4740

tcaggagttc aagaccagcc cggccaacct ggtgaaaccc catctctata aaaatacaaa 4800

aattagccgg gcatgatggc gggcgcctgt aatcccagtt acttgggagg ctgaggcagg 4860

agaatcacct gaacccggga ggcggaggtt gcagcgaacc gagatggcgc cactgcactc 4920

cagcctgggc gacagcgaga ctccagctca aaaaaaaaca aaaaccacgg gagaaaacgg 4980

ggaacattct cctcttggat cc 5002

<210> 47
<211> 687
<212> PRT
<213> Homo sapiens

<400> 47

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser
1 5 10 15

Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro
20 25 30

Glu Leu Ser Leu Lys Gly Thr Gln His Ile Met Gln Ala Gly Gln Thr
35 40 45

Leu His Leu Gln Cys Arg Gly Glu Ala Ala His Lys Trp Ser Leu Pro
50 55 60

Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser Ile Thr Lys Ser Ala
65 70 75 80

Cys Gly Arg Asn Gly Lys Gln Phe Cys Ser Thr Leu Thr Leu Asn Thr
85 90 95

Ala Gln Ala Asn His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val
100 105 110

Pro Thr Ser Lys Lys Lys Glu Thr Glu Ser Ala Ile Tyr Ile Phe Ile
115 120 125

Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu
130 135 140

Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val
145 150 155 160

Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr
165 170 175

Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe
180 185 190

Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu
195 200 205

Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg
210 215 220

Gln Thr Asn Thr Ile Ile Asp Val Gln Ile Ser Thr Pro Arg Pro Val
225 230 235 240

Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr
245 250 255

Pro Leu Asn Thr Arg Val Gln Met Thr Trp Ser Tyr Pro Asp Glu Lys
260 265 270

Asn Lys Arg Ala Ser Val Arg Arg Arg Ile Asp Gln Ser Asn Ser His
275 280 285

```
Ala Asn Ile Phe Tyr Ser Val Leu Thr Ile Asp Lys Met Gln Asn Lys
    290                 295                 300

Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser Gly Pro Ser Phe Lys
305                 310                 315                 320

Ser Val Asn Thr Ser Val His Ile Tyr Asp Lys Ala Phe Ile Thr Val
                325                 330                 335

Lys His Arg Lys Gln Gln Val Leu Glu Thr Val Ala Gly Lys Arg Ser
            340                 345                 350

Tyr Arg Leu Ser Met Lys Val Lys Ala Phe Pro Ser Pro Glu Val Val
        355                 360                 365

Trp Leu Lys Asp Gly Leu Pro Ala Thr Glu Lys Ser Ala Arg Tyr Leu
    370                 375                 380

Thr Arg Gly Tyr Ser Leu Ile Ile Lys Asp Val Thr Glu Glu Asp Ala
385                 390                 395                 400

Gly Asn Tyr Thr Ile Leu Leu Ser Ile Lys Gln Ser Asn Val Phe Lys
                405                 410                 415

Asn Leu Thr Ala Thr Leu Ile Val Asn Val Lys Pro Gln Ile Tyr Glu
            420                 425                 430

Lys Ala Val Ser Ser Phe Pro Asp Pro Ala Leu Tyr Pro Leu Gly Ser
        435                 440                 445

Arg Gln Ile Leu Thr Cys Thr Ala Tyr Gly Ile Pro Gln Pro Thr Ile
    450                 455                 460

Lys Trp Phe Trp His Pro Cys Asn His Asn His Ser Glu Ala Arg Cys
465                 470                 475                 480

Asp Phe Cys Ser Asn Asn Glu Glu Ser Phe Ile Leu Asp Ala Asp Ser
                485                 490                 495

Asn Met Gly Asn Arg Ile Glu Ser Ile Thr Gln Arg Met Ala Ile Ile
            500                 505                 510
```

```
Glu Gly Lys Asn Lys Met Ala Ser Thr Leu Val Val Ala Asp Ser Arg
        515                 520                 525

Ile Ser Gly Ile Tyr Ile Cys Ile Ala Ser Asn Lys Val Gly Thr Val
    530                 535                 540

Gly Arg Asn Ile Ser Phe Tyr Ile Thr Asp Val Pro Asn Gly Phe His
545                 550                 555                 560

Val Asn Leu Glu Lys Met Pro Thr Glu Gly Glu Asp Leu Lys Leu Ser
                565                 570                 575

Cys Thr Val Asn Lys Phe Leu Tyr Arg Asp Val Thr Trp Ile Leu Leu
            580                 585                 590

Arg Thr Val Asn Asn Arg Thr Met His Tyr Ser Ile Ser Lys Gln Lys
        595                 600                 605

Met Ala Ile Thr Lys Glu His Ser Ile Thr Leu Asn Leu Thr Ile Met
    610                 615                 620

Asn Val Ser Leu Gln Asp Ser Gly Thr Tyr Ala Cys Arg Ala Arg Asn
625                 630                 635                 640

Val Tyr Thr Gly Glu Glu Ile Leu Gln Lys Lys Glu Ile Thr Ile Arg
                645                 650                 655

Gly Glu His Cys Asn Lys Lys Ala Val Phe Ser Arg Ile Ser Lys Phe
            660                 665                 670

Lys Ser Thr Arg Asn Asp Cys Thr Thr Gln Ser Asn Val Lys His
        675                 680                 685
```

<210> 48
<211> 2651
<212> DNA
<213> Homo sapiens

<400> 48
gcggacactc ctctcggctc ctccccggca gcggcggcgg ctcggagcgg gctccggggc 60

tcgggtgcag cggccagcgg gcctggcggc gaggattacc cggggaagtg gttgtctcct 120

ggctggagcc gcgagacggg cgctcagggc gcggggccgg cggcggcgaa cgagaggacg 180

gactctggcg gccgggtcgt tggccggggg agcgcgggca ccgggcgagc aggccgcgtc 240

gcgctcacca tggtcagcta ctgggacacc ggggtcctgc tgtgcgcgct gctcagctgt 300

ctgcttctca caggatctag ttcaggttca aaattaaaag atcctgaact gagtttaaaa 360

ggcacccagc acatcatgca agcaggccag acactgcatc tccaatgcag gggggaagca 420

gcccataaat ggtctttgcc tgaaatggtg agtaaggaaa gcgaaaggct gagcataact 480

aaatctgcct gtggaagaaa tggcaaacaa ttctgcagta ctttaaccct gaacacagct 540

caagcaaacc acactggctt ctacagctgc aaatatctag ctgtacctac ttcaaagaag 600

aaggaaacag aatctgcaat ctatatattt attagtgata caggtagacc tttcgtagag 660

atgtacagtg aaatccccga aattatacac atgactgaag gaagggagct cgtcattccc 720

tgccgggtta cgtcacctaa catcactgtt actttaaaaa agtttccact tgacactttg 780

atccctgatg gaaaacgcat aatctgggac agtagaaagg gcttcatcat atcaaatgca 840

acgtacaaag aaatagggct tctgacctgt gaagcaacag tcaatgggca tttgtataag 900

acaaactatc tcacacatcg acaaaccaat acaatcatag atgtccaaat aagcacacca 960

cgcccagtca aattacttag aggccatact cttgtcctca attgtactgc taccactccc 1020

ttgaacacga gagttcaaat gacctggagt taccctgatg aaaaaaataa gagagcttcc 1080

gtaaggcgac gaattgacca aagcaattcc catgccaaca tattctacag tgttcttact 1140

attgacaaaa tgcagaacaa agacaaagga ctttatactt gtcgtgtaag gagtggacca 1200

tcattcaaat ctgttaacac ctcagtgcat atatatgata aagcattcat cactgtgaaa 1260

catcgaaaac agcaggtgct tgaaaccgta gctggcaagc ggtcttaccg gctctctatg 1320

aaagtgaagg catttccctc gccggaagtt gtatggttaa aagatgggtt acctgcgact 1380

gagaaatctg ctcgctattt gactcgtggc tactcgttaa ttatcaagga cgtaactgaa 1440

gaggatgcag ggaattatac aatcttgctg agcataaaac agtcaaatgt gtttaaaaac 1500

ctcactgcca ctctaattgt caatgtgaaa ccccagattt acgaaaaggc cgtgtcatcg 1560

tttccagacc cggctctcta cccactgggc agcagacaaa tcctgacttg taccgcatat 1620

ggtatccctc aacctacaat caagtggttc tggcacccct gtaaccataa tcattccgaa 1680

gcaaggtgtg acttttgttc caataatgaa gagtccttta tcctggatgc tgacagcaac 1740

atgggaaaca gaattgagag catcactcag cgcatggcaa taatagaagg aaagaataag 1800

atggctagca ccttggttgt ggctgactct agaatttctg gaatctacat ttgcatagct 1860

tccaataaag ttgggactgt gggaagaaac ataagctttt atatcacaga tgtgccaaat 1920

gggtttcatg ttaacttgga aaaaatgccg acggaaggag aggacctgaa actgtcttgc 1980

acagttaaca agttcttata cagagacgtt acttggattt tactgcggac agttaataac 2040

agaacaatgc actacagtat tagcaagcaa aaaatggcca tcactaagga gcactccatc 2100

actcttaatc ttaccatcat gaatgtttcc ctgcaagatt caggcaccta tgcctgcaga 2160

gccaggaatg tatacacagg ggaagaaatc ctccagaaga aagaaattac aatcagaggt 2220

gagcactgca acaaaaaggc tgttttctct cggatctcca aatttaaaag cacaaggaat 2280

gattgtacca cacaaagtaa tgtaaaacat taaaggactc attaaaaagt aacagttgtc 2340

tcatatcatc ttgatttatt gtcactgttg ctaactttca ggctcggagg agatgctcct 2400

cccaaaatga gttcggagat gatagcagta ataatgagac ccccgggctc cagctctggg 2460

ccccccattc aggccgaggg ggctgctccg gggggccgac ttggtgcacg tttggatttg 2520

gaggatccct gcactgcctt ctctgtgttt gttgctcttg ctgttttctc ctgcctgata 2580

aacaacaact tgggatgatc ctttccattt tgatgccaac ctctttttat ttttaagcgg 2640

cgccctatag t 2651

<210> 49
<211> 1321
<212> PRT
<213> Homo sapiens

<400> 49

Met Ser Asp Ser Val Ile Leu Arg Ser Ile Lys Lys Phe Gly Glu Glu
1 5 10 15

Asn Asp Gly Phe Glu Ser Asp Lys Ser Tyr Asn Asn Asp Lys Lys Ser
20 25 30

Arg Leu Gln Asp Glu Lys Lys Gly Asp Gly Val Arg Val Gly Phe Phe
35 40 45

Gln Leu Phe Arg Phe Ser Ser Ser Thr Asp Ile Trp Leu Met Phe Val
50 55 60

Gly Ser Leu Cys Ala Phe Leu His Gly Ile Ala Gln Pro Gly Val Leu
65 70 75 80

```
Leu Ile Phe Gly Thr Met Thr Asp Val Phe Ile Asp Tyr Asp Val Glu
                85                  90                  95

Leu Gln Glu Leu Gln Ile Pro Gly Lys Ala Cys Val Asn Asn Thr Ile
            100                 105                 110

Val Trp Thr Asn Ser Ser Leu Asn Gln Asn Met Thr Asn Gly Thr Arg
        115                 120                 125

Cys Gly Leu Leu Asn Ile Glu Ser Glu Met Ile Lys Phe Ala Ser Tyr
    130                 135                 140

Tyr Ala Gly Ile Ala Val Ala Val Leu Ile Thr Gly Tyr Ile Gln Ile
145                 150                 155                 160

Cys Phe Trp Val Ile Ala Ala Ala Arg Gln Ile Gln Lys Met Arg Lys
                165                 170                 175

Phe Tyr Phe Arg Arg Ile Met Arg Met Glu Ile Gly Trp Phe Asp Cys
            180                 185                 190

Asn Ser Val Gly Glu Leu Asn Thr Arg Phe Ser Asp Asp Ile Asn Lys
        195                 200                 205

Ile Asn Asp Ala Ile Ala Asp Gln Met Ala Leu Phe Ile Gln Arg Met
    210                 215                 220

Thr Ser Thr Ile Cys Gly Phe Leu Leu Gly Phe Phe Arg Gly Trp Lys
225                 230                 235                 240

Leu Thr Leu Val Ile Ile Ser Val Ser Pro Leu Ile Gly Ile Gly Ala
                245                 250                 255

Ala Thr Ile Gly Leu Ser Val Ser Lys Phe Thr Asp Tyr Glu Leu Lys
            260                 265                 270

Ala Tyr Ala Lys Ala Gly Val Val Ala Asp Glu Val Ile Ser Ser Met
        275                 280                 285

Arg Thr Val Ala Ala Phe Gly Gly Glu Lys Arg Glu Val Glu Arg Tyr
    290                 295                 300
```

Glu Lys Asn Leu Val Phe Ala Gln Arg Trp Gly Ile Arg Lys Gly Ile
305 310 315 320

Val Met Gly Phe Phe Thr Gly Phe Val Trp Cys Leu Ile Phe Leu Cys
325 330 335

Tyr Ala Val Ala Phe Trp Tyr Gly Ser Thr Leu Val Leu Asp Glu Gly
340 345 350

Glu Tyr Thr Pro Gly Thr Leu Val Gln Ile Phe Leu Ser Val Ile Val
355 360 365

Gly Ala Leu Asn Leu Gly Asn Ala Ser Pro Cys Leu Glu Ala Phe Ala
370 375 380

Thr Gly Arg Ala Ala Ala Thr Ser Ile Phe Glu Thr Ile Asp Arg Lys
385 390 395 400

Pro Ile Ile Asp Cys Met Ser Glu Asp Gly Tyr Lys Leu Asp Arg Ile
405 410 415

Lys Gly Glu Ile Glu Phe His Asn Val Thr Phe His Tyr Pro Ser Arg
420 425 430

Pro Glu Val Lys Ile Leu Asn Asp Leu Asn Met Val Ile Lys Pro Gly
435 440 445

Glu Met Thr Ala Leu Val Gly Pro Ser Gly Ala Gly Lys Ser Thr Ala
450 455 460

Leu Gln Leu Ile Gln Arg Phe Tyr Asp Pro Cys Glu Gly Met Val Thr
465 470 475 480

Val Asp Gly His Asp Ile Arg Ser Leu Asn Ile Gln Trp Leu Arg Asp
485 490 495

Gln Ile Gly Ile Val Glu Gln Glu Pro Val Leu Phe Ser Thr Thr Ile
500 505 510

Ala Glu Asn Ile Arg Tyr Gly Arg Glu Asp Ala Thr Met Glu Asp Ile
515 520 525

```
Val Gln Ala Ala Lys Glu Ala Asn Ala Tyr Asn Phe Ile Met Asp Leu
    530                 535                 540

Pro Gln Gln Phe Asp Thr Leu Val Gly Glu Gly Gly Gly Gln Met Ser
545                 550                 555                 560

Gly Gly Gln Lys Gln Arg Val Ala Ile Ala Arg Ala Leu Ile Arg Asn
                565                 570                 575

Pro Lys Ile Leu Leu Leu Asp Met Ala Thr Ser Ala Leu Asp Asn Glu
            580                 585                 590

Ser Glu Ala Met Val Gln Glu Val Leu Ser Lys Ile Gln His Gly His
        595                 600                 605

Thr Ile Ile Ser Val Ala His Arg Leu Ser Thr Val Arg Ala Ala Asp
    610                 615                 620

Thr Ile Ile Gly Phe Glu His Gly Thr Ala Val Glu Arg Gly Thr His
625                 630                 635                 640

Glu Glu Leu Leu Glu Arg Lys Gly Val Tyr Phe Thr Leu Val Thr Leu
                645                 650                 655

Gln Ser Gln Gly Asn Gln Ala Leu Asn Glu Glu Asp Ile Lys Asp Ala
            660                 665                 670

Thr Glu Asp Asp Met Leu Ala Arg Thr Phe Ser Arg Gly Ser Tyr Gln
        675                 680                 685

Asp Ser Leu Arg Ala Ser Ile Arg Gln Arg Ser Lys Ser Gln Leu Ser
    690                 695                 700

Tyr Leu Val His Glu Pro Pro Leu Ala Val Val Asp His Lys Ser Thr
705                 710                 715                 720

Tyr Glu Glu Asp Arg Lys Asp Lys Asp Ile Pro Val Gln Glu Glu Val
                725                 730                 735

Glu Pro Ala Pro Val Arg Arg Ile Leu Lys Phe Ser Ala Pro Glu Trp
            740                 745                 750
```

Pro Tyr Met Leu Val Gly Ser Val Gly Ala Ala Val Asn Gly Thr Val
755 760 765

Thr Pro Leu Tyr Ala Phe Leu Phe Ser Gln Ile Leu Gly Thr Phe Ser
770 775 780

Ile Pro Asp Lys Glu Glu Gln Arg Ser Gln Ile Asn Gly Val Cys Leu
785 790 795 800

Leu Phe Val Ala Met Gly Cys Val Ser Leu Phe Thr Gln Phe Leu Gln
805 810 815

Gly Tyr Ala Phe Ala Lys Ser Gly Glu Leu Leu Thr Lys Arg Leu Arg
820 825 830

Lys Phe Gly Phe Arg Ala Met Leu Gly Gln Asp Ile Ala Trp Phe Asp
835 840 845

Asp Leu Arg Asn Ser Pro Gly Ala Leu Thr Thr Arg Leu Ala Thr Asp
850 855 860

Ala Ser Gln Val Gln Gly Ala Ala Gly Ser Gln Ile Gly Met Ile Val
865 870 875 880

Asn Ser Phe Thr Asn Val Thr Val Ala Met Ile Ile Ala Phe Ser Phe
885 890 895

Ser Trp Lys Leu Ser Leu Val Ile Leu Cys Phe Phe Pro Phe Leu Ala
900 905 910

Leu Ser Gly Ala Thr Gln Thr Arg Met Leu Thr Gly Phe Ala Ser Arg
915 920 925

Asp Lys Gln Ala Leu Glu Met Val Gly Gln Ile Thr Asn Glu Ala Leu
930 935 940

Ser Asn Ile Arg Thr Val Ala Gly Ile Gly Lys Glu Arg Arg Phe Ile
945 950 955 960

Glu Ala Leu Glu Thr Glu Leu Glu Lys Pro Phe Lys Thr Ala Ile Gln
965 970 975

Lys Ala Asn Ile Tyr Gly Phe Cys Phe Ala Phe Ala Gln Cys Ile Met
980 985 990

Phe Ile Ala Asn Ser Ala Ser Tyr Arg Tyr Gly Gly Tyr Leu Ile Ser
995 1000 1005

Asn Glu Gly Leu His Phe Ser Tyr Val Phe Arg Val Ile Ser Ala
1010 1015 1020

Val Val Leu Ser Ala Thr Ala Leu Gly Arg Ala Phe Ser Tyr Thr
1025 1030 1035

Pro Ser Tyr Ala Lys Ala Lys Ile Ser Ala Ala Arg Phe Phe Gln
1040 1045 1050

Leu Leu Asp Arg Gln Pro Pro Ile Ser Val Tyr Asn Thr Ala Gly
1055 1060 1065

Glu Lys Trp Asp Asn Phe Gln Gly Lys Ile Asp Phe Val Asp Cys
1070 1075 1080

Lys Phe Thr Tyr Pro Ser Arg Pro Asp Ser Gln Val Leu Asn Gly
1085 1090 1095

Leu Ser Val Ser Ile Ser Pro Gly Gln Thr Leu Ala Phe Val Gly
1100 1105 1110

Ser Ser Gly Cys Gly Lys Ser Thr Ser Ile Gln Leu Leu Glu Arg
1115 1120 1125

Phe Tyr Asp Pro Asp Gln Gly Lys Val Met Ile Asp Gly His Asp
1130 1135 1140

Ser Lys Lys Val Asn Val Gln Phe Leu Arg Ser Asn Ile Gly Ile
1145 1150 1155

Val Ser Gln Glu Pro Val Leu Phe Ala Cys Ser Ile Met Asp Asn
1160 1165 1170

Ile Lys Tyr Gly Asp Asn Thr Lys Glu Ile Pro Met Glu Arg Val
1175 1180 1185

```
Ile Ala  Ala Ala Lys Gln Ala  Gln Leu His Asp Phe  Val Met Ser
    1190                 1195                 1200

Leu Pro  Glu Lys Tyr Glu Thr  Asn Val Gly Ser Gln  Gly Ser Gln
    1205                 1210                 1215

Leu Ser  Arg Gly Glu Lys Gln  Arg Ile Ala Ile Ala  Arg Ala Ile
    1220                 1225                 1230

Val Arg  Asp Pro Lys Ile Leu  Leu Leu Asp Glu Ala  Thr Ser Ala
    1235                 1240                 1245

Leu Asp  Thr Glu Ser Glu Lys  Thr Val Gln Val Ala  Leu Asp Lys
    1250                 1255                 1260

Ala Arg  Glu Gly Arg Thr Cys  Ile Val Ile Ala His  Arg Leu Ser
    1265                 1270                 1275

Thr Ile  Gln Asn Ala Asp Ile  Ile Ala Val Met Ala  Gln Gly Val
    1280                 1285                 1290

Val Ile  Glu Lys Gly Thr His  Glu Glu Leu Met Ala  Gln Lys Gly
    1295                 1300                 1305

Ala Tyr  Tyr Lys Leu Val Thr  Thr Gly Ser Pro Ile  Ser
    1310                 1315                 1320
```

<210> 50
<211> 4776
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (4208)..(4208)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (4210)..(4212)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (4227)..(4229)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (4231)..(4231)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (4253)..(4253)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (4677)..(4677)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (4691)..(4691)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (4707)..(4707)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (4721)..(4721)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (4752)..(4752)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (4754)..(4754)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (4772)..(4773)
<223> n is a, c, g, or t

<400> 50
gaatgatgaa aaccgaggtt ggaaaaggtt gtgaaacctt ttaactctcc acagtggagt 60

ccattatttc ctctggcttc ctcaaattca tattcacagg gtcgttggct gtgggttgca 120

attaccatgt ctgactcagt aattcttcga agtataaaga aatttggaga ggagaatgat 180

ggttttgagt cagataaatc atataataat gataagaaat caaggttaca agatgagaag 240

aaaggtgatg gcgttagagt tggcttcttt caattgtttc ggttttcttc atcaactgac 300

atttggctga tgtttgtggg aagtttgtgt gcatttctcc atggaatagc ccagccaggc 360

gtgctactca tttttggcac aatgacagat gtttttattg actacgacgt tgagttacaa 420

gaactccaga ttccaggaaa agcatgtgtg aataacacca ttgtatggac taacagttcc 480

ctcaaccaga acatgacaaa tggaacacgt tgtgggttgc tgaacatcga gagcgaaatg 540

atcaaatttg ccagttacta tgctggaatt gctgtcgcag tacttatcac aggatatatt 600

caaatatgct tttgggtcat tgccgcagct cgtcagatac agaaaatgag aaaatttttac 660

tttaggagaa taatgagaat ggaaataggg tggtttgact gcaattcagt gggggagctg 720

aatacaagat tctctgatga tattaataaa atcaatgatg ccatagctga ccaaatggcc 780

cttttcattc agcgcatgac ctcgaccatc tgtggtttcc tgttgggatt tttcaggggt 840

tggaaactga ccttggttat tatttctgtc agccctctca ttgggattgg agcagccacc 900

attggtctga gtgtgtccaa gtttacggac tatgagctga aggcctatgc caaagcaggg 960

gtggtggctg atgaagtcat ttcatcaatg agaacagtgg ctgcttttgg tggtgagaaa 1020

agagaggttg aaaggtatga gaaaaatctt gtgttcgccc agcgttgggg aattagaaaa 1080

ggaatagtga tgggattctt tactggattc gtgtggtgtc tcatcttttt gtgttatgca 1140

gtggccttct ggtacggctc cacacttgtc ctggatgaag gagaatatac accaggaacc 1200

cttgtccaga ttttcctcag tgtcatagta ggagctttaa atcttggcaa tgcctctcct 1260

tgtttggaag cctttgcaac tggacgtgca gcagccacca gcatttttga gacaatagac 1320

aggaaaccca tcattgactg catgtcagaa gatggttaca agttggatcg aatcaagggt 1380

gaaattgaat tccataatgt gaccttccat tatccttcca gaccagaggt gaagattcta 1440

aatgacctca acatggtcat taaaccaggg gaaatgacag ctctggtagg acccagtgga 1500

gctggaaaaa gtacagcact gcaactcatt cagcgattct atgacccctg tgaaggaatg 1560

gtgaccgtgg atggccatga cattcgctct cttaacattc agtggcttag agatcagatt 1620

gggatagtgg agcaagagcc agttctgttc tctaccacca ttgcagaaaa tattcgctat 1680

ggcagagaag atgcaacaat ggaagacata gtccaagctg ccaaggaggc caatgcctac 1740

aacttcatca tggacctgcc acagcaattt gacacccttg ttggagaagg aggaggccag 1800

atgagtggtg gccagaaaca aagggtagct atcgccagag ccctcatccg aaatcccaag 1860

attctgcttt tggacatggc cacctcagct ctggacaatg agagtgaagc catggtgcaa 1920

gaagtgctga gtaagattca gcatgggcac acaatcattt cagttgctca tcgcttgtct 1980

acggtcagag ctgcagatac catcattggt tttgaacatg gcactgcagt ggaaagaggg 2040

acccatgaag aattactgga aaggaaaggt gtttacttca ctctagtgac tttgcaaagc 2100

cagggaaatc aagctcttaa tgaagaggac ataaaggatg caactgaaga tgacatgctt 2160

gcgaggacct ttagcagagg gagctaccag gatagtttaa gggcttccat ccggcaacgc 2220

tccaagtctc agctttctta cctggtgcac gaacctccat tagctgttgt agatcataag 2280

tctacctatg aagaagatag aaaggacaag gacattcctg tgcaggaaga agttgaacct 2340

gccccagtta ggaggattct gaaattcagt gctccagaat ggccctacat gctggtaggg 2400

tctgtgggtg cagctgtgaa cgggacagtc acacccttgt atgccttttt attcagccag 2460

attcttggga ctttttcaat tcctgataaa gaggaacaaa ggtcacagat caatggtgtg 2520

tgcctacttt ttgtagcaat gggctgtgta tctcttttca cccaatttct acagggatat 2580

gcctttgcta aatctgggga gctcctaaca aaaaggctac gtaaatttgg tttcagggca 2640

atgctggggc aagatattgc ctggtttgat gacctcagaa atagccctgg agcattgaca 2700

acaagacttg ctacagatgc ttcccaagtt caaggggctg ccggctctca gatcgggatg 2760

atagtcaatt ccttcactaa cgtcactgtg gccatgatca ttgccttctc ctttagctgg 2820

aagctgagcc tggtcatctt gtgcttcttc cccttcttgg ctttatcagg agccacacag 2880

accaggatgt tgacaggatt tgcctctcga gataagcagg ccctggagat ggtgggacag 2940

attacaaatg aagccctcag taacatccgc actgttgctg gaattggaaa ggagaggcgg 3000

ttcattgaag cacttgagac tgagctggag aagcccttca agacagccat tcagaaagcc 3060

aatatttacg gattctgctt tgcctttgcc cagtgcatca tgtttattgc gaattctgct 3120

tcctacagat atggaggtta cttaatctcc aatgaggggc tccatttcag ctatgtgttc 3180

agggtgatct ctgcagttgt actgagtgca acagctcttg gaagagcctt ctcttacacc 3240

ccaagttatg caaaagctaa aatatcagct gcacgctttt ttcaactgct ggaccgacaa 3300

cccccaatca gtgtatacaa tactgcaggt gaaaaatggg acaacttcca ggggaagatt 3360

gattttgttg attgtaaatt tacatatcct tctcgacctg actcgcaagt tctgaatggt 3420

ctctcagtgt cgattagtcc agggcagaca ctggcgtttg ttgggagcag tggatgtggc 3480

aaaagcacta gcattcagct gttggaacgt ttctatgatc ctgatcaagg gaaggtgatg 3540

atagatggtc atgacagcaa aaaagtaaat gtccagttcc tccgctcaaa cattggaatt 3600

gtttcccagg aaccagtgtt gtttgcctgt agcataatgg acaatatcaa gtatggagac 3660

aacaccaaag aaattcccat ggaaagagtc atagcagctg caaaacaggc tcagctgcat 3720

gattttgtca tgtcactccc agagaaatat gaaactaacg ttgggtccca ggggtctcaa 3780

ctctctagag gggagaaaca acgcattgct attgctcggg ccattgtacg agatcctaaa 3840

atcttgctac tagatgaagc cacttctgcc ttagacacag aaagtgaaaa gacggtgcag 3900

gttgctctag acaaagccag agagggtcgg acctgcattg tcattgccca tcgcttgtcc 3960

accatccaga acgcggatat cattgctgtc atggcacagg gggtggtgat tgaaaagggg 4020

acccatgaag aactgatggc ccaaaaagga gcctactaca aactagtcac cactggatcc 4080

cccatcagtt gacccaatgc aagaatctca gacacacatg acgcaccagt tacaggggtt 4140

gtttttaaag aaaaaaacaa tcccagcacg agggattgct gggattgttt tttctttaaa 4200

gaagaatntn nntattttac ttttacnnnc nttttcctac atcggaatcc aanctaattt 4260

ctaatggcct tccataataa ttctgcttta gatgtgtata cagaaaatga aagaaactag 4320

ggtccatgtg agggaaaacc caatgtcaag tggcagctca gccaccactc agtgcttctc 4380

tgtgcaggag ccagtcctga ttaatatgtg ggaattagtg agacatcagg gagtaagtga 4440

cactttgaac tcctcaagga cagagaactg tctttcattt ttgaaccctc ggtgtacaca 4500

gaggcgggtc tgtaacaggc aatcaacaaa cgtttcttga gctagaccaa ggtcagattt 4560

gaaaagaaca gaaggactga agaccagctg tgtttcttaa ctaaatttgt ctttcaagtg 4620

aaaccagctt ccttcatctc taaggctaag gatagggaaa gggtgggatg ctctcangct 4680

gagggaggca naaagggaaa gtattancat gagctttcca nttagggctg ttgatttatg 4740

ctttaacttc anantgagtg tagggtggtg anncta 4776

<210> 51
<211> 138
<212> PRT
<213> Homo sapiens

<400> 51

Met Asp Thr Gln Thr His Ser Leu Pro Ile Thr His Thr Gln Leu His
1 5 10 15

Ser Asn Ser Gln Pro Gln Ser Arg Thr Cys Thr Arg His Cys Gln Thr
20 25 30

Phe Ser Gln Ser Cys Arg Gln Ser His Arg Gly Ser Arg Ser Gln Ser

35 40 45

Ser Ser Gln Ser Pro Ala Ser His Arg Asn Pro Thr Gly Ala His Ser
50 55 60

Ser Ser Gly His Gln Ser Gln Ser Pro Asn Thr Ser Pro Pro Pro Lys
65 70 75 80

Arg His Lys Lys Thr Met Asn Ser His His Ser Pro Met Arg Pro Thr
85 90 95

Ile Leu His Cys Arg Cys Pro Lys Asn Arg Lys Asn Leu Glu Gly Lys
100 105 110

Leu Lys Lys Lys Lys Met Ala Lys Arg Ile Gln Gln Val Tyr Lys Thr
115 120 125

Lys Thr Arg Ser Ser Gly Trp Lys Ser Asn
130 135

<210> 52
<211> 1776
<212> DNA
<213> Homo sapiens

<400> 52
agactcagct taatctgacc caagggctcc taccctgaac cagtagctgg gactatcccc 60

agggtacccc tgagagctgc cccagcctgg ggtgagggta aggggtaggg ggctttgtct 120

tggctgagcc acatctctca cacccctgtg gcctgggcat cataatcagc cccaactata 180

taaccaggtg ggcctgccag ggcctctgta aagctaggcc tgctgggaga ggatgaggag 240

gaggccctgc cctcaaacgt ggcctcctat ggacacccag actcacagcc ttcctatcac 300

ccacactcag ctccatagca actctcagcc ccaaagccgc acctgcaccc gccattgcca 360

aaccttcagc cagagttgca gacagagcca tcgtggcagc cggagccaga gctccagcca 420

gagcccggcc agccaccgca acccaactgg agcccacagc tcatccggcc accagagcca 480

gagtcccaac actagtccac caccaaagcg ccacaaaaag actatgaact cccaccactc 540

tcccatgcgg cccaccatcc tgcactgccg ctgccccaag aacagaaaga acttggaagg 600

caagctgaaa aagaaaaaaa tggccaagag gatccagcag gtgtacaaaa ccaagacgcg 660

gagctcaggt acccttaag gaggtgggga agggccaccg agccacagat gatggagagc 720

agaccttggg ggcagtgaga ggaaggctgc agccaggtca caaaggaacc acaggcaaga 780

aggaagaggg agaagagaaa caatggcagt tggctagctg aatgtatgat acgttgacgg 840

aaagtcttct ttgaaattgg atgggttgat taggaggatg gaaagatgga cagatagcag 900

ataagctaga tgaaagcatg aatggagttg agaggttggg ttgatgactg ggtgggtaaa 960

caataaatag gttatagaaa ggatagttgg aagaatgcat tggctgaatg ataggaagtt 1020

tggatacgat tagctggatg gatggataaa tggatgaatg cactggctgg ctagttattt 1080

ggttggttag gtagatgatc agtttgaaga ttgtggttgg tggatgaatt ggttagaaat 1140

agagttaaat agttgtagaa gttttgatgg gttggtttga ttggttaaat attatcttaa 1200

tagagtaata tagagtaatt gaataaacag agagaagaat agatatctag actaatggga 1260

tagaatggga aagaaatgtt gaataaatga atggaatgag tgaactaatg aatgggtgga 1320

tgacaaatgg aagggataaa tggatggata cctggattca cataggtcaa aaggacactg 1380

acggtagtct aaactctatc tatgtcccat atcaatcaca aatgagtagt tgtaagacct 1440

tacaggaggt caaggaggtc actgacttca tgaagtgctc agctattaaa ggttcctttc 1500

ccactcttat cccttaggat ggaaatccaa ctaatgagac cgcactcctt ggcttgttcc 1560

tgcgtgtttc acccaaagga gaaaatgcta ggatgaagtc aatcttcttg caggaacatg 1620

ttactatggt gatttctacg caacactaat taaagcttgt acctggaaga ctatccctga 1680

gtagtcattt tgatttcact aataaaggtg ttatgtgttt tgggggcctg cacaggggca 1740

gaaatgaatg ggggtaggat gccaagaagc ctgcag 1776

<210> 53
<211> 750
<212> PRT
<213> Homo sapiens

<400> 53

Met Gly Lys Ser Glu Ser Gln Met Asp Ile Thr Asp Ile Asn Thr Pro
1 5 10 15

Lys Pro Lys Lys Lys Gln Arg Trp Thr Arg Leu Glu Ile Ser Leu Ser
20 25 30

Val Leu Val Leu Leu Leu Thr Ile Ile Ala Val Arg Met Ile Ala Leu
35 40 45

Tyr Ala Thr Tyr Asp Asp Gly Ile Cys Lys Ser Ser Asp Cys Ile Lys
50 55 60

Ser Ala Ala Arg Leu Ile Gln Asn Met Asp Ala Thr Thr Glu Pro Cys
65 70 75 80

Arg Asp Phe Phe Lys Tyr Ala Cys Gly Gly Trp Leu Lys Arg Asn Val
85 90 95

Ile Pro Glu Thr Ser Ser Arg Tyr Gly Asn Phe Asp Ile Leu Arg Asp
100 105 110

Glu Leu Glu Val Val Leu Lys Asp Val Leu Gln Glu Pro Lys Thr Glu
115 120 125

Asp Ile Val Ala Val Gln Lys Ala Lys Ala Leu Tyr Arg Ser Cys Ile
130 135 140

Asn Glu Ser Ala Ile Asp Ser Arg Gly Gly Glu Pro Leu Leu Lys Leu
145 150 155 160

Leu Pro Asp Ile Tyr Gly Trp Pro Val Ala Thr Glu Asn Trp Glu Gln
165 170 175

Lys Tyr Gly Ala Ser Trp Thr Ala Glu Lys Ala Ile Ala Gln Leu Asn
180 185 190

Ser Lys Tyr Gly Lys Lys Val Leu Ile Asn Leu Phe Val Gly Thr Asp
195 200 205

Asp Lys Asn Ser Val Asn His Val Ile His Ile Asp Gln Pro Arg Leu
210 215 220

Gly Leu Pro Ser Arg Asp Tyr Tyr Glu Cys Thr Gly Ile Tyr Lys Glu
225 230 235 240

Ala Cys Thr Ala Tyr Val Asp Phe Met Ile Ser Val Ala Arg Leu Ile
245 250 255

Arg Gln Glu Glu Arg Leu Pro Ile Asp Glu Asn Gln Leu Ala Leu Glu
260 265 270

Met Asn Lys Val Met Glu Leu Glu Lys Glu Ile Ala Asn Ala Thr Ala
275 280 285

Lys Pro Glu Asp Arg Asn Asp Pro Met Leu Leu Tyr Asn Lys Met Arg
290 295 300

Leu Ala Gln Ile Gln Asn Asn Phe Ser Leu Glu Ile Asn Gly Lys Pro
305 310 315 320

Phe Ser Trp Leu Asn Phe Thr Asn Glu Ile Met Ser Thr Val Asn Ile
325 330 335

Ser Ile Thr Asn Glu Glu Asp Val Val Val Tyr Ala Pro Glu Tyr Leu
340 345 350

Thr Lys Leu Lys Pro Ile Leu Thr Lys Tyr Ser Ala Arg Asp Leu Gln
355 360 365

Asn Leu Met Ser Trp Arg Phe Ile Met Asp Leu Val Ser Ser Leu Ser
370 375 380

Arg Thr Tyr Lys Glu Ser Arg Asn Ala Phe Arg Lys Ala Leu Tyr Gly
385 390 395 400

Thr Thr Ser Glu Thr Ala Thr Trp Arg Arg Cys Ala Asn Tyr Val Asn
405 410 415

Gly Asn Met Glu Asn Ala Val Gly Arg Leu Tyr Val Glu Ala Ala Phe
420 425 430

Ala Gly Glu Ser Lys His Val Val Glu Asp Leu Ile Ala Gln Ile Arg
435 440 445

Glu Val Phe Ile Gln Thr Leu Asp Asp Leu Thr Trp Met Asp Ala Glu
450 455 460

Thr Lys Lys Arg Ala Glu Glu Lys Ala Leu Ala Ile Lys Glu Arg Ile
465 470 475 480

Gly Tyr Pro Asp Asp Ile Val Ser Asn Asp Asn Lys Leu Asn Asn Glu
485 490 495

Tyr Leu Glu Leu Asn Tyr Lys Glu Asp Glu Tyr Phe Glu Asn Ile Ile
500 505 510

Gln Asn Leu Lys Phe Ser Gln Ser Lys Gln Leu Lys Lys Leu Arg Glu
515 520 525

Lys Val Asp Lys Asp Glu Trp Ile Ser Gly Ala Ala Val Val Asn Ala
530 535 540

Phe Tyr Ser Ser Gly Arg Asn Gln Ile Val Phe Pro Ala Gly Ile Leu
545 550 555 560

Gln Pro Pro Phe Phe Ser Ala Gln Gln Ser Asn Ser Leu Asn Tyr Gly
565 570 575

Gly Ile Gly Met Val Ile Gly His Glu Ile Thr His Gly Phe Asp Asp
580 585 590

Asn Gly Arg Asn Phe Asn Lys Asp Gly Asp Leu Val Asp Trp Trp Thr
595 600 605

Gln Gln Ser Ala Ser Asn Phe Lys Glu Gln Ser Gln Cys Met Val Tyr
610 615 620

Gln Tyr Gly Asn Phe Ser Trp Asp Leu Ala Gly Gly Gln His Leu Asn
625 630 635 640

Gly Ile Asn Thr Leu Gly Glu Asn Ile Ala Asp Asn Gly Gly Leu Gly
645 650 655

Gln Ala Tyr Arg Ala Tyr Gln Asn Tyr Ile Lys Lys Asn Gly Glu Glu
660 665 670

Lys Leu Leu Pro Gly Leu Asp Leu Asn His Lys Gln Leu Phe Phe Leu
675 680 685

Asn Phe Ala Gln Val Trp Cys Gly Thr Tyr Arg Pro Glu Tyr Ala Val
690 695 700

Asn Ser Ile Lys Thr Asp Val His Ser Pro Gly Asn Phe Arg Ile Ile
705 710 715 720

Gly Thr Leu Gln Asn Ser Ala Glu Phe Ser Glu Ala Phe His Cys Arg
725 730 735

Lys Asn Ser Tyr Met Asn Pro Glu Lys Lys Cys Arg Val Trp
740 745 750

<210> 54
<211> 5508
<212> DNA
<213> Homo sapiens

<400> 54
gattttaggt gatgggcaag tcagaaagtc agatggatat aactgatatc aacactccaa 60

agccaaagaa gaaacagcga tggactcgac tggagatcag cctctcggtc cttgtcctgc 120

tcctcaccat catagctgtg agaatgatcg cactctatgc aacctacgat gatggtattt 180

gcaagtcatc agactgcata aaatcagctg ctcgactgat ccaaaacatg gatgccacca 240

ctgagccttg tagagacttt ttcaaatatg cttgcggagg ctggttgaaa cgtaatgtca 300

ttcccgagac cagctcccgt tacggcaact ttgacatttt aagagatgaa ctagaagtcg 360

ttttgaaaga tgtccttcaa gaacccaaaa ctgaagatat agtagcagtg cagaaagcaa 420

aagcattgta caggtcttgt ataaatgaat ctgctattga tagcagaggt ggagaacctc 480

tactcaaact gttaccagac atatatgggt ggccagtagc aacagaaaac tgggagcaaa 540

aatatggtgc ttcttggaca gctgaaaaag ctattgcaca actgaattct aaatatggga 600

aaaaagtcct tattaatttg tttgttggca ctgatgataa gaattctgtg aatcatgtaa 660

ttcatattga ccaacctcga cttggcctcc cttctagaga ttactatgaa tgcactggaa 720

tctataaaga ggcttgtaca gcatatgtgg attttatgat ttctgtggcc agattgattc 780

gtcaggaaga aagattgccc atcgatgaaa accagcttgc tttggaaatg aataaagtta 840

tggaattgga aaaagaaatt gccaatgcta cggctaaacc tgaagatcga aatgatccaa 900

tgcttctgta taacaagatg agattggccc agatccaaaa taacttttca ctagagatca 960

atgggaagcc attcagctgg ttgaatttca caaatgaaat catgtcaact gtgaatatta 1020

gtattacaaa tgaggaagat gtggttgttt atgctccaga atatttaacc aaacttaagc 1080

ccattcttac caaatattct gccagagatc ttcaaaattt aatgtcctgg agattcataa 1140

tggatcttgt aagcagcctc agccgaacct acaaggagtc cagaaatgct ttccgcaagg 1200

ccctttatgg tacaacctca gaaacagcaa cttggagacg ttgtgcaaac tatgtcaatg 1260

ggaatatgga aaatgctgtg gggaggcttt atgtggaagc agcatttgct ggagagagta 1320

aacatgtggt cgaggatttg attgcacaga tccgagaagt ttttattcag actttagatg 1380

acctcacttg gatggatgcc gagacaaaaa agagagctga agaaaaggcc ttagcaatta 1440

aagaaaggat cggctatcct gatgacattg tttcaaatga taacaaactg aataatgagt 1500

acctcgagtt gaactacaaa gaagatgaat acttcgagaa cataattcaa aatttgaaat 1560

tcagccaaag taaacaactg aagaagctcc gagaaaaggt ggacaaagat gagtggataa 1620

gtggagcagc tgtagtcaat gcattttact cttcaggaag aaatcagata gtcttcccag 1680

ccggcattct gcagcccccc ttctttagtg cccagcagtc caactcattg aactatgggg 1740

gcatcggcat ggtcatagga cacgaaatca cccatggctt cgatgacaat ggcagaaact 1800

ttaacaaaga tggagacctc gttgactggt ggactcaaca gtctgcaagt aactttaagg 1860

agcaatccca gtgcatggtg tatcagtatg gaaacttttc ctgggacctg gcaggtggac 1920

agcaccttaa tggaattaat acactgggag aaaacattgc tgataatgga ggtcttggtc 1980

aagcatacag agcctatcag aattatatta aaaagaatgg cgaagaaaaa ttacttcctg 2040

gacttgacct aaatcacaaa caactatttt tcttgaactt tgcacaggtg tggtgtggaa 2100

cctataggcc agagtatgcg gttaactcca ttaaaacaga tgtgcacagt ccaggcaatt 2160

tcaggattat tgggactttg cagaactctg cagagttttc agaagccttt cactgccgca 2220

agaattcata catgaatcca gaaaagaagt gccgggtttg gtgatcttca aaagaagcat 2280

tgcagccctt ggctagactt gccaacacca cagaaatggg gaattctcta atcgaaagaa 2340

aatgggccct aggggtcact gtactgactt gagggtgatt aacagagagg gcaccatcac 2400

aatacagata acattaggtt gtcctagaaa gggtgtggag ggaggaaggg ggtctaaggt 2460

ctatcaagtc aatcatttct cactgtgtac ataatgctta atttctaaag ataatattac 2520

tgtttatttc tgtttctcat atggtctacc agtttgctga tgtccctaga aaacaatgca 2580

aaacctttga ggtagaccag gatttctaat caaaagggaa aagaagatgt tgaagaatag 2640

agttaggcac cagaagaaga gtaggtgaca ctatagttta aaacacattg cctaactact 2700

agtttttact tttatttgca acatttacag tccttcaaaa tccttccaaa gaattcttat 2760

acacattggg gccttggagc ttacatagtt ttaaactcat ttttgccata catcagttat 2820

tcattctgtg atcatttatt ttaagcactc ttaaagcaaa aaatgaatgt ctaaaattgt 2880

tttttgttgt acctgctttg actgatgctg agattcttca ggcttcctgc aattttctaa 2940

gcaatttctt gctctatctc tcaaaacttg gtatttttca gagatttata taaatgtaaa 3000

aataataatt tttatattta attattaact acatttatga gtaactatta ttataggtaa 3060

tcaatgaata ttgaagtttc agcttaaaat aaacagttgt gaaccaagat ctataaagcg 3120

atatacagat gaaaatttga gactatttaa acttataaat catattgatg aaaagattta 3180

agcacaaact ttagggtaaa aattgcgatt ggacagttgt ctagagatat atatacttgt 3240

ggttttcaaa ttggactttc aaaattaaat ctgtccctga gagtgtctct gataaaaggg 3300

caaatctgca cctatgtagc tctgcatctc ctgtcttttc aggtttgtca tcagatggaa 3360

atattttgat aataaattga aattgtgaac tcattgctcc ctaagactgt gacaactgtc 3420

taactttaga agtgcatttc tgaatagaaa tgggaggcct ctgatggacc ttctagaatt 3480

ataagtcaca aagagttctg gaaaagaact gtttactgct tgataggaat tcatcttttg 3540

aggcttctgt tcctctcttt tcctgttgta ttgactattt tcgttcatta cttgattaag 3600

attttacaaa agaggagcac ttccaaaatt cttatttttc ctaacaaaag atgaaagcag 3660

ggaatttcta tctaaatgat gagtattagt tccctgtctc ttgaaaaatg cccatttgcc 3720

tttaaaaaaa aaagttacag aaatactata acatatgtac ataaattgca taaagcataa 3780

gtatacagtt caataaactt aactttaact gaacaatggc cctgtagcca gcacctgtaa 3840

gaaacagagc agtaccagcg ctctaaaagc acctccttgt cactttatta ctcccagaac 3900

aacaactatc ctgacttcta atatcattca ctagctttgc ctggttttgt cttttatgca 3960

gatagaatca atcagtatgt attcttttgt gcctggcttc tttctctcag ccttacattt 4020

gtgagattcc tctgtattgt gctgattgtg gatcttttca ttctcattgc agaataatgt 4080

tctattgtgg gacttattac aatttgttca tcctattgtt gatgggcact tgagaacttt 4140

ccattttggc gctattacaa atagtgcaac tatgaatgta ctgcatgtta ccatcttact 4200

tgagccttta atggacttat ttcttcaaat ccttccaaaa attattataa gcattgaaat 4260

tatagtttca agccaactgt ggataccctt acccttttcct cctttatcac aaccaccgtt 4320

acaagtatac ttatatttcc ctaaaataca tttaaaactt acctaagtga catttgtagt 4380

tggagtaata ggagcttcca gctctaataa aacagctgtc tctaacttat tttatttcca 4440

tcatgtcaga gcaggtgaag agccagaagt gaagagtgac tagtacaaat tataaaaagc 4500

cactagactc ttcactgtta gctttttaaa acattaggct cccatcccta tggaggaaca 4560

actctccagt gcctggatcc cctctgtcta caaatataag attttctggg cctaaaggat 4620

agatcaaagt caaaaatagc aatgcctccc tatccctcac acatccagac atcatgaatt 4680

ttacatggta ctcttgttga gttctataga gccttctgat gtctctaaag cactaccgat 4740

tctttggagt tgtcacatca gataagacat atctctaatt ccatccataa atccagttct 4800

actatggctg agttctggtc aaagaaagaa agtttagaag ctgagacaca aagggttggg 4860

agctgatgaa actcacaaat gatggtagga agaagctctc gacaataccc gttggcaagg 4920

agtctgcctc catgctgcag tgttcgagtg gattgtaggt gcaagatgga aaggattgta 4980

ggtgcaagct gtccagagaa aagagtcctt gttccagccc tattctgcca ctcctgacag 5040

ggtgaccttg ggtatttgca atattccttt gggcctctgc ttctctcacc taaaaaaaga 5100

gaattagatt atattggtgg ttctcagcaa gagaaggagt atgtgtccaa tgctgccttc 5160

ccatgaatct gtctcccagt tatgaatcag tgggcaggat aaactgaaaa ctcccattta 5220

agtgtctgaa tcgagtgaga caaaatttta gtccaaataa caagtaccaa agttttatca 5280

agtttgggtc tgtgctgctg ttactgttaa ccatttaagt ggggcaaaac cttgctaatt 5340

ttctcaaaag catttatcat tcttgttgcc acagctggag ctctcaaact aaaagacatt 5400

tgttattttg gaaagaagaa agactctatt ctcaaagttt cctaatcaga aatttttatc 5460

agtttccagt ctcaaaaata caaaataaaa acaaacgttt ttaatact 5508

<210> 55
<211> 79
<212> PRT
<213> Homo sapiens

<400> 55

Met Ala His Lys Gln Ile Tyr Tyr Ser Asp Lys Tyr Phe Asp Glu His
1 5 10 15

Tyr Glu Tyr Arg His Val Met Leu Pro Arg Glu Leu Ser Lys Gln Val
20 25 30

Pro Lys Thr His Leu Met Ser Glu Glu Glu Trp Arg Arg Leu Gly Val
35 40 45

Gln Gln Ser Leu Gly Trp Val His Tyr Met Ile His Glu Pro Glu Pro
50 55 60

His Ile Leu Leu Phe Arg Arg Pro Leu Pro Lys Asp Gln Gln Lys

65 70 75

<210> 56
<211> 627
<212> DNA
<213> Homo sapiens

<400> 56
agtctccggc gagttgttgc ctgggctgga cgtggttttg tctgctgcgc ccgctcttcg 60

cgctctcgtt tcattttctg cagcgcgcca cgaggatggc ccacaagcag atctactact 120

cggacaagta cttcgacgaa cactacgagt accggcatgt tatgttaccc agagaacttt 180

ccaaacaagt acctaaaact catctgatgt ctgaagagga gtggaggaga cttggtgtcc 240

aacagagtct aggctgggtt cattacatga ttcatgagcc agaaccacat attcttctct 300

ttagacgacc tcttccaaaa gatcaacaaa aatgaagttt atctggggat cgtcaaatct 360

ttttcaaatt taatgtatat gtgtatataa ggtagtattc agtgaatact tgagaaatgt 420

acaaatcttt catccatacc tgtgcatgag ctgtattctt cacagcaaca gagctcagtt 480

aaatgcaact gcaagtaggt tactgtaaga tgtttaagat aaaagttctt ccagtcagtt 540

tttctcttaa gtgcctgttt gagtttactg aaacagttta cttttgttca ataaagtttg 600

tatgttgcat ttaaaaaaaa aaaaaaa 627

<210> 57
<211> 5769
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (5512)..(5517)
<223> n is a, c, g, or t

<400> 57
gagctctcca tgcacacctg ttactgtttc tgtttttacc tgtaaatatc tgtctctgac 60

ttccatgtct catgcacctc tatagggcaa agactgtgtc ttaaacatca cggtagcctc 120

agcatgttgt gcaatcaagg ttttttttgtt tttgttcttt gttttttttt tggtattagc 180

tttatttgta tcattttgaa atttttatca aaaaagcagc gtgcctgctg tggttcccat 240

cctctgggat ttaggaatct ttacccgatt ctccatccaa gtctgtcttt cgtattctag 300

gctcttccta aagttgtcat tcacatatac cctccagaat tttatagggt gtataatctg 360

taacaactcg gaggaagcca attgcccttt agaaatatgg ctgcaattgc ctcacttcct 420

gtgtcatgtg actctcctag tcatcacatg acccatccac attgggaagc cagaattact 480

tgcaggagta acctagtgcc tatagctatg gcaggtacct gcatccttgt ttttgtttag 540

tggatcctct atccttcaga gactctggaa cccctgtgct cttctcctca tctagtgacc 600

ctgaggtgat ggagttttca agtccttcca gagaggtaag agagagagct cccaatcagc 660

attgtcacag tgcttctgga atcctggcac tggaatttaa tgaatgacag actctctttg 720

aatccagggc catcatggct ctttgagcaa ggcacagatg gaggggaggg tcgaagttga 780

aatgggtggg aagagtggtg gggagcatcc tgatttgggg tgggcagaga gttgtcatca 840

gaagggttgc agggagagct gcacccaggt gtctgtgggc cttgtcctaa tgaatgtggg 900

agaccaggcc atgggcaccc aaaggcagct aagccctgcc cgggagagta gttgaggggt 960

ggagagggac ttgcttttca gtcattcctc attctgtcct caggaatgtc ccaagccttc 1020

gggtagggta agcatcatgg ctggcagcct cacaggattg cttctacttc aggcagtgtc 1080

gtgggcatca gatgagtgag tcaaggcagt ggggaggtag cacagagcct cccttctgcc 1140

tcatagtcct ttggtagcct tccagtaagc tggtggtaga cttttagtag gtgctcaata 1200

aatccttttg agtgactgag accaactttg gggtgaggat ttttgaaacc gtcttcagtc 1260

tctccaaaca gctgtgtccg ttctccacat ccttgtcaga cctcacctct gcttgtgctc 1320

cctccctccc aggtggtgcc cctgcatccc taaaagcttc agtacagctc ggtggtctgt 1380

gtctgcaatg ccacatactg tgactcttga ccccccgacc tttcctgccc taggtgcctt 1440

cagccgctac aagagcagaa gcagtgggca ttggatggag ctgagtacag gaccatacag 1500

gctaattgca ccggcacagg taaccattac acccttcacc ccccgggcca ggctgggtcc 1560

tcctagaggt aaacggtgtc agtgatcacc atggagtttc tccctgggca ctgataaccc 1620

tgtggatgtc ctcaggcctg ctactgatcc tgcagccaga agttccagaa agtgaaggga 1680

tttggagggg ccgtgacaga tgcaggtgcc ctcaacatcc ttgccctgtc acccccctgcc 1740

cagaatttgc tacttaaatg gtacttctct gaagaagatg aggaggaagg ggacaggatg 1800

acatagagcc actgacactt ttctttgcca attctttgga ccctgacttc tgcccatccc 1860

tgacatttgg ttcctgtctt aatgccagtg aaataagatt tcgccgccta tcatctgcta 1920

actgctacgg actcaggctc agaaaggcct gcgcttcacc caggtgccag cctccacagg 1980

ttccaaccca ggagcccaag ttccttttgg ccctgactca gacactatta ggactggcaa 2040

gtgataagca gagtcccata ctctcctatt gactcggact accatatctt gatcatcctt 2100

ttctgtagga atcggatata acatcatctg ggtacccatg gccagctgtg acttctccat 2160

ccgcacctac acctatgcag acacccctga tgatttccag ttgcacaact tcagcctccc 2220

agaggaagat accaagctca aggtaggcat tctagctttt tcaggccctg agggccctga 2280

tgtctggggg ttgagaaact gtagggtagg tctgcttgta cagacatttt gtcccctgct 2340

gttttgtcct gggggtggga gggtgggggc taatggctga accggatgca ctggttgggc 2400

tagtatgtgt tccaactctg ggtgcttctc tcttcactac ctttgtctct agataccccc 2460

gattcaccga gccctgcagt tggcccagcg tcccgtttca ctccttgcca gcccctggac 2520

atcacccact tggctcaaga ccaggggagc ggggaatggg aaggggccac tcaagggaca 2580

gcccagagac atctaccacc agacctgggc cagatacatt gtgaagtaag ggatcaacaa 2640

ggatgtggga tcaggactgg cctccccttt ggccatgctg atctgtgtcc caaccctcaa 2700

cctggttcca cttccagatc tgcctgtcct cagctcacct ttctaccttc tgggcctttc 2760

aaccttgggc ctgtcagtct tgcccactcc atcaggcttc ctgttctctc ggtctggccc 2820

actttcttgg ctggatcatt catgaccttt ctcttgccag gttcctggat gcctatgctg 2880

agcacaagtt acagttctgg gcagtgacag gtgaaaatga gccttctgct gggctgttga 2940

gtggataccc cttccagtgc ctgggcttca cccctgaaca tcagcgagac ttcattgccc 3000

gtgacctagg tcctaccctt gccaacggta ctcaccacaa tgtccgccta ctcatgctgg 3060

atgaccaacg cttgctgctg ccccactggg caaaggtggt aaggcctgga cctccatggt 3120

gctccagtga ccttcaaatc cagcatccaa atgattggct cccaaactta gagggatttt 3180

tctacccaac tatggatccc tagagcacca ttccccggga cctccagggt gccatggatc 3240

ccacagttgg gacttgaaac ctctctaggg ctgggggtgg tagctcatgg ctataattcc 3300

agcactttgg gaaccaaggt gggtggatca cttgaaccta aggagttcaa gatgagcctg 3360

ggaaacatgg tgaaacccta actctacaaa aaaaaaaata gaaaagttag ccgggtgtgg 3420

tggtggcacg ctatagtccc agtattctgg aggctaaggc gggaggttta gttgagccta 3480

ggaatttcag gctgcagtga gctatgattg tgccactgta ctccagcctg tgtgacagag 3540

ggagaccctg tctcaaaaac aaaaacaaaa aatccctccc aaaacctctg tagttgcatt 3600

cttcccacca cctaattcag gattcctaca agaggaacta gaagttccag aagcctgtgg 3660

gcagggtcca gggtgacttg ttcttccttt gcaggtactg acagacccag aagcagctaa 3720

gtatgttcat ggtattgctg tacattggta cctggacttt ctggctccag ccaaagccac 3780

cctaagggag acacaccacc tgttccccaa caccatgctc tttgcctcag aggcctgtgt 3840

gggttccaag ttctgggagc agagtgtgcg gctaggctcc tgggatcgag ggatgcagta 3900

cagccacagc atcatcacag taagccaccc cagtctccct tcctgcaaag gagacctcag 3960

acccattagt agtctcacca aagactgata gaagcccttc ctgtccagct ttccccaggt 4020

agcctgccct tttgcgcaac tctggggaac catgattccc tgtcttgcct ttccttcaca 4080

ggtctgcaca cctcattgcc ccttttgcaa ctactgaggc acttgcagct gcctcagact 4140

tctcagctcc ccttgagatg cctggatctt cacaccccca actccttagc tactaaggaa 4200

tgtgccctca cagggctgac ctacccacag ctgcctctcc cacatgtgac ccttacctac 4260

actctctggg gacccccagt gttgagcctt tgtctctttg cctttgtcct taccctagaa 4320

cctcctgtac catgtggtcg gctggaccga ctggaaccca tcattgtaga catcaccaag 4380

cacacgtttt acaaacagcc catgttctac caccttggcc acttcaggtg agtggagggc 4440

gggcaccccc attccatacc aggcctatca tctcctacat cggatggctt acatcactct 4500

acaccacgag ggagcaggaa ggtgttcagg gtggaacctc ggaagaggca cacccatccc 4560

cttttgcacc atggaggcag gaagtgacta ggtagcaaca gaaaacccca atgcctgagg 4620

ctggactgcg atgcagaaaa gcagggtcag tgcccagcag catggctcca ggcctagaga 4680

gccagggcag agcctttgca ggagttatgg ggtgggtccg tgggtgggcg acttcttaga 4740

tgagggtttc atgggaggta ccccgaggga ctctgaccat ctgttcccac attcagcaag 4800

ttcattcctg agggctccca gagagtgggg ctggttgcca gtcagaagaa cgacccggac 4860

gcagtggcac tgatgcatcc cgatggctct cctgttgtgg tcgtcctaaa ccggtgaggg 4920

caatggtgag gtctgggaag tgggctgaag acagcgttgg gggccttggc aggatcacac 4980

tctcagcttc tcctccctgc tccctagctc ctctaaggat gtgcctctta ccatcaagga 5040

tcctgctgtg ggcttcctgg agacaatctc acctggctac tccattcaca cctacctgtg 5100

gcgtcgccag tgatggagca gatactcaag gaggcactgg gctcagcctg ggcattaaag 5160

ggacagagtc agctcacacg ctgtctgtga ctaaagaggg cacaacaggg ccagtgtgag 5220

cttacagcga cgtaagccca ggggcaatgg tttgggtgac tcactttccc ctctaggtgg 5280

tgcccagggc tggaggcccc tagaaaaaga tcagtaagcc ccagtgtccc cccagccccc 5340

atgcttatgt gaacatgcgc tgtgtgctgc ttgctttgga aactggcctg ggtccaggcc 5400

tagggtgagc tcactgtccg tacaaacaca agatcagggc tgagggtaag gaaaagaaga 5460

gactaggaaa gctgggccca aaactggaga ctgtttgtct ttcctggaga tnnnnnnctg 5520

ggcccgtgga gcagcagtgt cagcatcagg gcggaagcct taaagcagca gcgggtgtgc 5580

ccaggcaccc agatgattcc tatggcacca gccaggaaaa atggcagctc ttaaaggaga 5640

aaatgtttga gcccagtcag tgtgagtggc tttattctgg gtggcagcac ccgtgtccgg 5700

ctgtaccaac aacgaggagc acgggggcct ctggaagtca tgagagtaga aaaaccagtc 5760

ttggggagt 5769

<210> 58
<211> 732
<212> PRT
<213> Homo sapiens

<400> 58

Met Thr Glu Gly Thr Cys Leu Arg Arg Arg Gly Gly Pro Tyr Lys Thr
1 5 10 15

Glu Pro Ala Thr Asp Leu Gly Arg Trp Arg Leu Asn Cys Glu Arg Gly
20 25 30

Arg Gln Thr Trp Thr Tyr Leu Gln Asp Glu Arg Ala Gly Arg Glu Gln
35 40 45

Thr Gly Leu Glu Ala Tyr Ala Leu Gly Leu Asp Thr Lys Asn Tyr Phe
50 55 60

Lys Asp Leu Pro Lys Ala His Thr Ala Phe Glu Gly Ala Leu Asn Gly
65 70 75 80

Met Thr Phe Tyr Val Gly Leu Gln Ala Glu Asp Gly His Trp Thr Gly
85 90 95

Asp Tyr Gly Gly Pro Leu Phe Leu Leu Pro Gly Leu Leu Ile Thr Cys
100 105 110

His Val Ala Arg Ile Pro Leu Pro Ala Gly Tyr Arg Glu Glu Ile Val
115 120 125

Arg Tyr Leu Arg Ser Val Gln Leu Pro Asp Gly Gly Trp Gly Leu His
130 135 140

Ile Glu Asp Lys Ser Thr Val Phe Gly Thr Ala Leu Asn Tyr Val Ser
145 150 155 160

Leu Arg Ile Leu Gly Val Gly Pro Asp Asp Pro Asp Leu Val Arg Ala
165 170 175

Arg Asn Ile Leu His Lys Lys Gly Gly Ala Val Ala Ile Pro Ser Trp
180 185 190

Gly Lys Phe Trp Leu Ala Val Leu Asn Val Tyr Ser Trp Glu Gly Leu
195 200 205

Asn Thr Leu Phe Pro Glu Met Trp Leu Phe Pro Asp Trp Ala Pro Ala
210 215 220

His Pro Ser Thr Leu Trp Cys His Cys Arg Gln Val Tyr Leu Pro Met
225 230 235 240

Ser Tyr Cys Tyr Ala Val Arg Leu Ser Ala Ala Glu Asp Pro Leu Val
245 250 255

Gln Ser Leu Arg Gln Glu Leu Tyr Val Glu Asp Phe Ala Ser Ile Asp
260 265 270

Trp Leu Ala Gln Arg Asn Asn Val Ala Pro Asp Glu Leu Tyr Thr Pro
275 280 285

His Ser Trp Leu Leu Arg Val Val Tyr Ala Leu Leu Asn Leu Tyr Glu
290 295 300

His His His Ser Ala His Leu Arg Gln Arg Ala Val Gln Lys Leu Tyr
305 310 315 320

Glu His Ile Val Ala Asp Asp Arg Phe Thr Lys Ser Ile Ser Ile Gly
325 330 335

Pro Ile Ser Lys Thr Ile Asn Met Leu Val Arg Trp Tyr Val Asp Gly
340 345 350

Pro Ala Ser Thr Ala Phe Gln Glu His Val Ser Arg Ile Pro Asp Tyr
355 360 365

```
Leu Trp Met Gly Leu Asp Gly Met Lys Met Gln Gly Thr Asn Gly Ser
    370                 375                 380

Gln Ile Trp Asp Thr Ala Phe Ala Ile Gln Ala Leu Leu Glu Ala Gly
385                 390                 395                 400

Gly His His Arg Pro Glu Phe Ser Ser Cys Leu Gln Lys Ala His Glu
                405                 410                 415

Phe Leu Arg Leu Ser Gln Val Pro Asp Asn Pro Pro Asp Tyr Gln Lys
            420                 425                 430

Tyr Tyr Arg Gln Met Arg Lys Gly Gly Phe Ser Phe Ser Thr Leu Asp
        435                 440                 445

Cys Gly Trp Ile Val Ser Asp Cys Thr Ala Glu Ala Leu Lys Ala Val
    450                 455                 460

Leu Leu Leu Gln Glu Lys Cys Pro His Val Thr Glu His Ile Pro Arg
465                 470                 475                 480

Glu Arg Leu Cys Asp Ala Val Ala Val Leu Leu Asn Met Arg Asn Pro
                485                 490                 495

Asp Gly Gly Phe Ala Thr Tyr Glu Thr Lys Arg Gly Gly His Leu Leu
            500                 505                 510

Glu Leu Leu Asn Pro Ser Glu Val Phe Gly Asp Ile Met Ile Asp Tyr
        515                 520                 525

Thr Tyr Val Glu Cys Thr Ser Ala Val Met Gln Ala Leu Lys Tyr Phe
    530                 535                 540

His Lys Arg Phe Pro Glu His Arg Ala Ala Glu Ile Arg Glu Thr Leu
545                 550                 555                 560

Thr Gln Gly Leu Glu Phe Cys Arg Arg Gln Gln Arg Ala Asp Gly Ser
                565                 570                 575

Trp Glu Gly Ser Trp Gly Val Cys Phe Thr Tyr Gly Thr Trp Phe Gly
            580                 585                 590
```

Leu Glu Ala Phe Ala Cys Met Gly Gln Thr Tyr Arg Asp Gly Thr Ala
595 600 605

Cys Ala Glu Val Ser Arg Ala Cys Asp Phe Leu Leu Ser Arg Gln Met
610 615 620

Ala Asp Gly Gly Trp Gly Glu Asp Phe Glu Ser Cys Glu Glu Arg Arg
625 630 635 640

Tyr Leu Gln Ser Ala Gln Ser Gln Ile His Asn Thr Cys Trp Ala Met
645 650 655

Met Gly Leu Met Ala Val Arg His Pro Asp Ile Glu Ala Gln Glu Arg
660 665 670

Gly Val Arg Cys Leu Leu Glu Lys Gln Leu Pro Asn Gly Asp Trp Pro
675 680 685

Gln Glu Asn Ile Ala Gly Val Phe Asn Lys Ser Cys Ala Ile Ser Tyr
690 695 700

Thr Ser Tyr Arg Asn Ile Phe Pro Ile Trp Ala Leu Gly Arg Phe Ser
705 710 715 720

Gln Leu Tyr Pro Glu Arg Ala Leu Ala Gly His Pro
725 730

<210> 59
<211> 3206
<212> DNA
<213> Homo sapiens

<400> 59
cccttgccta ctgctcatgg gtgtggagac tgatattctg gaagactgat aggcagattt 60

actattaaca aacacatagt ctgtggccca gcaaagccac cccaatccct gcacaagggt 120

aaaaggccag cattagagca ctgcagcagc aatgacggag ggcacgtgtc tgcggcgccg 180

agggggcccc tacaagaccg agcccgccac cgacctcggc cgctggcgac tcaactgcga 240

gaggggccgg cagacgtgga cctacctgca ggacgagcgc gccggccgcg agcagaccgg 300

cctggaagcc tacgccctgg ggctggacac caagaattac tttaaggact tgcccaaagc 360

ccacaccgcc tttgaggggg ctctgaacgg gatgacattt tacgtggggc tgcaggctga 420

ggatgggcac tggacgggtg attatggtgg cccacttttc ctcctgccag gcctcctgat 480

cacttgccac gtggcacgca tccctctgcc agccggatac agagaagaga ttgtgcggta 540

cctgcggtca gtgcagctcc ctgacggtgg ctggggcctg cacattgagg ataagtccac 600

cgtgtttggg actgcgctca actatgtgtc tctcagaatt ctgggtgttg ggcctgacga 660

tcctgacctg gtacgagccc ggaacattct tcacaagaaa ggtggtgctg tggccatccc 720

ctcctggggg aagttctggc tggctgtcct gaatgtttac agctgggaag gcctcaatac 780

cctgttccca gagatgtggc tgtttcctga ctgggcaccg gcacacccct ccacactctg 840

gtgccactgc cggcaggtgt acctgcccat gagctactgc tacgccgttc ggctgagtgc 900

cgcggaagac ccgctggtcc agagcctccg ccaggagctc tatgtggagg acttcgccag 960

cattgactgg ctggcgcaga ggaacaacgt ggcccccgac gagctgtaca cgccccacag 1020

ctggctgctc cgcgtggtat atgcgctcct caacctgtat gagcaccacc acagtgccca 1080

cctgcggcag cgggccgtgc agaagctgta tgaacacatt gtggccgacg accgattcac 1140

caagagcatc agcatcggcc cgatctcgaa aaccatcaac atgcttgtgc gctggtatgt 1200

ggacgggccc gcctccactg ccttccagga gcatgtctcc agaatcccgg actatctctg 1260

gatgggcctt gacggcatga aaatgcaggg caccaacggc tcacagatct gggacaccgc 1320

attcgccatc caggctctgc ttgaggcggg cgggcaccac aggcccgagt tttcgtcctg 1380

cctgcagaag gctcatgagt tcctgaggct ctcacaggtc ccagataacc ctcccgacta 1440

ccagaagtac taccgccaga tgcgcaaggg tggcttctcc ttcagtacgc tggactgcgg 1500

ctggatcgtt tctgactgca cggctgaggc cttgaaggct gtgctgctcc tgcaggagaa 1560

gtgtccccat gtcaccgagc acatccccag agaacggctc tgcgatgctg tggctgtgct 1620

gctgaacatg agaaatccag atggagggtt cgccacctat gagaccaagc gtgggggggca 1680

cttgctggag ctgctgaacc cctcggaggt cttcggggac atcatgattg actacaccta 1740

tgtggagtgc acctcagccg tgatgcaggc gcttaagtat ttccacaagc gtttcccgga 1800

gcacagggca gcggagatcc gggagaccct cacgcagggc ttagagttct gtcggcggca 1860

gcagagggcc gatggctcct gggaaggctc ctggggagtt tgcttcacct acggcacctg 1920

gtttggcctg gaggccttcg cctgtatggg gcagacctac cgagatggga ctgcctgtgc 1980

agaggtctcc cgggcctgtg acttcctgct gtcccggcag atggcagacg gaggctgggg 2040

ggaggacttt gagtcctgcg aggagcggcg ttatttgcag agtgcccagt cccagatcca 2100

taacacatgc tgggccatga tggggctgat ggccgttcgg catcctgaca tcgaggccca 2160

ggagagagga gtccggtgtc tacttgagaa acagctcccc aatggcgact ggccgcagga 2220

aaacattgct ggggtcttca acaagtcctg tgccatctcc tacacgagct acaggaacat 2280

cttccccatc tgggccctcg gccgcttctc ccagctgtac cctgagagag cccttgctgg 2340

ccacccctga gaacatgcct acctgctggg tgccgtctgt gcgttccagt gaggccaagg 2400

ggtcctggcc gggttgggga gccctcccat aaccctgtct tgggctccaa cccctcaacc 2460

tctatctcat agatgtgaat ctgggggcca ggctggaggc agggatgggg acagggtggg 2520

tggcttagac tcttgatttt tactgtaggt tcatttctga aagtagcttg tcgggcttgg 2580

gtgaggaagg gggcacagga gccgtgaccc ctgaggaggc acagcgcctt ctgccacctc 2640

tgggcacggc ctcaaggtag tgaggctagg aggttttttc tgaccaatag ctgagttctt 2700

gggagaggag cagctgtgcc tgtgtgattc cttagtgtcg agtgggctct gggctggggt 2760

cggccctggg caggcttctc ctgcaccttt tgtctgctgg gctgagggac acgagggcaa 2820

ccctgtgaca atggcaggta gtgtgcatcc gtgaatagcc cagtgcgggg gttgctcatg 2880

gagcatcctg aggccgtgca gcagggagcc ccatgcccct gggtcgtgag cttgcctgcg 2940

tatggggtgg tgtcatggag cctcatgccc ctgggtcgtg agctcgcctg agtatggggt 3000

ggtgtcatgg agccgcatac ccctgggttg tgagctcgcc tgcatatgca gggtctgtca 3060

tggaacatcc caagtctgtg cagcagggag ccccatgccc ctgggacatg aacccacctg 3120

cgtggaatgc tgtttgtgag gtgtctacag ggtttatagt agtcttgtgg acacagaaat 3180

gcacagggga cacttacgga cacaga 3206

<210> 60
<211> 506
<212> DNA
<213> Homo sapiens

<400> 60
gacgacgact tgctgttcga ggatgtgtac gagctgtgcg aggtgatcgg aaagggtccc 60

ttcagtgttg tacgacgatg tatcaacaga gaaactgggc aacaatttgc tgtaaaaatt 120

gttgatgtag ccaagttcac atcaagtcca gggttaagta cagaagatct aaagcgggaa 180

gccagtatct gtcatatgct gaaacatcca cacattgtag agttattgga gacatatagc 240

tcagatggaa tgctttacat ggttttcgaa ttgtgagtgt gtattttaat tcttaaaggg 300

taaaacttga agcaatgttg gtgttggata atgctaacac ttttctcttg aaatttagca 360

gtagttgtga acttatctgt tcagaaagac ctaaagtcac aagaaaaaag gattatgtca 420

tcataaggtt tacagtggca aaggaagcaa aagctgggca tattcagtta ctcttcatgc 480

tttcagcatg cttcagagaa gagact 506

<210> 61
<211> 229
<212> DNA
<213> Homo sapiens

<400> 61
gagcctcaaa tatctccaaa atctgatacc aatccttttg attgtgaatt atattctgta 60

gctaccaaag aaggaagaag aaaactagga aggagtaagc acaaagatct cttcacattc 120

tccgggactg cggtaccaaa tatcagcaca gcacttcttg aaaaaggatg tagattttaa 180

tctgaacttt gaaccatcac tgaggtggcc cgccggtttc tgagccttc 229

<210> 62
<211> 614
<212> PRT
<213> Homo sapiens

<400> 62

Met Asp Gly Lys Val Ala Val Gln Glu Arg Gly Pro Pro Ala Val Ser
1 5 10 15

Trp Val Pro Glu Glu Gly Glu Lys Leu Asp Gln Glu Asp Glu Asp Gln
20 25 30

Val Lys Asp Arg Gly Gln Trp Thr Asn Lys Met Glu Phe Val Leu Ser
35 40 45

Val Ala Gly Glu Ile Ile Gly Leu Gly Asn Val Trp Arg Phe Pro Tyr
50 55 60

Leu Cys Tyr Lys Asn Gly Gly Gly Ala Phe Phe Ile Pro Tyr Phe Ile
65 70 75 80

Phe Phe Phe Val Cys Gly Ile Pro Val Phe Phe Leu Glu Val Ala Leu
85 90 95

Gly Gln Tyr Thr Ser Gln Gly Ser Val Thr Ala Trp Arg Lys Ile Cys
100 105 110

Pro Leu Phe Gln Gly Ile Gly Leu Ala Ser Val Val Ile Glu Ser Tyr
115 120 125

Leu Asn Val Tyr Tyr Ile Ile Ile Leu Ala Trp Ala Leu Phe Tyr Leu
130 135 140

Phe Ser Ser Phe Thr Ser Glu Leu Pro Trp Thr Thr Cys Asn Asn Phe
145 150 155 160

Trp Asn Thr Glu His Cys Thr Asp Phe Leu Asn His Ser Gly Ala Gly
165 170 175

Thr Val Thr Pro Phe Glu Asn Phe Thr Ser Pro Val Met Glu Phe Trp
180 185 190

Glu Arg Arg Val Leu Gly Ile Thr Ser Gly Ile His Asp Leu Gly Ser
195 200 205

Leu Arg Trp Glu Leu Ala Leu Cys Leu Leu Leu Ala Trp Val Ile Cys
210 215 220

Tyr Phe Cys Ile Trp Lys Gly Val Lys Ser Thr Gly Lys Val Val Tyr
225 230 235 240

Phe Thr Ala Thr Phe Pro Tyr Leu Met Leu Val Ile Leu Leu Ile Arg
245 250 255

Gly Val Thr Leu Pro Gly Ala Tyr Gln Gly Ile Ile Tyr Tyr Leu Lys
260 265 270

Pro Asp Leu Phe Arg Leu Lys Asp Pro Gln Val Trp Met Asp Ala Gly
275 280 285

Thr Gln Ile Phe Phe Ser Phe Ala Ile Cys Gln Gly Cys Leu Thr Ala
290 295 300

Leu Gly Ser Tyr Asn Lys Tyr His Asn Asn Cys Tyr Lys Asp Cys Ile
305 310 315 320

Ala Leu Cys Phe Leu Asn Ser Ala Thr Ser Phe Val Ala Gly Phe Val
325 330 335

Val Phe Ser Ile Leu Gly Phe Met Ser Gln Glu Gln Gly Val Pro Ile
340 345 350

Ser Glu Val Ala Glu Ser Gly Pro Gly Leu Ala Phe Ile Ala Phe Pro
355 360 365

Lys Ala Val Thr Met Met Pro Leu Ser Gln Leu Trp Ser Cys Leu Phe
370 375 380

Phe Ile Met Leu Ile Phe Leu Gly Leu Asp Ser Gln Phe Val Cys Val
385 390 395 400

Glu Cys Leu Val Thr Ala Ser Ile Asp Met Phe Pro Arg Gln Leu Arg
405 410 415

Lys Ser Gly Arg Arg Glu Leu Leu Ile Leu Thr Ile Ala Val Met Cys
420 425 430

Tyr Leu Ile Gly Leu Phe Leu Val Thr Glu Gly Gly Met Tyr Ile Phe
435 440 445

Gln Leu Phe Asp Tyr Tyr Ala Ser Ser Gly Ile Cys Leu Leu Phe Leu
450 455 460

Ser Leu Phe Glu Val Val Cys Ile Ser Trp Val Tyr Gly Ala Asp Arg
465 470 475 480

Phe Tyr Asp Asn Ile Glu Asp Met Ile Gly Tyr Arg Pro Trp Pro Leu
485 490 495

Val Lys Ile Ser Trp Leu Phe Leu Thr Pro Gly Leu Cys Leu Ala Thr
500 505 510

Phe Leu Phe Ser Leu Ser Lys Tyr Thr Pro Leu Lys Tyr Asn Asn Val
515 520 525

Tyr Val Tyr Pro Pro Trp Gly Tyr Ser Ile Gly Trp Phe Leu Ala Leu
530 535 540

Ser Ser Met Val Cys Val Pro Leu Phe Val Val Ile Thr Leu Leu Lys
545 550 555 560

Thr Arg Gly Pro Phe Arg Lys Arg Leu Arg His Val Ile Thr Pro Asp
565 570 575

Ser Ser Leu Pro Gln Pro Lys Gln His Pro Cys Leu Asp Gly Ser Ala
580 585 590

Gly Arg Asn Phe Gly Pro Ser Pro Thr Arg Glu Gly Leu Ile Ala Gly
595 600 605

Glu Lys Glu Thr His Leu
610

<210> 63
<211> 3410
<212> DNA
<213> Homo sapiens

<400> 63
gtaccggttc ggaattcccg ggtcgaccca cgcgtccgga aggctacaga gagagccagg 60

ttttggtgcc atgcacacag ggaaacttag agttcagaga gggggtgtga tttgcctgac 120

ctcacacagc aagttagaga cccagctcca cgactcattg tcttgctgcc cagagctgct 180

ggctcccctg tttactctga gctgatcgat caccttagca cacagctggc taggagagaa 240

ccatgcagtc acttcggcca cacctgcccg ttgacccttg ctacctcggc aggctttgat 300

cccttctgac ctggaggcca gaggctaggc tgaggtcact cagcagacat caaggacctg 360

ggcagatggg ccggctggga tggtggcgag ctgtacagat aaaaagggac atgaaaatga 420

aaagcccgag cctgagtttt catcacggtt ccactcctga gtggtcttgg gtgaatcact 480

tcatctgcca aggcctggat ttcctcatct gcaaactcag aaaactaagg ctttggccct 540

cgtcatcctg cccacccagc ggggcttccc aacccaccac acagccatgg acgggaaggt 600

ggcagtgcaa gagcgtgggc ctcctgcggt ctcctgggtc cccgaggagg gagagaagtt 660

ggaccaggaa gacgaggacc aggtgaagga tcggggccaa tggaccaaca agatggagtt 720

tgtgctgtca gtggccgggg agatcattgg gctgggcaat gtctggaggt ttccctatct 780

ctgctacaaa aacggaggtg gagccttctt catcccctac ttcatcttct tctttgtctg 840

cggcatcccg gtgttcttcc tggaggtggc gttgggccaa tacaccagcc aagggagtgt 900

cacagcctgg aggaagatct gccccctctt ccagggcatt ggtctggcat ctgtggtcat 960

cgagtcatat ttgaatgtct actacatcat catccttgcc tgggctctct tctacctgtt 1020

cagctccttc acttctgagc tgccctggac gacctgcaac aacttttgga acacagagca 1080

ttgcacggac tttctgaacc actcaggagc cggcacagtg accccatttg agaattttac 1140

ctcacctgtc atggaattct gggagagacg agttctgggc atcacctcgg gcatccatga 1200

cctgggctcc ctgcgctggg agctggccct gtgcctcctg ctcgcctggg tcatctgcta 1260

tttctgcatc tggaaggggg tcaagtccac aggcaaggtg gtttatttca cagccacgtt 1320

tccgtacctg atgcttgtca ttttgctgat cagaggtgtc acccttcccg gagcctacca 1380

gggcatcatc tactacttga agccagattt gttccgcctc aaggaccctc aggtgtggat 1440

ggatgcgggc acccagatct tcttctcctt tgccatctgc caggggtgcc tgacagccct 1500

gggcagctac aacaagtatc acaacaactg ctacaaggac tgcatcgccc tctgcttcct 1560

gaacagtgcc accagctttg tggctgggtt tgttgtcttc tccatcctgg gcttcatgtc 1620

ccaagagcaa ggggtgccca tttctgaagt ggccgagtca ggtcctgggc tggccttcat 1680

cgccttcccc aaggctgtga ctatgatgcc cttatcccag ctgtggtcct gcctgttctt 1740

tatcatgctc atattcctag ggctggacag ccagtttgtc tgtgtggagt gcctggtgac 1800

agcctccata gacatgttcc ccaggcagct ccggaagagc gggcggcgcg agctcctcat 1860

cctcaccatc gccgtcatgt gctacctgat agggcttttc ctggtcaccg agggcgggat 1920

gtacatcttc cagctgtttg actactatgc ttccagtggc atatgcctgc tgttcctgtc 1980

attgtttgaa gtggtctgca taagctgggt gtatggggcg gaccgtttct atgacaacat 2040

tgaggacatg attggctacc ggccatggcc cctggtgaag atctcctggc tcttcctgac 2100

ccctggactt tgcctggcca ctttcctctt ctccttgagc aagtacaccc ccctcaagta 2160

caacaacgtc tatgtgtacc cgccctgggg atactccatt ggctggttcc tggctctgtc 2220

ctccatggtc tgtgtcccac tcttcgtcgt catcaccctc ctgaagactc ggggtccttt 2280

caggaagcgt ctgcgtcacg tcatcacccc tgactccagt ctgccacagc ccaagcaaca 2340

tccctgcttg gatggcagtg ctggccggaa ctttgggccc tccccaacaa gggaaggact 2400

gatagccggg gagaaggaga cccatttgta gggtgtggcc agagcgaggc ggctcctaag 2460

ccgggaacct aggtcagggc caccctccat tctcagcgga cagcctctgc ctctgtctcc 2520

tgccacaatc ctgctgggaa ctctggagag ccacaggcac ccccagctgg aggccagact 2580

cctctcttgt gctagctgga gcagctcctt ccccttgct gataacacca ccactgggac 2640

gtgccatgtt gggacgccac tccctgtgga aggcaccatc gtttttataa agggggtct 2700

ttttggaggc cgccatctga ttgcaacacc tcgagttatg aggattccac tgtggggatg 2760

cctcttgtta gagcgtactg catttgtaca cggggagagg agctataatt ggaacgcaca 2820

ctgccgtcca atgtggagag cctgatggga caataccctg ttggaagtga caactgaaca 2880

cactgtgttg gatcggaggt tccgttaggg gatccttcct taggcttaac gacagaggca 2940

agcctttgca tgccgtcagt ctggagtttc ctccgagtct ctcatggcat ctccagctcc 3000

tgccctagtt ccgcactgtt cttgcagtgt ttcatcaact cctggagcat tggaatggaa 3060

ggggcttggg agatgattcc tagacttcac aaacactcgg catgcctccc tgcactgtcc 3120

gttcctctgc ccaaggccga tattgctaac tgatcacaga ttctttccca cctcacaatc 3180

ctccgaatgt gctccaggcg acaccatttg ccatcctgct tctaacgcaa acccctgact 3240

tcatggatga ggaacctgga gaccaaagag acaaagggac tttttcaagt tcacatgggg 3300

acccccttct tgggggccag agatatgact aaaaccttat ctccttgtgc tcaggccagt 3360

gtcttcccat taacccccctg ccttagttaa caagtgtgta tggattgcca 3410

<210> 64
<211> 496
<212> PRT
<213> Homo sapiens

<400> 64

Met Gly Thr Gln Lys Val Thr Pro Ala Leu Ile Phe Ala Ile Thr Val
1 5 10 15

Ala Thr Ile Gly Ser Phe Gln Phe Gly Tyr Asn Thr Gly Val Ile Asn
20 25 30

Ala Pro Glu Lys Ile Ile Lys Glu Phe Ile Asn Lys Thr Leu Thr Asp
35 40 45

Lys Gly Asn Ala Pro Pro Ser Glu Val Leu Leu Thr Ser Leu Trp Ser
50 55 60

Leu Ser Val Ala Ile Phe Ser Val Gly Gly Met Ile Gly Ser Phe Ser
65 70 75 80

Val Gly Leu Phe Val Asn Arg Phe Gly Arg Arg Asn Ser Met Leu Ile
85 90 95

Val Asn Leu Leu Ala Val Thr Gly Gly Cys Phe Met Gly Leu Cys Lys
100 105 110

Val Ala Lys Ser Val Glu Met Leu Ile Leu Gly Arg Leu Val Ile Gly
115 120 125

Leu Phe Cys Gly Leu Cys Thr Gly Phe Val Pro Met Tyr Ile Gly Glu
130 135 140

Ile Ser Pro Thr Ala Leu Arg Gly Ala Phe Gly Thr Leu Asn Gln Leu
145 150 155 160

Gly Ile Val Val Gly Ile Leu Val Ala Gln Ile Phe Gly Leu Glu Phe
165 170 175

Ile Leu Gly Ser Glu Glu Leu Trp Pro Leu Leu Leu Gly Phe Thr Ile
180 185 190

Leu Pro Ala Ile Leu Gln Ser Ala Ala Leu Pro Phe Cys Pro Glu Ser
195 200 205

Pro Arg Phe Leu Leu Ile Asn Arg Lys Glu Glu Glu Asn Ala Lys Gln
210 215 220

Ile Leu Gln Arg Leu Trp Gly Thr Gln Asp Val Ser Gln Asp Ile Gln
225 230 235 240

Glu Met Lys Asp Glu Ser Ala Arg Met Ser Gln Glu Lys Gln Val Thr
245 250 255

Val Leu Glu Leu Phe Arg Val Ser Ser Tyr Arg Gln Pro Ile Ile Ile
260 265 270

Ser Ile Val Leu Gln Leu Ser Gln Gln Leu Ser Gly Ile Asn Ala Val
275 280 285

Phe Tyr Tyr Ser Thr Gly Ile Phe Lys Asp Ala Gly Val Gln Glu Pro
290 295 300

```
Ile Tyr Ala Thr Ile Gly Ala Gly Val Val Asn Thr Ile Phe Thr Val
305                 310                 315                 320

Val Ser Leu Phe Leu Val Glu Arg Ala Gly Arg Arg Thr Leu His Met
                325                 330                 335

Ile Gly Leu Gly Gly Met Ala Phe Cys Ser Thr Leu Met Thr Val Ser
            340                 345                 350

Leu Leu Leu Lys Asp Asn Tyr Asn Gly Met Ser Phe Val Cys Ile Gly
        355                 360                 365

Ala Ile Leu Val Phe Val Ala Phe Phe Glu Ile Gly Pro Gly Pro Ile
    370                 375                 380

Pro Trp Phe Ile Val Ala Glu Leu Phe Ser Gln Gly Pro Arg Pro Ala
385                 390                 395                 400

Ala Met Ala Val Ala Gly Cys Ser Asn Trp Thr Ser Asn Phe Leu Val
                405                 410                 415

Gly Leu Leu Phe Pro Ser Ala Ala His Tyr Leu Gly Ala Tyr Val Phe
            420                 425                 430

Ile Ile Phe Thr Gly Phe Leu Ile Thr Phe Leu Ala Phe Thr Phe Phe
        435                 440                 445

Lys Val Pro Glu Thr Arg Gly Arg Thr Phe Glu Asp Ile Thr Arg Ala
    450                 455                 460

Phe Glu Gly Gln Ala His Gly Ala Asp Arg Ser Gly Lys Asp Gly Val
465                 470                 475                 480

Met Glu Met Asn Ser Ile Glu Pro Ala Lys Glu Thr Thr Thr Asn Val
                485                 490                 495
```

<210> 65
<211> 3915
<212> DNA
<213> Homo sapiens

<400> 65
gtggggtggg gtggggctgg gggcttgtcg ccctttcagg ctccaccctt tgcggagatt 60

ataaatagtc atgatcccag cgagacccag agatgcctgt aatggtgaga ctttggatcc 120

ttcctgagga cgtggagaaa actttctgct gagaaggaca ttttgaaggt tttgttggct 180

gaaaaagctg tttctggaat caccccctaga tctttcttga agacttgaat tagattacag 240

cgatggggac acagaaggtc accccagctc tgatatttgc catcacagtt gctacaatcg 300

gctctttcca atttggctac aacactgggg tcatcaatgc tcctgagaag atcataaagg 360

aatttatcaa taaaactttg acggacaagg gaaatgcccc accctctgag gtgctgctca 420

cgtctctctg gtccttgtct gtggccatat tttccgtcgg gggtatgatc ggctcctttt 480

ccgtcggact cttcgtcaac cgctttggca ggcgcaattc aatgctgatt gtcaacctgt 540

tggctgtcac tggtggctgc tttatgggac tgtgtaaagt agctaagtcg gttgaaatgc 600

tgatcctggg tcgcttggtt attggcctct tctgcggact ctgcacaggt tttgtgccca 660

tgtacattgg agagatctcg cctactgccc tgcggggtgc ctttggcact ctcaaccagc 720

tgggcatcgt tgttggaatt ctggtggccc agatctttgg tctggaattc atccttgggt 780

ctgaagagct atggccgctg ctactgggtt ttaccatcct tcctgctatc ctacaaagtg 840

cagcccttcc attttgccct gaaagtccca gatttttgct cattaacaga aaagaagagg 900

agaatgctaa gcagatcctc cagcggttgt ggggcaccca ggatgtatcc caagacatcc 960

aggagatgaa agatgagagt gcaaggatgt cacaagaaaa gcaagtcacc gtgctagagc 1020

tctttagagt gtccagctac cgacagccca tcatcatttc cattgtgctc cagctctctc 1080

agcagctctc tgggatcaat gctgtgttct attactcaac aggaatcttc aaggatgcag 1140

gtgttcaaga gcccatctat gccaccatcg gcgcgggtgt ggttaatact atcttcactg 1200

tagtttctct atttctggtg gaaagggcag gaagaaggac tctgcatatg ataggccttg 1260

gagggatggc tttttgttcc acgctcatga ctgtttcttt gttattaaag gataactata 1320

atgggatgag ctttgtctgt attggggcta tcttggtctt tgtagccttc tttgaaattg 1380

gaccaggccc cattccctgg tttattgtgg ccgaactctt cagccagggc ccccgcccag 1440

ctgcgatggc agtggccggc tgctccaact ggacctccaa cttcctagtc ggattgctct 1500

tcccctccgc tgctcactat ttaggagcct acgtttttat tatcttcacc ggcttcctca 1560

ttaccttctt ggcttttacc ttcttcaaag tccctgagac ccgtggcagg acttttgagg 1620

atatcacacg ggcctttgaa gggcaggcac acggtgcaga tagatctgga aaggacggcg 1680

tcatggagat gaacagcatc gagcctgcta aggagaccac caccaatgtc taagtcgtgc 1740

ctccttccac ctccctcccg gcatgggaaa gccacctctc cctcaacaag ggagagacct 1800

catcaggatg aacccaggac gcttctgaat gctgctactt aattcctttc tcatcccacg 1860

cactccatga gcaccccaag gctgcggttt gttggatctt caatggcttt ttaaatttta 1920

tttcctggac atcctcttct gcttaggaga gaccgagtga acctaccttc atttcaggag 1980

ggattggccg cttggcacat gacaactttg ccagcttttc ctcccttggg ttctgatatt 2040

gccgcactag gggatatagg agaggaaaag taaggtgcag ttcccccaac ctcagactta 2100

ccaggaagca gatacatatg agtgtggaag ccggagggtg tttatgtaag agcaccttcc 2160

tcacttccat acagctctac gtggcaaatt aacttgagtt ttatttattt tatcctctgg 2220

tttaattaca taatttttt ttttttactt taagtttcag gatacatgtg ccgaatgtgc 2280

aggtttgtta cataggtata tatatgccat gatggaaata tttatttttt taagcgtaat 2340

tttgccaaat aataaaaaca gaaggaaatt gagattagag ggaggtgttt aaagagaggt 2400

tatagagtag aagatttgat gctggagagg ttaaggtgca ataagaattt agggagaaat 2460

gttgttcatt attggagggt aaatgatgtg gtgcctgagg tctgtacgtt acctcttaac 2520

aatttctgtc cttcagatgg aaactcttta acttctcgta aaagtcatat acctatataa 2580

taaagctact gatttccttg gagcttttt ctttaagata atagtttaca tgtagtagta 2640

cttgaaatct aggattatta actaatatgg gcattgtagt taatgatggt tgatgggttc 2700

taattttgga tggagtccag ggaagagaaa gtgatttcta gaaagcctgt tcccctcact 2760

ggatgaaata actccttctt gtagtagtct cattactttt gaagtaatcc cgccacctat 2820

ctcgtgggag agccatccaa ataagaaacc taaaataatt ggttcttggt agagattcat 2880

tatttttcca ctttgttctt taggagattt taggtgttga ttttctgttg tattttaact 2940

catacctta aaggaattcc ccaaagaatg tttatagcaa acttggaatt tgtaacctca 3000

gctctgggag aggatttttt tctgagcgat tattatctaa agtgtgttgt tgctttaggc 3060

tcacggcacg cttgcgtatg tctgttacca tgtcactgtg gtcctatgcc gaatgccctc 3120

aggggacttg aatctttcca ataaaccagg tttagacagt atgagtcaat gtgcagtgta 3180

gcccacactt gagaggatga atgtatgtgc actgtcactt tgctctgggt ggaagtacgt 3240

tattgttgac ttatttctc tgtgtttgtt cctacagccc ctttttcata tgttgctcag 3300

tctccctttc ccttcttggt gcttacacat ctcagaccct ttagccaaac ccttgtcagt 3360

gacagtattt tggttcttag ttctcactgt tccctctgct cctggagcct ttgaataaaa 3420

atgcacgtag ctgaggccgg atgcggtggc tcacgcctgt aatcccagca ctttgggagg 3480

cctaggcggg cggtcagggg ttcgagacca gtctggccaa catcgtgaaa ccctgtctct 3540

actaaaaatg caaaaattag ccgggcgtgg tggcgggcgc ctgtaatccc agctacttgg 3600

gaagctgagg cgggagaatc atgtgaaccc gggacgcagg ggttgcagtg agcggagatc 3660

gcatcattgc actctagcct gggccacagg gcgagactcc gtctcaaaaa aaaaaaaatg 3720

cacatagcta tcgagtgtgc tttagcttga aaaggtgacc ttgcaacttc atgtcaactt 3780

tctggctcct caaacagtag gttggcagta aggcagggtc ccatttctca ctgagaagat 3840

tgtgaatatt tccatatgga ttttctattg ttactctggt tctttgtttt aaaataaaaa 3900

ttctgaatgt acacg 3915

<210> 66
<211> 2862
<212> DNA
<213> Homo sapiens

<400> 66
gccgagagcg ggatccgcgc tccctcggtc cttcctccct cccctcttgc ggcctcccgc 60

tgtcatctgg agccgctcct gccgcccccc ggcggcgacc gcgggaaggg ccggccccca 120

tccgcacccc tgaccccgga ggtcaacaac gggatggtcc ctgggtccca ggggaagaga 180

catcacccag taggagggag tacggtctag acagaggcca cgagggcggg agggggcgag 240

agtggagagt ggcccagctg gccagggtcg tctaagtgag aggaaaaggg agagggcggt 300

tgagaccagg ccctgaattc cgcgttcatc ttatcctgag gtctgtgggg acctgttgaa 360

ggactggggc aggggacgga cgcgggcatc cttccatttg gaacagccat tccggcagca 420

tcaggatggg gcggaggcaa agcggggagt gggcgaggca agtggtgctg taaacctgtg 480

cgagaagggg gcggtgactc taagggcagg aaggagccct ggtcacacac acactcccac 540

gcaaggtatt cagtgccgag tgtggccttg gtgctaggat tcaaagagga aaggaagaaa 600

actttccatt ctaaaagaaa ctccacgtga ggcgaagaag atgaaatata gtcagaaaac 660

cataccagta ggtggtaggt aaatgcagaa gtatttaaga gctcatacag gagtacctgc 720

ctcaggacag ggaatctgag atgctctgca gagctggatc ttaaagaacg gattaagttg 780

ataaatgatg catacgacat cctatagaag actgtcacca ccccacctca ctgatcagcc 840

ctctgcctac agccacaccc acagaacatt cagccatttc tcctgtggtt cccagcctgc 900

agcacagcgt ctgcacgtgg tgagggctcc caaatctctg aggaatgaat ggctcactgc 960

tgagagcaac cttctgggag ttcagggcat gtggaactgg aataagagca acgtgtgaac 1020

agattacagg aaggcaatgc aggacagctg gacccctttgg ggggaaactt atggggaaca 1080

cagttttctt acttataagc actgagattg cctgagaggg gagagatgat gcagagtgtc 1140

ccaaatgtat ttgacgtgga atccttttac cagcgaaaca tctcttgggc ctagagttct 1200

gaaaattgca ctttgaaaaa cactgctctc agctcttaca aacctcgtgt tttcatccta 1260

actgtgcttc agagaattgt gtcccagcag gaaaggaaac ccccgtataa ttccctacgt 1320

tgctagcatt tggaagtggg atgaaaatgg acctacattc aaacccctaa tttcaagctc 1380

tgaaggaggt accaggatcc atcacgatgc ttgtaaaatt gttcctttca ttttcctggt 1440

tgtaaactta tgcagactgt aaagtcaagg caagcctgtg cccagcaaat aataagaaaa 1500

taagggaggc atggtaaaca aaacaaaaca ctttgagagt tggtcaactt gctgttattt 1560

tgagctgttt ctaaaaatct cagggtagat tccctcccct gcttgcctcc ttaacccagt 1620

ccttttttctt cctcctccag gaactctgga atgctgacct acagtctgag ttcctgtgcc 1680

cttgcctggg gctgactctc tacttgacct gtaacccaca actgggcaag agaaaattct 1740

gcagccacag ctctgaggac atgagcaaaa tggtttccag acggaatgtc aaggattccc 1800

atgaagtgtc agggagtctt caggccacac ttcaggttat ctccttctct ttccctttc 1860

tgcttcacac ttgctctcat cctctttctc accccacatc tggtcagagg agataggaag 1920

gttcttgtta cctggtacaa gacaactttt ggaatcccag atattcagat tatttccct 1980

tttcctcttt gcaaatgata atactcacag ccaagaggca tcacccggat ccgaggctgc 2040

ttctccttag gacatgcaga cagaaggaga aggcggggct ggcagcctcc agtccacagc 2100

ctccctttct tcttccggcg atgattaact aggcctagac aatggagatc tacggcatac 2160

gcccagggcc tcctcttctc aagcatggct gatcagtcac tttcccgtct atccttcatt 2220

tattgaagcc aactatgaac gactaaagga aggatgagaa aagtcaccca aagtcaaagg 2280

ggacagcgtg ggagactgtt ctagacagaa ggaaacacct ttgcaaagac cctgaggaag 2340

gcaggggact ctccaggagc agaagggctg tgtggcttca gagtccacaa aagagagcag 2400

atacaggaca ctggctagag caggccctgg agcccgctgc tgtcctggag gccttgggga 2460

ggcccagtgt tcccagggtg gaagaagtag gggacagctt gacgtagtgg ctgttgatca 2520

gctgatatgg aagtatgtca ttttattaac aattgagaaa ggagtgctgt gcaattccat 2580

tcaatgccag tgatgcttat ggccgttttt atgagttctg tcattttcaa atgagcaaga 2640

ggaagcctct aaggggttt aagcagggac tgacgtaatc agatctgtgt ttttccaaag 2700

ggagagggag aaaaagaaca tttcttattt ttcaaaaaag gtaatgcaaa agcatcattc 2760

cacaattctc ttgtaatgaa aaaaataaat gcaaacttaa gcaaatccat cattctgaaa 2820

gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 2862

<210> 67
<211> 426
<212> PRT
<213> Homo sapiens

<400> 67

Met Pro Leu Leu Trp Leu Arg Gly Phe Leu Leu Ala Ser Cys Trp Ile
1 5 10 15

Ile Val Arg Ser Ser Pro Thr Pro Gly Ser Glu Gly His Ser Ala Ala
20 25 30

Pro Asp Cys Pro Ser Cys Ala Leu Ala Ala Leu Pro Lys Asp Val Pro
35 40 45

Asn Ser Gln Pro Glu Met Val Glu Ala Val Lys Lys His Ile Leu Asn
50 55 60

Met Leu His Leu Lys Lys Arg Pro Asp Val Thr Gln Pro Val Pro Lys
65 70 75 80

Ala Ala Leu Leu Asn Ala Ile Arg Lys Leu His Val Gly Lys Val Gly
85 90 95

Glu Asn Gly Tyr Val Glu Ile Glu Asp Asp Ile Gly Arg Arg Ala Glu
100 105 110

Met Asn Glu Leu Met Glu Gln Thr Ser Glu Ile Ile Thr Phe Ala Glu
115 120 125

Ser Gly Thr Ala Arg Lys Thr Leu His Phe Glu Ile Ser Lys Glu Gly
130 135 140

Ser Asp Leu Ser Val Val Glu Arg Ala Glu Val Trp Leu Phe Leu Lys
145 150 155 160

Val Pro Lys Ala Asn Arg Thr Arg Thr Lys Val Thr Ile Arg Leu Phe
165 170 175

Gln Gln Gln Lys His Pro Gln Gly Ser Leu Asp Thr Gly Glu Glu Ala
180 185 190

Glu Glu Val Gly Leu Lys Gly Glu Arg Ser Glu Leu Leu Leu Ser Glu
195 200 205

Lys Val Val Asp Ala Arg Lys Ser Thr Trp His Val Phe Pro Val Ser
210 215 220

Ser Ser Ile Gln Arg Leu Leu Asp Gln Gly Lys Ser Ser Leu Asp Val
225 230 235 240

Arg Ile Ala Cys Glu Gln Cys Gln Glu Ser Gly Ala Ser Leu Val Leu
245 250 255

Leu Gly Lys Lys Lys Lys Lys Glu Glu Glu Gly Glu Gly Lys Lys Lys
260 265 270

Gly Gly Gly Glu Gly Gly Ala Gly Ala Asp Glu Glu Lys Glu Gln Ser
275 280 285

His Arg Pro Phe Leu Met Leu Gln Ala Arg Gln Ser Glu Asp His Pro
290 295 300

His Arg Arg Arg Arg Arg Gly Leu Glu Cys Asp Gly Lys Val Asn Ile
305 310 315 320

Cys Cys Lys Lys Gln Phe Phe Val Ser Phe Lys Asp Ile Gly Trp Asn
325 330 335

Asp Trp Ile Ile Ala Pro Ser Gly Tyr His Ala Asn Tyr Cys Glu Gly
340 345 350

Glu Cys Pro Ser His Ile Ala Gly Thr Ser Gly Ser Ser Leu Ser Phe
355 360 365

His Ser Thr Val Ile Asn His Tyr Arg Met Arg Gly His Ser Pro Phe
370 375 380

Ala Asn Leu Lys Ser Cys Cys Val Pro Thr Lys Leu Arg Pro Met Ser
385 390 395 400

Met Leu Tyr Tyr Asp Asp Gly Gln Asn Ile Ile Lys Lys Asp Ile Gln
405 410 415

Asn Met Ile Val Glu Glu Cys Gly Cys Ser
420 425

<210> 68
<211> 1840
<212> DNA
<213> Homo sapiens

<400> 68
tccacacaca caaaaaacct gcgcgtgagg ggggaggaaa agcagggcct ttaaaaaggc 60

aatcacaaca acttttgctg ccaggatgcc cttgctttgg ctgagaggat ttctgttggc 120

aagttgctgg attatagtga ggagttcccc caccccagga tccgaggggc acagcgcggc 180

ccccgactgt ccgtcctgtg cgctggccgc cctcccaaag gatgtaccca actctcagcc 240

agagatggtg gaggccgtca agaagcacat tttaaacatg ctgcacttga agaagagacc 300

cgatgtcacc cagccggtac ccaaggcggc gcttctgaac gcgatcagaa agcttcatgt 360

gggcaaagtc ggggagaacg ggtatgtgga gatagaggat gacattggaa ggagggcaga 420

aatgaatgaa cttatggagc agacctcgga gatcatcacg tttgccgagt caggaacagc 480

caggaagacg ctgcacttcg agatttccaa ggaaggcagt gacctgtcag tggtggagcg 540

tgcagaagtc tggctcttcc taaaagtccc caaggccaac aggaccagga ccaaagtcac 600

catccgcctc ttccagcagc agaagcaccc gcagggcagc ttggacacag gggaagaggc 660

cgaggaagtg ggcttaaagg gggagaggag tgaactgttg ctctctgaaa aagtagtaga 720

cgctcggaag agcacctggc atgtcttccc tgtctccagc agcatccagc ggttgctgga 780

ccagggcaag agctccctgg acgttcggat tgcctgtgag cagtgccagg agagtggcgc 840

cagcttggtt ctcctgggca agaagaagaa gaaagaagag gaggggaag ggaaaaagaa 900

gggcggaggt gaaggtgggg caggagcaga tgaggaaaag gagcagtcgc acagaccttt 960

cctcatgctg caggcccggc agtctgaaga ccaccctcat cgccggcgtc ggcggggctt 1020

ggagtgtgat ggcaaggtca acatctgctg taagaaacag ttctttgtca gtttcaagga 1080

catcggctgg aatgactgga tcattgctcc ctctggctat catgccaact actgcgaggg 1140

tgagtgcccg agccatatag caggcacgtc cgggtcctca ctgtccttcc actcaacagt 1200

catcaaccac taccgcatgc ggggccatag ccccttgcc aacctcaaat cgtgctgtgt 1260

gcccaccaag ctgagaccca tgtccatgtt gtactatgat gatggtcaaa acatcatcaa 1320

aaaggacatt cagaacatga tcgtggagga gtgtgggtgc tcatagagtt gcccagccca 1380

gggggaaagg gagcaagagt tgtccagaga agacagtggc aaaatgaaga aatttttaag 1440

gtttctgagt taaccagaaa aatagaaatt aaaaacaaaa caaaacaaaa aaaaaaacaa 1500

aaaaaaacaa aagtaaatta aaaacaaacc tgatgaaaca gatgaaacag atgaaggaag 1560

atgtggaaat cttagcctgc cttagccagg gctcagagat gaagcagtga agagacagat 1620

tgggagggaa agggagaatg gtgtaccctt tatttcttct gaaatcacac tgatgacatc 1680

agttgtttaa acggggtatt gtcctttccc cccttgaggt tcccttgtga gcttgaatca 1740

accaatctga tctgcagtag tgtggactag aacaacccaa atagcatcta gaaagccatg 1800

agtttgaaag ggcccatcac aggcactttc ctagcctaat 1840

<210> 69
<211> 478
<212> PRT
<213> Homo sapiens

<400> 69

Met Gly Leu Ala Glu Tyr Phe Gly Phe Asp Asp His Asp Thr Asp Leu
1 5 10 15

Arg Thr Glu Leu Val Ala Gly Leu Thr Thr Phe Leu Ala Met Ser Tyr
20 25 30

Ile Val Leu Val Asn Pro Val Val Met Thr Gln Arg Thr Thr Ala Gly
35 40 45

Glu Val Val Lys Pro Gly Ile Ala Leu Ala Asn Tyr Ser His Asp Gln
50 55 60

Thr Val Gln Met Leu Ala Val Val Thr Leu Leu Ala Ser Gly Val Ala
65 70 75 80

Met Leu Val Met Ala Phe Tyr Ala Asn Arg Pro Phe Ala Leu Ala Pro
85 90 95

```
Gly Leu Gly Leu Asn Ala Phe Phe Ala Phe Thr Val Val Gly Thr Leu
            100                 105                 110

Gly Val Pro Trp Gln Thr Ala Leu Ala Ala Val Phe Thr Glu Gly Leu
        115                 120                 125

Leu Phe Ile Val Leu Thr Ala Val Gly Ala Arg Glu Tyr Val Ile Thr
    130                 135                 140

Leu Phe Pro Glu Pro Val Lys Leu Ala Val Gly Thr Gly Ile Gly Leu
145                 150                 155                 160

Tyr Leu Ala Ile Ile Gly Leu Glu Ala Met Gly Ile Val Val Gly Asp
                165                 170                 175

Ala Gly Thr Ile Leu Ala Leu Gly Asn Leu Ala Gln Asn Pro Val Ala
            180                 185                 190

Val Val Ser Ile Leu Gly Leu Phe Phe Thr Ile Ala Leu His Ala Arg
        195                 200                 205

Gly Val Thr Gly Ser Ile Val Leu Gly Ile Ile Ala Thr Ala Ala Thr
    210                 215                 220

Gly Gly Val Leu Thr Phe Ala Gly Val Val Asp Pro Gly Val Leu Ile
225                 230                 235                 240

Gly Asp Phe Val Arg Thr Gly Gly Ile Ala Thr Gln Arg Leu Pro His
                245                 250                 255

Ala Gln Tyr Asp Ile Thr Pro Leu Val Gly Ala Phe Leu Ala Gly Phe
            260                 265                 270

Gln Asp Ile Asp Ala Phe Ser Phe Ala Leu Ile Val Phe Thr Phe Phe
        275                 280                 285

Phe Val Asp Phe Phe Asp Thr Ala Gly Thr Leu Val Gly Val Gly Gln
    290                 295                 300

Ala Gly Gly Phe Leu Asn Thr Asp Gly Asn Leu Pro Asp Ala Asp Glu
305                 310                 315                 320
```

```
Pro Leu Met Ala Asp Ala Ile Gly Thr Thr Phe Gly Ala Ile Ile Gly
                325                 330                 335

Thr Ser Thr Val Thr Thr Tyr Ile Glu Ser Ala Thr Gly Val Glu Glu
            340                 345                 350

Gly Gly Arg Thr Gly Met Val Ala Leu Val Val Ala Val Leu Phe Phe
        355                 360                 365

Leu Ser Leu Leu Val Val Pro Leu Ala Ala Ala Ile Pro Gln Tyr Ala
    370                 375                 380

Ser His Ile Ala Leu Val Val Val Ala Leu Leu Met Leu Ala Asn Val
385                 390                 395                 400

Thr Ala Ile Asp Trp Asp Asp Ile Thr His Ser Ile Pro Ala Gly Leu
                405                 410                 415

Thr Ile Ile Val Met Pro Phe Thr Tyr Ser Ile Ala Tyr Gly Ile Ala
            420                 425                 430

Ala Gly Ile Val Ser Tyr Pro Val Val Lys Val Ala Thr Gly Asp Ala
        435                 440                 445

Asp Glu Val Ala Ile Gly Gln Trp Leu Leu Ala Ala Ala Phe Ile Val
    450                 455                 460

Tyr Phe Tyr Val Arg Thr Ser Gly Val Leu Ala Ala Ala Val
465                 470                 475
```